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Abstract 
Since van der Bruggen et al. (1991) first identified specific human tumour antigens of the 
MAGE family, numerous potential immunotherapeutic targets have been discovered, often 
belonging to the so-called cancer/testis (CT) gene family. In a search for novel epitopes from 
potential tumour target antigens, HAGE, a CT antigen, has been studied. It was first identified 
in a sarcoma and has since been reported in several carcinomas and leukaemias at the mRNA 
level only. This study proposed to investigate HAGE as a potential target for immunotherapy 
in a murine tumour model. HAGE mRNA was found to be expressed in a small proportion of 
carcinomas, some melanomas and in a strong proportion of chronic myeloid leukaemias as 
compared to normal tissues, which do not express HAGE with the exception of testis. HAGE 
protein levels were also confirmed on tissue sections and in cell lines in order to rule out any 
post-transcriptional modifications. Furthermore, HAGE has been previously described as 
member of the DEAD-box family of ATP-dependent RNA helicases but very little is known 
about its actual function. RNA helicases are involved in various steps of RNA metabolism and 
their over-expression has often been linked with tumorogenesis. Using a combination of 
silencing and transfection experiments, HAGE was proven to be critical for tumour cell 
proliferation. Next, the identification of candidate MHC class I and class II immunogenic 
peptides derived from the HAGE protein was undertaken by combining reverse immunology 
with the use of HLA transgenic mice. Four HLA-A2 peptides were found to be immunogenic 
in C57BL/6-HHDII mice with one of them being also naturally processed. Four HLA-DR1/-
DR4 peptides were defined as immunogenic in FVB/N-DR1 and C57BL/6-DR4 mice with two 
of them being also endogenously processed. The discovery of three novel HAGE-derived 
epitopes may then contribute to the range of immunotherapeutic targets for use in cancer 
vaccination programs. Finally, potent DNA-based vaccination strategies targeting HAGE were 
evaluated in an in vivo tumour model developed in HHDII-DR1, double transgenic mice. 
HAGE DNA vaccination by either gene gun or intra-muscular injection led to tumour 
protection and/or clearance in immunised animals. Also, the use of co-stimulatory molecules to 
boost the immune response induced by HAGE DNA vaccination was studied in a therapeutic 
setup and B7.2 appeared to be the most promising one. However, further work is needed to 
improve this tumour model and assess other methods of vaccination such as syngeneic 
dendritic cell-based vaccination or viral vaccination and the use of Semliki Forest virus. 
Collectively, these data demonstrate that HAGE represents a valid candidate target for several 
cancers and should maybe be included in future immunotherapeutic design. 
 Chapter 1: Introduction 
1.1 Cancer 
A tumour or a neoplasm is the result of an excessive and uncontrolled proliferation of a single 
normal cell, which has been transformed into a cancerous state following multiple cellular 
alterations and rendered resistant to apoptosis, cell-to-cell contact inhibition, growth factor 
removal or immune cells (Bertram, 2000). According to the latest figures obtained by the 
World Health Organisation (on line at http://www.who.int/cancer/en/), cancer is responsible for 
13% of deaths worldwide with approximately 8 million deaths a year and at least 11 million 
new cases diagnosed every year. The appearance of a malignant tumour is associated with 
multiple interrelated factors relevant to the subject itself (heredity, hormonal state, efficacy of 
immune defences), but also to its environment (life conditions, alimentary habits, exposition to 
diverse toxic or infectious agents). Smoking is for example a well known risk factor for lung 
cancer causation while similarly; ultra violet radiation from sunlight is strongly linked with 
melanoma, a common form of skin cancer (Ivry et al., 2006). Obesity was shown, by numerous 
epidemiological studies, to be associated with the development of cancers in a variety of 
tissues such as the oesophagus, colon, kidney, breast, pancreas, liver or gall bladder (Calle and 
Thun, 2004). It was recently demonstrated that almost 5% of cancer was directly and indirectly 
caused by a chronic infection with the likes of human papillomavirus in 98% of cases of 
cervical cancers, hepatitis B virus in some hepatocarcinoma, as well as Epstein Barr virus 
having a possible involvement in at least four different types of cancer including Burkitt’s 
lymphoma and nasopharyngeal carcinoma. Finally, spontaneous DNA damage during normal 
cell division can also lead to cancer. 
 
1.1.1 Cancer and tumoral transformation 
Each cell of the organism undergoes the duplication of its genomic content during the cell 
cycle before continuing its division process (Fig. 1.1). Each of the four phases (G1, S, G2 and 
M) of the cell cycle contains checkpoints required to ensure the integrity of the genetic material 
and which allows the cell to either go along with the division process following the repair of 
any DNA damage or start the complex pathway of programmed cell death (apoptosis) if the 
damage is simply too important. The conservation of the tumoral phenotype by cellular 
division is compatible with three mechanisms: 
- Alteration of the coding region or the regulation sequence by chemical or physical 
environmental influences. 
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Figure 1.1: Mammalian cell cycle (Adapted from www.cancerline.com). Cell cycle 
mechanisms control normal cell growth and division. Progression into each phase is tightly 
controlled by complexes formed of cyclins and cyclin-dependent kinases (Cdk) as well as 
tumour-suppressor genes such as p53 and retinoblastoma (Rb). Disruption of these 
checkpoints leads to uncontrolled cellular growth and development of tumoral phenotype. 
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- Alteration of the genome following the addition of foreign genetic materials such as viruses 
or other infectious agents. 
- Alteration of the structure of the chromatin due to epigenetic factors such as ageing mainly 
through DNA methylation. 
In spite of several cell divisions occurring throughout life, the development of a cancer cell 
remains a relatively rare event, mainly because of the need for multiple alterations to acquire 
the malignant phenotype. The number of alterations for a cell to become neoplastic is thought 
to be strictly tumour-dependent. However, this level can be correlated with increasing age and 
it is generally believed that at least five to six genetic hits are a pre-requisite for the formation 
of solid tumours in humans and that genetic alterations other than mutations can also transform 
cells such as translocation, amplification or loss of heterozygosity (LOH)(Cahill et al., 1999).  
Depending on the cancer types, genetic alterations affect a wide diversity of genes and it is 
generally acknowledged that only a small number of them are constantly the target. Akagi 
(2004) proposed that four phenomena must exist for the tumoral transformation to occur and 
these include the inactivation of the tumour-suppressor genes Rb and p53, the shortening of 
telomeres, the constant expression of activated Ras and the activation of protein phosphatase 
2A. Any DNA damage occurring on these pathways, which goes undetected by the checkpoints 
become fixed and is inherited by daughter cells, which can then acquire further mutations. The 
multistep hypothesis has therefore been advanced (Baak et al., 2003). Sequential mutations of 
genes in cases of head and neck, prostate or colorectal cancers have been detailed in the 
literature. The latter has been one of the first described sequences of events leading to the 
transformation of a normal colon cell into a metastatic carcinoma. The model, proposed by 
Fearon and Vogelstein (1990), described a mutation on the Ras gene as well as the LOH of 
chromosome 5q at an early stage of tumour development, followed by two mutations on the 
p53 gene and LOH of chromosome 18q at a later stage (Fig. 1.2).  
More recently, Forastiere et al. (2001) described an even more complicated sequence of events 
occurring in head and neck carcinomas with a succession of losses of heterozygosity on 
chromosome 9p (locus of cell cycle inhibitor p16) at an early stage, on chromosomes 17p 
(locus of p53) and 3p at an intermediary stage, and finally on chromosomes 11q, 13q and 14q 
at a later stage. Although these models were detailed in depth, they are a rather simplified 
version of what the reality is. Further studies are required for a better understanding of the 
tumour biological processes such as proliferation, differentiation, apoptosis or invasion, as well 
as tumour stages in relation with molecular events occurring inside the cells. Thus, by allowing  
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Figure 1.2: Multistep progression hypothesis of tumours in colon carcinoma (Adapted from 
Knudson., 2001). 
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a correlation between tumour-specific antigens and aggressiveness of the tumour, direct 
specific therapies targeting tumour-specific antigens, expressed at certain stages of the tumour-
development, could be developed and used accordingly by clinicians (Bertram, 2000). 
 
 1.1.2 Tumorogenesis and cellular specialisation 
DNA damage, initiated by mutagenic agents and responsible for the disruption of the normal 
functioning of the cell cycle, affects principally two groups of genes involved in the control of 
the cellular proliferation and differentiation, and called proto-oncogenes and tumour-
suppressor genes (Karpinets and Foy, 2005). 
 
 1.1.2.1 Oncogenes 
Oncogenes are a class of genes that stimulate cell growth. There are two types of oncogenes: 
viral oncogenes and cellular oncogenes or proto-oncogenes. Viral oncogenes can initiate and 
maintain cancers; one of the most studied being the Sarcoma or Src oncogene induced by Rous 
retrovirus (Martin, 1970; Martin, 2004). Although a rare event, these viral oncogenes derive 
from actual coding regions of cellular oncogenes, which have been taken up by these viruses 
and incorporated into their own DNA next to the coding regions that are essential for their 
survival. The host gene becomes part of the viral genome and is from then transcribed in 
infected cells under the viral promoter rather than the normal host, which would be highly 
regulated by a network of transcription factors. Over-expression of the gene causes the infected 
cells to escape growth regulation. 
Proto-oncogenes require to be “switched on” to take part in the induction of cancer. Although 
these are necessary, they are not sufficient on their own to cause cancer. Each cellular 
oncogene is involved either in the initiation or the maintenance of tumour development but 
needs another gene (viral or cellular) in a multistep process to achieve malignant tumour. 
Activation of proto-oncogenes into oncogenes can occur through various genetic alterations, 
among which mutations, translocation and amplification can be included. Some viruses can 
also insert their promoter in front of a proto-oncogene thereby causing the over-expression of 
the “particular” proto-oncogene and ultimately leading to excessive cell proliferation. Proto-
oncogenes encode for proteins, which are involved at different levels of cellular proliferation 
going from the transmission of extra-cellular signals via surface receptors to the intra-nuclear 
command of replication including growth factors, growth factor receptors, protein kinases, 
signal pathway transduction mediators and transcription factors (Peters, 1997). At the same 
time, proto-oncogenes also lead to the uncoupling of tumour cells from external regulatory 
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signals, meaning that factors secreted by normal surrounding cells cannot control the 
proliferation of cells homing these oncogenes, hence the neoplastic phenotype (Bertram, 2000; 
Lucas et al., 2002). The selection of cells having these activities, favoured by the acquired 
genetic instability, constitutes a pivotal point in tumour development. Molecules involved in 
this process are varied and include abnormal growth factors (FGF, EGF, VEGF, PDGF, and 
TGF-α) as well as abnormal growth factor receptors leading to their constitutive activation 
and/or their deregulation (EGFR)(Cross and Dexter, 1991). It is generally believed that genetic 
alterations required for invasion, metastasis or angiogenesis can be absent in the first steps of 
tumoral transformation but they are often acquired at the early stages of tumour formation. 
Vessels, characterising tumoral angiogenesis, develop from non-tumoral cells but distinguish 
themselves from normal vessels by their specific expression pattern of growth factors and 
growth factor receptors. The creation of these new vessels is consecutive to a modification of 
the balance between inhibitors and activators of angiogenesis secreted by tumour cells such as 
thrombospondin 1 and VEGF or FGF, respectively, with constitutive activation of Ras 
(Hanahan and Folkman, 1996). The capacity of tumour cells to invade tissues situated in the 
vicinity of the tumour constitutes a prime characteristic of aggressive tumours. Clear 
correlations have also been observed between the pattern of expression of molecules involved 
in inter-cellular adhesion and metastatic potential. For example, the variation of pattern of 
integrins can trigger the adaptation of tumour cells to different types of extra-cellular matrices 
during the metastatic process (Goepel et al., 1991). The second class of proteins involved in the 
metastatic process, as well as the angiogenic phenomenon, can be described as the family of 
proteases secreted by tumour or stroma cells and capable of degrading the extra-cellular matrix 
(Coussens and Werb, 1996). These proteases can be over-expressed and reciprocally, the 
expression of their respective inhibitors is often diminished. 
Cellular proliferation is also due to alterations in the signalling pathway with molecules such as 
phosphatases involved in the activation or the inhibition of protein kinases triggering 
constitutive activation of signalling pathways. Among all these pathways, the SOS-Ras-Raf-
MAPK cascade has a “privileged seat” as being the first identified (Parada et al., 1982). Indeed, 
Ras is activated in more than 25% of tumours and is capable, with the co-operation of other 
genes, to induce transformation by deregulating the Jnk and/or Erk pathways and therefore 
modifying biochemical and cytoskeletal properties of the transformed cells (Peters, 1997). On 
the other hand, experiments carried out in vitro in mouse cell lines showed that transfection of 
the Ras gene does not provide a sufficient signal to provoke tumoral transformation on its own 
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and that immortalisation of the cells is required prior to transfection with the Ras gene to 
induce the tumoral phenotype (Scholl et al., 2005). That is why mutations affecting the 
signalling pathway are often accompanied with mutations occurring further downstream of the 
signalling, mainly transcription factors. Proteins such as Fos, Jun or Myc are often affected by 
the process of mutagenesis and are normally responsible for the activation or the inhibition of 
genes involved in the cell cycle. Fos expression is directly modulated by phosphorylation by 
MAPK following activation of the Ras pathway while its stability and its DNA-binding 
capacity is affected by other protein kinases such as PKA or PKC (Greenberg et al., 1984; 
Milde-Langosch., 2005). Moreover, the frequency of its heterodimerisation with the other 
transcription factor Jun required to provide transcription signals often correlates with the 
severity of the cancer (Schutte et al., 1989). Myc, whose expression is also due to the 
activation of PKC (Greenberg et al., 1984), down-regulates the expression of the tumour-
suppressor p53, and promotes the expression of cyclin A and cyclin E among others, therefore 
forcing the cells into cell cycle and cell division (Peters, 1997; Mackay and Williams, 2003; 
Ponzielli et al., 2005).  
 
  1.1.2.2 Tumour-suppressor genes 
Mutations also occur on anti-oncogene genes, which limit the cellular proliferation such as the 
much studied tumour-suppressor p53 and Rb genes (Harris and Levine, 2005). Functions of 
tumour-suppressor genes are abolished or reduced by mechanisms such as loss of 
heterozygosity, methylation, cytogenetic aberrations, genetic mutations, and gain of auto-
inhibitory function or polymorphisms (Zingde., 2001). In most cases, the normal suppressor 
allele can function alongside the mutated allele, reinforcing the need for both genes to be 
inactivated before abolishment or reduction of function is seen. Moreover and contrary to 
oncogenes which are dominant and normally prevent development of viable embryo, defects in 
tumour-suppressor genes can be inherited (Bertram., 2000), and loss of heterozygosity, that is 
to say the loss of function of the second normal allele, will be detrimental as early onset 
tumours will be able to rise (Bamne et al., 2005; Fearnhead et al., 2004).  
The Rb pathway is the second metabolic pathway to be targeted in several cancers. Indeed, 
retinoblastoma, the most common ocular malignancy occurring early in child development, is 
due to mutations taking place in the Rb gene. The Rb protein functions as a checkpoint for cells 
to enter into S-phase. The molecule can be directly altered by mutations affecting the pockets 
of interactions with the E2F/DP transcription complex, genetic deletion or simple inhibition of 
its expression. Rb expression can also be modified following mutations on molecules 
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controlling its phosphorylation leaving the E2F/DP complex to act freely on the cell cycle. 
Indeed, overexpression of cyclins D, amplification of Cdk4 or inactivation of the ink4 inhibitor 
family have been linked with reduced or suppressed expression of Rb (Peters, 1997). 
The p53 tumour-suppressor gene is an important regulator of genomic stability, replicative 
senescence and premature senescence via the control of telomere length (Bertram., 2000). It 
controls, at least partially and in close collaboration with the Rb gene, mechanisms of DNA 
repair and cellular apoptosis and it also controls the blockade of the cell cycle via the p21 
molecule (Fig. 1.3)(Graeber et al., 1996; Linke et al., 1996)). This pathway, often considered 
“the guardian of the genome”, is inactivated in over 70% of all tumours while most of the 
genes present upstream or downstream of this pathway are also mutated (Levine., 1997). p53 
normally blocks the cell cycle progression by increasing the level of p21, which in return 
allows the dephosphorylation of the cyclin D/Cdk4 complexes (el-Deiry et al., 1993). 
Moreover, p53 can be down-regulated by the Mdm2 protein to allow progression into the cell 
cycle. For these two reasons, p53 represents a critical target in the formation of neoplasms. The 
inactivation of p53 is, in 90% of cases, due to punctual mutations mostly occurring in the 
DNA/protein interaction sites. It prevents the formation of hydrogen bonds between the p53 
protein and the DNA, and triggers a loss of function or a dominant effect associated with the 
stabilisation of the protein (Cho et al., 1994). This increase of protein half-life and its potential 
dominant effect over the wild type p53 protein play an important role in the possible 
appearance of an immune response against p53, strongly helped by the fact that the occurrence 
frequency of certain mutations is quite high providing a way of targeting these mutated p53-
expressing tumour cells. In summary, key regulatory proteins involved in cell growth and 
survival are affected by mutations and lead to the uncontrolled cell proliferation. 
 
1.1.3 Tumour-associated antigens and their classification 
Mutations occurring in proto-oncogenes and tumour-suppressor genes and the eventual 
incorporation of viral DNA into the human genome trigger a cascade of reactions affecting the 
expression or the structure of other genes. Proteins derived from these genes are called tumour-
associated antigens (TAA). Most investigations have focussed their attention in identifying 
them and more specifically the tumour rejection antigens, which are peptides derived from the 
tumour antigens, presented by major histocompatibility complex (MHC) molecules to T cells 
and capable of eliciting a tumour-specific T cell response. Bruggen et al (1991) identified the 
first tumour antigen from a melanoma patient tissue (MAGE-1) using gene cloning and 
demonstrated that it was capable of inducing a cytolytic response. 
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Figure 1.3: Cooperation between the two tumour-suppressor genes p53 and Rb for the 
regulation of the cell cycle. 
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Since then, many tumour antigens have been identified using a sequencing (HPLC-mass 
spectrometry) or a serological approach (SEREX) described in more details in chapter 5. Five 
major categories were established to classify tumour antigens (Table 1.1): 
 
Table 1.1: Examples of tumour antigens grouped into five categories 
Tumour antigens Tumour expression Healthy tissue 
expression 
Viral antigens 
      EBV 
     HBV 
     HPV 
     HTLV 
Tumour-specific unique antigens 
     Bcr/Abl 
     Ig idiotype 
Abnormally expressed antigens 
     HER-2/neu 
     MUC-1 
     PAP, PSA, PSMA 
     p53 (mutated) 
     p53 (non-mutated) 
     Ras (mutated) 
     WT-1, Proteinase-3 
Differentiation antigens 
     gp100, Mart-1, tyrosinase 
Cancer/testis antigens 
     MAGE-1, -3 and -6 
     BAGE, GAGE, XAGE 
     HAGE, NY-ESO-1 
     RAGE 
 
Burkitt’s and Hodgkin’s lymphoma 
Hepatocellular carcinoma 
Cervical cancer 
T cell leukaemia 
 
CML 
B cell non Hodgkin’s lymphoma 
 
Breast, ovary, lung carcinoma 
Many carcinomas 
Prostate carcinoma 
Breast, colon, other cancers 
Pancreatic, colon, lung cancers 
ALL, AML, CML 
CML, other cancers 
 
Melanoma 
 
Many carcinomas 
Bladder, gastric, other cancers 
Many carcinomas 
Many carcinomas 
 
None 
None 
None 
None 
 
None 
None 
 
Ubiquitous 
Breast 
Prostate 
None 
Ubiquitous 
None 
None 
 
Melanocytes 
 
Testis 
Testis 
Testis 
Retina 
 
_ Viral antigens: The identification of target antigens is conceptually simple when it is linked 
with tumoral transformation induced by viruses, with their molecules being foreign to the 
organism and the T cell receptors adapted to their recognition having no reasons to have been 
deleted and being deprived of auto-reactivity. Epstein-Barr virus (EBV), responsible for 
different types of lymphomas (Burkitt’s lymphoma, nasopharyngeal cancer, Hodgkin’s 
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lymphoma), is a classical example in humans (Murray et al., 1992). In the same fashion, 
human papillomavirus (HPV) is linked with the development of cervical cancers (Feltkamp et 
al., 1993), hepatitis B virus (HBV) with hepatocellular carcinoma (Koziel et al., 1995), and 
human T cell leukaemia virus (HTLV) with adult T cell leukaemia (Koenig et al., 1993). Not 
all of the viral proteins have the same immunotherapeutic interest as some viruses can go in 
latent phase expressing only a limited number of proteins. Also, tumour cells can contain only 
truncated viral genomes, limiting themselves to the expression of transforming genes such as 
E6 and E7 in HPV cases. Several clinical trials targeting viral antigens such as E6 and E7 in 
patients with cervical cancers resulted in encouraging results (Mahdavi and Monk, 2005). 
_ Tumour-specific unique antigens: The structural alteration of proteins involved in a direct or 
indirect fashion to the cell cycle and its control can lead to the transformation of a cell when its 
functional capacity is altered. Genes encoding cell cycle-activating proteins, proto-oncogenes 
or tumour-suppressor genes can potentially express antigenic proteins because of the presence 
of different amino acid sequences in these natural proteins. These modifications can result from 
chromosomal translocations (Bcr/Abl), point mutations or the creation of a chimerical protein 
by gene fusion (β-catenin, Cdk4, Ig idiotype, p53 and k-Ras)(Yang et al., 2006; Ruiz-Godoy et 
al., 2006). Modified peptides can bind to some HLA molecules and can therefore be stimulator 
of both cytotoxic and helper responses. These neo-antigens can have a real therapeutic interest 
if they are found recurrently in a large number of patients as they are often specific of an 
individual tumour or shared between specific histological tumour types. For example, Bcr/Abl 
is a well studied antigen in this group specific of chronic myeloid leukaemia and is 
characterised by an abnormal tyrosine kinase activity. It results from the translocation of 
genetic material between chromosomes 9 and 22 and causes the malignant transformation of 
haematopoietic stem cells (Deininger et al., 2000). Another interesting antigen is the 
immunoglobulin (Ig) idiotype made of unique heavy and light chains and specific of B cell 
lymphoma. Specific Igs are produced by gene fusion during B cell differentiation and could be 
used efficiently as targets (Ruffini et al., 2002). This category is often considered by many as 
being the most interesting because it provides the largest number of immunogenic epitopes. 
_ Abnormally-expressed genes: In a frequent fashion, the tumoral transformation is linked or 
accompanied with the over-expression, without any structural alterations, of proteins involved 
in the control of the cell cycle or in the natural senescent evolution of cells. For example, the 
telomerase enzyme protects the ends of chromosomes by forming DNA/protein complexes to 
prevent the progressive shortening of chromosome extremities during successive cellular 
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divisions (Murnane, 2006). Cells fall eventually in replicative cell senescence due to lack of 
telomerase activity (de-Lange., 2005). However, this enzyme is strongly expressed in most 
tumours. Tumour cells display considerable telomere shortening and other characteristics such 
as extensive chromosome fusion, which ultimately lead to the inability of tumour cells to 
senesce (Romanov et al., 2001). The up-regulation of the proto-oncogene HER-2/neu, coding 
for a membranous molecule involved in the transduction of activation signals, is often 
associated with the development of some adenocarcinoma (Tsiambas et al., 2006). Most of the 
tumour antigens identified till date, such as survivin, p53, Ras, hTERT and WT-1 belong to 
this group, and represent the most challenging aspect. In fact, it is conceivable to use these 
molecules as immunotherapeutic targets because this up-regulation often correlates with an 
over-presentation of the corresponding peptides at the surface of tumour cells via the HLA 
complex. However, there remains a need to design and identify proper peptide targets as they 
can be at the origin of a state of tolerance by clonal deletion, and in the opposite case, to ensure 
the absence of auto-reactivity against the organism. 
_ Differentiation antigens: These normal molecules of the organism are only expressed in 
specific tissues. Tyrosinase, MelanA/Mart1 molecule, gp100 glycoprotein are for example only 
expressed by melanocytes (Romero et al., 2004). In the same way, prostaglandin, prostate acid 
phosphatase (PAP), prostate-specific antigen (PSA) and prostate-specific membrane antigen 
(PSMA) are specific of the prostate tissue (Fong and Small, 2007). It is relatively easy to 
induce a T cell-based response against those proteins. In fact, they are not expressed at the 
thymus level and consequently, tolerance should not be linked to a clonal deletion but to a 
simple state of anergy, which can often be reversed (Engelhard et al., 2002). Inducing a T cell-
based response against these differentiation antigens can eradicate the tumour, but like other 
over-expressed antigens, can also have side-effects with concomitant destruction of the healthy 
tissues expressing the same antigens. The best example is melanoma where tumour regression 
can be accompanied with the destruction of healthy melanocytes and a loss of cutaneous 
pigmentation called vitiligo as observed in some clinical trials (Schreiber et al., 1999; Phan et 
al., 2003). The targeting of a differentiation antigen depends on the acceptable criteria for the 
organism of the destruction of healthy tissues expressing those as well.  
_ Cancer/testis (CT) antigens: In a frequent fashion, the tumoral transformation is accompanied 
with the re-activation of genes normally expressed at the embryonic level but not by healthy 
adult tissues, except testis. Examples are numerous such as the melanoma antigen MAGE, the 
bladder antigen BAGE and the α-fetoprotein over-expressed in some forms of hepatocellular 
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carcinoma. This category is of major interest as the expression of its members is only found in 
either germ cells from normal testis or placenta, or tumour cells. Germ cells are characterised 
by the lack of expression of MHC molecules, making them immuno-privileged. Therefore, 
finding and targeting CT antigens, which are processed and presented at the surface of tumour 
cells by MHC molecules to T lymphocytes, would allow the immune response to be directed 
against the tumour only and would eventually trigger tumour rejection. CT antigens are at the 
moment one of the most studied family in animal models and in clinical trials because of those 
characteristics. Melanoma antigen (MAGE) was the first CT antigen (van der Bruggen et al., 
1991) described of many others later identified such as GAGE, BAGE, LAGE, XAGE, 
semenogelin and NY-ESO-1. The latter is of major interest as it has been found that a humoral 
response against NY-ESO-1 CT antigen is elicited in a wide variety of tumours with high 
frequency, and was described as one of the most immunogenic CT antigen (Scanlan et al., 
2004; Valmori et al., 2005; Zhao et al., 2005; Velasquez and Lipkin, 2007). Helicase antigen 
(HAGE) also belongs to this category of antigens (Martelange et al., 2000).  
 
 1.1.4 Cancer stem cells 
In haematological malignancies and in some solid tumours such as brain, breast, colon, 
pancreas and prostate, there are compelling evidences that a small fraction of the tumour cell 
population is actually composed of cancer stem cells. Contrary to cancer cells, cancer stem 
cells have self renewal and proliferation properties of normal stem cells and are able to 
maintain the tumour mass (Costa et al., 2007). This observation led to the elaboration of new 
theories on how tumour cells survive and expand. In fact, it was thought that the tumour mass 
was composed of a heterogeneous population of cells all able to differentiate and proliferate. 
The new theory proposes that the tumour mass is still composed of a heterogeneous population 
of cells unable to divide and differentiate, and accompanied with a small unit of cancer stem 
cells with stem cell properties at the origin of the bulk of tumour cells suggesting that the 
transplantation of only one cancer stem cell is actually sufficient for the tumour formation 
(Reya et al., 2001).  
Moreover, stem cells are the oldest cells of the organism and it is legitimate to think that they 
are more prone to genetic mutations and epigenetic defects than any other cells. However, it is 
still not clear whether cancer arises from a mutated stem cell or from a downstream progenitor 
(Huang et al., 2007). Fusion of stem cells with cancer cells which have accumulated changes 
has also been suggested to explain the presence of this population of immortalised cells with 
transforming potential (Bjerkvig et al., 2005). Finally, genetic defects in tumour cells might 
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have the differentiation process of the cells rendering the behaviour of these cells very similar 
to the one of stem cell (Costa et al., 2007). 
This model of cancer stem cells would also explain issues of tumour recurrence and even 
metastases due to eventual chemo-resistant residual cancer stem cells in patients (Brabletz et 
al., 2005). Chemotherapy drugs challenge rapidly dividing cells and molecular targets that 
represent the bulk of the tumour but may not affect slowly growing stem cells, which in future 
can repopulate tumours. In theory, the identification of these cancer stem cells and a better 
understanding on how these might develop into cancer cells could provide new therapeutic 
targets to prevent tumour relapses. Interestingly, it was reported that some CT antigens are also 
expressed in human mesenchymal stem cells of the bone marrow. This indicates that CT 
antigens are not only a hallmark in gametogenesis but also in stem cells (Cronwright et al., 
2005). Because CT antigens are not expressed in normal non-stem cells, it is conceivable to 
think CT antigen expression found in tumours is actually coming from cancer cells with stem 
cell properties. Therefore, targeting these antigens by chemotherapy and/or immunotherapy 
could eventually improve considerably the treatment of cancer but further research will be 
needed to confirm the validity of the cancer stem cell model and provide efficient therapies.  
 
 1.1.5 Current treatments and their limitations 
Cancer can be treated by four approaches: surgery, radiotherapy, chemotherapy and hormonal 
therapy. Surgery, although radical, is by far the most effective treatment for single tumours but 
could prove useless or barely palliative if the cancer has metastasised to distant sites. Surgery 
can therefore be used in combination with chemotherapy and/or radiotherapy. Chemotherapy 
and radiotherapy both target rapidly dividing tumour cells. Chemotherapy relies on the 
administration of cytotoxic drugs that inhibit cell proliferation and ultimately lead to cell death 
while radiotherapy is based on the fragility of cancer cells and their inability to repair DNA 
damages brought on by the radiations. Unfortunately, other cells are also able to proliferate 
intensely and are affected by these two treatments. This leads to the appearance of severe side-
effects often overcoming the benefits of these treatments on tumour cells. Moreover, 
chemotherapy and radiotherapy are only effective when tumour cells are largely oxygenated 
and thus making badly perfused or hypoxic tumour cells able to proliferate. It can also be 
mentioned that, under certain circumstances, chemotherapy and radiotherapy can trigger 
adverse effects and promote tumour progression rather tumour regression (Kim and Tannock, 
2005). Finally, hormonal deprivation can be considered as tumours often rely on the supply of 
hormones, such as testosterone in prostate cancers, to grow. However, tumour cells often 
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develop mechanisms of resistance rendering the treatment unsuitable. In summary, cancer 
therapy requires the development of new treatment modalities allowing prolonged survival of 
the patients and improvements of life conditions by reducing cytotoxicity and increasing 
specificity. Immunotherapy can therefore be envisaged as a new pathway as the activation of 
immune cells to fight cancer cells can be directed and controlled to avoid side-effects. 
 
1.2 Anti-cancer immunity 
The concept of immune surveillance was introduced in the seventies by Macfarlane Burnet and 
Lewis Thomas (Burnet et al., 1970), but was suggested much earlier by Erhlich in 1909. This is 
based on the hypothesis that the immune system, because of its capacity to recognise tumour 
cells, could interact to prevent the apparition of tumours or at least limit their growth. Since 
then, several proofs have been accumulated to prove this concept. In humans, both CD4+ and 
CD8+ tumour-antigen-specific lymphocytes have been found in the bloodstream, in lymph 
nodes or infiltrating tumours of diverse origins (Jager et al., 2000)(Zeng et al., 2001). In the 
same way, natural killer (NK, NKT) cells are attracted by stress molecules secreted by tumour 
cells and recruited to destroy the latter (Bauer et al., 1999). In the last twenty years, tumour 
immunology has known considerable advances in the field of cytokines, receptors and their 
respective ligands directing lymphocyte activation, antigen processing and presentation, 
lymphocyte migration and molecular bases of tumour recognition by the immune system. 
Moreover, a large number of tumour antigens as well as some epitopes derived from these 
tumour antigens have been identified and constitute as many potential targets for cancer 
immunotherapy. However, despite these discoveries, cancer vaccination did not always lead to 
success as the tumour system can display means of counteracting the action of the host immune 
system. Nowadays and because of the increase in knowledge of tumours and tumour 
immunotherapy, researchers are moving towards a more specific and more adapted anti-tumour 
immunity. 
 
 1.2.1 Innate immunity and cancer 
Innate immunity is often referred to as the “non-specific” arm of the immune system. It is 
constitutively present and does not require immunological memory. Its primary role is to 
protect the organism by rapidly destroying any foreign pathogens that the body encounters on a 
day-to-day basis. This response is ensured by several effectors among which the most 
important are NK and NKT cells, both originating from lymphoid progenitor cells, and 
phagocytic cells such as macrophages and dendritic cells (DC) originating from myeloid 
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progenitor cells. These mediators of the innate immune system recognise pathogens through 
surface receptors, which are able to bind non-specifically a wide variety of ligands. This 
system was then described as the “pattern-recognition specific” system with receptors able to 
recognise conserved surface molecules specific for certain bacteria, viruses and other micro-
organisms (Janeway et al., 1991). Once recognition has taken place, cells of the innate immune 
system can engulf the pathogens by the process of phagocytosis, lyse the foreign bodies 
following the release of complement molecules, or finally activate the adaptive immune system 
via the use of antigen-presenting cells (APC). The response to external threat is rapid without 
the delays occasioned by clonal expansion (Adam et al., 2003). The differentiation between 
pathogen and host is mediated by, among others, members of the Toll-like receptor (TLR) 
family. So far, ten members of this family have been identified in mouse and humans and were 
found to be expressed by phagocytic cells, mostly macrophages and DC. They are able to 
recognise a plethora of ligands belonging to most pathogens such as lipoproteins and 
peptidoglycans (TLR2), double stranded RNA (TLR3), lipopolysaccharide (TLR4), flagellin 
(TLR5), and unmethylated CpG DNA motifs (TLR9)(Beutler et al., 2003). Immune cells of the 
innate system are stimulated by the activation of TLR and are responsible for the release of 
cytokines and chemokines, but also for the induction of the expression of co-stimulatory 
molecules by APC, critical for engaging the adaptive immune response. Antigen-presenting 
cells are indeed very important as they act as a link between the innate and the adaptive 
immune system and allow the development of a long-lasting and potent protection mediated by 
lymphocytes.  
Innate immune system is known to provide the first defence against infectious agents and is 
capable of initiating the adaptive immune system. It is now believed that it also plays the same 
role of immunoediting when cancer cells are involved. Effector cells of the innate system, 
present on the tumour site, are capable of sensing the tumour development and alert the 
immune system to its presence. It is not entirely clear how these effector cells realise the 
existence of a tumour cell but it is thought that uric acid released by damaged cells (Shi et al., 
2003) or simply the intrinsic biology of the tumour (Seong and Matzinger, 2004) are sufficient 
to provide the “danger signal” required by the innate system. A pro-inflammatory response can 
then follow the reception of this danger signal and the presence of TLR ligands such as heat 
shock proteins (HSP) on the tumour site allows the activation of DC and macrophages 
expressing TLR, consequently making the link with the adaptive immune system (Dunn et al., 
2004; Napolitani et al., 2005). Tumour cells are also able to produce a different type of danger 
signals, which allows the recruitment of other cells of the innate immune system. As mentioned 
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earlier, some tumours can develop in an oxygen-free environment leading to the expression of 
specific molecules, such as MHC class I chain-related proteins A and B (MICA/B) and UL16-
binding proteins, normally absent from tumours developing in non-hypoxic conditions 
(Papamichail et al., 2004). These ligands, present at the surface of tumour cells, can bind 
receptors found at the surface of NK and NKT cells called NK cell activating receptor or 
NKG2D, and activate the latter. In return, NK cells secrete interferon-γ (IFNγ), which is an 
important cytokine not only capable of directly killing tumour cells by blocking angiogenesis 
and reducing the metastatic potential of the tumour, but also by inducing the secretion of 
chemokines by tumour cells and surrounding healthy cells to attract lymphocytes, and acting 
on DC and macrophages to induce maturation and secretion of Interleukin (IL)-12 by these two 
cells for the activation of the adaptive immune response and more specifically cytotoxic T 
lymphocytes (CTL)(Degli-Esposti and Smyth, 2005)(Fig1.4). Moreover, molecules present at 
the surface of NK cells called killer inhibitory receptors (KIR) and C-type lectin-like receptors 
can specifically recognise and bind MHC class I molecules, hence inhibiting their tumoricidal 
action (Moretta et al., 1996). This system allows the maintenance of self-tolerance towards the 
normal cells of the organism, with most of them expressing MHC class I molecules. In an 
attempt to avoid recognition by cytotoxic T cells, tumour cells can down-regulate the 
expression of MHC class I molecules (Restiflo et al., 1993). This leads at the same time to the 
suppression of NK cell inhibition by KIR, causing these cells to be more sensitive to NK cell-
mediated lysis operating through the secretion of perforins and other reactive oxygen and 
nitrogen species. On the other hand, the role of NKT cells against tumour development is still 
unclear and controversial. This population of cells has characteristics of both NK and T cells 
and is secreting large quantities of cytokines, mainly IL-13, but research has shown that they 
can have both negative and positive effects on the immune system and the actual tumour, 
respectively (Terabe et al., 2000; Godfrey et al., 2000).  
The depletion of NK and NKT cells in mice indicated a higher susceptibility to chemically-
induced tumours (Dunn et al., 2004). More and more evidences are accumulated showing that 
these two populations of cells and especially the crosstalk between them and DC are crucial for 
an immune response, both innate and adaptive, against cancer to take place (Smyth et al., 
2005). B lymphocytes, macrophages and DC are the three most interesting subsets of cells 
involved in antigen capture, processing and presentation via MHC molecules to cells of the 
adaptive immune system in order to initiate a specific immune response against this antigen. 
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Figure 1.4: Impact of crosstalk between dendritic cells and natural killer cells on immunity 
to tumours. Crosstalk between DC and NK cells operates via the secretion of cytokines such as 
IFNα, IFNβ, IFNγ and IL-2. Secretion of IFNγ by NK cells acts on DC and macrophages to 
induce maturation and the secretion of IL-12 by these two APC. In turn IL-12 acts as an 
important mediator of the adaptive immune response. Moreover, NK cells once activated are 
capable of directly killing tumour cells that do not express inhibitory MHC class I through the 
secretion of perforins and reactive oxygen and nitrogen species (Taken from Degli-Esposti and 
Smyth, 2005). 
 
Impaired angiogenesis and 
reduced metastatic 
capacity of tumour 
DC
NK 
IFNγ 
IFNα, IFNβ, IL-2 
 
 
 
CTL 
IL-12 
Apoptotic 
tumour cell 
IFNγ 
Perforin 
IFNγ 
Perforin 
IFNγ 
 
HSP gp96 
MHC 
class Ilow 
RAE1 or 
H60 
NKG2D 
DC
Tumour cell 
NK cell inhibitory 
receptor 
   32 
However, it is generally admitted that although B cells and macrophages are efficient APC, DC 
are the most potent and important APC in the body, situated at the crossroad between innate 
and adaptive immune system. DC are capable of rapidly engulfing the antigen at its entry in the 
system, processing and presenting it to T cells together with the help of co-stimulatory 
molecules (Adam et al., 2005). It is for this reason that DC are nowadays one of the most talk-
about subjects in the research evolving around the study of the immune response and on how 
they could be used efficiently to treat infections but most of all cancer. 
As described earlier, the innate immune system initiates the anti-tumour response, resulting in 
the attraction of DC which phagocytose the tumour cell debris and apoptotic cell fragments 
ensuing from the destruction started by the innate mediators. Because of this ability and their 
natural morphology, DC are described as “the sentinels” of the immune system (Rafiq et al., 
2002). They originate from the bone marrow, travel through the blood and are seeded into non-
lymphoid tissues. These “immature” or “pre-conditioned” DC can engulf and process large 
quantities of antigens from cancer cells but have strong difficulties in activating T cells because 
of low expression levels of major histocompatibility complex (MHC) antigens and co-
stimulatory molecules (Gallucci et al., 1999). Following internalisation and processing, DC 
migrate via the bloodstream and afferent lymph to secondary lymph nodes and go through 
different stages of maturation by up-regulating MHC class I and class II molecules and co-
stimulatory molecules such as CD40 and B7. In the lymph nodes, they interact with T helper 
cells and CTL in the presence of cytokines such as IFNα in a mechanism called cross-
presentation. Co-stimulatory molecules bind to their ligands present on the surface of T cells 
(e.g.: CD40L and CD28, respectively) allowing co-conditioning of both DC and T cells (Ridge 
et al., 1998). Dendritic cells release several other cytokines such as TNFα, IL-1β and IL-12 
and become potent activators of T cell-based responses via antigen processing and antigen 
presentation on the surface in the context of MHC molecules (Girolomoni and Ricciardi-
Castagnoli, 1997). This area will be discussed in further details later on in Section 1.2.2.2. 
  
 1.2.2 Adaptive immunity 
The immune system protects the organism from non-self agents using proteins and cells that 
circulate the body. As described earlier, this mechanism starts with the innate response and 
ends with the adaptive system. The latter is mediated by the humoral response involving B 
cells and antibodies, and/or the cellular response relying mainly on the action of CD4+ T 
helper and CD8+ cytotoxic T cells. Because of the abnormal pattern of expression of 
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oncogenes, tumour-suppressor genes and TAA, a tumour cell can be used as a target for the 
adaptive immune system and although both B and T cell responses can have a critical role for 
the elimination of cancer cells, it is generally thought that the action of CD4+ and CD8+ T 
cells is the key factor for an efficient immune response against tumours bearing these antigens. 
   
  1.2.2.1 Humoral response and cancer 
B lymphocytes are responsible for the humoral response. Upon DC activation, a Th2 response 
can be elicited allowing the mounting of a B cell-based response, ultimately leading to B cell 
proliferation and differentiation into memory B cells and antibody-secreting plasma cells. 
However, in spite of this specific function, they can also internalise, process and present 
antigens to T lymphocytes. The latter become active and start secreting cytokines ensuring the 
development and the regulation of the humoral response (differentiation into plasma cells and 
isotypic commutation of antibodies). Several TAA have been identified through serological 
analysis of recombinant cDNA expression (SEREX) indicating that the humoral immune 
system is fully capable of eliciting an antibody response against tumours. The role of B 
lymphocytes in the anti-tumour response is still controversial. Indeed, it has been demonstrated 
that the adoptive transfer of B cells in T and B cell-depleted HPV16 mice was leading to the 
reinstatement of all the parameters required for full malignancy, that is to say, chronic 
inflammation, angiogenesis and tumour cell proliferation (de Visser et al., 2005). This result is 
in agreement with the observation that a strict Th2 response is detrimental to the anti-tumour 
response. Tumours might escape the action of CTL by down-regulating the expression of MHC 
class I molecules and orientate the adaptive immune system towards a humoral response more 
beneficial to their development. On the other hand, several monoclonal antibodies are 
nowadays available to treat certain forms of cancer with success indicating that antibodies are 
efficient anti-tumour agents, on their own or together with a Th1 response (Pegram et al., 1998; 
Plunkett and Miles, 2002). In conclusion, it seems that the balance between Th1 and Th2 
responses, as well as the presence of all the actors of the adaptive immune system (CD4+, 
CD8+ and B cells) are actually crucial to promote tumour rejection (Kao et al., 2006).  
 
  1.2.2.2 Cellular response and cancer 
The cellular response, with the help of APC from the innate system, relies on three subsets of T 
lymphocytes:  
_Cytotoxic T lymphocytes or CD8+ T cells recognise infected or transformed cells such as 
tumour cells and eliminate them. 
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_T helper 1 lymphocytes or CD4+ Th1 cells exchange information with antigen-presenting 
cells and play a crucial role in the activation of CTL. 
_T helper 2 cells or CD4+ Th2 cells, as mentioned above, mediate the development of B cells. 
Briefly, DC are attracted to the tumour site where they phagocyte tumour cell debris and 
apoptotic cell fragments ensured by the mediators of the innate response. Upon endocytosis of 
tumour material, DC migrate to the lymph nodes where they will meet and interact with CD4+ 
Th1 cells and CD8+ T cells. These three subsets of cells form a trivalent complex that results 
in the maturation of DC through cytokine and cell-surface receptor interactions between CD4+ 
T cells and DC, which in turn allows communications between CD8+ T cells and DC leading 
to the differentiation of CD8+ T cells into CTL. After activation, CTL and T helper cells can 
migrate back to the tumour site where they exert their antigen-specific killing of any tumour 
cells presenting the antigen against which they were pre-conditioned through the secretion of 
cytotoxic granules or by stimulating “death-receptors” expressed by tumour cells. This model 
of adaptive immune response is a simplified version of the reality. Many cytokines, such as IL-
2, IFNγ, IL-12 and IL-18 are also involved in this process but this does not stop the tumour to 
grow indicating that the system is not infallible, probably because of the tumour’s ability to 
escape recognition by avoiding the induction of “danger signals” whilst the tumour is relatively 
small and developing, or inducing a state of immune tolerance towards itself and an 
immunoselection of the tumour cells that can escape due to their genetic instability and are free 
to expand in an uncontrolled state. This system, although not perfect, underlines the crucial 
role of the TCR genes rearrangement during T cell differentiation and clonal expansion, the 
processing and the presentation of tumour-derived peptides by MHC molecules, and finally the 
interaction between the MHC molecules presenting antigenic tumour-derived peptides to the 
TCR of CD4+ and CD8+ T cells. 
   
  (a) Major histocompatibility complex and its polymorphisms 
Specific membranous molecules called major histocompatibility complex (MHC) antigens 
allow the immune system to do the discrimination between self, modified self and non-self 
antigens. Firstly discovered on human leukocytes as a result of their effects on transplantations, 
major histocompatibility complex (MHC) antigens are also termed HLA for human leukocyte 
antigens (McDevitt., 2000; Shiina et al., 2004). MHC molecules are proteins encoded by a 
group of genes situated in a specific region of chromosome 6 in humans and the equivalent H2 
genes on chromosome 17 in mice. In these regions, a certain number of loci encode proteins 
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exerting immunological functions very tightly linked to histocompatibility molecules and 
involved in the formation of MHC: peptide complexes. Indeed, these genes favour the 
processing (LMP2, LMP7), the transporting (TAP1, TAP2) to the endoplasmic reticulum (ER), 
or the loading (tapasin) of the antigenic peptides onto MHC class I and class II molecules. 
Genes coding for MHC molecules are grouped in 6 principal loci (A, B, C, DP, DQ and DR) 
including for each one a high number of alleles (Fig. 1.5). For each of these 6 genes, each 
person inherits 2 alleles, one from each parent. Because millions of combinations are possible, 
it is unlikely for two persons to have identical MHC molecules, except homozygous twins. 
Furthermore, this diversity provides the organism and the T cells with a plethora of antigenic 
peptides (Reche and Reinherz, 2003).  
These epitopes are presented on MHC molecules to the TCR of T lymphocytes (Neefjes and 
Momburg, 1993). T cell receptors are composed of two functional subunit clusters, α/β and γ, δ, 
ε, ζ, which shares the roles of antigen recognition and signal transduction, respectively. The α 
and β subunits have the property to interact with antigenic peptides loaded onto MHC class I 
and class II molecules. α and β proteins are each formed of a variable region (Vα and 
Vβ, V domain) connected by a short segment to a constant region (Cα and Cβ, C domain) 
having a refolding very similar to immunoglobulins (Ig). Vα and Vβ regions are encoded by a 
high number of genetic segments (V, D and J), which are juxtaposed through a series of site-
specific DNA recombinations during the development of T cells to create a large diversity of 
binding sites. TCR binding to the appropriate MHC: peptide complex in conjunction with 
either CD4 or CD8 binding (MHC class II and class I binding, respectively) allows the 
activation of the TCR intra-cellular domain. 
The γ, δ, ε and ζ subunits, like α/β, are transmembranous proteins but with very distinct 
structures from α/β. γ, δ and ε subunits form the multimeric CD3 complex. They have an extra-
cellular domain similar to Ig and an intra-cellular domain each carrying conserved repeated 
sequences called immunoreceptor tyrosine-based activations motifs (ITAM). These ITAM are 
essential to the signal transduction and the high number of motifs is an indication of the 
capacity to quantitatively and qualitatively regulate the signalling (Fig. 1.6). 
This signalling, in cooperation with co-stimulatory molecules such as CD28 and CD40, 
triggers a cascade of reactions allowing full T cell activation. In summary, the quality of the 
MHC-peptide-TCR interaction is crucial to ensure a proper antigen presentation and a strong T 
cell activation (Saito and Yamasaki, 2003).  
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Figure 1.5: Distribution of MHC genes in humans (Adapted from 
pathmicro.med.sc.edu/ghaffar/mhc2000.htm). 
 
 
Figure 1.6: Schematic representation of TCR structure. The TCR is composed of two chains 
(α and β), themselves constituted of one variable (V) and one constant (C) region each. The 
multimeric CD3 complex is formed by the γ, δ, ε and ξ subunits. ITAM, responsible for the 
signal transduction, are represented by rectangles in the intra-cellular domain. 
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MHC glycoproteins are grouped in two classes of MHC class I and MHC class II molecules: 
_Genes coding for MHC class I molecules are divided into three loci: HLA-A, -B and –C. Each 
of these loci has a high number of alleles; 649 alleles for the A locus, 1029 for B and 350 for C 
have been identified (www.anthonynolan.com/HIG). It is also worth mentioning that, 
depending on the population of origin, each of these alleles has a different frequency (e.g.: 19% 
and 30% of the african and caucasian populations are HLA-A2-positive, 
respectively)(www.ashi-hla.org). Encoded molecules are membrane-spanning glycoproteins 
formed by an integral protein of 45kDa and presenting three external domains, α1, α2 and α3. 
The latter is sustained non-covalently by a globular protein of 12kDa encoded by a gene on 
chromosome 15 and termed β2-microglobulin, which is essential to the structure, the activity 
and the expression of class I antigens (Fig. 1.7a). The specific way that the α1 and α2 domain 
conform generates the peptide-binding cleft. It is generally admitted that peptides binding to 
this groove are of 8-11 amino acids in length (Bjorkman et al., 1987; McDevitt., 2000). MHC 
class I molecules are found in lymphoid tissues and on nucleated cells, even though some 
tissues such as thymic epithelia, hepatocytes, kidney or brain can show relatively low levels. 
Their function is to present peptides of predominantly intra-cellular origin to CD8+ T cells. 
Peptides recognised as a threat by CD8+ T cells, such as bacteria- or virus-derived, will lead to 
the elimination of the infected cells (Adam et al., 2003). 
_Genes coding for MHC class II molecules are divided into three loci: HLA-DP, -DQ and –
DR, each of them having several alleles. Like MHC class I alleles, the frequency of each of 
these MHC class II alleles in a determined population is variable (e.g.: 10% and 17% of the 
caucasian population are HLA-DR1- and HLA-DR4-positive, respectively)(www.ashi-hla.org). 
Encoded membrane-spanning glycoproteins are heterodimers formed by two non-covalently 
linked chains (α and β) of 33kDa and 28kDa, respectively, each of them containing two 
external domains (α1/α2 and β1/β2)(Fig. 1.7b). Furthermore, there are variations in the MHC 
repertoire with the production of multiple types of α and β chains for each type of MHC class 
II molecules. There are five α chains (1 DRα, 2 DPα and 2 DQα) and eight β chains (3 to 4 
DRβ, 2 DPβ and 2 DQβ) (Campbell and Trowsdale, 1993).  
A high number of combinations of α and β chains and consequently a huge number of binding 
peptides are therefore available to propose a strong immune protection, providing that the 
individual is heterozygous (Lipsitch et al., 2003). Unlike the binding groove of MHC class I 
molecules, α1 and β1 form a peptide-binding cleft with an opened structure allowing the 
binding of longer peptides (13-18 amino acids in length)(Rudensky et al., 1991). 
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Figure 1.7: Structure of MHC class I and class II molecules. a) Top: Class I MHC with a 
membrane-spanning integral protein with three external domains (α1, α2 and α3) associated 
with β2-microglobulin. Bottom: crystallography representing a MHC class I molecule (α 
chain: dark blue, β2-microglobulin: light blue) presenting an antigenic peptide (white) to a 
TCR (α and β chains: yellow and green, respectively)(Taken from pathmicro.med.sc.edu); b) 
Top: Class II MHC made of two transmembranous chains (α and β) with two external domains 
for each of them (respectively α1, α2 and β1, β2). Bottom: crystallography representing a 
MHC class II molecule (α chain: green, β chain: red) presenting an antigenic peptide (white) 
to a TCR (α and β chains: yellow and blue, respectively)(Taken from www.usm.maine.edu). 
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MHC class II expression is found on the surface of professional APC (DC, B cells and 
macrophages), in lymphoid tissues and can be induced with TNFα or interferons in other 
nucleated cells (Schartner et al., 2005). Their function is to present peptides of pre-dominantly 
extra-cellular origin to CD4+ T cells, which orchestrate the adaptive immune response as 
CD4+ T cells are critical for the activation of other cells and the generation of a long-lasting 
memory CTL response (reviewed by Assudani et al., 2007). 
Disparities in MHC molecules between patients and donors are the main reasons for graft 
failures and graft-versus-host diseases. The discovery of minor histocompatibility antigens 
complicated this understanding as they were reported to account for similar consequences in 
HLA-matched transplantation procedures such as allogeneic bone marrow (Goulmy, 1996) or 
stem cell (Falkenburg et al., 2003) transplantations between MHC-identical individuals. 
However, minor antigens, such as HA-1 and HA-2, could be interesting targets for cancer 
immunotherapy as they were shown to be responsible for a graft-versus-leukaemia effect in 
leukaemia patients (Hambach and Goulmy, 2005) providing that the right signals are emitted 
with adapted CD4+ T cell help and lack of inhibition from NKG2/CD94 engagement 
(Robertson et al., 2007). 
 
(b) Antigen processing and presentation 
As described previously, the adaptive immune response relies on the activation of CD4+ and 
CD8+ T cells following the binding of their TCR to antigenic peptides presented by MHC class 
II and class I molecules, respectively. These T cell epitopes derived from the target protein are 
usually between 8 and 18 amino acids in length depending on whether they are restricted to 
MHC class I or class II molecules. For a peptide to be presented in this context, the protein 
must undergo a cascade of reactions that will ultimately lead to their transport and cleavage of 
this peptide. These reactions differ according to the origin of the proteins. Indeed, endogenous 
proteins follow pre-dominantly the MHC class I pathway, while exogenous proteins undergo 
pre-dominantly the MHC class II pathway. 
 
(i) MHC class I processing: The proteolysis of endogenous proteins into antigenic 
determinants takes place within the cytoplasm and is mediated mainly by a multi-catalytic 
complex called the proteasome and other peptidases (Kloetzel and Ossendorp, 2003). Most of 
the proteins synthesised by the cell that are no longer required, damaged or “foreign” are 
eliminated by the proteasome following poly-ubiquitinylation, which allows the unfolding of 
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the protein and acts as a signal for their degradation (Jariel-Encontre et al., 1995). These 
peptides are then propelled in an ATP-dependent manner into the ER lumen using the 
heterodimeric transporter-associated with antigen processing (TAP), consisting of two subunits 
TAP1 and TAP2 and encoded by genes within the MHC (Ortmann et al., 1997). The α chain 
and β2-microglobulin of MHC class I molecules are assembled within the ER lumen with the 
help of three chaperones called calreticulin, calnexin and ERp57 (Neefjes and Momburg, 1993; 
Williams and Watts, 1995). A fourth chaperone, tapasin, allows the translocation of peptides to 
the MHC class I binding groove and prevents the degradation of class I - β2-microglobulin 
dimers (Reits et al., 2000). MHC class I molecules are stabilised through the process of peptide 
binding and the complex is finally transported from the ER lumen to the Golgi apparatus 
before finally reaching the cytoplasmic membrane using a Golgi vesicle to present the peptides 
to the TCR of CD8+ T cells (Fig. 1.8). The cell provides a continuous exposition of a sample 
of its peptidic content. A fragment, from an abnormal or intruder protein presented by a MHC 
class I molecule, induces an immune response by reacting with cytotoxic CD8+ lymphocytes 
and ensuring a true immune surveillance that eliminate cells presenting foreign antigenic 
determinants.  
 
(ii) MHC class II processing: Extra-cellular antigens that are endocytosed by APC via 
phagocytosis result in antigens being presented in the context of MHC class II for CD4 
recognition. Engulfed proteins enter the endocytic pathway, where they will be degraded. 
Endosomes become more acidic as they mature and finally fuse with lysozymes allowing the 
degradation of the antigens by acid proteases, reductases and unfoldases activated in the low 
pH environment. Members of the acid proteases include the cathepsins B, D, S and L 
(Janeway., 2001). Like MHC class I, the α and β chain are assembled in the ER lumen to form 
the αβ heterodimer. At this stage, a third chain associates to the heterodimer to form a 
heterotrimer. This chain is known as the invariant chain (Ii), prevents the binding of any 
polypeptides present in the ER lumen and is thought to be important for the trafficking of the 
class II molecules to the endosomal compartments (Bikoff et al., 1993). The endosomal 
vesicles containing the MHC class II molecules fuse with the ones containing the antigenic 
peptides. In this new compartment, Ii is cleaved by cathepsin L or S and the class II-associated 
invariant peptide (CLIP) is left inside the MHC class II groove (Bennet et al., 1992). CLIP is 
finally exchanged for an antigenic peptide with the help of MHC-like molecules known as 
HLA-DM and HLA-DO. These molecules are involved in the process called peptide editing,  
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Figure 1.8: MHC class I and class II processing. On the left hand side: endogenous pathway 
showing digestion of the cytosolic antigenic protein by the proteasome, integration in the 
endoplasmic reticulum of antigenic peptides by TAP, binding of these peptides to MHC class I 
molecules and presentation at the cell surface to CD8+ T-lymphocytes. On the right hand side: 
exogenous pathway detailing the proteolysis of an exogenous antigen in endocytic 
compartments, the incorporation of the resulting antigenic peptides in the MHC class II groove 
instead of CLIP and the presentation at the cell surface to B- and CD4+ T cells (Taken from 
Neefjes and Momburg, 1993).    
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which is based on the stabilisation of the MHC class II: peptide complex and the continuous 
exchange of antigenic peptides until the higher affinity between the two molecules is found. 
Upon stabilisation, the complex is finally transported to the plasma membrane to present the 
peptide to the TCR of CD4+ T cells (Fig. 1.8). Interestingly and although the endocytic 
pathway and exogenous proteins remain the major providers of peptides to class II molecules, 
endogenous antigens can also enter the MHC class II pathway and elicit a T helper response. 
Indeed, it was shown that the generation of MHC class II-restricted endogenously synthesised 
epitopes is independent of the proteasome and the TAP complexes, and might overlap with the 
classical endosomal pathway for presentation of exogenously synthesised peptides 
(Dissanayake et al., 2005). This is an important factor when considering the antigen-specific 
recognition of class II positive tumour cells by CD4+ T cells. 
 
(c) The pivotal role of CD4+ T cells in anti-tumour immunity 
Over the past two decades, most of the tumour immunotherapy research has focused on 
developing a way to stimulate CD8+ T cells as they can exert specific cytotoxicity against 
tumour cells. However, more and more evidence has accumulated showing the importance of a 
CD4+ T cell help in anti-tumour immunity. CD4+ T lymphocytes act upon recognition by their 
TCR of antigenic peptides presented in the context of MHC class II. These peptides come from 
tumour-derived proteins that have been either endogenously processed by the tumour itself or 
by mature APC that have ingested and digested exogenous tumour-derived proteins. The 
recognition of antigenic peptides occurs through the TCR and is assisted by a new accessory 
protein, the CD4 molecule, which binds to the proximal domains of the α and β chains of the 
MHC class II molecules. This cell population is specialised in the production of cytokines (e.g.: 
IFNγ, IL-2, -4, -5, -6, -10, -12 or -13), which stimulate or regulate the activation of CD8+ 
cytotoxic T cells or B lymphocytes. Therefore, CD4+ T cells are essential for the development 
of strong effector responses, orientating the immune system according to the produced 
cytokine profile towards a cytolytic response (cellular differentiation of Th1 CD4+ T cells, 
IFNγ, IL-2 and -12 production), or a production of antibodies by differentiated B lymphocytes 
(cellular differentiation of Th2 CD4+ T cells, IL-4, -5, -6, -10 and -13 production).  
CD4+ T lymphocytes can therefore regulate virtually all antigen-specific immune responses. 
Indeed, the Th1 subset can be characterised by the secretion of IL-2 required for the 
proliferation of cytotoxic T cells, and IFNγ, which can have many effects such as the up-
regulation of the immunoproteasome and MHC class I and class II molecules in both APC and 
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tumour cells resulting in increase presentation for the CTL. On the other hand, the Th2 subset 
of CD4+ T cell population can facilitate the uptake of antigens by promoting the generation of 
antibodies. Antibodies may bind to tumour antigens and other apoptotic bodies and assist to 
their opsonisation via the binding of the Fc fragment of antibodies to the Fc receptors present 
on the surface of APC, which ultimately leads to cross-presentation. However, the involvement 
of antibodies in the anti-tumour response remains unclear. Moreover, Th2 cells are often 
associated with tumour growth by both facilitating angiogenesis and inhibiting cellular 
responses and although Th2 cells have also been linked with tumour-infiltrating granulocytes 
such as eosinophils, which exert an anti-tumour cytotoxicity (Ellyard et al., 2007), it is 
generally believed that the modulation of the balance between the two subsets is more 
important for the elimination of cancer cells than one subset or the other on its own, and is 
required to generate the appropriate response against an altered self threat (Tanaka et al., 2000).  
Also, a sub-population of CD4+CD25+ T cells, also called T regulatory cells (Treg), with an 
immunosuppressive activity and an involvement in peripheral tolerance mechanisms was 
identified (Thornton and Shevach, 1998). T regulatory cells can occur either naturally 
following selection in the thymus as an anti-self repertoire or induced in the periphery with the 
expression of the CD25 marker upon the action of immunosuppressive cytokines such as IL-10, 
TGFβ (Von Boehmer H, 2005) or more controversially IL-2 secreted by Th1 cells in the 
tumour environment (Antony et al., 2006). These antigen-specific cells can decrease the anti-
tumoral response by altering the ability of APC to activate CD4+ and CD8+ T cells. Their 
mechanism of suppression is not yet fully understood but evidence of their involvement in the 
anti-tumour response accumulate and imply a careful study to find a balance between 
maintenance of tissue integrity by avoiding autoimmune response to take place and induction 
of a potent tumour-specific immune response allowing successful tumour regression (Assudani 
et al., 2006).  
The majority of the help provided by CD4+ T cells comes from the Th1 subset of CD4+ T 
lymphocytes, which interacts with professional APC to induce a strong CTL response 
(Assudani et al., 2007). This CTL “licensing” by Th1 cells can be summed up in three 
consecutive steps. First, CD4+ T cells interact with pre-conditioned DC through the CD40 
pathway and take part in the maturation of both cell types (O’Sullivan and Thomas, 2003). 
This pathway and more specifically the levels of CD40 were shown to correlate with the 
efficacy of the anti-tumour response. Indeed, the higher level, the higher chances are for the 
tumour to regress underlining the critical role of Th1 cells (Murugaiyan et al., 2007). At this 
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stage, mature and conditioned DC can activate naive CD8+ T cells on their own (Ridge et al., 
1998). Secondly, mature DC process and present high quantities of peptides in the context of 
MHC class I and class II molecules to both CD8+ and CD4+ T cells, respectively. Following 
formation of a trivalent complex between DC, CD4+ and CD8+ T cells and upon antigenic 
recognition by the TCR, Th1 cells allows the long-lasting persistence of CTL and the 
generation of memory CD8+ T cells (Smith et al., 2004; van Mierlo et al., 2004). Indeed, it 
seems that cognate recognition of the same antigen on the same DC by CD4+ and CD8+ T 
cells is the best way to generate an efficient CTL response composed of long-lasting effector 
CTL and CD8+ T cells with a memory phenotype that can be readily re-activated upon re-
exposure to the antigen. More recently, it was demonstrated that CD4+ Th1 cells can acquire 
MHC class I: peptide complexes from DC and directly present them to CD8+ T cells for their 
activation (Xiang et al., 2005). Finally, Th1 have been shown to be crucial for the re-activation 
of memory CD8+ T cells (Gao et al., 2002). This model of CD4+ T cell help varies from one 
study to another depending on the model and the nature of the antigen used. Indeed, a pathogen 
may lead to the immediate activation of CD8+ T cells without extemporaneous conditioning of 
DC because of the danger signals it brings, while the chronic state of cancer may require a 
primary signal through CD40-CD40L ligation to induce an anti-tumour immune response. That 
is why, CD4+ T cell help remains a subject of research and a source of controversy.  
Apart from providing a strong long-lasting CTL response, CD4+ Th1 cells can also mediate 
tumour regression on their own (Daniel et al., 2005). Indeed, some CD4+ T cells are capable of 
directly recognising antigenic peptides presented by MHC class II molecules on the surface of 
tumour cells and exerting cytotoxic activity. A number of mechanisms have been proposed to 
explain this phenomenon. Upon antigen recognition, Th1 cells can secrete TNFα (Tite et al., 
1990). They can mediate tumour cell apoptosis by engaging Fas ligand (FasL) (Schattner et al., 
1996; Bagot et al., 1998; Echchakir et al., 2000; Dicker et al., 2005) or TNF-related apoptosis-
inducing ligands (TRAIL)(Thomas and Hersey, 1998; Dicker et al., 2005) with their respective 
receptors present on the surface of target cells. Like CD8+ T cells, some Th1 cells were shown 
to be capable of excreting granzymes and perforins to destroy tumour cells (Echchakir et al., 
2000; Dorothee et al., 2002). Finally, secretion of IFNγ by CD4+ T cells was also proven to 
have pro-apoptotic and anti-proliferative effects on tumour cells through the activation of 
macrophages, the release of reactive oxygen and nitrogen species by the latter, and the 
secretion of IL-12 by the macrophages, which appears to induce apoptosis when they are 
directly in contact with the tumour cells (Tsung et al., 1997; Tsung et al., 2002; Ikeda et al., 
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2002). However, these CD4+-specific cytotoxicity only represents a minor mechanism of the 
anti-tumour immunity as it relies on the expression of MHC class II molecules, which, 
depending on the tumour type, are often absent from the surface of tumour cells.  
Models of adoptive transfer have largely undermined the role of CD4+ T cells as when these 
therapies were transferred to clinic, a clinical response was rarely obtained despite the 
generation of tumour-specific CTL (Cormier et al., 1997; Wang et al., 1999). On the other 
hand, co-transfer of CD4+ T cells with the CD8+ T cells has been shown to prolong the 
survival of adoptively transferred TIL  (Blattman et al., 2003) and improve the direct clinical 
outcome (Rosenberg and Dudley, 2004). Altogether, these data suggest that CD4+ T cell help 
is required to generate a correct anti-tumour response by allowing the DC to license CTL, 
efficiently activating CTL, recruiting other immune cells and mediating direct or indirect 
tumour cell killing (Fig. 1.9). 
 
(d) The effector role of CD8+ T cells in anti-tumour immunity 
Research has focused over the years on priming CTL to specifically lyse and eradicate tumour 
cells after recognition of the MHC: peptide complex (Pardoll et al., 1998). Using adoptive 
transfer of T cells in tumour-bearing hosts, CTL can invade at the initial tumour site as well as 
at distal locations and trigger potent anti-tumour immunity as shown in mice (Ryan et al., 2001) 
and in humans (Dudley et al., 2001). It has been proved that there is an inverse correlation 
between the amount of CD8+ tumour-infiltrating lymphocytes (TIL) and the tumour outcome, 
and this was observed in a variety of cancer such as melanoma, breast, prostate or colon 
carcinoma (Dunn et al., 2004). Cytotoxic T cells exert their function using two main lysis 
pathways: one based on the release of granzymes and perforins and the other one based on the 
triggering of apoptosis via Fas or TRAIL signalling (Andersen et al., 2006). A third pathway 
can also be considered with the recruitment of macrophages at the tumour site after the release 
of IFNγ by activated CTL. Release of complement proteins at the tumour site will then help in 
the phagocytosis of cancer cells by these macrophages (Dredge et al., 2002)(Fig. 1.10). 
Naive CD8+ T lymphocytes differentiate in cytotoxic effectors following engagement of their 
TCR and recognition of peptides associated with class I antigen on APC (de Haan et al., 2000). 
The activation of their effector function depends strongly on the quality of the TCR/peptide 
interaction and on the number of TCR engaged in a sequential fashion. These lymphocytes 
generally end their functional maturation with both co-stimulatory and cytokine signals.  
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Figure 1.9: Model of the functions of CD4+ T cells in anti-tumour immunity. The priming 
phase of CD4+ T cells involves antigen uptake and processing by BM-DC. The latter presents 
class I and class II peptides to CD8+ and CD4+ T cells, respectively. This triggers a chain of 
reactions whereby Th1 and Th2 cytokines are secreted to recruit eosinophils and macrophages, 
respectively. In parallel, this complex of CD4+-CD8+-DC will also activate both CD4+ and 
CD8+ T cells, which will directly kill tumour cells. 
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Figure 1.10: Mechanisms of action of cytotoxic T cells against tumour cells. The three 
pathways of cytolysis are initiated by the presentation of a tumour-derived class I peptide to 
the TCR. Transcription of genes encoding for FasL and TRAIL takes place. FasL-Fas 
connection is made with the tumour cell to trigger an apoptotic cascade. IFNγ is released to 
attract macrophages, which, in return will attack the tumour cell. Finally, the MHC class I-
TCR interaction stimulates the release of perforins and granzymes by exocytosis allowing the 
tumour cell to lyse. 
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Indeed, the activation of CD8+ T cells is strongly dependent on the help brought by T helper 
cells recognising an antigen on the same APC (Ridge et al., 1998). Activated T helper cells 
release co-stimulatory molecules such as IL-2, which then contributes to the activation of 
CD8+ T cells. CD8+ T cell activation is still largely studied and remains controversial as other 
pathways of activation have been found. In fact, depending on the affinity of the antigenic 
peptide for class I molecules and its avidity for TCR, a CD8+ T cell-based response can occur 
in the absence of CD4+ T cells (Schoenberger et al., 1998). Activation of CD8+ T cells can 
also occur sequentially with first, the recognition of an antigen by a T helper cell delivering a 
signal to the APC and secondly, the stimulation of CD8+ T cells following the reception of that 
signal (Ridge et al., 1998). Finally, priming of CD8+ T cells can take place using the important 
CD40-CD40L co-stimulatory pathway with an APC without the help of CD4+ T cells (van 
Mierlo et al., 2004)(Fig. 1.11). Altogether, these data suggest that activation of CD8+ T cells is 
critical for successful immunotherapy against certain types of malignancies.  
 
1.3 Tolerance, tumour evasion and their relevance to cancer 
 1.3.1 T-cell selection and tumour immunology 
The immune system is composed of a society of cells mostly originating from the bone marrow. 
The inventory of T lymphocytes is built in two steps. In a first step, lymphoid progenitors 
reach the thymus where they enter different stages of development. T cells, originally negative 
for CD4 and CD8 molecules become positive for either CD4 or CD8. Following this evolution, 
T cells undergo central tolerance mechanisms. A diversified inventory is constituted in which 
TCR genes are rearranged by a unique combination mechanism along the cellular 
differentiation process (See Section 1.2.2.2). This new repertoire of TCR allows the organism 
to face any possible antigen. Secondly, T cells undergo negative and positive selection 
processes. T cells, having no or too high affinity for self-antigens, are negatively selected and 
deleted by apoptosis. However, potentially auto-reactive T cells can escape this surveillance 
mechanism and attack cells presenting self-antigens in the periphery (Anderton et al., 2002).  
On the other hand, T cells with medium affinity for MHC: peptide complexes are positively 
selected upon reception of survival signals. T cell development and primary T cell selection 
processes occur mainly in the cortical region of the thymus. T cells then migrate to the medulla 
where they undergo further negative selection. Indeed, T cells meet thymic epithelial cells, 
which have been shown to present self antigens expressed in all cells as well as tissue-specific 
antigens, and upon self-antigen recognition, auto-reacting T cells are deleted. 
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Figure 1.11: Activation of CD8+ T lymphocytes. The priming phase of CD8+ T cells, strongly 
relying on the presence of bone marrow-derived dendritic cells to allow their activation and 
proliferation, can be summarised by three major mechanisms. A: a DC presents an antigenic 
epitope with strong binding affinity and strong avidity to a CD8+ T cell. B: a DC presents at 
the same time or sequentially a class II and a class I peptide to a CD4+ and a CD8+ T cell, 
respectively. C:  A CD40-CD40L connection is made between a DC and a CD8+ T cell. 
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Finally, it can also be mentioned that some of the cells that never meet any of the antigens they 
are specific for, die by neglect due to the lack of survival signals. Positively-selected CD4+ and 
CD8+ T cells migrate to peripheric lymph nodes where they browse the antigen pool presented 
by APC and other cells to identify anything abnormal. In summary, these stringent central 
tolerance mechanisms allow the emergence of an immune system capable of answering 
efficiently and appropriately to the large diversity of antigens, while limiting the danger to 
develop auto-immune diseases. Once the maturation of T lymphocytes has taken place, 
apoptosis continues to have a major role in the homeostatic control of the immune system. 
Indeed, following antigen presentation and recognition, T lymphocytes are activated, triggering 
a phase of clonal expansion of reactive cells. Once the antigen is no more present, the activated 
clones start a phase of decline in order to come back to a state of equilibrium. This come-back 
is ensured by the apoptotic elimination of the T cell excess, leaving the remaining cells to 
constitute a pool of memory T cells (Krammer, 2000). The immune system is therefore 
equipped with a large plasticity over the T cell development and activation because of a tight 
control of apoptosis. 
The deregulation of this process can have harmful consequences. Indeed, the defects of certain 
pro-apoptotic genes such as CD95, CD95L or Bim can provoke the development of auto-
immune diseases while a massive apoptosis can lead to the disappearance of T lymphocytes 
(Zhang and Insel, 2004). Altogether, these facts indicate that tolerance is a well-controlled 
mechanism preventing developed T cells to react against self antigens. That is why overcoming 
tolerance to generate an immune response against over-expressed or differentiation antigens, 
represents a difficult task.  
 
 1.3.2 Mechanisms of tumour evasion 
Over the last two decades, tumour immunology has undergone real changes with the discovery 
of cytokines and more recently the identification of tumour-associated antigens making 
immunotherapy a fourth modality of cancer treatment (surgery, radio- and chemotherapy being 
the first three). It has now become clear that the activation of natural and/or specific effector 
cells is an essential step to the anti-tumour response. However, the latter does not seem 
sufficient to allow tumour eradication. In fact, these effectors undergo alterations and 
modifications compelled by the tumour. In a more general manner, the tumour is capable of 
fighting, almost paralysing the host immune system. Besides classical mechanisms of tumour 
escape such as the loss of MHC expression and the alteration of the antigen presentation, the 
tumour develop strategies allowing it to acquire resistance to anti-tumour lysis factors by 
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creating an environment, which can deviate the local immune reaction and facilitate tumour 
proliferation. Therefore, tumour escape concerns the tumour target itself as well as the immune 
system (Müller et al., 2002). 
 
(i) Escape mechanisms associated with the tumour cell: The decrease or the loss of 
expression of MHC molecules by tumours is quite frequent, particularly in metastases (Garrido 
et al., 1997; Marincola et al., 2000) with several studies showing a direct correlation between 
the weak MHC class I expression and the poor prognosis or a high frequency of metastatic 
lesions (Ferrone and Marincola, 1995; Gudmundsdottir et al., 2000). The alteration of MHC 
class I expression takes place mostly during their synthesis. Mutations in β2-microglobulin, α 
chain or transcriptional factors responsible for the transcription of MHC genes have all been 
described (Paschen et al., 2003; Garcia-Lora et al., 2003). Glycosylation and MHC class I 
transport inhibitions, as well as decrease of their expression by viruses have also been reported 
(Benitez et al., 1998). Decreased or absent HLA expression has been observed in about 16 to 
50% of human solid tumours including breast carcinoma, colorectal carcinoma, prostate 
adenocarcinoma and melanoma (Khong and Restifo, 2002). In the well-studied DISC/GM-
CSF/CT26 tumour model, down-regulation of MHC class I molecules was found in 60% of 
mice with progressive tumour growth but absent in mice with regressive tumours (Ali et al., 
2002;  Ahmad et al., 2004). In another murine model, it has been proved that the transfection 
of a MHC class I molecule in tumour cells is capable of inducing tumour eradication and loss 
of invasive capacities (Tanaka et al., 1985). It is also worth mentioning that in certain cases, 
the loss of MHC class I expression can make the tumours more susceptible to the lysis by NK 
cells because of the suppression of the inhibition exerted by KIR and NKG2A molecules.  
The loss of expression of tumour antigens also corresponds to a mechanism of tumour escape, 
often resulting from genetic modifications in one or several tumour cells. This loss of antigen 
recognised by specific CTL has been observed in many murine and human tumours (de Plaen 
et al., 1988; Lehmann et al., 2000). The loss or the decrease of MHC class I molecules is often 
associated with the actual processing of the tumour antigen. Therefore, antigen processing can 
be affected by mutations occurring on LMP2 and LMP7 genes, which are important subunits in 
the immunoproteasome, or TAP genes, which are involved in the transport of antigenic 
peptides from the cytosol to the ER lumen. This leads to a flawed antigen presentation. That is 
why the loss of antigen expression and the selection of tumour variants, which are escaping the 
immunosurveillance, constitute a real issue at which anti-tumour vaccination is confronted. It is 
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easy to think that the simultaneous vaccination against several different tumour antigens could 
reduce the likelihood of selecting tumour variants having lost the antigen.  
Several studies also underline the importance of the down-regulation of co-stimulatory 
molecules such as B7.1 or B7.2 by tumour cells rendering the latter less immunogenic by 
preventing a more efficient tumour-specific CTL generation. Transfection of B7 molecules in 
tumour cells can lead to tumour regression in animal models (Bueler and Mulligan, 1996) and 
there are also evidences that the transfection of tumour cell lines with B7 molecules allows the 
generation of a stronger CTL response, in vitro (Heuer et al., 1996). These results strongly 
prove that TCR engagement without the appropriate co-stimulatory signal provided by their 
respective ligands (in case of B7 molecules, CD28) can lead to hyporeactivity or even 
lymphocyte anergy. Another more controversial way for the tumour to escape is to express 
FasL at their surface. This molecule binds its receptor, Fas, on the surface of T cells and 
triggers their apoptosis. This phenomenon has been observed in different types of cancers such 
as leukaemia (Tanaka et al., 1996), colon carcinoma (O’Connell et al., 1999) and melanoma 
(Hahne et al., 1996). However, it has also been observed that transfection of tumour cells with 
FasL makes the anti-tumour response more efficient with an improved tumour reject (Arai et 
al., 1997). Finally, tumour cells can secrete several immunosuppressive factors such as the well 
described IL-10, TGFβ and indoleamine 2,3-dioxygenase (IDO) contributing to tumour 
tolerance by suppressing T cells and activating Treg (Uyttenhove et al., 2003; Munn and 
Mellor, 2007).  
Nitrogen monoxide (Bogdan et al., 2000), prostaglandins E (Roper and Phipps, 1994) and 
gangliosides (McKallip et al., 1999) all participate with different mechanisms, such as effector 
cells, apoptosis or antigen processing and presentation inhibitions, to the tumour escape 
phenomenon. Tumour cells can acquire resistance to lysis mediated by CTL or NK cells. In 
fact, these anti-tumour effectors use two major pathways to exert their cytotoxic activity 
against target cells: the release of cytotoxic granules or the triggering of apoptosis involving 
death receptors (section 1.2.2.2). Certain tumour cells lose their capacity to bind perforins, 
preventing the piercing of the tumour cell membranes by the latter (Lehmann et al., 2000). 
Tumour cells can also start producing a serine protease inhibitor called PI9, which specifically 
inhibit the action of granzyme B stopping the induction of apoptosis by the latter (Medema et 
al., 2001). Tumour cells can become resistant to apoptotic signals triggered by the caspase or 
the mitochondrial pathways. This resistant mechanism is quite complex. It involves 
membranous, cytoplasmic and nuclear determinants, and affects Fas (Medema et al., 1999), 
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TRAIL (Ashkenazi et al., 1999) and TNFα signalling (Lejeune et al., 1998). Finally, tumour 
cells can be rendered resistant to cellular cytotoxicity following chemotherapy treatments. 
Certain drugs lead to the production of anti-apoptotic transcription such as NF-κB, 
consequently preventing the transmission of apoptotic signals initiated by death receptors in 
contact of effector cells (Baldwin, 2001). This kind of crossed resistance represents a major 
handicap for the development of cancer vaccination as immunotherapy is often used following 
failure or together with chemotherapy. 
 
(ii) Escape mechanisms associated with the immune system: Several studies showed that TIL 
can present functional alterations that are translated by a weak proliferation under the action of 
cytokines (e.g.: IL-2) and a decreased cytotoxic activity (Maccalli et al., 1999). This can be 
explained by anomalies in the ζ chain of the CD3 complex and in certain protein kinases 
involved in the primary steps of TCR signalling (Lai et al., 1996). Cytotoxic T lymphocyte 
associated molecule 4 (CTLA-4) is another molecule linked with the actual down-regulation of 
the immune response. This molecule is structurally very similar to CD28 and binds also CD28 
ligands (i.e.: B7 molecules) but with higher affinity. Its expression is limited to T and B 
lymphocytes but by binding B7 molecules, the CTLA-4 molecule brings a negative control on 
activated T cell proliferation by transmitting an inhibitory signal (Carreno et al., 2000). 
It is generally admitted that a specific anti-tumour response results from equilibrium between 
immunoregulatory and immunosuppressive cytokines present in the tumour environment. It 
was described earlier that tumour cells can secrete immunosuppressive cytokines to defend 
themselves against the immune response but paradoxically, certain T lymphocytes are capable 
of secreting cytokines with identical functions and auto-inhibit themselves. Tumour-infiltrating 
lymphocytes and more specifically Th2 cells have been shown to produce IL-10 in non-small 
cell lung carcinoma (Asselin-Paturel et al., 1998). Regulatory T cells have been also described 
at the tumour site inhibiting tumour-specific CTL via the secretion of immunosuppressive 
cytokines (IL-10 and/or TGFβ) or the expression at their surface of inhibitory molecules such 
as CTLA-4 (Von Boehmer., 2005). Treg cells account for 2 to 5% of the total population of 
CD4+ T cells in humans and are generally characterised by a CD4+CD25+Foxp3+ phenotype 
although other variants have also been identified. Naturally occurring Treg are likely to be 
selected in the thymus and capable of maintaining peripheral tolerance to self antigens. 
Generation of these suppressor cells depends on the ectopical expression of organ-specific 
antigens in the thymus and in fact, leads to the protection of tumours expressing self antigens. 
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Moreover, Treg can also be induced by a whole new range of peptide ligands specifically 
presented by tumour cells (Wang et al., 2004; Wang et al., 2005) suggesting the idea that these 
Treg may come from CD4+CD25- T cells which have been converted to CD4+CD25+ Treg 
because of the surrounding suppressive cytokines present at the tumour site or after direct 
interaction with naturally occurring Treg according to the “infectious” tolerance theory 
(Dieckmann et al., 2002). They have been extensively studied in cancer patients and there are 
increasing evidence of their presence within lymphoid tissues, peripheral blood and tumour-
infiltrated lymphocytes (Ichihara et al., 2003). Several studies demonstrated the link between 
presence of Treg in lymph nodes surrounding the tumour and impaired cell-mediated immunity 
as well as their contribution to tumour growth (Curiel et al., 2004; Kawaida et al., 2005). Treg 
have also been pointed out as the major reason for failed immunotherapies. Recently, a study 
showed that a CTL response was obtained after immunisation of melanoma patients with 
peptide- or tumour lysate-pulsed APC which peaked at seven days post-immunisation. The 
CTL response was then in decline reaching the pre-vaccine level 28 days after administration 
of the vaccine. This decrease correlated with the expansion of IL-10-secreting Treg in post-
vaccine peripheral blood lymphocytes (Chakraborty et al., 2004), emphasising the involvement 
of Treg not only in the maintenance of tolerance but also in the down-regulation of the anti-
tumour response. 
Finally, another study has described the involvement of activation induced cell death (AICD) 
in tumour escape (Malmberg et al., 2001). This mechanism normally occurs at the end of the T 
cell response. However, in some cases, AICD could be deregulated and leads to the elimination 
of the T cell compartment. Although several strategies of tumour escape have been described, 
our knowledge of the conflict between the tumour and the immune system remains 
hypothetical and fragmentary. A better understanding of these two systems should allow the 
development of more adapted and more efficient cancer immunotherapy.  
 
1.4 Cancer vaccines 
The immune system, because of its capability to actively destroy emerging tumour cells, 
represents a formidable tool to use in order to eliminate tumour cells that have escaped 
immunosurveillance. Until now, a large variety of mechanisms have been developed to achieve 
this goal and thwart tumour invasion. These can be summed up in three main headings: active 
immunotherapy which activates the anti-tumour response directly within the patient; adoptive 
immunotherapy which relies on ex vivo T cell stimulation before transfer back to the patient; 
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and finally passive immunotherapy mostly based on the administration of immune-effectors 
molecules such as Ig. 
 
 1.4.1 Active immunotherapy 
(i) Whole cell vaccines: Immunotherapy against cancer started with the development of whole 
cell vaccines. Irradiated autologous or allogeneic tumour cells were administered to patients 
together with an adjuvant (e.g.: BCG), modified with a hapten to make the cells more 
immunogenic (Berd., 2001), or cultured in a cocktail of cytokines such as IL-2, GM-CSF and 
IL-6 to promote MHC class I and class II presentation prior to re-injection (Zhang et al., 2005). 
The frequency of positive responses remains however low with tumour regression observed in 
only 10 to 30% of patients (Weber., 2000; Zhang et al., 2005). Subsequently, cells were 
engineered to express cytokines or co-stimulatory molecules to improve their immunogenicity 
(Ali et al., 2000). Several cytokine genes have been introduced in melanoma cell lines and 
other human tumours such as prostate or kidney in order to immunise patients with metastatic 
tumours. Clinical trials in melanoma or kidney cancer were carried out using autologous 
tumour cells transfected to express cytokines such as IL-2, -7, IFNγ or GM-CSF. Only a small 
proportion of patients responded partially or completely to these treatments. Indeed, only 20 to 
30% of the patients showed delayed hypersensitivity (DTH) and this result varies little when 
each cytokine were compared (Parmiani et al., 2000). In another phase I study, autologous 
melanoma tumour cells have been transfected with IL-12 gene in order to generate primarily a 
Th1-orientated response. A DTH reaction has been obtained in 2 out of 7 patients only, while 
only one of them showed tumour-specific CD4+ and CD8+ TIL (Sun et al., 1998). It is worth 
mentioning that only a small number of autologous tumour cells can be generated and that the 
standardisation of allogeneic tumour cell lines, easier to prepare and this in large quantity, 
should be undertaken. They also present the advantages of being administrable to all patients 
and that the cross-presentation by MHC molecules of the tumour cell lines to T cells does not 
need to match the MHC of the recipient to induce an immune reaction. Nevertheless, the use of 
cell lines for immunotherapy should be strictly controlled to ensure consistency of the vaccine 
as the genetic material, hence the expression of tumour-associated antigens and the 
immunogenicity, can evolve considerably over multiple passages. 
 
(ii) Heat shock protein vaccines: Heat shock proteins (HSP) are considered natural adjuvants 
appearing to be promoters of the anti-tumour vaccination because of their ability to bind 
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antigenic peptides and chaperone these peptides to APC in order to stimulate naive T cells in 
lymph nodes. This system has been proved to generate potent immune response in mice 
(Srivastava et al., 1998), and HSP96, HSP70, HSP90, HSP110, grp170 and calreticulin have 
all been found able to generate an anti-tumour response (Binder et al., 2004). They generate 
considerable interests as they are the first natural mammalian adjuvants to have been identified 
and are able to activate all the arms of the immune response going from CTL, B cells, NK cells 
to DC (Schild et al., 2000). Moreover, the ability of HSP to overcome tolerance by stimulating 
APC and generating co-stimulatory signals have been suggested (Li et al., 2002). Consequently, 
clinical trials have been initiated in patients carrying histologically-varied tumours with 
autologous HSP96 vaccines. No toxicity was observed and 50% of the patients tested 
developed a tumour-specific CTL response. One of them even showed marked reduction of the 
lesion size by more than 50% after the third immunisation and four other patients demonstrated 
stabilisation of the disease from 3 to 7 months (Janetzki et al., 2000). However and despite 
their immunologic interest, this approach needs to check whether autologous HSP do present 
epitopes recognised by the patient CTL.  
 
(iii) Peptide vaccines: The arrival of new technologies allowed the construction of new types 
of vaccination founded on the identification of genes encoding TAA and peptide epitopes 
derived from these TAA and recognised by CTL in the context of MHC class I. Advantages of 
using peptides are numerous as patients can be screened for the expression of TAA by PCR or 
immunohistochemistry; it is relatively easy to synthesise and cost-effective; it is easy to 
administrate in clinic and monitor in vitro the presence of an epitope-specific immune response. 
Peptides derived from melanoma antigens such as the differentiation antigens (e.g.: 
MelanA/MART-1, gp100 and tyrosinase) and CT antigens (e.g.: MAGE-1 and -3) were the 
first used in phase I/II clinical trials. Marchand et al. (1999) showed significantly different 
results: 28% of HLA-A1 patients treated with a HLA-A1 MAGE-3 peptide responded 
clinically with complete remission while a different epitope from the same protein presented in 
the context of HLA-A2 or a HLA-A1 peptide from MAGE-1 induced a clinical response in 
only 11% of tested patients. In another study, MART-1-derived peptides injected together with 
an adjuvant, in that case incomplete Freund’s adjuvant (IFA), allowed the production of 
peptide-specific CTL but no clinical response (Rosenberg et al., 1998). Clinical response was 
then achieved in 42% of patients when MART-1 vaccine was associated with strong systemic 
administration of IL-2 (Rosenberg et al., 1998). In order to increase the efficiency of peptide 
presentation, melanoma antigens have been co-administrated with GM-CSF. Although this 
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approach appeared successful at short term, most of the tumours re-appeared with only 11% of 
the patients showing beneficial responses and increased peptide-specific CTL (Jager et al., 
1996). Another recently identified antigen belonging to the CT antigen family, NY-ESO-1 has 
proved to be strongly immunogenic with at least 50% of patients with melanoma mounting B 
and T cell responses. When administrated with GM-CSF, a specific CTL response was 
accompanied with a stabilisation of the disease and objective regression of a few metastases in 
60% of patients (Jager et al., 2000). Moreover, peptides have also been used to immunise 
patients with cancers from different histological origin such as colon adenocarcinoma with 
Ras-derived peptides (Gjertsen et al., 2001), breast carcinoma with HER2/Neu-derived 
peptides (Knutson et al., 2001), or chronic myeloid leukaemia (CML) with Bcr/Abl-derived 
peptides (Pinilla-Ibartz et al., 2000). Like previously described, peptide vaccination generated 
specific CTL responses but only a very small proportion of them led to noticeable tumour 
regression.  
Tolerance, immune escape, lack of MHC class II peptides, the importance of the adjuvant and 
the dose/schedule used for immunisation can all explain the very low clinical efficacy of 
peptide vaccination. Fortunately, a lot of efforts are put into improving these results by 
combining CTL epitopes with T helper epitopes to induce and sustain a more potent CTL 
response. Results achieved in animal models have been encouraging (Rojas et al., 2005) and 
clinical trials using combination of peptides or single peptides with dual class I and class II 
binding abilities are currently ongoing (Zeng et al., 2002). Others have tried to modify the 
anchor residues of CTL epitopes to improve their affinity to their respective MHC class I 
molecules and TCR and induce a stronger immune response. Rosenberg et al. (1998) proved 
that this hypothesis could have beneficial applications. Several studies are also looking at 
delivery systems such as liposomes (Ludewig et al., 2001; Malik et al., 2007), nanobeads 
(Kalkanidis et al., 2006) or in combination with stronger adjuvants such as CpG 
oligonucleotides (Davila et al., 2003; Peng et al., 2005) to increase T cell avidity upon better 
presentation to the APC without severe and toxic side-effects (Fifis et al., 2004). Finally, there 
is a common understanding that peptides are more efficient in eliciting a specific T cell 
response than whole proteins (Disis et al., 1996). However, anti-idiotype antibody-based 
vaccines raised a lot of interests. Indeed, by displaying partial amino acid sequence homology, 
anti-idiotype antibodies are proteins capable of mimicking the activity of tumour antigens such 
as HER2/neu and CEA, and effectively overcome unresponsiveness of the adaptive immune 
system to tumour cells over-expressing the nominal antigen. Promising results were obtained in 
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mice (Mohanty et al., 2007; Pignatari et al., 2007) and clinical trials in humans are currently 
ongoing to assess this revolutionnary protein-based vaccine modality. 
 
(iv) Dendritic cell vaccines: The knowledge of DC physiology and their potent antigen 
presenting capacities allowed their use for the vaccination of mice with tumours. Dendritic 
cells bring numerous advantages as they can act as nature’s own adjuvants. Their utilisation 
became also possible in humans because of new technologies allowing the generation of high 
quantities of autologous DC from monocyte origin or deriving from CD34+ cells of patients by 
culturing them in vitro in the presence of GM-CSF and IL-4 (Siena et al., 1995). It has then 
been demonstrated that autologous DC loaded ex vivo with peptides or tumour cell lysates were 
capable of efficiently presenting TAA to T cells (Nieda et al., 1998; Moyer et al., 2006). 
Several clinical studies have been initiated to analyse the therapeutic value of this approach in 
patients with cancer. Patients with melanoma were vaccinated with autologous DC loaded with 
MHC class I MART-1, tyrosinase or gp100 peptides, or with tumour cell lysates. A clinical 
response was obtained in 25% of patients treated out of 32 patients, with approximately 50% of 
them developing specific CTL responses (Schadendorf et al., 2000). Another study using a 
MAGE-3 peptide loaded to autologous DC without any adjuvants showed a high frequency of 
CTL responses (Marchand et al., 1999). Nevertheless, no significant clinical regression of 
metastatic lesions has been obtained even though few cutaneous metastases disappeared 
(Thurner et al., 1999). This approach of vaccination did not prove successful when autologous 
DC were loaded with prostate antigens such as PSA, PSMA or PAP with or without GM-CSF 
administration for the treatment of prostate cancer with less than 2% of clinical responses, even 
though PSA levels decreased by up to 50% in at least 30% of the 107 patients tested (Lodge et 
al., 2000). It is interesting to underline the use of tumour cell lysates to provide DC with TAA. 
Despite containing also self antigens and hence increasing the risk of auto-immunity, it 
corresponds to a practical source of antigens for vaccinations and this approach has been used 
in melanoma (Schadendorf et al., 2000). However, complementary information on the tumour 
itself are required to define the TAA present in these lysates in order to be able to monitor and 
evaluate their immunogenicity. Another interesting approach is the fusion between DC and 
tumour cells. The end product is an APC capable of presenting all the repertory of TAA 
present in the tumour cells (Rosenblatt et al., 2005). After studies in animals (Weigel et al., 
2006), this technique has been utilised in patients with melanoma or kidney cancer. 
Unfortunately, vaccination with these hybrids led to contradictory results with 13% of clinical 
responses in melanoma while this same approach allowed tumour regression in 40% of patients 
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with renal cell carcinoma (Kugler et al., 2000). Dendritic cells play a critical role in 
vaccination strategies as it was shown in whole cell tumour vaccine engineered to express GM-
CSF, which is a potent mitogenic factor required by DC for the induction of an intermediate 
stage of differentiation whereby antigen uptake and presentation is improved (Caux et al., 
1992). The genetically-modified tumour cells, in comparison with wild-type tumour cells, were 
shown to trigger a potent systemic anti-tumour immunity as a result of DC infiltration, lymph 
node migration and activation of CTL (Dranoff et al., 1993). However, no significant clinical 
results have really been obtained in a number of phase III clinical trials. In order to overcome 
the issues associated with traditional DC vaccines, different strategies were adopted. Dendritic 
cells can indeed be transfected with mRNA derived from the tumour cells (Heiser et al., 2000; 
Peng et al., 2006), or with an expression vector encoding the full cDNA sequences of TAA 
(Yang et al., 2000) together or not with a stimulating cytokine such as IL-18 to increase CTL 
activity (Cao et al., 2007), enabling targeted loading of TAA-derived peptides in the antigen 
processing pathways. Another way of circumventing these difficulties is to improve the 
maturation status of the prepared DC by transfecting them with co-stimulatory molecules or 
maturation factors, such as CD40L or GM-CSF, so that they can be co-administrated to 
patients with antigen-loaded DC and strong maturation factors such as anti-CD40 monoclonal 
antibodies or CpG oligonucleotides (Hanks et al., 2005). This system should allow the DC to 
provide sufficient levels of T cell activation signals in order to overcome tolerance and 
hopefully lead to better clinical responses. Finally, DC can be modified to secrete 
immunostimulatory molecules such as IL-2, -12 or IFNγ to improve CTL response levels. 
Murine models and clinical trials have shown promising results using this methodology 
(Murphy et al., 1996; Huttner et al., 2005). Recently, different subsets of DC have been 
identified capable of inducing different levels of CTL activation depending on the cocktails of 
cytokines used for their maturation and activation. For example, it seems that IL-15 can have a 
more potent effect on the final CTL stimulation than IL-4 (Mohamadzadeh et al., 2001; Feili-
Hariri et al., 2005). Interestingly, another study reported that depending on the activating 
factors used, interferon-secreting killer DC with tumour killing capabilities could be generated 
in mice (Chan et al., 2006). In summary, DC potentially represents a formidable tool for cancer 
immunotherapy but so far, clinical trials have proven to be inconclusive. Therefore, it seems 
that a better understanding of the maturation and activation processes of DC are required to 
enhance potential immune responses and standardise the immunisation procedures such as site 
of vaccination, dose, schedule and injection. 
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(v) DNA vaccines: Another mean allowing the elaboration of vaccines against defined antigens 
is based on the utilisation of genes coding for TAA. The advantage of this method is the 
possibility to induce the expression of an entire antigenic protein including both MHC class I 
and class II epitopes that are not restricted to the specific MHC haplotypes, and activate both 
arms of the adaptive immune system (i.e.: B and T cells, respectively)(Ulmer et al., 1993). 
DNA vaccines were first used in animal models before being applied to humans. They can be 
administrated by different routes such as intramuscular, intramucosal, intranasal or into the 
dermis using gene gun technology after coating of the DNA with gold. DNA doses have been 
shown to be independent of the species with fairly similar amounts used to raise responses. 
However, the route of administration seems to be critical as injection of DNA extra-cellularly 
requires 100 to 1,000 times more DNA to induce immune responses than gene gun targeting 
introducing DNA directly inside cells (Fynan et al., 1993). This is quite relevant as it allows 
easy standardisation of the technique and an easy transfer of this mode of immunisation from 
animal models to humans. Moreover, the immunogenicity of DNA vaccines is increased 
because of the presence of bacterial CpG oligonucleotide sequences, which are known for their 
capacity to promote cytokine secretion and danger signalisation leading to optimum activation 
of the APC (Pisetsky, 1996). Finally, DNA vaccines are unlikely to integrate the host’s 
genomic DNA or be neutralised by anti-DNA antibodies (Nichols et al., 1995; Gilkeson et al., 
1996). Depending on the route of immunisation, the DNA can either be picked up by epidermal 
Langherans cells following gene gun bombardments or be moved by blood flow from the 
muscles to the spleen or other lymph nodes (Winegar et al., 1996). More recent studies have 
shown that gene gun bombardment with DNA-gold particles predominantly generates Th2 
responses while intramuscular immunisation preferentially leads to Th1 responses emphasising 
the importance of the route of immunisation for DNA vaccines (Weiss et al., 2002). 
Furthermore, single or multi-insert plasmids can be used for DNA vaccinations meaning that a 
TAA gene could eventually be combined with modulators of the immune response such as co-
stimulatory molecules (e.g.: B7-1, -2) or cytokines (e.g.: GM-CSF, IL-12) in order to increase 
the immunogenicity of the receiving cells, which process and present the encoded TAA 
(Iwasaki et al., 1997). However, DNA vaccines have been proved to be so far weakly 
immunogenic but they represent a real interest when combined in prime-boost vaccinations 
protocols. Indeed, prime-boosting strategies involving DNA followed by virus vaccinations 
showed promising results by allowing expansion of TAA-specific T cells and selection of T 
cells with the highest avidity against the respective TAA (Palmowski et al., 2002; Woodland, 
2004).  
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(vi) Viral vector vaccines: This approach was first carried out in animals with a variety of 
DNA vectors able to bring DNA to APC. They represent a very interesting and promising 
possibility as they can initiate a strong immune response and break tolerance, which is of a 
major interest regarding immunisation against self or differentiation antigens. Retroviruses, 
lentiviruses, adenoviruses, alphaviruses, poxviruses and Herpes simplex viruses have all been 
tested in animal models with promising results and are in clinical trials with tumour antigens 
such as PSA or CEA or with immunoregulatory molecules such as GM-CSF (Aarts et al., 
2002). Many of them can be disabled, have limited toxicity upon systemic or intratumour 
injection, infect dividing and non-dividing cells and integrate large inserts of genetic 
information (Ali et al., 2002; Stripecke et al., 2003). However, they can have limiting factors 
as hosts can already have produced blocking antibodies against some of these viruses. 
Immunodominance can also take place as viral antigens are often more immunogenic than 
tumour antigens. In order to circumvent these difficulties, immunomodulatory molecules can 
be combined with TAA to enhance the potency of such vectors. Among all these families, 
alphaviruses and herpes simplex viruses are of particular interest. Indeed, recombinant 
alphaviruses such as Semliki Forest Virus require the co-transfection of a helper plasmid for 
the making of infective viral particles (DiCiommo and Bremner, 1998; Atkins et al., 1999). 
Following viral infection, the cells die by apoptosis facilitating cross-presentation by DC. 
Disabled infectious single cycle-Herpes simplex virus (DISC-HSV) and its immunotherapeutic 
have been largely studied in murine tumour model (Boursnell et al., 1997; Rees et al., 2002; 
Ahmad et al., 2005). Intratumour injection of DISC/GM-CSF has been shown to lead up to 
70% of the mice rejecting the tumour and once combined with other modalities, further 
therapeutic advantages could be achieved (Ali et al., 2002; Ali et al., 2004). 
Each of these families of viruses mentioned earlier have relevant properties for gene therapy 
and more and more efforts are put into trying to blend these properties into a single viral vector 
in order to develop the “perfect” viral vector that could be used on its own as a potent tool for 
cancer immunotherapy or in prime-boost strategies (Kay et al., 2002; Woodland., 2004).  
 
 1.4.2 Adoptive immunotherapy 
Adoptive immunotherapy is based on the observation that specific T lymphocytes with a 
therapeutic activity are absent or in insufficient numbers in patients. Tumour infiltrating cells 
isolated from autologous tumours or allogeneic donor cells can be amplified and activated in 
vitro, and injected to the deficient host in large quantities to obtain the desired therapeutic 
effect. Allogeneic transplantation has shown to be very successful in haematological 
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malignancies. Indeed, T cells seem to mediate a graft-versus-leukaemia reaction following 
ablation of tumour cells, high doses of chemo- or radiotherapy and allogeneic bone marrow or 
haematopoietic stem cell transfer (June, 2007). Autologous adoptive immunotherapy has more 
applications when solid tumours are involved. The first application of adoptive cell transfer in 
immunotherapy was against melanoma in combination with high doses of IL-2. Objective 
tumour responses were successfully obtained in 35% of the vaccinated patients (Rosenberg et 
al., 1994). This frequency was at this moment higher than any other tumour vaccinations 
undertaken so far. The same group later improved this result to 50% by performing 
lymphoablative chemotherapy followed by adoptive transfer of polyclonal T cell lines 
containing CD4+ and CD8+ T cells specifically recognising the tumour (Dudley et al., 2002). 
Subsequent trials using the same immunisation protocol and larger cohorts of melanoma 
patients with metastases in distant sites such as lung, brain, liver or lymph nodes, showed 
similar figures (Rosenberg and Dudley, 2004, Dudley et al., 2005). By removing homeostatic 
cytokines such as IL-7 or IL-15 and by depleting Treg, lymphoablation probably encourages 
the expansion of tumour-reactive T cells. These results were confirmed when tumour-bearing 
mice were depleted from CD4+ T cells, re-infused with tumour-specific CD8+ T cells and 
CD4+CD25- T helper cells only, and showed noticeable tumour regression. Regression was 
however abrogated when CD4+CD25+ Treg were re-infused (Antony et al., 2005). Rosenberg 
and colleagues also developed a novel technology involving the transfer of tumour antigen-
specific TCR gene into autologous T cells prior to T cell re-infusion. This technique was 
applied to different tumour antigens such as gp100 (Morgan et al., 2003), MART-1 (Rosenberg 
and Dudley, 2004) or NY-ESO-1 (Zhao et al., 2005), and led not only to the expansion of 
tumour antigen-specific T cells with high avidity for their respective antigen, but also to 
significant clinical regressions in some patients. Altogether, these results are very promising as 
they show that high avidity tumour-specific T cells can induce tumour regression when used in 
the right context and that the development of genetically engineered T cells for adoptive 
immunotherapy can only improve the outcome. 
 
 1.4.3 Passive immunotherapy 
Tumour antigen-specific monoclonal antibodies (mAb) are the main actors of passive 
immunotherapy and have demonstrated a high degree of success in some forms of cancer. The 
identification of several surface expression markers on tumour cells allowed their development 
even though their mechanisms of action remain hypothetic. The first theory behind the effects 
of mAb is the triggering of the antibody-dependent cellular cytotoxicity (ADCC). Monoclonal 
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antibodies bind to the antigens they are specific for and lead to the mechanism of opsonisation 
by phagocytes expressing the complement receptors, the immediate killing of tumour cells and 
an inflammatory reaction. One of the most widely used mAb is an anti-CD20 mAb (Rituximab) 
for the treatment of B cell lymphoma and appears to function through ADCC. The other 
hypothesis suggests that the effects of mAb are due to the variable regions, which bind to the 
tumour cell surface and might block the access to growth factors required for tumorogenesis or 
inhibit a signalling cascade. Therefore, mAb might stop tumour growth and induce apoptosis of 
target cells. Trastuzumab, commercially known as Herceptin, specifically targets the 
membrane-bound HER2 protein, a tyrosinase kinase receptor. Upon binding, the mAb leads to 
a cessation of the signalling cascade that normally follows HER2 activation and tumour cell 
death by apoptosis (Viani et al., 2007). Other activity of mAb that have been suggested is an 
anti-angiogenic activity. Finally, mAb can be conjugated with a cytotoxic agent such as a 
radioactive compound or a cytotoxic drug. The clinical trials with an anti-CD20 mAb coupled 
with a radioisotope demonstrated that an antibody can efficiently bring the radioisotope in 
contact or at proximity of tumour cells (Witzig et al., 2007). Further work is being carried out 
to develop new mAb conjugated to all sorts of toxins, radioisotopes or pro-drugs that can be 
activated by systemic administration of activator compounds, or able to cross-link effector cells 
of the immune system so that the latter can exert their action directly at the tumour site. 
 
1.5 HAGE as a target for immunotherapy 
There is an ever increasing need for new targets to treat cancer considering the limitations of 
some of the current therapies (section 1.1.5). Therefore, it is valuable to identify new 
immunogenic TAA that could be potentially targeted by immunotherapy for late stage diseases 
or in a combination therapy with more traditional treatments at early stages to prevent tumour 
cell proliferation and invasion. HAGE might be such antigen. It was first identified with 
sarcoma antigen (SAGE) using representational difference analysis, a technique that basically 
relies on the subtraction of the total RNA expression from normal tissues such as uterus, breast, 
colon and heart with the total RNA expression from a sarcoma cell line. The two cDNA clones 
were identified as tumour-specific with pattern of expression very similar to the genes from the 
MAGE family (Martelange et al., 2000). HAGE gene was mapped on chromosome 6 (6q12-
q13) by radiation hybrid analysis and encodes a putative 73kDa protein. Analysis of the protein 
sequence of HAGE revealed that it has a DEAD box characteristic of the family of ATP-
dependent RNA helicases. The sequence also displayed 55% homology with DDX5 (p68), 
another member of this family. RNA metabolism, control of cell cycle, spermatogenesis and 
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embryogenesis are among the possible processes that HAGE might be involved in. However, 
little is known about its localisation or its function (Martelange et al., 2000; Rocak and Linder, 
2004). Northern blot analysis showed that HAGE transcripts were present at a level that was 
100-fold higher in many tumours of various histological types than in normal tissues except 
testis (Martelange et al., 2000). HAGE was later found to be over-expressed in a small number 
of normal salivary glands but in a higher proportion in benign and malignant salivary gland 
neoplasms (Nagel et al., 2003). HAGE is also over-expressed in more than 50% of CML, in 
20% of acute myeloid leukaemia (AML)(Adams et al., 2002) and more than 40% of multiple 
myeloma (Condomines et al., 2007), and although HAGE is present in a small numbers of lung 
cancers (Martelange et al., 2000), there is no correlation between HAGE gene expression and 
clinicopathological factors indicating that the detection of HAGE in this type of cancer has 
limited usefulness (Sasaki et al., 2003). A recent study described the methylation status of the 
HAGE gene in CML patients and cell lines, and showed that like most CT antigens, 
hypomethylation of the HAGE gene promoter correlated with increase of HAGE expression, 
and that its expression was strongly associated with advanced disease and poor prognosis 
suggesting a potential role of HAGE in cellular proliferation and as a marker of disease 
progression (Roman-Gomez et al., 2007). 
Considering the expression pattern and the diversity of HAGE expression in different tumours, 
HAGE might be potentially used as a target for immunotherapy. This study proposes to 
investigate the immunotherapeutic potential of HAGE in a murine model as a pre-requisite for 
using HAGE as a potential cancer vaccine in patients. Firstly, HAGE will be validated as a 
target for immunotherapy by confirming its tumour-specific expression at the mRNA and 
protein level in various cell lines, as well as normal and abnormal human tissues. Following its 
validation, this study aims at the identification of immunogenic class I and II peptides derived 
from HAGE for immunotherapy and immunomonitoring. Ultimately, potent vaccination 
strategies such as DNA or viral vaccines will be developed and evaluated in prophylactic and 
therapeutic experiments. 
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Chapter 2: Materials and Methods 
2.1  General laboratory consumables and equipments 
 2.1.1 Reagents and list of producers 
Reagents were stored as per manufacturer instructions and used before the expiry date. 
Culture media Supplier 
DMEM, IMDM, RPMI Bio Whittaker Europe 
Opti-MEM Gibco Life Technologies 
 
Supplements to culture media Supplier 
Fungizone Promega 
Geneticin (G418) Promega 
HEPES Bio Whittaker Europe 
Foetal calf serum Bio Whittaker Europe 
Glutamine Bio Whittaker Europe 
Penicillin/Streptomycin Bio Whittaker Europe 
2-mercaptoethanol Sigma 
 
Other cell culture reagents Supplier 
Dimethyl sulfoxide (DMSO) Sigma 
Incomplete Freund’s adjuvant (IFA) Sigma 
Lipopolysaccharide (LPS) Sigma 
Phosphate buffer saline (PBS) Bio Whittaker Europe 
Polyinosinic polycytidylic acid (Poly I.C) Sigma 
Trypan blue Sigma 
Trypsin/Versene Bio Whittaker Europe 
 
Chemical reagents Supplier 
Acetic acid Fischer Scientific 
Acetone Acros Organics 
Acrylamide-bis Geneflow 
Agar Oxoid Ltd 
Agarose Bioline 
α-chymotrypsin Sigma 
Ampicillin Sigma 
Anhydrous ethanol Sigma 
Aprotinin Sigma 
Aza-deoxycytidine (AZAC) Sigma 
Bovine serum albumin (BSA) ICN Biomedicals 
Calcium chloride (CaCl2) Sigma 
Chromium-51 Amersham Biosciences 
Dextran sulphate Sigma 
Dithiothreitol (DTT) Sigma 
DNA ladder (1kp Plus) Gibco Life Technologies 
dNTP Bioline 
ECL Western Blotting reagents Amersham Biosciences 
Ethanol BDH 
Ethidium bromide Sigma 
Ethyldiamine tetraacetic acid (EDTA) Sigma 
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Fluorescent mounting media Dako 
Gill haematoxylin solution Sigma 
Glucose Sigma 
Glutaraldehyde Sigma 
Glycerol Sigma 
Goat serum Sigma 
Gold microcarriers (1.0µm) BioRad 
Harris haematoxylin solution Sigma 
Hydrochloric acid (HCl) Fischer Scientific  
Hydrogen peroxide (H2O2) Sigma 
Interferin Polyplus Transfection 
Isopropanol Sigma 
Isoton Beckman-Coulter 
Lipofectamine 2000 Invitrogen 
Marvel Premier Brands 
Magnesium chloride (MgCl2) Fischer Scientific or Promega 
Methanol Acros Organics 
Murine GM-CSF Biosource 
Murine IL-2 Biosource 
1.5M Tris-HCl, pH 6.8 or pH 8.8 Geneflow 
Orange G Sigma 
Paraformaldehyde Sigma 
Phenol/Chloroform/Isoamyl alcohol Sigma 
Phosphate buffer saline (PBS)(1X) Bio Whittaker Europe 
Phosphate buffer saline (PBS)(Tablets) Oxoid 
Phusion HF buffer Finnzymes 
Phusion DNA polymerase Finnzymes 
Poly vinyl pyrrolidone (PVP) Sigma 
Ponceau S solution Sigma 
Potassium acetate (KOAc) Sigma 
Potassium ferricyanide (K3Fe(CN)6) Sigma 
Potassium ferrocyanide (K4Fe(CN)6) Sigma 
Propidium iodide Sigma 
Rabbit liver powder Sigma 
Restriction enzymes Promega or New England Biolabs 
RNA-STAT 60 Biogenesis 
Sodium azide (NaN3) Sigma 
Sodium chloride (NaCl) Fischer Scientific 
Sodium dodecyl sulphate (SDS) Sigma 
Sodium hydroxide (NaOH) Fischer Scientific 
Sodium phosphate dibasic (Na2HPO4) Sigma 
Sodium phosphate monobasic (NaH2PO4) Sigma 
Spermidine Sigma 
SYBR green supermix BioRad 
Trichostatin A (TSA) Sigma  
Tris Fischer Scientific 
Trizma base Sigma 
Tryptone Oxoid Ltd 
Tween 20 Sigma 
2-methylbutane (Isopentane) Acros Organics 
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Vitamin E Sigma 
Xylene Acros Organics  
Yeast extracts Oxoid Ltd 
Zeocin Invitrogen 
 
Immunochemical reagents  Supplier 
Goat anti-hamster-FITC Serotec 
Goat anti-mouse-FITC Sigma 
Goat anti-rabbit-biotin DAKO 
Goat anti-rabbit-HRP DAKO 
Goat anti-rat-FITC  Sigma 
Hamster anti-mouse CD11c BD Biosciences 
HB54 (mouse anti-HLA-A2.1) Hybridoma 
L243 (mouse anti-HLA-DR) Hybridoma 
Mouse anti-FLAG-M2-FITC Sigma 
Rabbit anti-HAGE polyclonal serum Dr. Ashley J. Knights (Tuebingen University) 
Rat anti-mouse CD45R Serotec 
Rat anti-mouse CD80(B7.1)-PE BD Biosciences 
Rat anti-mouse CD86(B7.2)-PE BD Biosciences 
Rat anti-mouse DEC205 Serotec 
Rat anti-mouse F4/80 Serotec 
Rat anti-mouse 4.1BBL-PE BD Biosciences 
Streptavidin-HRP Zymed 
 
Plasmids 
pcDNA3.1, pBudCE4.1 Invitrogen 
pSCAb, pSCAhelper, pSHAME2a Dr. Rod Bremner (University of Toronto) 
 
Kits Supplier 
Reverse transcription: 
M-MLV Reverse Trancriptase kit Promega 
 
Immunohistochemistry: 
ABC and DAB kits Vector Laboratories 
 
Cloning: 
T4 ligase kit Promega 
 
DNA extraction from agarose gel: 
Geneflow DNA isolation kit Geneflow 
 
Generation of SFV viruses: 
ProFection Mammalian transfection system Promega 
 
Lymphocyte depletion: 
Mouse CD4: Dynabeads mouse CD4 Dynal 
Mouse CD8: Dynabeads mouse CD8 Dynal 
 
ELISA: 
Mouse IFNγ or IL-5 R&D Systems 
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 2.1.2 Equipment 
Glassware    
Pyrex glassware was washed in teepol, rinsed twice in distilled water and autoclaved 
 
Disposable equipment and plastic-ware Supplier 
BD microlance 3 needles (0.5ml, 1ml) Becton Dickenson 
Bijou tubes (5ml)  Sterilin 
Cryovials (1.2ml)  TPP 
8-chamber slides 
ELISA plates (96-well) Costar 
Eppendorf tubes (0.5ml, 1.5ml) Sarstedt 
FACS tubes   Elkay 
Filter tips (10µl, 200µl, 1ml) Sarstedt 
Flat bottom culture dishes (6-, 24-, 96-well) Sarstedt 
Hyperfilm ECL films Amersham   
96-well plate harvester filters Perkin Elmer 
Pasteur pipettes  Sarstedt 
PCR tubes   Micronic Systems 
Petri dishes   Sarstedt 
Round bottom culture dishes (96-well) Sarstedt 
Scalpels   Swann Morton 
Screw top tubes (15ml, 50ml) Sarstedt 
Serological pipettes (5ml, 10ml, 25ml) Sarstedt 
Syringes (10ml)  Becton Dickenson 
Tefzel tubing  BioRad  
Tips (20µl, 200µl, 1ml) Sarstedt 
T25, T75, T175 tissue culture flasks Sarstedt 
Universal tubes (20ml) Sterilin 
0.2µm filters  Sartorius 
 
Equipment   Supplier 
Centrifuge, microcentrifuge MSE 
Class II safety cabinets Walker 
Confocal microscope Leica 
Cryostore   Forma Scientific 
Drying cabinet  Scientific Laboratory Supplies 
Dynabeads separation unit Dynal 
Electrophoresis gel tanks BioRad 
Flow cytometer  Beckman-Coulter 
Helios gene gun  BioRad 
Microscope   Nikon 
Microwave   Matsui 
-80°C freezer  Revco 
96-well plate reader  Tecan 
96-well plate harvester Packard 
PCR thermal cycler  Thermo Hybaid 
Power packs   BioRad 
Real time PCR thermal cycler BioRad 
Refrigerated microcentrifuge Hettich Zentrifugen 
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Semi-dry transfer apparatus BioRad 
37°C, 5% CO2 incubator Forma Scientific 
Top count scintillation counter Packard 
Tubing prep station  BioRad 
UV spectrophotometer Sanyo 
UV transilluminator  Ultra Violet Products 
Water baths Grant instruments 
 
 2.1.3 Buffers 
(i) Buffers for tissue cultures 
Trypan Blue:  White cell counting solution: 
0.1% (v/v) solution of Trypan blue in PBS  0.6% (v/v) acetic acid in PBS 
 
(ii) Buffers used for DNA or protein analysis and polymerase chain reaction (PCR) 
50X TAE:   1.4% agarose gel electrophoresis: 
242g tris   1.4g agarose 
57.1ml glacial acetic acid 100ml 1X TAE 
100ml 0.5M EDTA (pH 8.0) 10µl Ethidium bromide 
Completed to 1000ml with ddH2O 
 
Orange G DNA loading buffer: Wash buffer: 
0.25% (w/v) orange G 25ml 10X Wash solution 
30% (v/v) glycerol  100ml Ethanol 
Completed to final volume with ddH2O Completed to 250ml with ddH2O  
     
Tris buffer saline (TBS): TBS-Tween 20-(Marvel):  
1.21g Tris   0.05% Tween 20 
22.33g NaCl   (5% (w/v) Marvel) 
pH adjusted to 7.5 with HCl Completed to final volume with TBS 
Completed to 1000ml with ddH2O 
 
Resolving gel buffer: Stacking buffer: 
1165µl 30% (w/v) Acrylamide-bis 466.5µl 30% (w/v) Acrylamide-bis 
875µl 1.5M Tris-HCl, pH 8.8 875µl 1.5M Tris-HCl, pH 6.8 
1460µl ddH2O  2158.5µl ddH2O 
35µl 10% (w/v) APS 35µl 10% (w/v) APS 
3.5µl TEMED  3.5µl TEMED 
 
Running buffer:  Transfer buffer: 
0.25M Trizma base  48M Tris 
2M Glycine   39mM Glycine 
1% (w/v) SDS  20% (v/v) methanol 
Completed to 1000ml with ddH2O Completed to 1000ml with ddH2O 
 
Reducing sample buffer: ECL chemioluminescence reagent: 
0.5M Tris-HCl, pH 6.8 1 volume solution A 
2% (w/v) SDS  1 volume solution B 
10% (v/v) glycerol 
1% DTT 
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Completed to final volume with ddH2O 
(iii) Buffers for flow cytometry 
Permeabilisation solution: Fixation solution: 
1% (v/v) paraformaldehyde in PBS 70% (v/v) ethanol in PBS 
 
FACS buffer: 
0.1% (w/v) BSA 
0.02% (w/v) NaN3 
1X PBS 
 
(iv) Buffers for immunohistochemistry 
Primary antibody  Secondary antibody: 
100µg/ml rabbit anti-HAGE antibody 10µg/ml goat anti-rabbit IgG-biotin 
5% (v/v) goat serum 1.5% (v/v) goat serum 
Completed to final volume with PBS Completed to final volume with PBS 
 
ABC reagent:  DAB reagent: 
2.5ml PBS   2.5ml ddH2O 
1 drop reagent A  1 drop buffer 
1 drop reagent B  2 drops DAB 
    1 drop H2O2 
 
(v) Buffers for bacteria culture 
LB broth:   LB  Agar: 
5g NaCl   5g NaCl 
10g tryptone   10g tryptone 
5g yeast extracts  5g yeast extracts 
pH adjusted to 7.0 with NaOH 15g agar 
Completed to 1000ml with ddH2O pH adjusted to 7.0 with NaOH 
    Completed to 1000ml with ddH2O 
 
(vi) Buffers for alkaline lysis 
0.2M Tris-HCl buffer: GTE solution: 
12.1g Tris 50mM glucose 
pH adjusted to 8.0 with HCl 25mM Tris-HCl (pH 8.0) 
Completed to 1l with ddH2O 10mM EDTA 
 
KOAc solution:  NaOH/SDS solution: 
60ml 5M potassium acetate 0.2M NaOH  
11.5ml glacial acetic acid 1% (w/v) SDS 
28.5ml ddH2O  ddH2O 
 
0.2M Tris-HCl buffer: 
12.1g Tris 
pH adjusted to 8.0 with HCl 
Completed to 1000ml with ddH2O 
 
 
 
 
   71 
 
(vii) Buffers for ELISA 
Wash buffer:  Stop solution: 
0.05% (v/v) Tween 20 in PBS 2N H2SO4 
 
Block buffer:  Substrate solution: 
1% (w/v) BSA  1 volume colour reagent A (R&D Systems) 
5% (w/v) sucrose  1 volume colour reagent B (R&D Systems) 
0.05% (w/v) NaN3 
Completed to final volume with PBS 
 
Reagent diluent for IL-5: Reagent diluent for IFNγ: 
1% (w/v) BSA  0.1% (w/v) BSA 
Completed to final volume with PBS 0.05% (v/v) Tween 20 
    Completed to final volume with PBS 
 
(viii) Buffers for X-Gal assay 
X-Gal solution :  Glutaraldehyde solution: 
0.2% (v/v) X-Gal  0.1M sodium phosphate pH 7.0 
1mM MgCl2   1mM MgCl2 
150mM NaCl  0.25% (v/v) Glutaraldehyde 
3.3mM K3Fe(CN)6 
3.3mM K4Fe(CN)6 
40mM NaH2PO4 
60mM Na2HPO4 
 
 2.1.4 Primary culture media 
Culture media were prepared and used within a month. Complete BM-DC medium was 
prepared fresh just before use. 
T cell media:   
RPMI   
10% (v/v) FCS 
2mM L-glutamine  
20mM HEPES 
50µM 2-mercaptoethanol 
50U/ml Penicillin/Streptomycin 
0.25µg/ml Fungizone 
 
BM-DC media: 
RPMI 
5% (v/v) FCS 
2mM L-glutamine 
10mM HEPES 
50µM 2-mercaptoethanol 
25U/ml Penicillin/Streptomycin 
0.25µg/ml Fungizone 
 
Complete BM-DC media: 
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BM-DC media + 1ng/ml mGM-CSF 
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2.1.5 Cell lines and media 
Various cell lines in this study are described below in table 2.1. 
Table 2.1: Cell lines and their descriptions 
Name Description Media Source 
ALC Murine lymphoma 
RPMI+10% (v/v) 
FCS+2mM L-glutamine 
500µg/ml G418 
Dr. C. Baxevanis (Saint 
Savas Cancer hospital, 
Athens) 
ALC/HAGE Murine lymphoma, HAGE-positive 
RPMI+10% (v/v) 
FCS+500µg/ml 
G418+50µg/ml Zeocin 
Nottingham Trent 
University 
BHK-21 Syrian hamster kidney DMEM+10% (v/v) FCS ATCC 
CMLT-1 Chronic myeloid leukaemia 
RPMI+10% (v/v) 
FCS+2mM L-glutamine 
Prof. I. Dodi (Anthony 
Nolan Institute, London) 
ESTDAB-07 Human melanoma RPMI+10% (v/v) FCS+2mM L-glutamine 
Prof. D. Schadendorff 
(Tuebingen University) 
ESTDAB-17 Human melanoma RPMI+10% (v/v) FCS+2mM L-glutamine 
Prof. D. Schadendorff 
(Tuebingen University) 
ESTDAB-27 Human melanoma RPMI+10% (v/v) FCS+2mM L-glutamine 
Prof. D. Schadendorff 
(Tuebingen University) 
ESTDAB-34 Human melanoma RPMI+10% (v/v) FCS+2mM L-glutamine 
Prof. D. Schadendorff 
(Tuebingen University) 
ESTDAB-95 Human melanoma RPMI+10% (v/v) FCS+2mM L-glutamine 
Prof. D. Schadendorff 
(Tuebingen University) 
KCL-22 Chronic myeloid leukaemia 
RPMI+10% (v/v) 
FCS+2mM L-glutamine 
Prof. I. Dodi (Anthony 
Nolan Institute, London) 
K812 Chronic myeloid leukaemia 
RPMI+10% (v/v) 
FCS+2mM L-glutamine 
Prof. I. Dodi (Anthony 
Nolan Institute, London) 
K562 Chronic myeloid leukaemia 
RPMI+10% (v/v) 
FCS+2mM L-glutamine ATCC 
KYO-1 Chronic myeloid leukaemia 
RPMI+10% (v/v) 
FCS+2mM L-glutamine 
Prof. I. Dodi (Anthony 
Nolan Institute, London) 
NALM-1 Chronic myeloid leukaemia 
RPMI+10% (v/v) 
FCS+2mM L-glutamine 
Prof. I. Dodi (Anthony 
Nolan Institute, London) 
RMA/S-A2 Transgenic lymphoblastoid 
RPMI+10% (v/v) 
FCS+2mM L-glutamine 
Prof. F. Lemonnier 
(Institut Pasteur, Paris) 
293 Human embryo kidney DMEM+10% (v/v) FCS ICRF 
UCHM-1 Chronic myeloid leukaemia 
RPMI+10% (v/v) 
FCS+2mM L-glutamine 
Prof. I. Dodi (Anthony 
Nolan Institute, London) 
U937 Human histiocytic lymphoma 
RPMI+10% (v/v) 
FCS+2mM L-glutamine University of Sheffield 
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2.2 Methods 
 2.2.1 Expression analysis 
  2.2.1.1 RNA extraction and cDNA synthesis 
Total RNA was isolated from cell lines and tissues using RNA STAT-60 following 
manufacturer’s instructions. Briefly, tissues were grounded to a powder in liquid nitrogen and 
1ml of RNA STAT-60 added to them and stored at room temperature (RT) for 5 minutes. 
0.2ml of chloroform was added and the homogenate shaken vigorously for 60 seconds and left 
at RT for 3 minutes. Samples were then centrifuged at 14,000rpm for 10 minutes. The aqueous 
phase was transferred to a fresh tube and 0.5ml of isopropanol was added to them. Samples 
were incubated at RT for 10 minutes followed by centrifugation at 12,000rpm for 15 minutes. 
Supernatant was discarded and the pellet washed with 70% (v/v) ethanol. RNA pellet was then 
dried and re-suspended in molecular grade water and the concentration and purity of the RNA 
was measured on a UV spectrophotometer. 
RNA was then reverse transcribed into cDNA as follows. 2µg of RNA was taken in a tube 
along with 0.5µg of Oligo-d(t15) primers. Tube was heated at 70°C for 5 minutes and then 
placed on ice. The following mix was then added to the tube: 5µl of 5X Reaction buffer, 1µl of 
dNTP (12.5mM), 25 units of RNasin ribonuclease inhibitor, 200 units of M-MLV reverse 
transcriptase. Nuclease free water (ddH2O) was then added to make the final volume to 25µl. 
Content of the tube was gently mixed and heated at 39.2°C for 80 minutes followed by cooling 
on ice and heating at 95°C for 5 minutes before storing at -20°C. 
   
  2.2.1.2 PCR amplification 
PCR was performed on a DNA thermal cycler. Primers were supplied by MWG Biotech. Cell 
lines and tissues were all pre-screened for housekeeping gene 18S ribosome, which yielded a 
110bp product. For HAGE screening by conventional RT-PCR, primers used were 5’-
CCTTTCAATGTTATCCTGAG-3’ and 5’-TATTCTTCAGATTGACGAAG-3’, which 
yielded a 432bp product. For amplification by PCR, 2µl of cDNA was supplemented with 4µl 
of 5X Phusion HF buffer, 0.4µl of 10mM dNTP, 20pmol of each of primer solutions, 1 unit of 
Phusion DNA polymerase, and ddH2O to a final volume of 20µl. 
PCR for HAGE was initiated by a melting step at 98°C for 30 seconds, followed by 32 cycles 
of denaturation at 98°C for 10 seconds, annealing at 54°C for 30 seconds and extension at 
72°C for 20 seconds. It was followed by a final extension step at 72°C for 10 minutes. All the 
primers used for the study are listed below in table 2.2. 
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Table 2.2: Primers used for PCR of HAGE 
Conventional PCR primers of GAPDH and HAGE 
GAPDH Forward 5’-ACCACCAACTGCTTAGCACC-3’ 
GAPDH Reverse 5’-CCATCCACAGTCTTCTGGGT-3’ 
HAGE Forward 5’-CCTTTCAATGTTATCCTGAG-3’ 
HAGE Reverse 5’-TATTCTTCAGATTGACGAAG-3’ 
 
PCR products were visualised using 1.4% (w/v) agarose gel containing 1µg/ml of ethidium 
bromide. 
 
 2.2.1.3 Real time quantitative PCR 
Samples of breast, gastric and colon carcinoma mRNA, along with patient-matched normal 
tissue mRNA, were kindly provided by Dr. Aija Line (Latvia). Samples of melanoma and head 
& neck carcinoma were kindly provided by Prof. D. Schadendorff (Germany) and Dr. R. Ferris 
(USA), respectively. Samples of CML were kindly provided by Dr. R. Clark. Samples of 
mRNA from normal tissues were purchased from Clontech. Human cell lines are described 
above. Primers were supplied by MWG Biotech. Reverse transcription of the mRNA was 
performed as described earlier with exception of using Random primers instead of Oligo-d(t15) 
primers. For preparing the standard curve, cDNA from a HAGE-positive cell line (ESTDAB-
27) was serially diluted. Primers for various genes (GAPDH, h18S, HAGE, p53, Bcr/Abl, 
OAS1 and STAT1) were designed with the assistance of the primer Vs program at the 
following website: (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). All the primers, 
described in table 2.3, were designed to generate PCR products of under 250bp in size to 
optimise the RT-Q-PCR. 
RT-Q-PCR was performed using a BioRad real time Thermocycler using SYBR green 
fluorescent dye. Thermocycling for each reaction was done in a final volume of 12.5µl 
containing 0.5µl of cDNA template, 6.5µl of SYBR green supermix containing high fidelity 
DNA polymerase, and 20pmol of each of the gene-specific primer solutions. This was then 
made up to 12.5µl with ddH2O. RT-Q-PCR was initiated by a melting step at 98°C for 30 
seconds, followed by 45 cycles of denaturation at 98°C for 10 seconds, annealing at the 
corresponding annealing temperatures indicated in table 2.3 for 30 seconds and extension at 
72°C for 20 seconds. It was followed by a final extension step at 72°C for 10 minutes and a 
stop step at 98°C for 1 minute. Finally, a dissociation curve was created by doing 0.5°C 
increment going from the annealing temperature to the denaturation temperature.  
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Table 2.3: Sequences of primers used for RT-Q-PCR and respective annealing temperatures 
Real time PCR primers and respective annealing temperature 
Bcr/Abl Forward 5’-TCCACTCAGCCACTGGATTTAA-3’ 
Bcr/Abl Reverse 5’-TGAGGCTCAAAGTCAGATGCTACT-3’ 62°C 
h18S Forward 5’-CAACTTTCGATGGTAGTCG-3’ 
H18S Reverse 5’-CCTTCCTTGGATGTGGTA-3’ 54°C 
GAPDH Forward 5’-ACCACCAACTGCTTAGCACC-3’ 
GAPDH Reverse 5’-CCATCCACAGTCTTCTGGGT-3’ 54°C 
HAGE Forward 5’-GGAGATCGGCCATTGATAGA-3’ 
HAGE Reverse 5’-GGATTGGGGATAGGTCGTTT-3’ 66°C 
OAS1 Forward 5’-CAAGCTCAAGAGCCTCATCC-3’ 
OAS1 Reverse 5’-TGGGCTGTGTTGAAATGTGT-3’ 59°C 
p53 Forward 5’-GTGGAAGGAAATTTGCGTGT-3’ 
p53 Reverse 5’-CCAGTGTGATGATGGTGAGG-3’ 66°C 
STAT1 Forward 5’-AAATTCCTGGAGCAGGTTCA-3’ 
STAT1 Reverse 5’-TGGCCCCAGTCACTTAATC-3’ 59°C 
 
 2.2.1.4 Cell lysate preparation 
ESTDAB-07 and -27 melanoma cell lines have been described in section 2.1.4. Cells were 
harvested and washed twice in ice cold PBS at 1,500rpm for 3 minutes at 4°C. Cell pellets 
were re-suspended in 100µl of ddH2O for lysis. Tubes were sonicated for 5 minutes before 
being agitated for 30 minutes at 4°C. Tubes were than centrifugated at 14,000rpm for 30 
minutes at 4°C and supernatants transferred to fresh tubes. Samples were stored at -80°C until 
analysis by protein assay and SDS-PAGE.  
 
 2.2.1.5 Protein assay for SDS-PAGE samples 
Protein concentration was determined in the lysates preparation by performing a BioRad Dc 
protein assay as described by the manufacturer’s protocol. The standard was made of BSA 
diluted in water in serial dilution. Briefly, 25µl of Reagent A was added to 5µl of samples. To 
each well, 200µl of Reagent B was then added. Each sample was run in duplicate. The reaction 
was left to develop for 15 minutes at RT and the plate was read at 750nm on a Tecan 96-well 
plate reader. 
 
  2.2.1.6 SDS-PAGE and transfer 
Reducing sample buffer was added to all samples and boiled for 5 minutes at 95°C to denature 
proteins, before being loaded (30µg) on the polyacrylamide gel. As a standard, 30µg of BSA 
was run with the samples. The gel (100cm2) was run at 90V through the 4% stacking gel and 
   77 
120V through the 10% resolving gel using electrophoresis. Proteins were then transferred at 
13V onto nitrocellulose membrane for 40 minutes using a semi-dry transfer unit according to 
manufacturer’s instructions. 
 
 2.2.1.7 Immunoprobing 
Membranes were stained with Ponceau S, and the standard lane was cut from the rest of the 
membrane. The membrane blocked overnight in TBS-Tween 20-Marvel under constant 
agitation. At the same time, the primary rabbit anti-HAGE antibody (a kind gift from Dr. A. 
Knights, Tuebingen University), was first adsorbed with rabbit liver powder overnight at 4°C. 
After centrifugation, the supernatant was then added at 1:1000 dilution in TBS-Tween 20-
Marvel and incubated for 2 hours at RT. After washing the membrane four times for 15 
minutes in TBS-Tween 20 at RT, the secondary HRP-conjugated antibody was added to the 
membrane at a 1:1000 dilution in TBS-Tween 20-Marvel and incubated for 2 hours at RT. The 
membrane was washed four times for 15 minutes in TBS-Tween 20 at RT, and revealed using 
ECL chemioluminescence kit. Hyperfilm ECL films were used to detect the luminescence. 
 
  2.2.1.8 Fluorescent activated cell sorting (FACS) 
2-5*105 cells were used per tube. Cells were washed twice in FACS buffer and incubated on 
ice for 30 minutes with primary antibody. Rat anti-mouse CD80, CD86, 4.1BBL, 
Macrophage/Monocyte marker (F4/80), DEC205, Ia/Ie (murine class II), CD45R, mouse anti-
HLA-A2, HLA-DR, FLAG, rabbit anti-HAGE and hamster anti-mouse CD11c antibodies were 
used in these experiments. Appropriate isotype controls were used in each experiment. 
Following incubation with the primary antibody, cells were washed twice in FACS buffer and 
incubated for 30 minutes on ice with FITC- or PE-conjugated goat anti-rat IgG, goat anti-
mouse IgG, goat anti-rabbit IgG or goat anti-hamster IgG as secondary antibody accordingly. 
Finally, cells were washed twice in FACS buffer and re-suspended in 400µl of Isoton and 
FACS analysis was performed on the flow cytometer. In cell cycle analysis, 2-5*105 cells were 
used per tube. 100µl of 10µg/ml of propidium iodide (PI) was added to the cells. After 5 
minutes at 37°C, FACS analysis was performed on the flow cytometer. 
 
  2.2.1.9 Immunofluorescence 
A day prior to staining, 2*104 adherent cells or 1*105 non-adherent cells were plated in 8-
chamber slides. Media were removed and cells were consecutively permeabilised and fixed 
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with 1% (w/v) paraformaldehyde and 70% ethanol, respectively, each for 10 minutes at RT. 
Rat anti-mouse CD80, CD86, 4.1BBL, mouse anti-HLA-DR, FLAG and rabbit anti-HAGE 
were used in these experiments. Appropriate isotype controls were used in each experiment. 
Following incubation with the primary antibody, cells were washed twice in FACS buffer and 
incubated for 30 minutes on ice with FITC- or PE-conjugated goat anti-rat IgG, goat anti-
mouse IgG or goat anti-rabbit IgG as secondary antibody accordingly. Finally, cells were 
washed twice in FACS buffer. Slides were dried at 37°C, mounted with fluorescent mounting 
media and left overnight at 4°C. Slides were finally studied under confocal microscope the 
following day. 
 
  2.2.1.10 Immunohistochemistry 
Paraffin-embedded multiple normal and tumour tissue microarrays were purchased from US 
Biomax. Frozen melanoma and head & neck carcinoma tissue sections were kindly provided 
by Prof. D. Schadendorff (Germany) and Dr. R. Ferris (USA), respectively. Prior to 
immunohistochemistry, antigen retrieval was carried out on paraffin-embedded tissues. Briefly, 
sections were de-waxed in xylene and re-hydrated in graded ethanol (100%, 100% and 70% 
(v/v)). Slides were consecutively rinse in tap water and in ddH2O before being heated up in 
0.01M citrate buffer pH 6.0 for 10 minutes in the microwave in order to perform antigen 
retrieval. Once again, slides were consecutively rinsed in tap water and in ddH2O. At this stage, 
both frozen and paraffin-embedded tissues can undergo immunohistochemistry. 0.03% (v/v) 
H202 diluted in 1X PBS was added to the tissue sections for 5 minutes before being washed 
with PBS. Sections were then blocked for 10 minutes with 10% (v/v) serum made from the 
species of the secondary antibody. In the case of HAGE, goat serum was used. Following 
incubation, the serum was removed and 100µg/ml of the primary antibody (adsorbed rabbit 
anti-HAGE) was added for overnight incubation at 4°C. Slides were then washed in 1X PBS 
and 10µg/ml of the secondary antibody (biotin-conjugated goat anti-rabbit IgG) was added. 
Slides were incubated for 30 minutes at RT and washed thoroughly with 1X PBS. The ABC 
reagent was laid onto the slides, left to react with secondary antibodies for 30 minutes at RT 
and washed off with PBS. The DAB reagent was added to the sections in order to react with 
the ABC reagent for 10 minutes at RT and washed off with ddH2O. Finally, frozen and 
paraffin-embedded sections were counterstained in Gill’s and Harris’ staining, respectively, 
and fixed consecutively in graded ethanol (70%, 100%, 100% (v/v)) and in xylene. Slides were 
mounted, air-dried and observed under the microscope. Staining intensities were semi-
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quantitatively evaluated as positively stained according to the following categories: -, no 
staining; 1+, weak but detectable; 2+: moderate, 3+, intense. For each tissue, a histologic score 
(H-score) value was derived by summing the percentage of cells that stained at each intensity 
category and multiplying that by the weighted intensity of the staining. In each slide, five 
different areas were assessed under the microscope (x40 magnification) and the average score 
was used. 
 
 2.2.2 Gene induction or silencing 
  2.2.2.1 DNA transfection 
Lipofectamine 2000 was used to transfect cells as electroporation was found to result in very 
high cell mortality. Transfection was done as per manufacturer’s instructions. Briefly, 6*105 
cells in suspension or 5*104 adherent cells in 500µl of culture media were plated per well in a 
24-well plate. 24 hours later, 1.2µg of expression plasmid DNA was diluted in 50ml of Opti-
MEM medium for each well. At the same time, 2ml of lipofectamine was diluted in 50ml of 
Opti-MEM medium for each well. After 5 minutes at RT, DNA and lipofectamine were 
combined, gently mixed and incubated for 20 minutes at RT in order to allow the formation of 
DNA-lipofectamine complexes. 100µl of the required mixture was then added to each of the 
wells containing cells and medium. Wells were mixed by gently rocking the plate back and 
forth. 24 hours later, medium in the wells was removed and 1ml of fresh culture medium 
containing 500µg/ml G418 or 50µg/ml zeocin was added in its place. The selective antibiotic 
was chosen in agreement with the mammalian resistance gene expressed by the plasmid used 
for transfection. Transiently-transfected cells were then left to grow to confluency for 48 hours 
for expression analysis by RT-PCR, FACS or immunofluorescence. 48 hours after transfection, 
stably-transfected cells were made by plating 100 cells per well in 200µl of selective medium 
in a 96-well plate. Upon repeated splitting in 96-well plates, cells growing in the selective 
media were harvested and put back into culture in a 24-well plate to bulk-up. Cells were then 
left to grow to confluency after which time; the cells were pooled and put into culture in T25 
flasks for expression analysis by RT-PCR and storage in liquid nitrogen. 
 
  2.2.2.2 Small interfering RNA (siRNA) transfection 
SiRNA transfection was carried out using Interferin following manufacturer’s protocol. Briefly, 
2*104 adherent cells in 500µl of culture media were plated in a 24-well plate. On the day of 
transfection, 1µl of 40µM HAGE siRNA (sense: 5’-AUUAGAGAGGAAGGUUUGA-3’; anti-
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sense: 5’-UCAAACCUUCCUCUCUAAU-3’) from Eurogentec was diluted in 100µl of Opti-
MEM media and vortexed. 5µl of Interferin was then added and the mixture was thoroughly 
vortexed for 10 seconds before being incubated for 10 minutes at RT. While incubating, the 
medium was removed and replaced with 100µl of fresh media. 100µl of siRNA-Interferin 
mixture was given to cells while rocking the plate back and forth. After 6-hour incubation at 
37°C, 5% CO2, 500µl of fresh medium was added. 24 hours later, media in the wells was 
removed and 1ml of fresh culture media was added in its place. Expression analysis was then 
carried out by real time PCR and immunofluorescence to observe HAGE silencing and its 
effects were evaluated by performing proliferation assays using Trypan blue exclusion and 
thymidine incorporation, and cell cycle analysis using propidium iodide DNA staining. 
 
 2.2.2 Cloning of human HAGE and murine co-stimulatory molecules  
 2.2.3.1 Enzyme digestion 
Plasmids or PCR amplicons were digested with two restriction enzymes, in order to generate 
the correct overhangs for ligation, depending on the sequence of the cDNA cloned and the 
restriction enzymes available in the multiple cloning sites of the original and the receiving 
expression vectors. Briefly, 6µl of DNA was mixed with 1µl of restriction enzyme-specific 
buffer, 1µl of 1X BSA and 1µl of each restriction enzyme for a total volume of 10µl. Tubes 
were incubated for 1-2 hours at the restriction enzyme’s optimal temperature. A negative 
control was included whereby the restriction enzymes had been omitted from the reaction mix 
and replaced with ddH2O. The restriction enzyme digestion products were then run on a 1.4% 
(w/v) agarose gel and visualised under UV light. 
 
  2.2.3.2 Band extraction of DNA 
As described above, DNA was run on a 1.4% (w/v) agarose gel. Bands were visualised by 
placing the gel on a UV transilluminator. The DNA of interest was then excised from the gel 
and extracted using Geneflow DNA isolation kit following the manufacturer’s protocol. Briefly, 
the gel was dissolved in a solution of NaI at 55°C for 5 minutes. 30µl of glass powder was then 
added to the re-suspended DNA and incubated for 5 minutes at RT with intermittent mixing. 
Following incubation, the DNA, now bound to the glass powder, was washed three times in 
wash buffer. After the last wash, the DNA was centrifuged at 14,000rpm and the supernatant 
was discarded. The pellet was then re-suspended in 30µl of ddH2O. DNA was eluted from the 
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glass powder by incubation at 55°C for 5 minutes. The DNA present in the supernatant was 
finally harvested following centrifugation at 14,000rpm for 45 seconds. 
 
  2.2.3.3 DNA ligation 
Ligation of HAGE, mB7.1, mB7.2 and m4.1BBL cDNA into their new expression vectors was 
done using T4 ligase as per the manufacturer’s instructions. Briefly, 7µl of the required 
digested insert was added to 1µl of the double digested plasmid with 1µl of T4 buffer and 1µl 
of T4 ligase for a total volume of 10µl. This mixture was then left overnight at 4°C in order to 
complete the ligation process. 
 
  2.2.3.4 Transformation into XL1-Blue E.coli and bulking up 
XL1-Blue is a competent strain of Escherischia coli used for routine nucleotide transformation 
and cloning procedures. For transformation, a previously prepared aliquot of XL1-B was taken 
and defrosted on ice. 10µl of the ligation mix was added to the bacteria and incubated on ice 
for 30 minutes. Following incubation, cells were heat-shocked at 42°C for 3 minutes and 
cooled on ice. 250µl of LB media was then added and cells were incubated at 37°C in a shaker 
for 1 hour. 150µl of transformed cells were then plated onto LB agar plates containing either 
50µg/ml ampicillin or 30µg/ml zeocin depending on the resistance gene expressed by the 
plasmid used for transformation. Plates were left on the bench for 5 minutes to allow the 
absorption of media before being inverted and put into a 37°C incubator overnight. The 
following morning 10 universals containing 3ml of LB broth plus 50µg/ml ampicillin or 
30µg/ml zeocin were set up. Isolated colonies from the agar plates were then picked using a 
pipette tip and cells were placed in a 37°C shaker to grow overnight. 
 
  2.2.3.5 DNA isolation and sequencing 
1.5 ml of each of the overnight cultures, prepared as above, was harvested and the bacteria 
pelleted by centrifuging at 14,000rpm for 5 minutes. Pellets were re-suspended in 100µl of 
cold GTE and incubated for 5 minutes. Following this incubation, 200µl of 1% (w/v) 
SDS/0.2M NaOH was added and the pellets incubated on ice for 5 minutes. 150µl of KOAc 
was added, the samples vortexed and incubated on ice for a further 5 minutes. Samples were 
centrifuged as before and supernatants collected. 800µl of chloroform-isoamyl alcohol was 
then added and the samples were vortexed then centrifuged as before for 5 minutes. Upper 
layers were collected and 1ml of absolute ethanol added to each sample. These were then 
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incubated at room temperature for 15 minutes. Samples were centrifuged at 14,000 rpm for 15 
minutes in order to pellet DNA. Supernatants were discarded and the DNA pellets washed with 
500µl of 70% ethanol. Samples were centrifuged at 14,000rpm for 5 minutes and the tubes 
inverted onto tissue paper to dry out the DNA. Samples were then air-dried for 30 minutes. 
Finally the DNA was re-suspended in 50µl of ddH2O with 1µl RNase (final concentration of 
20µg/ml). Sequencing by MWG Biotech was used to confirm sequences of the cloned cDNA. 
 
 2.2.4 Animals and immunisation 
  2.2.4.1 Animals 
Mouse class I (H-2) knockout C57BL/6 HLA-A2.1 mice (HHDII) and C57BL/6 HLA-A2.1/-
DR1 (HHDII-DR1) animals were received as a generous gift from Dr. F. Lemonnier (Institut 
Pasteur, Paris). FVB/N-DR1 animals were received as a generous gift from Dr. M. Altmann 
(MRC Clinical Sciences Center, London). Mouse class II (I-Ab) knockout C57BL/6-DR4 mice 
were purchased from Taconic, USA. HHDII, HHDII-DR1, FVB/N-DR1 or C57BL/6-DR4 F2 
mating positive animals were maintained inbred by ensuring they have a common F0 ancestor. 
Colonies were bred at Nottingham Trent University animal house in accordance with the Home 
Office Codes of Practice for the housing and care of animals. 
 
  2.2.4.2 Peptides and peptide immunisation 
HAGE protein sequence was screened for peptides binding to HLA-A2.1 using a web-based 
algorithm (www.syfpeithi.de). Peptides (Table 2.4) were chosen based on their binding score, 
synthesised (Alta Biosciences) and dissolved in 100% DMSO to a working concentration of 
10mg/ml and then stored at -80°C. Each HHDII mouse was immunised at the base of the tail 
with 100µl of a peptide/IFA emulsion containing 100µg of peptide and 140µg of helper 
peptide (HepB) in 50% IFA. One round of immunisation was undertaken. 
 
Table 2.4: HAGE-derived HLA-A2 peptides to test for cytotoxicity 
Peptide name Sequence HLA-A2 binding score 
HAGE 103 IIQEQPESL 24 
HAGE 126 AVIDNFVKKL 24 
HAGE 296 YLMPGFIHLV 30 
HAGE 506 DLILGNISV 25 
HAGE 507 LILGNISVE 17 
HAGE 508 ILGNISVESL 28 
HAGE 509 LGNISVESL 19 
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HAGE 551 LDVHDVTHV 16 
 
HAGE protein sequence was also screened for peptides binding to both HLA-DR1 and -DR4 
using the same algorithm as before. Peptides (Table 2.5) were chosen based on their binding 
score, synthesised and re-suspended as described above. Each FVB/N-DR1 or C57BL/6-DR4 
mouse was immunised at the base of the tail with 100µl of a peptide/IFA emulsion containing 
100µg of peptide in 50% IFA. Two rounds of immunisation with the same peptide were 
undertaken at 7-day intervals. 
 
Table 2.5: HAGE-derived HLA-DR1 and –DR4 peptides used in proliferation assays 
Peptide name Sequence HLA-DR1 binding score 
HLA-DR4 
binding score 
HAGE 109 ESLVKIFGSKAMQTK 28 26 
HAGE 195 KKNFYKESTATSAMS 26 28 
HAGE 338 KYSYKGLRSVCVYGG 33 28 
HAGE 505 SDLILGNISVESLHGD 22 20 
HAGE 506-II DLILGNISVESLHGD 22 20 
HAGE 545 DLASRGLDVHDVTHV 18 16 
 
  2.2.4.3 Plasmid, DNA bullets and DNA immunisation 
Expression vectors encoding HAGE and/or murine co-stimulatory molecules were coated onto 
1.0µm gold microcarriers using manufacturer’s instructions. Briefly, 36µg of DNA was mixed 
with 200µl of 0.05M spermidine containing 16.6mg of gold. After sonication, 200µl of 1M 
CaCl2 were added dropwise to the mix whilst sonicating and the mixture was incubated for 10 
minutes at RT. The DNA-gold mixture was then washed three times in anhydrous ethanol and 
re-suspended in 2ml of 0.025mg/ml PVP. Whilst the tube was sonicating, the sample was 
loaded into a dried Tefzel tubing and left to stand for 30 minutes in a Tubing Prep Station. The 
dry ethanol was gently removed using a syringe leaving the gold undisturbed. Nitrogen was 
turned on and the tubing was left spinning for five minutes. Once totally dried, the tubing was 
removed from the station and cut using a guillotine. DNA bullets were stored at 4°C until used 
for immunisation. Each HHDII, HHDII-DR1, FVB/N-DR1 or C57BL/6-DR4 mouse was 
immunised with one bullet containing human and/or mouse DNA using a Helios gene gun. 
Three rounds of immunisation were undertaken at 7-day intervals. Naked DNA immunisation 
was also used in in vivo challenge experiments. 100µg of DNA in serum free media per 
HHDII/DR1 mice was administrated twice intra-muscularly at 7-day interval.  
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  2.2.4.4 Dendritic cells, transfection and DC immunisation 
The preparation of dendritic cells used was adapted from Inaba et al. (1992). Briefly, mouse 
hind limbs were harvested and bones were flushed with BM-DC media after removing muscles 
and knuckles. Cells were washed, re-suspended in 2ml of BM-DC media and counted in 0.6% 
(v/v) acetic acid and 0.1% (v/v) Trypan blue. Cells were plated out in 24-well plates at 1*106 
cells per ml per well of BM-DC media containing 1ng/ml of murine GM-CSF. After two days, 
cells were harvested and re-plated in a 24-well plate at 1.2*106 cells per ml of BM-DC media 
containing 1ng/ml of mGM-CSF, and transfected with the pSHAME2a/HAGE plasmid using 
lipofectamine as described in section 2.1.1.1.  
On the fourth day, 1µg/ml of LPS and 500µg/ml of G418 were added to induce complete 
maturation and selection of positively-transfected BM-DC. On the fifth day, cells were 
harvested, washed, re-suspended in serum free media and counted. Dendritic cell immunisation 
was then induced by intra-dermal injection of 2*106 cells in the right flank of HHDII and 
HLA-DR4 transgenic mice. 
 
  2.2.4.5 Recombinant Semliki Forest Virus and SFV immunisation 
(i) Generation of SFV virus 
pSCAβ, pSCAhelper and pSHAME2a plasmids were kindly provided by Dr. Rod Bremner 
from the University of Toronto. For production of infective viral particles, pSCAβ or 
pSHAME2a and pSCAhelper plasmids were co-transfected in 293 cells at different molar 
ratios. Calcium phosphate transfection combines with 1:3 molar ratio of expression plasmid: 
helper plasmid was used in all experiments. Calcium phosphate transfection was performed 
using the ProFection mammalian transfection system following manufacturer’s instructions. 
Briefly, 293 cells were plated at 5*105 cells per 3ml per well in a 6-well plate a day before 
transfection. On the day of transfection, cells were washed once and media was replaced 3 
hours before transfection. DNA and HBS solutions were prepared in two separate 1.5ml tubes. 
12µg of DNA was diluted in ddH2O and 37µl of 2M CaCl2 for a final volume of 300µl. This 
DNA mixture was added to 300µl of 2X HBS solution in another tube with constant vortexing. 
The DNA-HBS-CaCl2 mix was incubated for 30 minutes and added to the cells dropwise. After 
incubating the plate for 16-18 hours at 37°C, 5% CO2, medium was removed from transfected 
cells. Cells were then washed once with PBS and fresh medium was added to the cells. After a 
further 48-hour incubation, medium containing the lysed cells and virus was harvested 
following a freeze-thaw cycle and spun at 2,000rpm for 10 minutes at 4°C. The supernatant 
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containing the virus was transferred into a fresh tube and stored at -20°C until use. Generated 
viruses were inactive and prior to use, they were activated by adding 1-20th of total volume of 
10mg/ml of α-chymotrypsin to cleave the p62 glycoprotein into E2 and E3 proteins. After 1-
hour incubation at RT, 10mg/ml of aprotinin was added to 1/15th of total volume to stop the 
protease activity. 
 
(ii) Viral titration 
In order to calculate the virus titre, BHK-21 cells were infected with different volumes of 
activated virus for 60 minutes at 37°C. After incubation, cells were washed once with PBS and 
incubated for 24 hours after addition of fresh media. To visualise cells infected by SFV-βgal, 
X-gal assay was performed. Briefly, cells were washed twice with PBS and fixed with 
glutaraldehyde for 15 minutes at 37°C. Cells were washed twice with PBS followed by the 
addition of 1ml per well of X-gal solution. Colour was allowed to develop overnight at RT and 
blue cells were counted. Titre was calculated taking into consideration the number of infected 
and uninfected cells as well as the surface area of a well in 6-well plates. 
For titration of SFV/HAGE virus, after infection of BHK-21 cells as above, infected cells were 
visualised by immunohistochemistry. 24 hours after infection, cells were fixed with -20°C 
methanol for 1 minute followed by the addition of mouse anti-FLAG primary antibody. 
Following 1-hour incubation at RT, cells were washed twice and secondary HRP-conjugated 
goat anti-mouse antibody was added. After further 30-minute incubation at RT, cells were 
washed and stained with DAB solution. Colour was allowed to develop and dark brown 
infected cells were counted to determine the titre. 
 
  2.2.4.6 In vivo challenge experiments 
In prophylactic experiments, HHDII/DR1 mice were challenge with 6*105 ALC/HAGE cells 
one week after the last DNA immunisation. In therapeutic experiments, HHDII/DR1 were 
challenged first with 6*105 ALC/HAGE cells and then immunised three to seven days later 
with DNA vaccines. Animals were monitored three times a week for tumour development and 
size, and were sacrificed when the tumour reached a size of 1cm2 according to the Home 
Office guidelines. 
 
 2.2.5 T cell preparation and cytotoxicity in mice 
  2.2.5.1 Preparation of LPS blasts 
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Spleens were harvested from naïve mice and cells were flushed out with T cell medium. LPS 
blasts were set up in a T75 flask by culturing 60*106 spleen cells in T cell medium 
supplemented with 1mg of LPS, 7µg/ml of dextran sulphate and 40µg/ml of Vitamin E. After 
48 hours, cells from LPS blasts were harvested, washed, re-suspended in 5ml of T cell medium 
and irradiated with caesium for 8 minutes at the University of Nottingham. These LPS blasts 
were washed again and pulsed with 100µg/ml of the relevant or irrelevant peptide for 1 hour at 
37°C. After washing, these cells were used for in vitro re-stimulation of the splenocytes 
harvested from immunised mice. 
 
  2.2.5.2 In vitro re-stimulation of murine splenocytes with LPS blasts 
One week after the last immunisation, spleens were harvested from the immunised mice and 
single cell suspensions were prepared in sterile conditions. Cells were counted, re-suspended 
and set up in a T25 flask at 25*106 cells/5ml. Finally, 5*106 irradiated and peptide-pulsed LPS 
blasts per 5ml were added to the splenocytes to make a final volume of 10ml in each T25 flask. 
Supernatants were usually collected on day 3 and 5 of the re-stimulation for cytokine testing. 
 
  2.2.5.3 Chromium release cytotoxicity assay 
On day 5 of the in vitro re-stimulation, splenocytes were harvested, washed twice in serum free 
media, re-suspended in T cell media, counted and used as effector cells. RMA/S- 
A2 target cells were pulsed with 10µg/ml of the relevant or irrelevant peptide a day prior to the 
cytotoxicity assay. On the day of the assay, RMA/S-A2 target cells were harvested, washed 
and labelled with 1.85MBq of chromium-51. A standard 4-hour chromium-release assay was 
performed and the percentage specific cytotoxicity was determined using the following 
equation: 
 
 
 
 2.2.6 BM-DC, T cell generation and proliferation assay in mice 
  2.2.6.1 Murine BM-DC generation for proliferation 
Bone marrow-derived dendritic cells were generated as described in section 2.2.4.4. Cells were 
washed with fresh media every two days and on day 7, BM-DC were re-plated at 5*105 cells 
(Experimental release – Spontaneous release) 
(Maximum release – Spontaneous release) Percentage of cytotoxicity = 
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per ml per well and pulsed with 10µg/ml of the peptide of interest for 4 hours. LPS was added 
at 1µg/ml to induce complete maturation. The following day, BM-DC were washed twice in T 
cell media, re-suspended in 2ml and then pulsed with 10µg/ml of relevant or irrelevant peptide 
for 4 hours at 37°C, 5% CO2. These cells were plated at 5 x 103 per well together with the 
responder cells in a round bottom 96-well plate. 
 
  2.2.6.2 In vitro re-stimulation of murine splenocytes with peptides 
Spleens of immunised animals were harvested seven days after the last immunisation and cells 
were flushed out with T cell media. The cell suspension was then washed, counted and plated 
in 24-well plates at 2.5x106 cells per well in 1ml of T cell media containing 10µg/ml of the 
relevant peptide. Splenocytes were cultured for 6 days at 37°C, 5% CO2 prior to CD8+ T cell 
depletion. On day 13, cells were used at 5x104 cells per well as responders for the proliferation 
assay. In parallel, splenocytes were also cultured with irrelevant peptide as a control for 
specific cytokine release. 
 
  2.2.6.3 Murine CD8+ T cell depletion 
On day 7, depletions were done using CD8-specific dynabeads by following the 
manufacturer’s instructions. Briefly, CD8+ T cells attached to the beads were depleted using a 
magnet. The remaining cells were collected, counted, re-plated at 2.5*106 per ml in T cell 
media containing 20U/ml of murine IL-2 and incubated for another week at 37°C, 5% CO2. 
Purity was assessed by FACS analysis and the preparations were about 98% free of the 
depleted T cell population (data not shown). 
 
  2.2.6.4 Proliferation assay for murine T cells 
Responder T-cells were counted and plated at 5x104 cells per well in 96-well plates. Peptide-
pulsed syngeneic BM-DC were used as APC in all the experiments. Responder cells were co-
cultured with BM-DC either pulsed with the relevant peptide, an irrelevant peptide or no 
peptide in some experiments. Pulsed BM-DC were added to the wells at a density of 5*103 
cells per well. To ascertain the MHC restriction of the response, a MHC blocking antibody 
(2mg/ml L243 anti HLA-DR) was added to the culture when possible. A matched isotype 
control antibody was also used in these experiments. Each culture was performed in 
quadruplicate for approximately 60 hours. Tritiated thymidine was added 18 hours prior to 
harvesting at a final concentration of 0.037MBq/ml. Cells were harvested using a 96-well 
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harvester onto a 96-well filter plate and 40µl of scintillation fluid was added to each of the 
filter wells. Filters were counted for 1 minute per well with a Top-Count scintillation counter. 
 
  2.2.6.5 Enzyme-linked immunosorbent assay (ELISA) 
Splenocytes from the animals were prepared as outlined in Sections 2.2.5.1 and 2.2.6.2. 
Supernatants were collected into a 1.5ml tube and stored at 4°C until required. IFNγ and IL-5 
ELISA were respectively carried out using mouse IFNγ and IL-5 R&D ELISA kits by 
following the manufacturer’s instructions. Briefly, a 96-well ELISA plate was coated with 
100µl of the diluted capture antibody, sealed and incubated overnight at RT. The plate was 
washed with wash buffer three times and blotted against tissue paper. The plate was then 
blocked by adding 300µl of block buffer to each well and left for incubation for 1 hour at RT 
before being washed as before. 100µl of samples or standards in reagent diluent were added to 
each well and the plate was incubated for 2 hours at RT. The washing step was repeated as 
before. 100µl of the detection antibody, diluted in reagent diluent, was added to each well and 
the plate was incubated for 2 hours at RT. The washing step was repeated as described 
previously. 100µl of the working dilution of Streptavidin-HRP was added to each well and the 
plate was covered and incubated for 20 minutes at RT. The washing step was repeated as 
before. 100µl of the substrate solution was added to each well and the plate was incubated for 
20 minutes at RT. 50µl of stop solution was added to each well and the plate was gently tapped 
to ensure thorough mixing. Optical density of each well was determined at 450nm on a Tecan 
96-well plate reader. 
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Chapter 3: Validation of HAGE as a potential antigen for immunotherapy 
3.1 Introduction 
Since van der Bruggen et al. (1991) first discovered specific human tumour antigens of the 
MAGE family, numerous other TAA have been identified forming a large pool of potential 
immunotherapeutic targets against cancer. Tumour antigen-based vaccination had different 
degrees of success whether newly designed vaccines were administrated to mice or humans. 
Indeed, antigen-specific vaccinations targeting MAGE, MelanA/MART-1, tyrosinase, gp100, 
and HER2/neu were shown to be very successful in both prophylactic and therapeutic 
experiments in murine models (Goldberg et al., 2005; Prins et al., 2003; Lachman et al., 2001) 
but very elusive in human clinical trials (Rosenberg et al., 1998; Anichini et al., 1999; Knutson 
et al., 2001). One of the reasons for their failure may partly be due to the choice of antigens 
targeted. Indeed, these antigens might simply be weakly immunogenic and the discovery of 
strongly immunogenic tumour-related proteins such as the cancer/testis antigen NY-ESO-1, 
capable of inducing an immune response in more than 50% of patients, is essential for the 
future development of immunotherapy strategies (Jäger et al., 2000).  
Virally-induced cancers have been targeted with known viral antigens, which are proving to be 
successful in clinical trials, such is the case of E6/E7 cancer vaccines against HPV in cervical 
cancers (Adams et al., 2001). Viral antigens are highly immunogenic and have not been 
previously encountered by the immune response, therefore thwarting the problem of tolerance. 
Furthermore, only infected normal and cancer cells express these antigens, thereby preventing 
the generation of an auto-immune response. Unfortunately, most human cancers are caused by 
environmental and genetic factors. Identification of tumour-specific unique non-viral antigens 
would provide good targets for immunotherapy. However, this approach cannot be applied to 
patients with cancer as it is time-consuming and expensive. Therefore, shared tumour antigens, 
which are not expressed in normal cells but expressed in a variety of tumours, represent ideal 
targets. That is why a major focus has been the study of the so-called CT antigen family. 
Cancer/testis genes are usually normally expressed in some immunoprivileged normal tissues 
including testis and placenta, exhibit highly tumour tissue-restricted expression and were 
shown to be immunogenic in cancer patients. In a search for new potential tumour target 
antigens, a CT antigen, first identified in a human sarcoma and called HAGE, has been studied. 
HAGE over-expression was reported in different types of cancer (e.g. breast, lung, prostate, 
colon or skin) and at various frequencies (5%, 32%, 22%, 31% or 17% respectively) (Scanlan 
et al., 2004). It was also found in 50% of CML (Adams et al., 2002).  
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HAGE, also named DDX43, is a member of the DEAD-box family of ATP-dependent RNA 
helicases and despite the description of more than 500 members across species (Boeckmann et 
al., 2003), consensus sequences characterising this family remain unchanged. Indeed, members 
of this family are characterised by the presence of nine conserved motifs among which the Q-
motif, motifs I, II (also called D-E-A-D box as a single letter code of Asp-Glu-Ala-Asp) and IV 
bind and hydrolyse ATP molecules, while motifs Ia, Ib, IV and V are thought to interact with 
the RNA substrate. These sequences form two distinct domains connected by a linker region 
called SAT, which is thought to allow conformational changes of the helicase core to adapt to 
its substrate (Caruthers and McKay, 2002)(Fig. 3.1). RNA helicases are often described as the 
driving forces behind RNA metabolism. They have various functions but because of their large 
similarity, one can assume that the enzymatic activity will also be quite similar. Functions of 
RNA helicases in RNA metabolism are still not clear but they seem to be involved in processes 
such as transcription, pre-mRNA splicing, ribosome biogenesis, cytoplasmic transport, 
translation initiation/elongation, organelle gene expression and RNA decay (Rocak and Linder, 
2004). Because of the importance the interactions between RNA and helicases seem to fulfill, it 
is critical that the assembly occurs in an energy-dependent manner to ensure appropriate 
complexation and correct triggering of forthcoming events. Furthermore, RNA helicases have 
very low affinity for RNA in vitro suggesting that they probably need the help of other 
ribonucleoprotein complexes in order to have optimal enzymatic activity and substrate 
specificity (Silverman et al., 2003). This low specificity towards RNA in vitro does not easily 
render the identification of a specific role or a functioning mechanism for each of these 
molecules in vivo. It is now globally hypothesised that RNA helicases browse RNA in 
bidirectional fashion (i.e.: either 5’ to 3’, or 3’ to 5’) using the energy gained from the ATP 
hydrolysis until they encounter ribonucleoprotein-RNA complexes. The helicase activity then 
allows the dissociation of RNA from the ribonucleoproteins to which they have high affinity 
(Cordin et al., 2006). Consequently, it becomes legitimate to think that splicing, RNA export, 
ribosome biogenesis and translation constitute an ideal “playground” for these enzymes. These 
RNA helicases have already been suggested to play a major role in cancer development based 
upon their deregulation of expression and/or their involvement in the regulation of molecules 
associated with cancer. Indeed, DDX1 is an example of RNA helicases reported in different 
tumours. DDX1 was shown to be regularly co-amplified with the transcription factor MycN in 
neuroblastoma and retinoblastoma (Amler et al., 1996; Godbout et al., 1998) leading the 
authors to imply that transcription of some DEAD-box genes could be regulated through 
interaction with members of the proto-oncogenic Myc family.  
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Figure 3.1: Conserved motifs of DEAD proteins and their interactions with ATP. Nine 
conserved motifs have been identified. The Q-motif and motifs I and II (also called DEAD motif) 
are required for the binding of ATP and its hydrolysis. Motif III seems to be involved in the 
conformational changes required for helicase activity. Finally, the remaining motifs (Ia, Ib, IV 
and V) might be involved in RNA binding, however further evidence are needed to confirm this 
hypothesis (Taken from Rocak and Linder, 2004).  
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DDX2 is over-expressed in melanoma and the induced down-regulation of this gene resulted in 
the inhibition of the proliferation (Eberle et al., 2002). DDX5 (p68), which showed 55% 
homology with HAGE, is normally implicated in growth regulation by acting as a 
transcriptional co-activator of estrogen-receptor α (Wilson et al., 2004). It was also 
demonstrated to be associated with the histone deacetylase 1 molecule, a well-known 
transcriptional repression protein (Wilson et al., 2004). However, once phosphorylated at its 
tyrosine residues, DDX5 stops exerting its normal functions and was associated with abnormal 
cell proliferation in colorectal carcinoma (Yang et al., 2005). Like HAGE, RCK gene encodes 
a protein, named DDX6 or rck/p54 protein, belonging to this family of RNA helicases. Despite 
DDX6 mRNA being ubiquitously found in all normal tissues, the protein is not expressed in 
normal lumbar and lung tissues. However, DDX6 was constantly present at moderate levels in 
neuroblastoma, glioblastoma, rhabdomyosarcoma and lung cancer cell lines suggesting an 
eventual role of DDX6 in the process of tumorogenesis (Akao et al., 1995).  
One can be critical of some of these studies as the actual translation of the mRNA into a 
protein in tumour tissues has not always been demonstrated. Indeed, mRNA expression does 
not always correlate with protein expression in normal (Rogel et al., 1985) and abnormal 
tissues (Chen et al., 2002) emphasising the need to determine whether TAA such as HAGE or 
DDX1 are not only expressed at the message level but also at the protein level in those tissues. 
In order to validate HAGE as a potential target for immunotherapy, the first step was to 
confirm that the HAGE gene was silent in normal tissues, except testis. Expression at the 
mRNA level was quantified using real time PCR and protein levels were compared with 
mRNA levels using immunohistochemistry. The second step was to confirm previous 
publications describing the actual over-expression of HAGE in some cancer tissues. Cancer 
samples, cancer tissues with patient-matched normal tissues and cancer cell lines were used in 
real time PCR, immunohistochemistry and immunofluorescence experiments. Furthermore, 
RNA helicases seem to play a critical role in RNA metabolism but also in cancer cell 
transformation and proliferation. The eventual implication of HAGE in tumorogenesis offers a 
major advantage in targeting this product for immunotherapy, namely that tumours may be 
unable to escape an adoptive immune response by downregulating the target molecule. Hence, 
a series of experiments relying mainly on immunofluorescence, gene silencing and gene 
induction were designed to determine the localisation of HAGE inside the cell and give an 
insight on HAGE function and its relationship with tumorogenesis. 
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3.2 Results 
 3.2.1 Expression of HAGE in human normal tissues 
Although few studies have reported the pattern of HAGE expression in a wide array of tumour 
types, a more complete study is required before HAGE can be considered a potential candidate 
for immunotherapy. Therefore, the analysis of HAGE expression included a large number of 
normal tissues as well as a larger cohort of tumours of different tissue origins. Moreover, 
unlike previous studies describing HAGE expression at the mRNA level, a more thorough 
analysis was undertaken combining the determination of the expression of HAGE at both 
mRNA and protein levels. Normal tissue mRNA were purchased and conventional RT-PCR 
analysis was carried out using primers originally described by Martelange et al. (2000) with the 
RT-PCR conditions detailed in the Materials and Methods section. Briefly, 2µg of RNA was 
used to reverse transcribe and generate cDNA using random primers from the samples and 
semi-quantitative RT-PCR was performed for 32 cycles. Normalisation of the experiment was 
carried out using 18S ribosome RNA. In contrast to previous reports (Martelange et al., 2000; 
Adams et al., 2002), normal tissues such as brain, heart, kidney, liver, prostate, and peripheral 
blood mononuclear cells (PBMC) all tested positive for the expression of HAGE, although to a 
much weaker extent than seen in testis (Fig. 3.2). In addition, expression of the tumour-
suppressor gene p53 was found at equal levels in all normal tissues.  
To enable the validation of this analysis, the more sensitive technique of real time quantitative 
RT-PCR (RT-Q-PCR) was performed. Primers for HAGE and p53 were designed to 
distinguish between genomic DNA and the cDNA templates so that no genomic DNA 
amplification could occur and that the PCR amplicons would be under the 250bp limit as 
suggested by Bustin (2000). Primers for HAGE, p53 and Bcr/Abl give a product size of 220bp, 
184bp and 90bp, respectively. Similarly, 2µg of RNA was used to reverse transcribe and 
generate cDNA using random primers. Maximum volume was used for samples with very low 
concentration of RNA. Real time PCR was performed for 45 cycles and relative gene 
expression was estimated by dividing the starting quantity of the studied gene by that of 
housekeeping genes. It is noteworthy that two different housekeeping genes were used, 
GAPDH and ribosomal 18S RNA as suggested by several published studies (Bustin., 2000). 
High values of 18S RNA were observed leading to low relative gene expression, whereas 
GAPDH values were the most consistent and were therefore used for the determination of 
relative gene expressions in all future analyses.  
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Figure 3.2: Expression of HAGE and p53 in human normal tissues by RT-PCR. This figure 
represents the semi-quantitative analysis of expression of HAGE and p53 in normal tissues and in 
PBMC, using water and a HAGE-negative cell line (ESTDAB-07) as negative controls, as well as a 
HAGE-positive cell line (ESTDAB-27) and testis as positive controls. PCR products for 18S ribosome, 
HAGE and p53 should be of 110, 432 and 184bp, respectively. 
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As seen in Fig. 3.3, relative HAGE expression was proved to be undetectable or extremely low 
in all the normal tissues tested when compared to testis, which value was arbitrarily set as one. 
Importantly, relative HAGE expression was also found to be undetectable in normal PBMC 
from four healthy donors. In this experiment, p53 mRNA was present in all the normal tissues 
tested but at various levels. These RT-Q-PCR results are in contradiction with the results 
achieved by semi-quantitative RT-PCR and will be discussed later. However, and because of 
its sensitivity, its specificity and the low levels of mRNA from tumour tissues obtained through 
different collaborations, RT-Q-PCR was chosen as the method of choice for all subsequent 
analyses of HAGE expression in tumour tissues and for the validation of this study.  
To date, HAGE has only been described as a putative protein due to the fact that this CT 
antigen has only been detected at the message level. As no commercial antibodies were 
available at the time of the study, antisera were produced in rabbits against HAGE peptides 
predicted to be antigenic in silico (Dr. A. Knights, Tuebingen University). These sera were 
controlled by Western-blotting on cell lysates generated from a previously described HAGE 
positive melanoma cell line and resulted in a band on the developed membrane with a mass in 
the region of 73kDa, the expected mass for the HAGE gene product. Bands of different sizes 
also showed up and this unspecificity was largely resolved by incubating the antisera overnight 
with rabbit liver powder at 4°C while shaking. Upon centrifugation, supernatants were 
harvested, tested and showed much improved specificity although further work is needed to 
investigate as to the nature of the contamination by 2D gel analysis, tryptic digestion and 
tandem mass spectrometry (Fig. 3.4). Once the quality and the specificity were confirmed, 
antisera were applied to normal tissue microarrays, multiple tumour tissue microarrays and 
tumour sections in immunohistochemistry staining procedures, and to melanoma cell lines in 
immunofluorescence protocols.  
Multiple normal tissue microarrays were stained for HAGE expression following antigen 
retrieval, antiserum incubation and DAB staining. Fig. 3.5 demonstrates that whilst no 
significant staining of normal tissues was observed (Fig. 3.5A-K); normal testis tissues showed 
positive staining with the antiserum (Fig. 3.5L). Therefore, protein expression was shown to 
correlate with mRNA levels observed earlier by RT-Q-PCR. Importantly, HAGE could not be 
detected in the thymus by immunohistochemistry suggesting that HAGE-specific T cells would 
not be deleted by central tolerance mechanisms (Fig. 3.5J).  
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Figure 3.3: Expression of HAGE and p53 in human normal tissues by RT-Q-PCR. Real time 
PCR analysis was carried out on 7 human normal tissues and 4 PBMC samples from healthy 
donors. The experiment was carried out once and data are expressed relative to the mRNA 
level of normal testis, arbitrarily set as 1. 
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Figure 3.4: Western-blot of human melanoma cell lines. 30µg of protein was loaded in each 
lane and Western-blot performed by probing with anti-HAGE antibody, either neat (1 and 2) 
or after adsorption with rabbit liver powder (4, 5, and 6). (1) ESTDAB-27, (2) ESTDAB-07, (3) 
Protein marker, (4) ESTDAB-27, (5) ESTDAB-07 and (6) secondary antibody only. 
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Figure 3.5: Immunohistochemistry staining for HAGE protein expression in multiple 
normal tissue microarrays. Immunohistochemistry staining demonstrates the in vivo 
expression of HAGE at the protein level in testis (L), but not in bladder (A), brain (B), larynx 
(D), liver (E), lung (F), kidney (G), skin (I), thymus (J) or uterus (K). Some staining was 
obtained in oesophagus (C) and in ovaries (H). Objective magnification: x20. 
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3.2.2 Expression of HAGE in human CML samples 
Previously published studies have shown HAGE over-expression in human CML samples 
using conventional RT-PCR. In an attempt to confirm these results HAGE as a target for 
immunotherapy, HAGE expression was also investigated in CML samples using RT-Q-PCR. 
Two groups of ten patients with high and low Bcr/Abl:Abl ratio were assessed (Fig 3.6A and B, 
respectively). As seen in Fig. 3.6A, the relative expression of HAGE is 10 to 180 times the one 
observed in normal total blood cells (TBC) in 90% of CML samples with high Bcr/Abl:Abl 
ratio. On the other hand, the relative expression of HAGE was only 5 to 20 times that observed 
in TBC in 50% of CML samples with low Bcr/Abl:Abl ratio (Fig. 3.6B). It is also worth noting 
that the relative expression of p53 was quite low and constant in all these samples while the 
relative expressions of HAGE and Bcr/Abl were generally very similar. However, HAGE 
expression at the protein level remains to be confirmed in TBC of healthy and CML donors, as 
mRNA and protein expression was shown to be discordant in some cases (Rogel et al., 1985; 
Chen et al., 2002). The eventual correlation between HAGE expression and Bcr/Abl levels in 
CML patients will be discussed further in the discussion.  
 
 3.2.3 Expression of HAGE in solid tumour tissues 
Other studies have not only focused on haematological malignancies but included solid 
tumours. Indeed, HAGE expression has been demonstrated to a lower proportion in brain, 
colon, lung and prostate cancers, among others (Martelange et al., 2000; Nagel et al., 2003). In 
this study, mRNA from breast, colon, gastric, and head & neck carcinoma were available with 
mRNA from patient-matched normal tissues allowing direct comparison of the levels of 
expression in both tissue types. Real time PCR was carried out and results were summarised in 
Fig. 3.7. The overall relative expression of HAGE is higher in normal breast tissues than in 
breast carcinoma. However, this might be largely influenced by the low number of samples 
provided (n=10) as well as the very low and/or poor quality RNA in six of these samples in 
which either the housekeeping gene and/or HAGE could not be detected. Individual patient 
variation could only be compared in four samples with two of them (Br6 and Br9) having a 
dramatic increase in HAGE expression of more than 10 times the expression in normal breast 
tissues (Fig. 3.7A). Increased number of breast samples might be required to conclusively 
suggest HAGE over-expression in breast carcinoma (See Appendix 2). 
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Figure 3.6: Expression of HAGE, p53 and Bcr/Abl in chronic myeloid leukaemia. Real time 
PCR analysis was carried out on 20 CML samples and normal total blood cells (TBC). In A: 
10 CML samples from patients with high Bcr/Abl:Abl ratio and in B: 10 CML samples with 
low Bcr/Abl:Abl ratio. The experiment was carried out once and data are expressed relative to 
the mRNA level of TBC, arbitrarily set as 1. 
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Figure 3.7: Expression of HAGE in different carcinoma and patient-matched normal tissues. 
(1) Graph analysing tumour and normal tissues from patients. (2) Individual patient variation 
of HAGE expression. Analyses were carried out using breast (A), colorectal (B), gastric (C) 
and head & neck (HN) (D) carcinoma samples. Paired Student T tests were performed to 
compare statistical differences between carcinoma and patient-matched normal tissues. This 
experiment was carried out once. 
B1 B2 
C2 C1 
D1 D2 
A1 A2 
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The relative expression of HAGE was not found to be statistically different between colorectal 
carcinoma and patient-matched normal colon tissues. Similarly to breast cancer tissues, this 
might be due to the low number of samples available (n=10) and the fact that HAGE 
expression could not be detected in some cancers. Indeed, individual HAGE expression levels 
showed an increase in two out of seven samples (Co100 and Co103), out of which patient 
Co103 had a clear increase (>10 times) (Fig. 3.7B). Interestingly, these two patients’ colorectal 
carcinoma did not show any differences with the other patients in term of cancer stage or 
differentiation but in term of localisation as they are mainly situated in both the rectum and the 
sigmoid (See Appendix 2). However, more samples would be required to link HAGE 
expression with cancer localisation in patients with colorectal carcinoma. Similarly, results in 
gastric cancers and normal tissues did not show significant differences. However, a clear 
increase of HAGE expression can was observed in two out of nine samples. Indeed, only 
Ga418 and Ga440 respectively presented a doubling and a trebling of HAGE expression in 
gastric cancer tissues (Fig. 3.7C). Unfortunately, HAGE expression level could not be 
correlated with cancer grade, differentiation status or localisation (See Appendix 2). 
Finally, four head & neck carcinoma with patient-matched normal tissues were also available 
and results showed that average HAGE expression was increased in head & neck cancer 
samples as compared to normal head & neck tissues but did not reach the level of statistical 
significance. Moreover, HAGE expression in the patient-matched normal tissues was 
multiplied by two to five folds in the cancer tissues of patients HN28 and HN36 (Fig. 3.7D). 
These results led us to further investigate the expression of HAGE at the mRNA level in head 
& neck carcinoma. Through collaboration with Dr. Robert Ferris (Pittsburgh University), we 
were able to obtain a further ten patient cDNA samples in order to confirm and extend these 
results. Interestingly, 40% of these samples showed a dramatic increase of HAGE expression 
in HN03-1036, HN04-1649, HN05-1833 and HN05-1842 samples being 1.5, 14, 6.5 and 2 
times the HAGE expression in testis, respectively (Fig. 3.8). It is noteworthy to say that p53 
was also over-expressed but to a lesser extent than HAGE in 40% of the samples tested. 
Following these results, paraffin-embedded tissue sections from these four patients plus one 
negative control (HN05-1903) were obtained and immunohistochemistry was carried out in 
order to confirm not only the expression of HAGE at the message level but also at the protein 
level. Positive staining was obtained in HN04-1649, HN05-1833 and HN05-1842 with the 
staining intensity correlating with the message intensity observed earlier. On the other hand, 
both HN03-1036 and the negative control HN05-1903 did not demonstrate any staining at all 
(Fig. 3.9). 
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Figure 3.8: Expression of HAGE and p53 in head & neck carcinoma. Real time PCR 
analysis of 10 primary tumours from patients with head & neck carcinoma, ESTDAB-07 
(negative control), ESTDAB-27 and testis (positive controls). The experiment was carried out 
once and data are expressed relative to the mRNA level of normal testis, arbitrarily set as 1. 
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Figure 3.9: Immunohistochemistry staining for HAGE protein expression in head & neck 
carcinoma sections. Immunohistochemistry staining demonstrates the in vivo expression of 
HAGE at the protein level in HN04-1649, HN05-1833 and HN05-1842, but not in HN03-1036 
and HN05-1903 section. No non-specific secondary staining was obtained in all samples. 
Objective magnification: x20. 
Secondary Ab only HAGE Ab 
HN03-1036 
HN04-1649 
HN05-1833 
HN05-1842 
HN05-1903 
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The lack of HAGE expression at the protein level in HN03-1036 could be explained by the fact 
that this sample showed the lowest HAGE expression at the message level or that not all the 
mRNA was translated into protein. Further samples and clinical data will therefore be needed 
to confirm this hypothesis and investigate the link if any between cancer stage, differentiation 
or localisation and HAGE expression. 
Using an identical study process, ten tissues from melanoma patients were analysed. Total 
RNA was extracted for subsequent RT-Q-PCR analysis and frozen tissue sections were 
prepared using a cryostat when possible for immunohistochemistry staining. Relative HAGE 
expression in these samples was compared with the relative HAGE expression in a HAGE-
negative melanoma cell line (ESTDAB-07), HAGE-positive melanoma cell line (ESTDAB-27) 
and testis, which value was arbitrarily set as one. In two of these samples (Mel781 and 
Mel793), relative HAGE expression almost reached two times the one in testis and three times 
the one in ESTDAB-27. Moreover, relative HAGE expression was also detected in three other 
samples but to a lesser extent (Mel429, Mel488 and Mel512)(Fig. 3.10). HAGE staining by 
immunohistochemistry was performed on six of these tissue samples and demonstrated positive 
coloration in Mel429, Mel488 and Mel793. Samples that were negative for HAGE expression 
at the message level remained negative at the protein level (Mel789, Mel791 and Mel816)(Fig. 
3.11).  
Finally, immunohistochemistry was performed on multiple cancer microarrays in order to find 
out whether HAGE is also expressed at the protein level in other forms of cancers. Cancers that 
have not been described earlier in the litterature or that are difficult to obtain were selected and 
studied. Bladder, liver, lung, thymus, uterus and testis cancers all showed positive staining. 
Interestingly and in correlation with earlier experiments, upper jaw cancer, which is a form of 
head & neck carcinoma, colon and skin cancers were also positively stained. In contrast, 
kidney and two other forms of head & neck carcinoma (cheek and larynx) did not indicate any 
staining (Fig. 3.12). Expression differences were evaluated and scored on an inverted 
microscope using the H-score system representing levels of staining intensity (See Section 
2.2.1.10). H-scores of normal and abnormal tissues as well as head & neck carcinoma and 
melanoma samples were summarised in table 3.1. 
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Figure 3.10: Expression of HAGE in melanoma. Real time PCR analysis of 10 primary 
tumours from patients with melanoma, ESTDAB-07 (negative control), ESTDAB-27 and testis 
(positive controls). The experiment was carried out once and data are expressed relative to the 
mRNA level of normal testis, arbitrarily set as 1. 
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Figure 3.11: Immunohistochemistry staining for HAGE protein expression in melanoma 
sections. Immunohistochemistry staining demonstrates the in vivo expression of HAGE at the 
protein level in Mel429, Mel488 and Mel793, but not in Mel789, Mel791 and Mel816 samples. 
No non-specific secondary staining was obtained in all samples. Objective magnification: x20. 
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Figure 3.12: Immunohistochemistry staining for HAGE protein expression in multiple 
cancer tissue microarrays. Immunohistochemistry staining demonstrates the in vivo expression 
of HAGE at the protein level in bladder tumour (A), colon tumour (C), liver tumour (F), lung 
tumour (G), melanoma (H), thymus tumour (I), upper jaw tumour (J), uterus tumour (K)  and 
seminoma (L), but not in cheek tumour (B), kidney tumour (D) or larynx tumour (E). Objective 
magnification: x20. 
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Table 3.1: Scoring of immunohistochemistry sections 
Normal tissues 
(Tissue/H-score) 
Malignant tissues 
(Tissue/H-score) 
Head&neck carcinoma 
(Samples/H-score) 
Melanoma 
(Samples/H-score) 
Bladder / 0 
Brain / 0 
Larynx / 0 
Liver / 0 
Lung / 0 
Kidney / 0 
Oesophagus / 0 
Ovaries / 0 
Skin / 0 
Thymus / 0 
Uterus / 0 
Testis / 300 
Bladder / 150 
Cheek / 0 
Colon / 240 
Kidney / 0 
Larynx / 0 
Liver / 150 
Lung / 150 
Skin / 300 
Thymus / 300  
Upper jaw / 50  
Uterus / 300 
Testis / 300 
HN03-1036 / 0 
HN04-1649 / 210 
HN05-1833 / 100 
HN05-1842 / 160 
HN05-1903 / 0 
 
 
 
 
 
 
 
Mel429 / 10  
Mel488 /  5 
Mel789 / 0 
Mel791 / 0 
Mel793 /  20 
Mel816 /0 
 
 
 
 
 
 
 
Thus, HAGE seems to be expressed at higher levels in tumour cells than in normal cells and it 
is also noteworthy to mention that HAGE seems to be for the majority located in the nucleus 
according to the immunohistochemistry study carried out here, although granular staining 
inside the cytoplasm could also be observed when sections were looked at higher magnification. 
This suggests that HAGE could be exploited as a target for immunotherapy where the immune 
response would be predominantly directed against tumour cells with no serious risk of 
autoimmune reactions.  
 
 3.2.4 Expression of HAGE in human cancer cell lines 
Taking advantage of the availability of a large number of CML, melanoma and head & neck 
carcinoma cell lines, analysis of HAGE expression was carried out using RT-Q-PCR. Seven 
CML, five melanoma and four head & neck carcinoma cell lines were grown under similar 
culture conditions and total RNA was extracted. Upon reverse transcription, real time PCR was 
performed and showed interesting results. Indeed, all CML cell lines expressed HAGE at the 
same level as normal total blood cells (Fig. 3.13). However, expression of HAGE in these cell 
lines proved to be extremely low when compared to testis (Data not shown).  
This result is in correlation with a recent study by Roman-Gomez et al., (2007), which 
investigated the methylation status of the HAGE promoter in CML cell lines and CML patients 
in chronic or blast crisis. HAGE promoter appeared to be strongly hypermethylated in CML 
cell lines in contrast with CML cells from patients, which would influence its mRNA 
expression.  
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Figure 3.13: Relative expression of HAGE in CML cell lines. Real time PCR analysis of 7 
CML cell lines. The experiment was carried out once and data are expressed relative to the 
mRNA level of TBC, arbitrarily set as 1. 
 
   110 
Following this observation, K562 and Kyo-1 cells were treated with a demethylating agent 5’-
aza-2’-deoxycytidine (AZAC), together or not with a deacetylase inhibitor called trichostatin A 
(TSA) in order to determine whether HAGE repression could be reversed, at least at the mRNA 
level. The demethylating agent increased considerably the expression of HAGE in the CML 
cell lines tested. Trichostatin A did not have any effects on its own but seemed to act 
synergistically when co-incubated with AZAC leading to an even more impressive increase of 
HAGE expression (Fig. 3.14). Moreover, differences between cells treated with AZAC and 
TSA and cells treated with diluent only were statistically significant. It is also worth 
mentionning that because of the nature of these treatments, cells stopped proliferating as 
demonstrated by tritiated thymidine incorporation (Data not shown).  
High levels of HAGE mRNA expression was observed in ESTDAB-17, -27, -34 and -95 
although to a lower extent than in testis, whereas ESTDAB-07 did not express HAGE at all. 
Interestingly, HAGE mRNA could not be detected in most of the head & neck cell lines tested 
(BB30, BB49 and ILUS) or only at a very low level (SENY) when compared with testis (Fig. 
3.15). Again, the specific promoter methylation status of cancer/testis antigens such as HAGE 
in solid tumour cell lines might be involved in its expression or rather its lack of expression 
and explain these results. These results might lead us to be careful when working with cell 
lines as opposed to tumour tissues. This finding will be addressed further in the discussion. 
As mentionned previously, the cancer/testis antigen HAGE had been described as a putative 
protein and no studies have actually demonstrated the translation of HAGE mRNA into protein. 
In order to determine the localisation pattern of HAGE inside the cells, HAGE-negative and 
HAGE-positive melanoma cell lines were grown in a multi-chamber slide, fixed, permeabilised 
and observed by immunofluorescence after staining for HAGE. Secondary antibody tagged 
with fluorescein highlights the expression and localisation of HAGE within the cells. High 
levels of protein could be detected in ESTDAB-17, -27, -34 and -95 (Fig. 3.16C, 3.16D, 3.16E 
and 3.16F, respectively) but none in ESTDAB-07 (Fig. 3.16B) and none in the secondary alone 
(Fig. 3.16A). HAGE was observed to be localised mainly in the cytoplasm, at least in this 
melanoma cell line, which again seems to be in opposite to the results obtained with fresh 
tissues. 
 
3.2.5 Role of HAGE  
Little is known about HAGE function in the cell. Roles in the control of the cell cycle or in the 
RNA metabolism have been so far suggested and hypotheses have mainly relied on the study 
of its protein structure and its conserved domains. 
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Figure 3.14: Relative HAGE expression in CML cell lines following demethylation and/or 
inhibition of deacetylase. Real time PCR analysis showed that treatment with the 
demethylating agent AZAC (A) of CML cell lines increased dramatically the relative 
expression of HAGE, and that this effect was synergistically enhanced when cells were also 
treated with the deacetylase inhibitor TSA (T). This experiment was carried out once in 
triplicates (n=1). *** p<0.001 is the statistical difference between control cells and cells 
treated with AZAC, and between cells treated with AZAC and cells treated with both AZAC and 
TSA determined by paired Student T test. 
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Figure 3.15: Expression of HAGE in melanoma and head & neck carcinoma cell lines. Real 
time PCR analysis of 5 melanoma cell lines (ESTDAB-07, -17, -27, -34 and -95) and 4 head & 
neck carcinoma cell lines (BB30, BB49, ILUS and SENY). The experiment was carried out 
once and data are expressed relative to the mRNA level of normal testis, arbitrarily set as 1. 
*** 
*** 
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Figure 3.16: Immunofluorescence assay for HAGE protein expression analysis and 
localisation in melanoma cell lines. Immunofluorescence was observed under confocal 
microscope in HAGE-positive ESTDAB-17 (C), -27 (D), -34 (E) and -95 (F) but not in HAGE-
negative ESTDAB-07 (B). No non-specific secondary antibody staining was obtained (A). 
Cytoplasmic HAGE protein localisation can be observed. Objective magnification: x40. 
F 
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In order to further investigate the eventual function of HAGE inside the cells, a series of 
experiments based on the use of siRNA to silence HAGE expression or the use of plasmid 
encoding HAGE to express HAGE have been designed. Briefly, HAGE-positive ESTDAB-27 
melanoma cells were grown in a 24-well plate. Once 60% confluence was reached, cells were 
transfected with either control siRNA or HAGE siRNA mixed with the transfection reagent 
Interferin. Total RNA was extracted after one, three and seven days in order to check HAGE 
silencing at the message level by RT-Q-PCR. As seen in Fig. 3.17A, two HAGE siRNA were 
tested and both appeared equally efficient in silencing HAGE as about 90% knockdown was 
achieved after 24 hours. Moreover, HAGE expression was not affected by the control siRNA 
or the treatment of the cells with the transfection reagent only. A time course was then carried 
out in order to see the duration of the silencing and a decrease to 60% and 50% knockdown 
was observed after three and seven days, respectively (Fig. 3.17B). In the same period, cells in 
culture were fixed, permeabilised, stained for the expression of HAGE and observed under 
confocal microscope as described in section 3.2.2 in order to confirm HAGE silencing at the 
protein level.  
Twenty-four hours after HAGE siRNA transfection, cells still showed fluorescent staining 
under confocal microscope but this signal dramatically decreased to almost total disappearance 
three days after HAGE siRNA transfection (Fig. 3.17C). This indicates that not only HAGE 
mRNA knockdown after 24 hours was successfully obtained but also total HAGE protein 
silencing after three days, offering a window of opportunity to observe the effects of HAGE 
silencing on the cells. 
HAGE silencing was therefore repeated and cell morphology was recorded under microscope. 
The cells did not show any structural alterations and did not seem to go under either apoptosis 
or necrosis. They remained adherent and only their proliferation seemed to be changed (Data 
not shown). Following these observations, a proliferation assay relying on the incorporation of 
tritiated thymidine was performed three and seven days following HAGE siRNA transfection. 
Proliferations were then compared with cells treated with the transfection reagent only and 
with cells transfected with a control siRNA. Fig. 3.18 shows a statistically significant decrease 
of the proliferation of cells transfected with HAGE siRNA when compared with cells 
transfected with the control siRNA. This decrease occurred three days after transfection but not 
after seven days. This is probably due to the reduced effect of HAGE siRNA on HAGE mRNA 
expression and the reinstallement of the normal production of HAGE proteins.  
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Figure 3.17: HAGE silencing of a HAGE-positive melanoma cell line. (A) Real time PCR 
analysis showing the percentage of HAGE knockdown following transfection of a HAGE-
positive melanoma cell line with 2 different HAGE siRNA. (B) Time course carried out by real 
time PCR indicating HAGE silencing evolution against time. RT-Q-PCR results shown are 
representative of two independent experiments carried out in triplicates (n=2). (C) 
Immunofluorescence assay demonstrating reduced HAGE protein expression three days after 
transfection, but not after 24 hours. Objective magnification: x40.  
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Figure 3.18: Proliferation assay following HAGE silencing. Reduced proliferation of HAGE-
positive melanoma cell line was observed upon HAGE silencing. This experiment was carried 
out twice in triplicates (n=2). ** p<0.01 is the statistical difference between cells transfected 
with a control siRNA and HAGE siRNA determined by paired Student T test. 
** 
** 
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Moreover, siRNA transfection with or without the help of cationic lipids such as the 
transfection reagent Interferin used in this experiment can potentially induce an interferon-
based response affecting the expression of both target gene and interferon-responsive genes, 
and the interpretation of the results. Oligoadenylate synthase 1 (OAS1) and signal transduced 
and activator of transcription 1 (STAT1) are two interferon-responsive genes, the expression of 
which were shown to be altered upon siRNA transfection (Fish et al., 2004; Ma et al., 2005). In 
this experiment, both OAS1 and STAT1 showed no or very little changes in expression by real 
time PCR (Data not shown). These results indicate that the effects observed earlier with RNA 
interference on HAGE-positive cells are not interferon-related or due to the transfectant but are 
indeed caused by HAGE silencing. 
Following on from these results, a reverse experiment was carried out whereby HAGE-
negative ESTDAB-07 melanoma cells were grown in a 24-well plate and transiently 
transfected with the pBudCE4.1 plasmid encoding HAGE cDNA mixed with the transfection 
reagent Lipofectamine 2000. Upon transfection, ESTDAB-07 cells expressed HAGE at a much 
higher level than HAGE-positive ESTDAB-27 cells (Fig. 3.19A). Moreover, the lack of HAGE 
expression was not affected by the treatment of the cells with Lipofectamine 2000. In the same 
way as described earlier, a time course was carried out, the results of which indicated that 
HAGE mRNA was strongly present one and three days following transfection. On the other 
hand, HAGE could barely be detected seven days following transfection (Fig. 3.19B). 
Immunofluorescence then confirmed the translation of HAGE mRNA into a protein two days 
after transfecting ESTDAB-07 cells with no real difference in term of fluorescence intensity 
when compared to control ESTDAB-27 cells (Fig. 3.19C); the efficiency of HAGE cDNA 
expression was therefore confirmed. The experiment was repeated and, non-transfected and 
transfected ESTDAB-07 cells were this time labelled with tritiated thymidine to measure their 
proliferation. Fig. 3.20 shows a statistically significant increase of the proliferation of 
ESTDAB-07 cells transfected with HAGE cDNA after seven days. This result correlates with 
the results obtained when HAGE was silenced suggesting that HAGE is not only expressed in 
some tumour cells but also involved in the proliferation of the latter. Martelange et al. (2000) 
suggested an eventual function of HAGE in the control of the cell cycle and this would 
correlate with the results described above. Propidium iodide was therefore used to stain cells 
transfected with either control or HAGE siRNA in order to establish the consequences of 
HAGE silencing on the cell cycle. Following staining, FACS was used for the analysis of the 
cells. Interestingly, HAGE silencing did not affect any of the phases composing the cell cycle 
(Data not shown).  
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Figure 3.19: HAGE transfection of a HAGE-negative melanoma cell line. (A) Real time PCR 
analysis showing the percentage of HAGE over-expression following transfection of the 
HAGE-negative ESTDAB-07 melanoma cell line. (B) Time course carried out by real time PCR 
indicating HAGE over-expression evolution against time. RT-Q-PCR results shown are 
representative of two independent experiments carried out in triplicates (n=2). (C) 
Immunofluorescence assay demonstrating increased HAGE protein expression two days after 
transfection of ESTDAB-07 cells with HAGE cDNA. Objective magnification: x40. 
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Figure 3.20: Proliferation assay following HAGE transfection. Increased proliferation of the 
HAGE-negative ESTDAB-07 melanoma cell line was observed upon HAGE cDNA transfection. 
This experiment was carried out twice in triplicates (n=2). ** p<0.01 is the statistical 
difference between non-transfected ESTDAB-07 and HAGE-transfected ESTDAB-07 
determined by paired Student T test. 
** 
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3.3 Discussion 
In this chapter, an attempt to validate the tumour-associated gene, HAGE, as a potential 
antigen for cancer immunotherapy was described. HAGE was initially identified by Martelange 
et al., (2000) who applied the technique of cDNA substraction analysis to identify novel genes 
with tumour-specific expression. HAGE was discovered on a wide range of tumour tissues at 
levels at least 100-fold that of normal tissues, with the exception of testis where this gene was 
shown to be highly expressed. Furthermore, the expression of this gene could be induced with 
the demethylating agent AZAC, a classical feature of cancer/testis genes (Scanlan et al., 2002). 
Therefore, the authors defined this gene as being a member of the CT family and concluded 
that based on their tumour-specific expression; they may represent potential targets for 
immunotherapeutic vaccination of cancer. However, in previous reports, the expression of 
HAGE was not studied in normal tissues. This information is critical if one wants to use HAGE 
as a target for immunotherapy. mRNA HAGE expression was therefore first determined using 
conventional semi-quantitative RT-PCR. Results showed that HAGE was expressed in normal 
tissues such as brain, heart, liver or even PBMC, although to a much lesser extent when 
compared with testis. HAGE expression was also detected at low levels in 66% and 80% of 
AML and CML PBMC, respectively, suggesting an over-expression of HAGE in cancer tissues 
(See Appendix 1).  
Conventional PCR may be misleading because the signal intensity is not directly proportional 
to the amount of amplified DNA and optimised PCR conditions may result in increased 
sensitivity. Indeed, a study by Nagel et al. (2003) into CT gene expression in benign and 
malignant neoplasms of the salivary glands, detected HAGE expression in 2/5 healthy salivary 
gland tissues; a discrepancy from previous findings that they also attributed to the use of a 
more sensitive RT-PCR method. Thus, the question of the level of HAGE expression in 
healthy versus malignant tissues still remained and therefore was addressed through the use of 
real time quantitative PCR. This technique did not detect HAGE expression in a wide array of 
normal tissues or normal PBMC with the exception of testis where HAGE expression was 
found to be at least a 1,000-fold higher than in any normal tissue tested.  
Subsequent to studies by Martelange et al. (2000), Adams et al. (2002) analysed a large cohort 
of myelogenous leukaemia by conventional RT-PCR to investigate the question as to whether 
haematological malignancies express CT genes. They detected HAGE expression in 23% and 
57% of the AML and CML samples tested, respectively. In this study, the expression of HAGE 
was then assessed by real time PCR on 20 CML samples. Real time PCR detected HAGE 
levels from five to almost 180-fold higher than in normal total blood cells in 70% of samples 
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tested, a proportion of HAGE-positive patients largely superior to the one described by Adams 
et al. (2002). Interestingly, these CML samples were composed of two groups of 10 having 
either low or high Bcr/Abl:Abl ratios respectively, namely that samples with low Bcr/Abl:Abl 
ratio relates to patients successfully responding to treatment with Imatinib and reciprocally. 
Real time PCR showed that Bcr/Abl:Abl ratio correlated with HAGE expression with the latter 
being between five to 20-fold higher than in TBC in 50% of samples with low Bcr/Abl:Abl 
ratio, and 20 to 180-fold higher than in TBC in 90% of samples with high Bcr/Abl:Abl ratio. 
These results suggest that HAGE is not only associated with advanced CML disease and poor 
prognosis as shown in a recent study by Roman-Gomez et al. (2007) but is also possibly 
involved in the pathogenesis of CML.  
HAGE was previously shown to be over-expressed in various solid tumours such as bladder, 
brain, breast, colon, esophagus, liver, lung and skin cancers (Martelange et al., 2000). In order 
to validate HAGE as a target for therapy, we confirmed the expression of HAGE in various 
solid tumours obtained from patients and compared it to normal tissues whenever possible. 
HAGE was found to be over-expressed in breast, colon and gastric carcinoma with a tumour to 
normal ratio superior to two, in 2 out of 4 breast cancers, in 2 out of 7 colorectal cancers and in 
2 out of 9 gastric cancers. However, mean expression level analyses were not statistically 
different for any of these three types of cancer. In individual breast cancers, this result was 
much higher than the previously published study by Martelange et al. (2000), where 
approximately only 5% of breast cancers were shown to over-express HAGE. This discrepancy 
might be due to the low number of samples with good RNA quality but also to the sensitivity 
of the real time PCR technique. With a larger number of individual colorectal cancers with 
good quality RNA samples, the HAGE expression frequency obtained (28%) correlated with 
the previously published study (31%) by Martelange et al. (2000). Finally, the largest cohort of 
individual cancers with patient-matched normal tissues was carried out in gastric tissues and 
showed increased HAGE expression in only 22%. Unfortunately, there are no previous reports 
of HAGE in gastric tissues. Further samples would be required to really demonstrate an over-
expression of HAGE in gastric carcinoma. Although clinical data were available for all these 
samples, no correlation between HAGE expression and cancer stages or cancer invasion 
involving lymph nodes could be drawn from these results. However, more relevant results were 
obtained with head & neck carcinoma. Indeed, HAGE over-expression was obtained in 75% of 
individual head & neck cancers. Despite the lack of comparison with previously published 
studies and the small number of samples tested, results were convincing enough to pursue this 
analysis on a larger cohort. Ten further samples were obtained and in spite of the lack of 
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patient-matched normal tissues, the analysis was carried out in comparison with testis. The 
frequency of HAGE-positive individual head & neck carcinoma was reduced to about 40% 
with a tumour to testis ratio superior to two. Similarly, 10 melanoma tissues became available 
for HAGE expression analysis and the frequency of HAGE-positive individual melanoma 
reached 50%. However, in these HAGE-positive melanoma samples, only two of them 
demonstrated expression of HAGE of about two-fold the expression in testis and three-fold the 
expression in a HAGE-positive melanoma cell line. This observation reduced the frequency to 
20%, a result in agreement with the previously published study (17%) by Scanlan et al. (2004). 
However, considering that the expression of testis is at least a 1000-fold higher than in any 
normal tissue, it is legitimate to consider that HAGE over-expression in head & neck 
carcinoma and melanoma would achieve a larger number when compared to patient-matched 
normal tissues, hence increasing considerably the frequencies obtained in this study.  
The difficulty in the interpretation of the results strongly depends on the referentials used in the 
analysis. The use of normal testis as a tool of comparison for solid tumours can be criticised as 
it does not offer a correct representation of the actual expression of a tumour-associated antigen 
in a given normal tissue. Unfortunately, because of the rarety of cancer samples from patients 
and the difficult justification for harvesting both malignant and healthy surrounding tissues, it 
is often impossible to always rely on the provision of patient-matched normal tissues for a 
comprehensive and true analysis. Moreover, the source of RNA as well as the methodology 
used for obtaining the tissue is also another essential aspect to consider during analysis of 
tumour antigens. Radical surgery was used to harvest all the tissues tested in this study. It 
results in a tissue consisting of different cell types and in a total RNA considerably diluted as a 
consequence of the presence of heterogenous cell populations. A critical breakthrough came 
from the development of laser capture microdissection (LCM) allowing for the specific 
isolation of foci of tumour cells from a heterogenous tumour population. A brief laser pulse is 
directed towards a specific area to specifically select and isolate individual areas or cells. 
Recently, two tumour-associated antigens, MTA1 and T21, were investigated in prostate 
cancer samples resulting from radical prostatectomy and LCM-isolated prostate tissues. 
Expression analysis of these two antigens gave significantly different results (Walton T., 
unpublished data; Miles et al., 2007). 
Knowing that the HAGE promoter, like any other cancer/testis gene promoter, is strongly 
susceptible to the methylation status of its CpG islands (Scanlan et al., 2004), it became of 
interest to determine whether tumour cell lines deriving from either haematological 
malignancies or solid tumours do express HAGE and at what level. Seven CML, five 
   122 
melanoma and four head & neck carcinoma cell lines were therefore evaluated. Unfortunately, 
this experiment failed to demonstrate expression of HAGE in CML and head & neck 
carcinoma cell lines and only melanoma cell lines were able to demonstrate HAGE expression 
levels comparable to testis, although to a lower extent. Furthermore, treatment of some of these 
CML cell lines with the DNA methyltransferase inhibitor AZAC confirmed this hypothesis 
with a sudden raise of HAGE expression synergistically enhanced when the deacetylase 
inhibitor TSA was also added to the cells. Certain cancer cell lines have an increased rate of 
hypermethylation of certain CpG islands and less global genomic hypomethylation, while 
others are perfectly capable of retaining and presenting the same epigenetic profile of the 
original tumour cell type (Roman-Gomez et al., 2005), which would explain the discrepancies 
between the different cell lines used in this experiment. The latters are of interest as they can 
provide a viable model for in vitro experiments but also a good tool of comparison for 
expression analysis in clinical samples.  
However, these data are all restricted to the detection of HAGE on the message level and 
discrepancies between RNA and protein levels are common finding due to factors such as the 
varying stability of different mRNA molecules, the regulatory process of translation, post-
translational modifications and proteasomal degradation (Rogel et al., 1985; Chen et al., 2002). 
Therefore, to truly evaluate the expression of HAGE in normal and malignant tissues, analysis 
on the protein level was required. Using a polyclonal antiserum generated against HAGE 
peptides predicted in silico to be antigenic and exposed on the surface of the protein, 
immunohistochemistry and immunofluorescence were respectively carried out on tumour 
tissues and tumour cell lines to underline the putative 73kDa HAGE protein. This should also 
provide further details regarding the protein’s subcellular localisation. The antiserum allowed 
the confirmation of the non-expression of HAGE at the protein level in all the normal tissues 
tested, except in testis where the intensity of the staining is quite high. It also allowed checking 
whether there is a correlation between mRNA expression and protein expression whenever 
tissues and RNA from the same tissues were both available. Immunohistochemistry staining 
was carried out on five head & neck carcinoma and six melanoma tissue sections. Only three of 
the four HAGE-positive head & neck carcinoma sections and all four of the HAGE-positive 
melanoma sections demonstrated positive staining. Samples negative for HAGE expression by 
real time PCR remained negative after staining of their respective tumour sections. Moreover, 
the intensity of HAGE staining was not proportional to the intensity of the message level 
obtained by real time PCR. Indeed, one head & neck carcinoma sample (HN04-1649) shows a 
mRNA expression 14-fold higher than in normal testis. However, the intensity of the staining 
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of this same tissue was much lower to the one of normal testis probably suggesting that HAGE 
might present a different protein turnover tissue to tissue or that the translation of HAGE 
mRNA into a protein is somehow strongly down-regulated in certain tumour tissues. Evidence 
obtained by the staining of a multitumour microarray supported the second hypothesis as the 
staining intensity in other forms of cancers occurring in bladder, colon, liver, lung, thymus or 
testis matches the intensity observed in normal testis. Since the ultimate goal of this study was 
to induce an immune response against the HAGE protein, high protein expression levels are 
not necessarily a prerequesite for a CTL-mediated response. P53-specific CTL were previously 
shown to be able to recognise tumour cells expressing moderate or low levels of p53, 
suggesting that the protein turnover is more important for a CTL-mediated response than the 
actual steady-state level of expression (Vierboom et al., 2000). Therefore, protein expression 
study should be followed by a degradation study in order to find out the turnover of the protein. 
The next major question that comes to mind is: “is HAGE involved in the tumorogenesis 
process and to what extent?” Immunohistochemistry and immunofluorescence showed that 
HAGE protein can be found in both nuclear and cytoplasm with a characteristic granular 
expression. Some RNA helicases are able to play a role in different processes of the RNA 
metabolism in spite of taking place in very different cellular compartments (Charroux et al., 
1999; Charroux et al., 2000). In these studies, the DEAD-box putative RNA helicase Gemin3 
was thought to be involved in the formation of the survival of the motor neuron complex, 
which leads to spinal muscular atrophy if compromised. It was found in both cytoplasm, gems 
(i.e.: nuclear bodies) and nucleoli suggesting roles in the spliceosomal assembly of small 
ribonucleoproteins with RNA, preribosomal RNA processing and ribosome assembly. This 
statement would explain the ubiquitous expression of HAGE inside the cells with HAGE being 
expressed depending on the cellular needs or the cellular state at the moment of the tumour 
section or tumour cell fixation.  
Gene silencing mediated by small interference RNA (siRNA) has been extensively used in the 
past few years for gene function studies. Two HAGE siRNA were therefore designed and then 
synthesised, and transfection of a HAGE-positive melanoma cell line with siRNA was 
optimised. Both siRNA led to a satisfactory knockdown of HAGE expression at the message 
and at the protein levels one day and three days after transfection, respectively. Cell 
morphology and cell cycle were not affected but cell proliferation was noticeably reduced. 
Proliferation assays confirmed that observation. Furthermore, real time PCR of OAS1 and 
STAT1 confirmed that the reduced proliferation observed following HAGE silencing was not 
interferon- or transfection reagent-related as both gene expressions remained unaltered upon 
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siRNA transfection. A HAGE-negative melanoma cell line was then transfected with HAGE 
cDNA and the reverse reaction happened with increased tritiated thymidine incorporation and 
therefore increased proliferation. Like DDX1 (Godbout et al., 1998), DDX2 (Eberle et al., 
2002) and DDX5 (Yang et al., 2005), evidence suggests that the DEAD-box RNA helicase 
HAGE is involved in tumour cell proliferation. In support of this hypothesis, Roman-Gomez et 
al. (2007) showed that the hypomethylation status of HAGE promoter directly correlates with 
HAGE expression and high levels of HAGE mRNA are generally linked with advanced CML 
disease, i.e. CML patients in blast crisis, and poor clinical outcome. Is HAGE at the origin of 
poorly responding CML or at the receiving end of the genomic instability that reigns in patients 
with high Bcr/Abl:Abl ratio? The evidence argues against the second alternative as HAGE 
expression was found in both groups of CML samples tested in this study although at a 
different degree.  
Proteins that are overexpressed in tumours or show tumour-specific expression as well as 
having roles believed to be associated with tumoral transformation make attractive vaccination 
targets for tumour immunotherapy, as this may prevent the tumour from down-regulating the 
gene as a method of tumour escape. Although more refined studies will be required to pinpoint 
the exact function of HAGE, mRNA and protein studies were sufficient to safely consider 
HAGE as an ideal antigen in several cancers. 
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Chapter 4: Cloning of HAGE and murine co-stimulatory molecules 
4.1 Introduction 
Gene therapy can be defined as the introduction of a gene that has been cloned or manufactured 
in a cell in order to treat a disease, be it in an infectious disease or in cancer. Gene-based 
immunisation represents a convenient entity as it is widely applicable to the majority of the 
population, without the requirement of identifying naturally processed peptides for different 
MHC haplotypes. Theoretically, the transfer of a gene encoding a tumour antigen should allow 
both the endogenous process and presentation of this antigen to T lymphocytes, and an 
adjuvant effect coming from the vector itself through the CpG sequences included in the 
bacterial DNA. They can be very easily synthesised in clinical grade and at low costs. 
Moreover, a large panel of routes of administrations can be used allowing the activation of both 
innate and adaptive arms of the immune system (Pavlenko et al., 2004). Two gene-based 
therapies can be characterised: naked DNA and viral/bacterial vectors. Furthermore, these 
vectors can be directly used in immunisation procedures in vivo or to augment the 
immunogenicity or the antigen-presenting ability of tumour cells, APC and immune cells ex 
vivo.  
Before considering the use of viral vectors, it is important to mention that naked DNA can have 
a surprising efficiency when injected in vivo in some tissues such as muscles or subcutaneous 
tissue. Indeed, the efficiency of gene transfer is superior to other non-viral vectors in the tissues 
quoted earlier with long term protein expression detectable up to two months after 
immunisation, even though the entry mechanism of naked DNA into the cell remains unknown 
(Wolff et al., 1990). Plasmid vaccination consists of a bacteria-derived plasmid backbone 
encoding the gene of interest. Plasmids used for immunisation are usually composed of an 
expression cassette including a promoter and a polyadenylation signal, an antigen encoding 
gene sequence, an origin of replication and a selection marker for propagation of plasmids in 
bacteria. With the help of molecular biology tools and the knowledge of human genome 
sequences, it is now possible to virtually clone any gene from the human genome. Furthermore, 
many routes of administrations are available with each having different properties or leading to 
different immunological outcomes. Naked DNA immunisation can take place intramuscularly, 
intraperitoneally or intradermally where it is thought to be taken up by resident APC either 
directly after immunisation or following cross-priming and the release of proteins from 
transfected muscle cells having undergone apoptosis. Administration can also occur orally 
through the mucosal route or be coupled with physical methods of transfer such as 
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electroporation (Rizzuto et al., 1999) or gene gun allowing the subcutaneous injection of gold-
coated DNA particles (Yang et al., 1990). These techniques allow the local skin APC 
(Langerhans cells) to be directly transfected. Moreover, the delivery of DNA doses as low as 1 
µg by gene gun were shown to generate potent immune responses, which is 100 to 1,000 less 
DNA than any other modes of vaccination. Interestingly, it seems that routes of administration 
influence the polarisation of the immune response (Kwissa et al., 2000). Indeed, intra-muscular 
or intra-dermal saline-DNA immunisation has been reported to generate a Th1 response and 
the production of IgG2a antibodies in mice, whereas cutaneous gene gun immunisation tends to 
lead to a Th2 response and IgG1 antibody production. These results might largely be 
influenced by the different populations of cells integrating the DNA (Feltquate et al., 1997; 
Torres et al., 1997) and have since been contradicted by multiple evidences indicating CTL-
mediated anti-tumour protection following gene gun-mediated DNA immunisation in mice 
(Bowne et al., 1999; Gold et al., 2003). Unfortunately, although clinical trials have 
demonstrated that gene-based immunisation was capable of inducing tumour-specific T 
lymphocyte responses, these did not lead to an objective positive clinical response (Tsang et al., 
1995). One possible explanation is that most tumour antigens used in these trials are self 
antigens and therefore the level of tolerance exceeds that of stimulation induced by these 
methods. 
By nature, viruses represent an excellent mean of introducing genetic material in a cell 
mimicking natural viral infection and thereby generating more potent immune responses. 
However, the possibility of progressive viral infection, especially in immuno-compromised 
patients, still raises a major concern. Nowadays, for most of viral systems used, the target cell 
is infected by a virus unable to replicate and therefore non-pathogenic. In practice, the virus is 
rendered unable to replicate by removing replicating sequences and substituting them with a 
therapeutic gene cassette. Cell lines, which have been genetically altered or have the ability in 
their genome to replicate the attenuated virus, are used to produce and expand the number of 
viral copies in vitro. Also, natural host restriction can prevent the multiplication in human cells 
of some viruses such as avipox virus derived vectors (Kay et al., 2001). Finally, it is worth 
mentionning that in order to have a prolonged effect on the immune system, viruses must have 
a very low intrinsic immunogenicity to avoid their neutralisation by circulating antibodies, 
which would hinder their efficacy as therapeutic vectors. Seven major families have been so far 
used in cancer immunotherapy: adenovirus (Guse et al., 2007), adeno-associated virus (Sun et 
al., 2002), alphavirus (DiCiommo and Bremner, 1998), avipox virus (Chakraborty et al., 2007), 
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herpes simplex virus (Ali et al., 2000; Ali et al., 2002), retrovirus (Heemskerk et al., 1999; 
Chan et al., 2005) and vaccinia virus (Chakraborty et al., 2007). These families present 
different modes of functioning, different duration of gene expression or different safety levels. 
Depending on these characteristics summarised in table 4.1, these viruses offer both advantages 
and disadvantages. 
 
Table 4.1: Characteristics of different viral vectors (Adapted from Bonnet et al., 2000) 
Vector Biology 
Pre-existing 
immunity in 
humans 
Duration of 
gene 
expression 
Safety 
Adenovirus 
 
Adeno-
associated virus 
Alphavirus 
 
 
Avipox virus 
 
 
 
 
Herpes simplex 
virus 
Retrovirus 
 
Vaccinia virus 
 
 
 
Double-
stranded DNA 
Single-stranded 
DNA 
RNA viruses 
with replicon 
 
Double-
stranded DNA 
non –replicative 
in mammalian 
cells 
Double-
stranded DNA  
Diploid RNA 
strand 
Double-
stranded DNA 
replicative in 
mammalian cell 
Yes 
 
Yes 
 
No 
 
 
Yes 
 
 
 
 
Yes 
 
No 
 
Yes 
 
 
 
Transient 
 
Transient 
 
Good 
 
 
Transient 
 
 
 
 
Transient 
 
Good 
 
Transient 
 
 
 
Good 
 
Risk of insertional 
mutagenesis 
Safe in animals, not 
fully characterised in 
humans 
Very good 
 
 
 
 
Neurovirulence, 
insertional mutagenesis 
Risk of insertional 
mutagenesis 
Well documented safety 
 
 
 
 
According to these characteristics, the alphaviruses represent an interesting option as there are 
no signs of pre-existing immunity in humans and thus, avoiding an eventual humoral response, 
which would immediately suppress the beneficial effects of the vaccination. Furthermore, the 
gene transduced by the virus is readily expressed once inside the cells with so far no 
documented risks of insertional mutagenesis, at least in animals. Sindbis virus, Venezuelan 
equine encephalitis virus and Semliki forest virus (SFV) are three commonly used alphaviruses 
with proven delivery abilities. They are characterised by a single-stranded RNA genome of 
about 12kb surrounded by an icosahedral capsid protein shell. In this study, SFV was chosen as 
a vector for the development of new vaccine strategies. Semliki forest virus’ single-stranded 
RNA is enveloped by a nucleocapsid. The latter is composed of 240 copies of the capsid 
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protein attached together. This shell is surrounded by an extra lipid bilayer from the host cells 
spiked with glycoproteins encoded by the E1, E2 and E3 nucleotide sequences of the viral 
genome. The two open reading frames of the SFV RNA encode four non-structural proteins, as 
well as capsid and envelope proteins, respectively. Semliki forest viruses bind to different cell 
surface receptors to infect cells and upon transduction, the production of SFV proteins comes 
in place of the host cell protein synthesis (Lundstrom., 2003).  
With the help of genetic manipulation, the infection efficiency, the applicability to a wide 
range of hosts, the safety and the complexity of the system were improved considerably. 
Indeed, large amount of work has been carried out on SFV to enhance its original features in 
order to create a more efficient recombinant SFV vector for immunotherapy.  In the original 
SFV expression vector, structural protein coding regions were substituted with the gene of 
interest and following co-transfection of the gene coding RNA with a helper RNA encoding the 
viral structural proteins, recombinant SFV particles were produced (Liljestrom and Garoff, 
1991). As a safety mechanism during in vitro transfection experiments or in vivo therapeutic 
applications, the p62 structural protein coding region was also mutated rendering the generated 
viruses inactive if not proteolytically treated with α-chymotrypsin. However, the handling of a 
RNA-based SFV expression system requires specific conditions, which were overcome by 
constructing a DNA-based system (DiCiommo and Bremner, 1998). The SP6 promoter was 
replaced with a RNA polymerase II-dependent cytomegalovirus enhancer/promoter to drive the 
transcription in vivo. Helper and replicon plasmids with the above characteristics were 
engineered and further improved with the expansion of the multiple cloning site and the 
addition of FLAG and HIS10 epitope and affinity tags (DiCiommo et al., 2004). Co-
transfection with both helper and replicon plasmids allows the generation of a large quantity of 
recombinant SFV vectors, the transduction of a large variety of mammalian and non-
mammalian cells, the rapid production of high levels of proteins, programmed cell death in 
host cells and protection against tumour challenges. Tumour protection with recombinant SFV 
vectors was achieved in several animal models (Daemen et al., 2000; Daemen et al., 2003; 
Huckriede et al., 2003; Ni et al., 2004) and immune responses were also generated in immuno-
tolerant mice indicating the ability of SFV to break tolerance (Riezebos-Brilman et al., 2005) 
This efficiency towards tumours can also be further enhanced following encapsulation of SFV 
particles into liposomes (Lundstrom and Boulikas, 2003). Altogether, these facts led us to the 
elaboration of new SFV-based strategies targeting specifically the HAGE antigen. 
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In order to investigate application of plasmid DNA vaccination for generating immune 
response to HAGE, this study describes the construction of a plasmid expression vector 
(pBudCE4.1) encoding HAGE. Also, naive T cells respond poorly to antigen unless secondary 
signals are provided by co-stimulatory molecules expressed on the surface of APC. Expression 
of co-stimulatory molecules offers several advantages as it allows the activation of pathogen-
specific T cells and minimises the risks of mounting an adaptive immune response against self 
(Fig. 4.1). In most cases, these signals are cell-to-cell contact-dependent, although some 
soluble factors have also demonstrated co-stimulatory abilities (Weaver and Unanue., 1990). 
Over the years, B7.1 and B7.2 ligands and their common receptor CD28 have emerged as 
crucial molecules for T cell proliferation and IL-2 secretion. Unfortunately, both molecules can 
lead to opposite effects as they are also capable of binding CTLA-4 with greater affinity, a 
receptor homologuous to CD28 but with inhibitory properties (Chambers and Allison, 1997). 
That is why several studies have looked at other co-stimulatory molecules such as 4.1BBL, 
which binds with high affinity to its receptor 4.1BB. Like B7 molecules, 4.1BBL is inducible 
and found on APC. Upon binding to its receptor, 4.1BBL allows activation and differentiation 
of both CD4+ and CD8+ T cells (Vinay and Kwon, 1998). Interestingly, CD28 co-stimulatory 
signalling can be potentiated by 4.1BB signalling (Hurtado et al., 1995). In this study, murine 
genes of these three co-stimulatory molecules (mB7.1, mB7.2 and m4.1BBL) were each cloned 
into pBudCE4.1/HAGE in order to obtain a single vector encoding simultaneously a TAA and 
a co-stimulatory molecule and investigate the co-stimulation of the immune response. Finally, 
HAGE was cloned into a SFV vector and viruses were generated. Following each cloning, 
protein production by the various vectors generated was confirmed. 
 
4.2 Results 
 4.2.1 Cloning of HAGE into the mammalian expression vector pBudCE4.1 
The making of a tumour model to target HAGE in HHDII-DR1 double transgenic mice 
requires the transfection with HAGE DNA of a murine cancer cell line (ALC) already stably 
transfected to express a HLA-A2 construct. Unfortunately, the HLA-A2 construct contains a 
resistance cassette (neomycin), which is identical to the one proposed by the pcDNA3/HAGE 
expression vector kindly provided by Prof. Thierry Boon (Ludwig Institute, Brussels). 
Therefore, there is a need to subclone the full open reading sequence of HAGE from pcDNA3 
into another expression vector, which has a different resistance mechanism in order to be able 
to positively select HAGE-expressing ALC transfectants. HAGE cDNA was then cloned into 
the mammalian expression vector pBudCE4.1 containing a zeocin selection marker.  
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APC T cell
Negative co-stimulation
Stimulation / signal 1MHC
TCRαβ
CD4/CD8
Positive co-stimulation / signal 2CD28
B7.1
B7.2
Positive co-stimulationICOS-L ICOS
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CD40 CD40L
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OX-40L OX40
Positive co-stimulation / signal 2
 
 
Figure 4.1: Co-stimulation of the T cell response. At least two signals are required for 
optimal T cell activation: antigen recognition provided by the formation of MHC-peptide-TCR 
complexes and co-stimulation provided by the ligation of co-stimulatory molecules expressed 
on the surface of APC to their receptors found on the surface of T cells. This T cell activation 
can also be negatively regulated to induce T cell tolerance and limit the immune response 
(Adapted from www.ebioscience.com/ebioscience/whatsnew/costim.htm). Highlighted in red 
are the two modes of positive co-stimulation investigated in this project. 
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The pcDNA3/HAGE and pBudCE4.1 expression vectors were first double digested with 
HindIII and XbaI restriction enzymes and run on agarose gel. Digested corresponding bands of 
HAGE and pBudCE4.1 were gel extracted and ligated overnight at 4°C with T4 DNA ligase 
enzyme, followed by plating on LB agar with zeocin and selection of clones (Fig. 4.2). After 
three attempts, clones were confirmed to contain HAGE by restriction digestion. Indeed, a 
band corresponding to 1,950bp could be detected in 10 out of 10 clones (Fig.4.3). This plasmid 
was then used for stably transfecting ALC cells as well as immunising transgenic mice with 
HAGE DNA. 
 
 4.2.2 Cloning of murine co-stimulatory molecules into the mammalian expression 
vector pBudCE4.1/HAGE 
The pcDNA3.1/Zeo-B7.1, -B7.2 and -4.1BBL expression vectors were kindly provided by Dr. 
Barbara Guinn (King’s college). The pBudCE4.1 expression vector contains two multiple 
cloning sites allowing the association of a tumour-associated antigen such as HAGE with a co-
stimulatory molecule for different vaccine strategies. Murine B7.1, B7.2 and 4.1BBL were 
therefore each cloned into pBudCE4.1/HAGE. Primers including restriction sites were 
specifically designed to allow PCR amplification and cloning of each co-stimulatory molecule 
into pBudCE4.1/HAGE. Primer sequences and respective annealing temperatures were 
summarised in table 4.2. 
 
Table 4.2: Sequences of primers used for cloning of murine co-stimulatory molecules into 
pBudCE4.1/HAGE and their respective annealing temperatures 
Primers for cloning and respective annealing temperature 
B7.1F with KpnI site 5’-TCTAGGTACCATGGCTTGCAATTGTCAG-3’ 
B7.1R with BstBI site 5’-TCTATTCGAACTAAAGGAAGACGGTCTG-3’ 
66°C 
B7.2F with KpnI site 5’-TCTAGGTACCATGGACCCCAGATGC-3’ 
B7.2Rwith BstBI site 5’-TCTATTCGAATCACTCTGCATTTGGTTTTGC-3’ 
67°C 
4.1BBLF with XhoI site 5’-TCTACTCGAGATGGACCAGCACACACTT-3’ 
4.1BBLR with BglII site 5’-TCTAAGATCTTCATTCCCATGGGTTGTC-3’ 
67°C 
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Figure 4.2: Diagrammatic representation of the construction of the plasmid 
pBudCE4.1/HAGE. The pcDNA3/HAGE and pBudCE4.1 vectors were first digested with 
restriction enzymes HindIII and XbaI. The digested products were purified by gel purification 
and desired fragments were selected for ligation. After ligation, the cDNA for HAGE was 
inserted into the pBudCE4.1 plasmid. 
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Figure 4.3: Agarose gel electrophoresis after double digestion of pBudCE4.1/HAGE clones. 
After double digestion with HindIII and XbaI, a band corresponding to 1.9kb could be detected 
in 10 out of 10 clones picked, indicating successful cloning of HAGE into the pBudCE4.1 
mammalian expression vector. 
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  4.2.2.1 Cloning of mB7.1 into pBudCE4.1/HAGE 
Full length murine B7.1 was first amplified from pcDNA3.1/Zeo-B7.1 using RT-PCR for 32 
cycles using a high fidelity Taq polymerase (Phusion, Finnzymes). After amplification, PCR 
amplicons and pBudCE4.1/HAGE were double digested with BstBI and KpnI restriction 
enzymes. Restriction digests were run on an agarose gel and a band corresponding to 921bp 
(mB7.1) was clearly visible and was gel extracted together with the band corresponding to the 
linearised pBudCE4.1/HAGE plasmid. Upon overnight ligation at 4°C with T4 DNA ligase 
enzyme, competent XL1-Blue E.coli were transformed and plated on LB agar with zeocin (Fig. 
4.4). Clones were selected and screened for murine B7.1 by restriction digestion. As seen in 
Fig. 4.5, band corresponding to 921bp could be detected in 7 out of 10 clones picked and full 
length mB7.1 was obtained with 100% identical sequence to published mB7.1 sequence in two 
of them upon sequencing.  
 
  4.2.2.2 Cloning of mB7.2 into pBudCE4.1/HAGE 
Full length murine B7.2 was first amplified from pcDNA3.1/Zeo-B7.2 using RT-PCR for 32 
cycles using a high fidelity Taq polymerase (Phusion, Finnzymes). After amplification, PCR 
amplicons and pBudCE4.1/HAGE were double digested with BstBI and KpnI restriction 
enzymes. Restriction digests were run on an agarose gel and a band corresponding to 930bp 
(mB7.2) was clearly visible and was gel extracted together with the band corresponding to the 
linearised pBudCE4.1/HAGE plasmid. Upon overnight ligation at 4°C with T4 DNA ligase 
enzyme, competent XL1-Blue E.coli were transformed and plated on LB agar with zeocin (Fig. 
4.6). Clones were selected and screened for murine B7.2 by restriction digestion. As seen in 
Fig. 4.7, band corresponding to 930bp could be detected in 9 out of 10 clones picked and full 
length mB7.2 was obtained with 100% identical sequence to published mB7.2 sequence in four 
of them upon sequencing. 
 
  4.2.2.3 Cloning of m4.1BBL into pBudCE4.1/HAGE 
Finally, full length murine 4.1BBL was first amplified from pcDNA3.1/Zeo-4.1BBL using RT-
PCR for 32 cycles using a high fidelity Taq polymerase (Phusion, Finnzymes). After 
amplification, PCR amplicons and pBudCE4.1/HAGE were double digested with BglII and 
XhoI restriction enzymes. Restriction digests were run on an agarose gel and a band 
corresponding to 930bp (m4.1BBL) was clearly visible and was gel extracted together with the 
band corresponding to the linearised pBudCE4.1/HAGE plasmid.  
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Figure 4.4: Diagrammatic representation of the construction of the plasmid 
pBudCE4.1/HAGE/mB7.1. The mB7.1 cDNA was first PCR up. The PCR amplicons and the 
pBudCE4.1/HAGE vector were digested with restriction enzymes BstBI and KpnI. The digested 
products were purified by gel purification and desired fragments were selected for ligation. 
After ligation, the cDNA for mB7.1 was inserted into the pBudCE4.1/HAGE plasmid. 
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Figure 4.5: Agarose gel electrophoresis after double digestion of pBudCE4.1/HAGE/mB7.1 
clones. After double digestion with BstBI and KpnI, a band corresponding to 921bp could be 
detected in 7 out of 10 clones picked, indicating successful cloning of mB7.1 into the 
pBudCE4.1/HAGE mammalian expression vector. 
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Figure 4.6: Diagrammatic representation of the construction of the plasmid 
pBudCE4.1/HAGE/mB7.2. The mB7.2 cDNA was first PCR up. The PCR amplicons and the 
pBudCE4.1/HAGE vector were digested with restriction enzymes BstBI and KpnI. The digested 
products were purified by gel purification and desired fragments were selected for ligation. 
After ligation, the cDNA for mB7.2 was inserted into the pBudCE4.1/HAGE plasmid. 
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Figure 4.7: Agarose gel electrophoresis after double digestion of pBudCE4.1/HAGE/mB7.2 
clones. After double digestion with BstBI and KpnI, a band corresponding to 930bp could be 
detected in 9 out of 10 clones picked, indicating successful cloning of mB7.2 into the 
pBudCE4.1/HAGE mammalian expression vector. 
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Upon overnight ligation at 4°C with T4 DNA ligase enzyme, competent XL1-Blue E.coli were 
transformed and plated on LB agar with zeocin (Fig. 4.8). Clones were selected and screened 
for murine 4.1BBL by restriction digestion. As seen in Fig. 4.9, band corresponding to 930bp 
could be detected in 2 out of 10 clones picked and full length m4.1BBL was obtained with 
100% identical sequence to published m4.1BBL sequence in one of them upon sequencing. 
 
  4.2.2.4 Expression of cloned mB7.1, mB7.2 and m4.1BBL at the protein level 
To confirm HAGE, mB7.1, mB7.2 and m4.1BBL protein expression by pBudCE4.1 vectors, 
ESTDAB-07 cells were grown in a multi-chamber slide and transfected with pBudCE4.1 
encoding for both HAGE and mB7.1, mB7.2 or m4.1BBL using lipofectamine 2000 reagent 
and following manufacturer’s instructions (See Section 2.2.2.1). Two days after transfection, 
cells were fixed, permeabilised and stained for HAGE and either mB7.1, mB7.2 or m4.1BBL 
expression for confocal analysis. Secondary antibody tagged with fluorescein (FITC) 
highlights the expression and localisation of HAGE within the cells. High level of HAGE 
protein expression, mainly localised in the cytoplasm, was achieved in about 90% of 
transfected cells when ESTDAB-07 cells were transfected with any of the plasmids containing 
HAGE. Primary antibodies conjugated with phycoerythrin (PE) highlight the expression and 
localisation of the murine co-stimulatory molecules within the cells. Expression of murine co-
stimulatory molecules could be detected at different levels of intensity on the cell membrane of 
about 20% of transfected cells. On the other hand, neither cells transiently transfected with the 
empty plasmid nor cells incubated with FITC- and PE-conjugated secondary antibodies 
showed staining (Fig. 4.10). 
 
 4.2.3 Cloning of HAGE into pSHAME2a vector for SFV generation 
Plasmids for SFV generation were kindly provided by Dr. Rod Bremner (University of 
Toronto). In order to generate SFV/HAGE viruses, HAGE sequence had to be cloned into 
pSHAME2a vector. To subclone HAGE sequence from pcDNA3/HAGE expression vector, 
pcDNA3/HAGE was double digested with BamHI and NsiI restriction enzymes along with 
pSHAME2a vector. Digested pSHAME2a vector and HAGE band were gel extracted and 
ligated overnight as described before (Fig. 4.11). Clones of vector from transfected XL1-Blue 
bacteria were isolated and screened for insertion of HAGE cDNA by repeating the BamHI-NsiI 
double digestion. As seen in Fig. 4.12, four clones with HAGE insertion were detected and 
were further used for confirmation of protein produ
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Figure 4.8: Diagrammatic representation of the construction of the plasmid 
pBudCE4.1/HAGE/m4.1BBL. The m4.1BBL cDNA was first PCR up. The PCR amplicons and 
the pBudCE4.1/HAGE vector were digested with restriction enzymes BglII and XhoI. The 
digested products were purified by gel purification and desired fragments were selected for 
ligation. After ligation, the cDNA for m4.1BBL was into the pBudCE4.1/HAGE plasmid. 
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Figure 4.9: Agarose gel electrophoresis after double digestion of pBudCE4.1/HAGE/ 
m4.1BBL clones. After double digestion with BglII and XhoI, a band corresponding to 930bp 
could be detected in 2 out of 10 clones picked, indicating successful cloning of m4.1BBL into 
the pBudCE4.1/HAGE mammalian expression vector. 
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Figure 4.10: Immunofluorescence assay for HAGE and murine co-stimulatory molecules 
expression analysis and localisation in a melanoma cell line. Immunofluorescence was 
observed under a confocal microscope in ESTDAB-07 cells transiently transfected with 
pBudCE4.1/HAGE (A), pBudCE4.1/HAGE/mB7.1 (B), pBudCE4.1/HAGE/mB7.2 (C) and 
pBudCE4.1/HAGE/m4.1BBL (D). No non-specific staining was obtained when transfected cells 
were incubated with both FITC- and PE-conjugated isotype control antibodies only (1) or 
when cells were transiently transfected with the empty plasmid and stained for protein 
expression (2). HAGE protein expression is mainly localised in the cytoplasm (green) while 
murine co-stimulatory molecules are found on the membrane (red)(3). It is worth mentioning 
that staining of mB7.1 and m4.1BBL molecules will have to be repeated with increased 
concentrations of primary antibodies and functioning confocal microscope. 
   139 
PCMV
BGH pA
F1 ori
SV40
Ampicillin
ColE1
SV40
Neomycin
HAGE
HindIII
XbaI
pcDNA3/HAGE
Restriction
Digestion
And ligation
pSHAME2a
PCMV
nsP1-4
capsid δsP
3’UTR
A69
SV40 
term
Ampicillin
B
a
m
H
I
B
lp
I
B
ss
H
I
C
la
I
N
siI A
v
rI
I
A
pa
I
X
m
a
I
B
a
m
H
I
B
lp
I
B
ss
H
I
C
la
I
N
siI A
v
rI
I
A
pa
I
X
m
a
I pSHAME2a
PCMV
nsP1-4
capsid δsP
3’UTR
A69
SV40 
term
Ampicillin
HAGE
NsiIBamHI
 
 
Figure 4.11: Diagrammatic representation of the construction of the plasmid 
pSHAME2a/HAGE. The pcDNA3/HAGE and pSHAME2a vectors were first digested with 
restriction enzymes BamHI and NsiI. The digested products were purified by gel purification 
and desired fragments were selected for ligation. After ligation, the cDNA for HAGE was 
inserted into the pSHAME2a plasmid. 
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Figure 4.12: Agarose gel electrophoresis after double digestion of pSHAME2a/HAGE 
clones. After double digestion with BamHI and NsiI, a band corresponding to 1.9kb could be 
detected in 4 out of 10 clones picked, indicating successful cloning of HAGE into the 
pSHAME2a mammalian expression vector. 
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To confirm protein production of HAGE protein by pSHAME2a/HAGE vector, murine bone 
marrow-derived dendritic cells (BM-DC) were transfected with the vector using Lipofectamine 
2000 and protein production was tested 48 hours later after staining for the FLAG tag. 
Secondary antibody tagged with fluorescein highlights the expression and localisation of 
HAGE within the cells. HAGE was found to be mostly localised in the nucleus as seen in Fig. 
4.13 and expressed at the protein level in about 70% of transfected BM-DC. This result 
confirmed the ability of BM-DC to express HAGE at the protein level upon transfection as 
well as the validity of the utilisation of BM-DC transiently transfected to express HAGE in 
immunisation procedures. 
 
 4.2.4 Generation of SFV viruses 
Semliki Forest Virus generation requires co-transfection of the helper plasmid as well as the 
replicon plasmid containing the gene of interest (β-gal or HAGE). Factors, such as method of 
transfection and molar ratios of the two plasmids can affect the titre of virus generated. 
Calcium phosphate precipitation (Promega) and electroporation were both available as 
transfection methods. Using 293 cells, it appeared that transfection with calcium phosphate 
offered the best virus yield (Data not shown). Viral titration appeared to be slightly improved 
when 1:2 and 1:3 molar ratios were used, although no significant differences were observed. 
However, a molar ratio of 1:3 generated the highest titrations (up to 1.7*106 IU/ml) and it was 
decided to use this ratio for all future experiments (Fig. 4.14).  
Finally, to confirm HAGE protein production in cells infected with SFV-HAGE, BHK-21 cells 
were infected with 1*106 IU/ml of the activated virus for one hour and generation of FLAG-
tagged protein was visualised using immunohistochemistry. Briefly, anti-FLAG antibody and 
HRP-conjugated anti-mouse secondary antibody were sequentially added to infected BHK-21 
cells. DAB solution was then added to the cells with brown staining indicative of the 
production of the protein. As seen in Fig. 4.15, dark brown staining was achieved in infected 
BHK-21 cells suggesting the production of the FLAG-tagged HAGE protein whilst no or only 
little background staining was observed in control cells. Moreover, immunohistochemistry 
revealed HAGE to be mostly localised in the nucleus, which agrees with earlier results 
demonstrating by immunofluorescence the expression of HAGE in pSHAME2a/HAGE-
transfected BM-DC. 
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Figure 4.13: Immunofluorescence assay for HAGE protein expression analysis and 
localisation in bone marrow-derived dendritic cells. Immunofluorescence was observed under 
a confocal microscope in BM-DC transiently transfected with pSHAME2a/HAGE (A). 
pBudCE4. No non-specific or very limited staining was obtained when cells were incubated 
with no antibody (1) or with FITC-conjugated secondary antibody only (2). HAGE protein 
expression is mainly localised in the nucleus. 
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Figure 4.14: X-gal assay on BHK-21 cells 48 hours after infection with SFV/β-gal. The X-
gal assay demonstrates the infection of BHK-21 cells by SFV/β-gal appearing in blue (B). No 
non-specific staining was obtained in non-infected cells (A). 
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Figure 4.15: Immunohistochemistry staining of BHK-21 cells 48 hours after infection with 
SFV/HAGE. The immunohistochemistry demonstrates the infection of BHK-21 cells by 
SFV/HAGE appearing in brown (B). Little non-specific secondary staining was obtained in 
non-infected cells (A). 
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4.3 Discussion 
Nucleic acid vaccination presents numerous advantages, among which the variety of forms 
such as plasmid or viral DNA depending on the targeted application, the flexibility and the 
specificity of generating immune responses against multiple antigens and in certain cases 
polarising that response, and finally the duration of the effects with direct protein expression in 
vivo for several months contrary to whole protein vaccination often considered to be expensive, 
time-consuming and short-lived as injected proteins are likely to be degraded in a few days. 
Immune prevention and rejection responses have been generated with various modes of 
vaccination such as peptide, DNA or virus. Identification of immunogenic and naturally 
processed peptides from tumour antigens can be now relatively quick via the use of reverse 
immunology and transgenic mice. However, it still remains difficult in the case of self antigens. 
Indeed, deletion or tolerisation via central and peripheral tolerance mechanisms suppresses 
most T cells specific for high affinity epitopes from self antigens leaving several medium 
affinity peptides to be identified, which is expensive and time-consuming. DNA-based 
vaccination with whole gene or only sequences of it allows the overcoming of this situation. 
DNA vaccines also present another advantage as they are not restricted to HLA haplotypes of 
patients meaning that the whole population can be targeted. The efficiency of these vaccines 
can also be further enhanced by associating antigen genes with various co-stimulatory 
molecule or cytokine genes (Guinn et al., 1999; Liu et al., 2004), by orientating the antigens to 
a preferred processing pathway with specific signal sequences (Liu et al., 2004; Stevenson et 
al., 2004) or by adding a pathogen-derived sequence to provide critical CD4+ T cell help 
(Buchan et al., 2005).  
In this study, HAGE cDNA was cloned in a mammalian expression vector in order to 
investigate endogenous process of immunogenic HAGE-derived peptides and xenogeneic 
immunisation in a HAGE-positive tumour model. Upon successful assembly and construction 
of the expression vector, it was critical to confirm that it performed accordingly in in vitro 
experiments before moving into in vivo studies. A HAGE-negative melanoma cell line was 
therefore transiently transfected with the expression vector using Lipofectamine 2000. HAGE 
expression at the mRNA level was confirmed by RT-Q-PCR (data not shown). However, 
mRNA level of a gene does not always correlate with its protein expression. Transfection of 
the same cell line was then repeated and protein expression of HAGE was determined after two 
days by immunofluorescence. High level of HAGE expression was observed in transfected 
cells compared to control cells transfected with the empty plasmid or stained with secondary 
antibody only. The expression vector used for cloning HAGE is characterised by two multiple 
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cloning sites with two independent promoters, therefore enabling the cloning of another 
antigen, a cytokine or a co-stimulatory molecule in order to enhance the efficiency of the 
elaborated vaccine. In this study, the murine co-stimulatory molecules mB7.1, mB7.2 and 
m4.1BBL were selected and cloned into the remaining free multiple cloning site. Following 
sequencing and confirmation that sequences cloned were 100% identical to published 
sequences, expression of these co-stimulatory molecules at the protein level was studied by 
immunofluorescence using PE-conjugated primary antibodies 48 hours after cellular 
transfection. Expression of mB7.1, mB7.2 and m4.1BBL was observed on the surface of 
transfected cells compared to cells stained with PE-conjugated isotype control antibody only, 
or cells transfected with the empty plasmid and stained for the expression of the murine co-
stimulatory molecules. Altogether, these data confirmed that expression vectors encoding 
HAGE only or together with a murine co-stimulatory molecule could be used in a xenogeneic 
tumour model. 
Furthermore, tumour vaccines based on naked DNA only do not always lead to beneficial 
effects depending on the immunogenicity of the antigen used. The immune system often 
requires a stronger signal and this could be provided by viral or bacterial vectors allowing not 
only the activation of both arms of the immune system and the infection of different cell types, 
but also the breakage of tolerance whenever antigens with low immunogenic potential such as 
self antigens are used in tumour vaccination procedures. Viral and bacterial vectors have been 
extensively used for in vitro modification of cells or in vivo immunotherapeutic experiments in 
animals and humans. Adenovirus and poxvirus have been so far the most widely used viral 
vectors but like other viral and bacterial vectors, they present a certain number of limitations. 
Among them, there is always the risk of generating replication-competent vectors in vivo, 
which could be detrimental for cancer patients with immuno-suppressed organisms. Several 
studies have described the utilisation of alphaviruses such as Semliki Forest virus in 
immunotherapeutic strategies. Indeed, SFV offers a certain level of safety in vaccination 
approaches as their production requires the co-transfection of both helper and replicon 
plasmids, as well as an activation brought by the α-chymotrypsin-dependent cleavage of the 
p62 structural protein (DiCiommo et al., 2004). 
As an alternate to naked DNA immunisation, HAGE cDNA was then cloned in the SFV 
replicon vector in order to investigate the potential of SFV-based vaccines to target HAGE-
expressing tumour cells. Upon successful assembly and construction of the expression vector 
pSHAME2a/HAGE, transient transfection of murine BM-DC and immunofluorescence 
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analysis confirmed the expression of HAGE at the protein level, a result critical before 
performing in vivo studies. Also, the generation of recombinant SFV viruses strongly depends 
on various parameters such as the method of transfection or the molar ratio of the two required 
plasmids. The co-transfection of β-gal reporter plasmid with the helper plasmid allowed easy 
optimisation of virus production and titration. Firstly, the efficiency of two transfection 
techniques (calcium phosphate precipitation and electroporation) was compared. Higher viral 
titres were reached when calcium phosphate precipitation was used to transfect 293 cells. 
Indeed, this method was proved to be the cheapest and the most reliable, which is in correlation 
with previous publications (DiCiommo and Bremner, 1998) and earlier experiments carried out 
in our laboratory comparing the calcium phosphate method with Lipofectamine 2000 and 
GeneJuice (Assudani D., unpublished data). Thereafter, different molar ratios of helper to 
replicon plasmids were trialled in order to determine the optimum mixture capable of 
generating the highest viral titre. Although differences were not significant, results showed that 
a molar ratio of 1:3 was slightly better and used for virus generation. Such a ratio ensures that 
all the cells transfected with the replicon plasmid will also be transfected with the helper 
plasmid being in higher concentration. All these new parameters were considered and applied 
to the production of recombinant SFV/HAGE viruses. Upon activation, BHK-21 cells were 
infected and high levels of HAGE expression were detected by immunohistochemistry staining 
indicating both viral activity and efficacy. 
In conclusion, expression vectors for HAGE alone or combined with a murine co-stimulatory 
molecule, as well as the SFV vector for HAGE were constructed and their capacity to produce 
proteins in vitro were confirmed using transfection experiments. However, the efficiency of 
developed DNA and viral vectors to generate an immune response and prevent or reject tumour 
cells in vivo requires further investigation. 
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Chapter 5: Epitope identification from HAGE 
5.1 Introduction 
Since the discovery of the first human tumour-associated antigen and CTL epitope derived 
from this TAA, several differents strategies have been used for the identification of MHC class 
I and class II epitopes. They can now be grouped in two major categories termed direct 
immunology and reverse immunology.  
 
(i) Direct immunology: The first category can be sub-grouped into a genetic or a biochemical 
approach for the discovery of TAA-derived epitopes. Indeed, cell lines expressing the relevant 
MHC molecules and transfected with DNA or cDNA libraries from tumour cells can be created 
and then tested by measuring the in vitro reactivity of tumour-infiltrating lymphocytes. Using 
this technique, MAGE-1 was the first TAA to be identified by T. Boon and colleagues (van der 
Bruggen et al., 1991). The same group applied this technique to identify the BAGE and GAGE 
antigens. Adapting this method in vivo, the group of S. Rosenberg identified several other 
tumour antigens such as MART-1, gp100 and tyrosinase (Kawakami et al., 1994). Later 
improvement of this technique based on the utilisation of truncated regions of MAGE-1 DNA 
allowed the identification of the first CTL peptide target (Traversari et al., 1992). Since then, 
several CTL and T helper targets contained within these TAA have been identified using this 
technique (Halder et al., 1997, Smith et al., 2001). However, the improvement with more 
efficient expression libraries to discover relevant epitopes does not compensate for the 
difficulties encountered in generating CD4+ and/or CD8+ T cell clones from TIL and the time 
spent in completing these experiments. That is why researchers have looked into a more direct 
approach using the biochemical properties of MHC molecules. Three major techniques were 
developed. The first one extracted total cellular peptides with a very acidic solution to provoke 
total cell lysis. Unfortunately, only a fraction of the extracted peptides were actually class I-
related (Falk et al., 1990). The second technique developed is highly specific and relies on the 
purification of MHC class I complexes from cell lysates using class I allele-specific 
monoclonal antibodies. This method has to date been the most commonly applied for the 
identification of MHC class I epitopes, although not only surface bound MHC class I:peptide 
complexes were isolated but also those trafficking from the endosomal pathway as well as 
those still contained within the ER (Nikolic-Zugic and Carbone, 1991). The third and last 
biochemical approach relies on the brief exposure of viable cells to a low pH buffer (i.e.: citrate 
phosphate buffer at pH 3.3). Acid stripping exploits the property of the non-covalent link 
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between the α1 domain of the MHC class I heavy chain and β2-microglobulin and that low pH 
can weaken and destabilise MHC: peptide complexes (Storkus et al., 1991). These MHC 
peptides, also referred to as “HLA peptidome”, can then be separated by means of reverse 
phase chromatography and sequenced using tandem mass spectrometric techniques. 
Interestingly, this approach was improved by transfecting tumour cell lines with a truncated 
version of the MHC genes and resulting in the secretion of soluble MHC:peptide complexes 
easily purifiable and analysable (Barnea et al., 2002). This technique has been applied to the 
identification of MHC class I peptides from both cultured tumour cell lines (Ramakrishna et al., 
2003) and primary tumour material (Flad et al., 1998) and several tumour-associated peptides 
have since been discovered (Clark et al., 2001; Bonner et al., 2002). There are several 
advantages in using a biochemical approach as both high and low-to-moderate affinity peptides 
can be isolated and sequenced. Also, this is the only current method revealing eventual post-
translational modifications carried by MHC epitopes such as phosphorylation (Zarling et al., 
2000), deamidation (Skipper et al., 1996) and glycosylation (Haurum et al., 1999). Moreover, a 
recent study described a new form of post-translational modifications that could also be 
detected by these approaches, resulting from the generation of peptide-splice variants from 
short MHC-restricted peptides comprised of two non-contiguous sections of the same protein 
within the proteasome, although the frequency of this phenomenon remains to be defined 
(Hanada et al., 2004; Vigneron et al., 2004). With these methods, a large amount of peptides 
needs to be isolated from tumour cell lines and/or tumour masses for analysis and sequencing, 
but the constant development of mass spectrometry technology and the improvement in term of 
sensitivity of the equipments diminishes the importance of this limiting factor and increases the 
capacity to identify low number of tumour-specific peptides among thousands of irrelevant 
normal peptides. Mild acid elution has so far largely been used for the identification of MHC 
class I peptides but proved inefficient for the identification of MHC class II peptides as MHC 
class II molecules remain stable at this mild pH and can only be eluted at much lower pH, 
which is generally detrimental to the cells (D. Barry, personal communication). Interestingly, 
this direct approach can be used in combination with reverse immunology. Indeed, potential 
epitopes from CEA and p53 have been identified following prediction of an epitope, calibration 
of the analysis apparatus with the synthetic peptide to assist in its identification and finally, 
detection of the suspected epitope in the actual tumour samples (Schirle et al., 2000). However, 
identification of peptides bound to MHC molecules on the surface of tumour cells does not 
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guarantee their immunogenicity (Rojas et al., 2005) and therefore, requires further in vivo and 
in vitro analyses. 
 
(ii) Reverse immunology: Reverse immunology, on the other hand, starts from a known 
sequence and attempts to predict potential CTL or T helper epitopes using a combination of 
known MHC binding motifs and the sequence of the antigen of interest. Tumour antigen amino 
acid sequences can be analysed in silico by computer-based algorithms to predict antigenic 
determinants from tumour antigens that could be useful for immunotherapy. These 
determinants are predicted by the presence or absence of key anchor residues in positions 
known to favour interactions with the MHC binding groove of interest. For example, positions 
2 and 9 are the key anchor motifs for HLA-A0201 and binding would be enabled by the 
presence of aliphatic amino acids such as leucine, isoleucine, valine or methionine at these 
positions. However, these algorithms tend to have low levels of accuracy as other positions are 
not taken into account and the presence of a large and bulky amino acid in the middle of 
sequence between positions 2 and 9 might actually interfere with the binding. That is why 
models considering the whole amino acid sequences have been developed. These algorithms or 
“motif matrices” attribute negative or positive values to each amino acid depending on the 
MHC binding cleft it will interact with. BIMAS (www.bimas.cit.nih.gov) and SYFPEITHI 
(www.syfpeithi.de) are the two most commonly used of these programs and can calculate 
binding affinity to various MHC haplotypes of peptides derived from a given tumour antigen 
with greater accuracy. The major drawback of these two algorithms remains the lack of natural 
processing prediction and later versions are now taking proteasomal cleavage prediction into 
account enhancing considerably the likelihood of identifying a “true” CTL or T helper epitope. 
However, proteasomal cleavage prediction and binding affinity determination do not guarantee 
the immunogenicity of a given peptide (Rojas et al., 2005). So, depending on their scores, 
peptides are synthesised and screened for their immunogenicity, their natural processing and 
their presentation in the context of MHC molecules in both in vivo and in vitro experiments 
with human PBMC and transgenic mouse models, respectively.  
Several MHC class I and class II peptides from various TAA such as gp100, MAGE, MART-1 
or p53 have been so far described based on this approach (Touloukian et al., 2000; Zarour et al., 
2000; Bar-Haim et al., 2004; Rojas et al., 2005). The combination of transgenic mouse models 
expressing single human MHC molecules or double class I and class II HLA molecules with or 
without knockout murine MHC molecules, with reverse immunology brings several advantages 
as it shortens considerably time and resources, allows pre-clinical investigations to the 
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applicability of predicted peptides for vaccination programs, in addition to peptide 
immunogenicity and natural processing that are determined in vitro in highly controlled and 
artificial settings after in vivo challenge with peptides and genes, respectively. It is also worth 
mentionning that several class I and class II peptides have been shown to be processed 
identically in transgenic mouse models and in humans (Theobald et al., 1995; Theobald et al., 
1997; Rojas et al., 2005), although not all peptides are necessarily processed in a same manner 
(Street et al., 2002). The only major drawback of this technique is the availability of mice 
transgenic for the HLA molecules with the highest frequencies such as HLA-A0201, -DR0101 
and –DR0401. Interestingly, one further method relies on the power of artificial neural 
networks, a self-trained system capable of determining peptides with immunological interest 
with very high accuracy. Indeed, peptides predicted to be immunogenic were detected in 
melanoma patients and found to be able to potentiate a peptide-specific CTL response 
(Bredenbeck et al., 2005), the only disadvantage being the large amount of data required to 
train the system. Moreover, none of these peptides were predicted to be HLA ligands by more 
common algorithms suggesting that several low-to-moderate affinity but immunodominant 
peptides could be neglected by more conventional methods of reverse immunology. 
Reverse immunology in conjunction with the use of transgenic mice was considered the most 
appropriate for the purpose of this study. In order to investigate the immunogenicity of HAGE, 
peptides predicted to be immunogenic by web-based algorithms were synthesised and tested in 
HHDII (HLA-A0201) mice for their ability to generate CTL responses in a MHC class I model, 
and in HLA-DR0101 and HLA-DR0401 mice for their capacity to generate T helper responses 
in a MHC class II model. Following evaluation of their immunogenicity, peptides were further 
analysed for their natural processing using HAGE cDNA immunisation and in vitro peptide re-
stimulation. 
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5.2 Results 
 5.2.1 Identification of HLA-A0201 restricted peptides from HAGE using HHDII 
transgenic mice 
  5.2.1.1 Immunogenicity of peptides predicted from HAGE sequence for HLA-A2 
In order to ascertain the immunogenicity of peptides predicted from HAGE sequence for HLA-
A0201, HHDII transgenic mice were immunised once with 100µg of the MHC class I peptides 
in 1:1 emulsion with IFA as described by Rojas et al. (2005). Murine MHC class II peptide 
derived from hepatitis B was used as a helper peptide for each immunisation. Seven days after 
immunisation, splenocytes were harvested and re-stimulated in vitro with LPS blasts pulsed 
with relevant peptide for five days. On day 6, the immunogenicity of the peptides was 
determined by measuring the capacity of T cells generated against these peptides to kill 
peptide-pulsed target cells in a standard four-hour chromium release assay. In this experiment, 
RMAS/A2 cells, pulsed with either relevant or irrelevant peptide, were used as targets to 
determine the specificity of the response. Results showed that after one round of immunisation, 
a peptide-specific cytotoxic response was achieved with four out of eight peptides tested. 
Peptide-specific killing of pulsed RMAS/A2 cells was detected for peptides HAGE 103, 
HAGE 126, HAGE 296 and HAGE 506-I with cytotoxic responses ranging from 20% to up to 
80% with the highest effector to target ratio. Minimal lysis of RMAS/A2 cells pulsed with 
irrelevant peptides was observed confirming the specificity of the immune response (Fig. 5.1). 
Furthermore, the lysis was completely blocked by HLA/A2 antibody indicating that T cells 
generated were killing in a HLA-A2-restricted manner (Data not shown). These results were 
later confirmed by conducting syngeneic peptide-pulsed DC immunisation. Briefly, HHDII 
transgenic mice were immunised intra-dermally with 2*106 BM-DC generated in vitro 
according to the method of Inaba and colleagues (1992) and loaded with 40µg of the MHC 
class I peptides as described by Rojas et al. (2005). Seven days after immunisation, splenocytes 
were harvested and prepared as described earlier. RMAS/A2 cells were pulsed with either 
relevant or irrelevant peptide and used as targets in a cytotoxicity assay. Peptide-specific 
killing of pulsed RMAS/A2 cells was also detected for peptides HAGE 103, HAGE 126, 
HAGE 296 and HAGE 506-I with similar cytotoxicity levels to peptide immunisation, whilst 
leading to minimal lysis of target cells pulsed with irrelevant peptides (Fig. 5.2).  
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Figure 5.1: Cytotoxicity assay using T cells generated from HHDII transgenic mice 
immunised with HAGE-derived class I peptides. Mice were immunised with HAGE 103 (A: 
IIQEQPESL), HAGE 126 (B: AVIDNFVKKL), HAGE 296 (C: YLMPGFIHLV) and HAGE 
506-I (D: DLILGNISV) peptides and cytotoxicity assays were carried out after in vitro re-
stimulation of immunised cells with these peptides or with an irrelevant one. *p<0.05, 
**p<0.01, ***p<0.001 are the statistical differences between HAGE-derived class I peptides 
and Irrelevant determined by unpaired Student T test n=a/b with “a” being the number of mice 
responding to the peptide immunisation and used to represent these graphs, and “b” being the 
total number of mice immunised. 
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Figure 5.2: Cytotoxicity assay using T cells generated from HHDII transgenic mice 
immunised with DC pulsed with HAGE-derived class I peptides. Mice were immunised with 
DC pulsed with HAGE 103 (A: IIQEQPESL), HAGE 126 (B: AVIDNFVKKL), HAGE 296 (C: 
YLMPGFIHLV) and HAGE 506-I (D: DLILGNISV) peptides, and cytotoxicity assays were 
carried out after in vitro re-stimulation of immunised cells with these peptides or with an 
irrelevant one.  **p<0.01, ***p<0.001 are the statistical differences between HAGE-derived 
class I peptides and Irrelevant determined by unpaired Student T test. n=a/b with “a” being 
the number of mice responding to the peptide immunisation and used to represent these graphs, 
and “b” being the total number of mice immunised. 
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Moreover, supernatants from the in vitro re-stimulation culture were harvested on day 3 and 
day 5 to measure IFNγ production by ELISA. Peptides HAGE 103, HAGE 126 and HAGE 
506-I allowed significant levels of peptide-specific IFNγ secretion on day 5 of the culture. 
Peptide HAGE 296, which was found to be the most immunogenic peptide with up to 80% 
killing of target cells in 80% of the mice immunised, seemed to induce significant levels of 
peptide-specific IFNγ secretion in both day 3 and day 5 of the experiment (Fig. 5.3). On the 
other hand, T cells could not be generated against peptides HAGE 507, HAGE 508, HAGE 509 
and HAGE 551 and hence, were defined as non-immunogenic and no further experiments were 
carried out with these peptides (Data not shown). Results of the immunisation of HHDII 
transgenic mice with HAGE-derived MHC class I peptides were summarised in table 5.1. 
 
Table 5.1: Immunogenic HAGE-derived MHC class I peptides. 
Peptides Immunogenicity Cytotoxicity (p<0.05) 
IFNγ secretion 
(p<0.05) 
HAGE 103 Yes 8/10 2/3 
HAGE 126 Yes 5/9 1/2 
HAGE 296 Yes 7/8 4/4 
HAGE 506-I Yes 4/7 1/2 
HAGE 507 No 0/3 Not done 
HAGE 508 No 0/6 Not done 
HAGE 509 No 0/3 Not done 
HAGE 551 No 0/3 Not done 
 
  5.2.1.2 Determination of natural processing of immunogenic class I peptides 
In order to confirm if any of the four identified immunogenic class I peptides detailed in the 
table above were endogenously processed by the proteasome and naturally presented at the cell 
surface by HLA-A0201 molecules, two methods of immunisation were selected. They rely on 
the injection of gold-coated HAGE-encoding plasmid DNA by gene gun or syngeneic BM-DC 
prepared ex vivo and transfected to express HAGE in HHDII transgenic mice. In order to 
validate the gene gun strategy, p53 cDNA was used as a positive control to check the quality of 
DNA bullets, gene gun immunisation and in vitro experiments. This control consisted of three 
rounds of gene gun immunisation at seven-day intervals of a p53-encoding plasmid and in vitro 
re-stimulation with peptides p53 149 (Theobald et al., 1995; Chikamatsu et al., 1999), which 
was previously reported to be naturally endogenously processed. 
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Figure 5.3: IFNγ secretion analysis by ELISA following in vitro re-stimulation with HAGE-
derived class I peptides. Cytokine analysis was carried out on supernatants harvested on day 3 
and 5 of the in vitro re-stimulation with HAGE 103 (A: IIQEQPESL), HAGE 126 (B: 
AVIDNFVKKL), HAGE 296 (C: YLMPGFIHLV) and HAGE 506-I (D: DLILGNISV) peptides. 
*p<0.05, **p<0.01, ***p<0.001 are the statistical differences between HAGE-derived class I 
peptides and Irrelevant determined by unpaired Student T test. n=a/b with “a” being the 
number of mice responding to the peptide immunisation and used to represent these graphs, 
and “b” being the total number of mice tested. 
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At the same time, another group of HHDII transgenic mice received three rounds of gene gun 
immunisation at seven-day intervals of a HAGE-encoding plasmid. Splenocytes were 
harvested and re-stimulated in vitro with irradiated LPS blasts pulsed with any of the four 
immunogenic HAGE-derived class I peptides. Following the five-day period of in vitro re-
stimulation, T cells generated against these peptides were evaluated in a cytotoxicity assay 
against target cells pulsed with the p53 149 peptide for mice immunised with the p53-encoding 
plasmid or immunogenic HAGE-derived class I peptides for mice immunised with the HAGE-
encoding plasmid. As predicted, peptide p53 149 triggered a peptide-specific cytotoxic 
response in every HHDII transgenic mouse tested with up to 80% of peptide-pulsed target cells 
killed, whereas no killing of irrelevant targets was observed. This result allowed not only to 
rule out any faults in the procedure, but also to confirm the production and the natural 
processing of the p53 protein as well as the presentation of peptide p53 149 in vivo to prime 
specific T cells, which were then expanded in vitro with the use of LPS blasts. Contrary to 
peptide p53 149, none of the four immunogenic HAGE-derived class I peptides led to 
statistically significant cytotoxicities, suggesting that none of these peptides were naturally 
processed by the proteasome and presented to T cells via HLA-A0201 molecules (Fig. 5.4A). 
Other strategies were also used to confirm these findings by evaluating the ability of T cells 
generated against these peptides to specifically kill HLA-A0201-positive/HAGE-positive 
tumour cell line such as K562-A2 and similar results were unfortunately obtained (Data not 
shown). Interestingly, significantly different results were obtained when HHDII transgenic 
mice were immunised with one round of syngeneic BM-DC transfected to express the HAGE 
protein. Indeed, cytotoxic responses reaching almost 40% of total cell lysis were achieved in 
five out of eight mice tested when splenocytes were re-stimulated in vitro with peptide HAGE 
126. None of the other immunogenic HAGE-derived class I peptides led to significant killing 
of peptide-pulsed target cells (Fig. 5.4B). As a control experiment, HHDII transgenic mice 
received one round of syngeneic BM-DC transfected with an empty plasmid and splenocytes 
were re-stimulated in vitro with peptide HAGE 126. No cytotoxic response was achieved in 
both mice tested indicating that CD8+ T cell responses observed earlier were actually due to 
the immunisation with syngeneic BM-DC expressing HAGE and not the in vitro re-stimulation 
(Data not shown). Moreover, supernatants from the in vitro re-stimulation culture were 
harvested on day 2 and day 5 to measure IFNγ production by ELISA. 
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Figure 5.4: Cytotoxicity assay and IFNγ secretion using T cells generated from HHDII 
transgenic mice immunised with HAGE DNA. Mice were either immunised with gold-coated 
pcDNA3/HAGE plasmid (A) or with syngeneic BM-DC transiently transfected with 
pcDNA3/HAGE (B). Cytotoxicity assays were carried out after in vitro re-stimulation of 
immunised cells with immunogenic HAGE-derived class I peptides. Cytokine analysis (C) was 
carried out on supernatants harvested on day 3 and 5 of the in vitro re-stimulation with HAGE 
103 (A: IIQEQPESL), HAGE 126 (B: AVIDNFVKKL), HAGE 296 (C: YLMPGFIHLV) and 
HAGE 506-I (D: DLILGNISV) peptides. ***p<0.001 are the statistical differences between 
HAGE-derived class I peptides and Irrelevant determined by unpaired Student T test. n=a/b 
with “a” being the number of mice responding to the peptide immunisation and used to 
represent these graphs, and “b” being the total number of mice tested. 
Only peptide HAGE 126 allowed significant levels of peptide-specific IFNγ secretion on both 
day 2 and day 5 of the culture (Fig. 5.4C). These results were later confirmed when HHDII 
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mice were immunised with one round of syngeneic BM-DC pulsed with a HAGE-positive 
K562 cell lysate, and in vitro re-stimulation with HAGE 126 decamer. Indeed, peptide-specific 
cytotoxic response of 25% was achieved in one out of two mice (Data not shown). Altogether, 
these results indicate that peptide HAGE 126 is naturally processed by the proteasome, 
presented at the cell surface by HLA-A0201 molecules to T cells and capable of eliciting both 
cytotoxic and IFNγ-based responses, at least in mice. 
 
 5.2.2 Identification of HLA-DR restricted peptides from HAGE using HLA-DR0101 
and HLA-DR0401 transgenic mice 
  5.2.2.1 Immunogenicity of peptides predicted from HAGE sequence for HLA-DR1 
and HLA-DR4 
In order to ascertain the immunogenicity of peptides predicted from HAGE sequence for HLA-
DR0101 and HLA-DR0401, FVB/N-DR1 and C57BL/6-DR4 transgenic mice were immunised 
twice at a seven-day interval with 100µg of the MHC class II peptides in 1:1 emulsion with 
IFA as described in methods section. Seven days after the last immunisation, splenocytes were 
harvested and re-stimulated in vitro with the peptides for 6 days. Upon CD8+ T cell depletion, 
these cells were then co-cultured with peptide-pulsed syngeneic BM-DC in order to detect 
peptide-specific proliferation using tritiated thymidine incorporation assay. None of the six 
HAGE-derived class II peptides were able to trigger peptide-specific CD4+ T cell proliferation 
(Data not shown). However, when splenocytes from immunised animals were cultured for one 
week in presence of the peptide and then rested for another week in presence of murine IL-2 
after depletion of CD8+ T cells, peptides HAGE 109, HAGE 198, HAGE 338 and HAGE 506-
II were able to induce peptide-specific CD4+ T cell proliferation in both HLA-DR1 (Fig. 5.5) 
and HLA-DR4 (Fig. 5.6) transgenic mice. Moreover, peptide-specific proliferations to these 
four peptides were blocked by the addition in the culture of an anti-DR blocking antibody 
(L243) but not by the isotype control antibody, demonstrating the MHC class II restriction of 
the responses observed. Supernatants from the in vitro re-stimulation culture were harvested on 
day 3 and day 5 to measure IFNγ and IL-5 production by ELISA. 
   158 
 
HAGE 109
0
200
400
600
800
1000
T-cells+DC
pep
T-cells+DC
Irr
T-cells+DC
pep+L243
T-cells+DC
pep+ctrl Ab
cp
m
 
A
HAGE 195
0
200
400
600
800
1000
1200
T-cells+DC
pep
T-cells+DC
Irr
T-cells+DC
pep+L243
T-cells+DC
pep+ctrl Ab
cp
m
 
A
 
 
HAGE 338
0
200
400
600
800
1000
T-cells+DC
pep
T-cells+DC
Irr
T-cells+DC
pep+L243
T-cells+DC
pep+ctrl Ab
cp
m
 
A
HAGE 506-II
0
200
400
600
800
1000
1200
T-cells+DC
pep
T-cells+DC
Irr
T-cells+DC
pep+L243
T-cells+DC
pep+ctrl Ab
cp
m
 
A
 
 
 
Figure 5.5: Proliferation results of HAGE-derived MHC class II peptides in HLA-DR1 
transgenic mice. Mice were immunised with 100µg of peptide in 1:1 dilution with IFA and 
boosted one week later. Splenocytes were harvested a week later and re-stimulated in vitro 
with HAGE 109 (A: ESLVKIFGSKAMQTK), HAGE 195 (B: KKNFYKESTATSAMS), 
HAGE 338 (C: KYSYKGLRSVCVYGG) and HAGE 506-II (D: DLILGNISVESLHGD) 
peptides for 7 days and then tested for proliferation by incubating them with syngeneic BM-DC 
pulsed with peptide. p<0.05, **p<0.01, ***p<0.001 are the statistical differences between 
HAGE-derived class II peptides and Irrelevant, or between L243 antibody and isotype control 
antibody determined by unpaired Student T test. n=a/b with “a” being the number of mice 
responding to the peptide immunisation and used to represent these graphs, and “b” being the 
total number of mice immunised. 
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Figure 5.6: Proliferation results of HAGE-derived MHC class II peptides in HLA-DR4 
transgenic mice. Mice were immunised with 100µg of peptide in 1:1 dilution with IFA and 
boosted one week later. Splenocytes were harvested a week later and re-stimulated in vitro 
with HAGE 109 (A: ESLVKIFGSKAMQTK), HAGE 195 (B: KKNFYKESTATSAMS), 
HAGE 338 (C: KYSYKGLRSVCVYGG) and HAGE 506-II (D: DLILGNISVESLHGD) 
peptides for 7 days and then tested for proliferation by incubating them with syngeneic BM-DC 
pulsed with peptide. p<0.05, **p<0.01, ***p<0.001 are the statistical differences between 
HAGE-derived class II peptides and Irrelevant, or between L243 antibody and isotype control 
antibody determined by unpaired Student T test. n=a/b with “a” being the number of mice 
responding to the peptide immunisation and used to represent these graphs, and “b” being the 
total number of mice immunised. 
 
C D 
B A 
*** 
** 
*** 
*** 
*** 
*** 
*** * 
n=2/2 n=2/4 
n=2/4 n=3/4 
   160 
Peptides HAGE 109, HAGE 195, HAGE 338 and HAGE 506-II  allowed significant levels of 
peptide-specific IFNγ secretion on day 3 of the culture but only peptides HAGE 338 and 
HAGE 506-II induced peptide-specific IFNγ secretion on day 5 of the culture (Fig. 5.7A). 
These results suggest that not only CD4+ T cell proliferation but also Th1/IFNγ release could 
be achieved with these four HAGE-derived class II peptides in a peptide-specific manner. It is 
worth mentionning that peptides HAGE 109 and HAGE 338 also triggered secretion of IL-5 on 
day 3 of the culture indicating that both of these peptides may be able to induce both Th1/IFNγ 
and Th2/IL-5 releases in a peptide-specific fashion (Fig. 5.7B). These results confirmed the 
immunogenicity of these four HAGE-derived class II peptides. On the other hand, T cells could 
not be generated against peptides HAGE 505 and HAGE 545 and hence, were defined as non-
immunogenic and no further experiments were carried out with these peptides (Data not 
shown). Results of the immunisation of HLA-DR1 and HLA-DR4 transgenic mice with 
HAGE-derived MHC class II peptides were summarised in table 5.2. 
 
Table 5.2: Immunogenic HAGE-derived MHC class II peptides 
Peptides Immunogenicity 
Proliferation 
in DR1 
(p<0.05) 
Proliferation 
in DR4 
(p<0.05) 
IFNγ in 
DR1/DR4 
(p<0.05) 
IL-5 in 
DR1/DR4 
(p<0.05) 
HAGE 109 Yes 4/4 3/4 4/4 2/4 
HAGE 195 Yes 4/4 2/4 3/4 0/4 
HAGE 338 Yes 4/4 2/4 3/4 1/4 
HAGE 505 No 0/2 0/2 0/4 0/4 
HAGE 506-II Yes 2/2 2/2 3/4 0/4 
HAGE 545 No 0/2 0/2 0/4 0/4 
 
  5.2.2.2 Determination of natural processing of immunogenic class II peptides 
In order to confirm if any of the four identified immunogenic class II peptides detailed in table 
5.2 were endogenously processed and naturally presented at the cell surface by HLA-DR0401 
molecules, both gene gun immunisation with gold-coated HAGE-encoding DNA bullets and 
injection of syngeneic BM-DC prepared ex vivo and transfected to express HAGE were carried 
out in C57BL/6-DR4 transgenic mice. After three rounds of DNA immunisation, spleens of 
immunised animals were harvested and splenocytes were re-stimulated in vitro with HAGE-
derived class II peptides. After a week of stimulation and a week of rest in presence of murine 
IL-2, proliferation assays were performed with peptide-pulsed BM-DC.  
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Figure 5.7: IFNγ and IL-5 secretion analysis by ELISA following in vitro re-stimulation with 
HAGE-derived class II peptides. IFNγ (A) and IL-5 (B) analysis was carried out on 
supernatants harvested on day 3 and 5 of the in vitro re-stimulation of DR4-positive 
splenocytes with HAGE 109 (ESLVKIFGSKAMQTK), HAGE 195 (KKNFYKESTATSAMS), 
HAGE 338 (KYSYKGLRSVCVYGG) and HAGE 506-II (DLILGNISVESLHGD) peptides. 
*p<0.05, **p<0.01 are the statistical differences between HAGE-derived class II peptides and 
Irrelevant determined by unpaired Student T test. n=a/b with “a” being the number of mice 
responding to the peptide immunisation and used to represent these graphs, and “b” being the 
total number of mice tested. 
 
 
 
 
Results showed that peptides HAGE 338 and HAGE 506-II, but not HAGE 109 or HAGE 195, 
were able to induce a peptide-specific CD4+ T cell proliferation in 50% and 100% of mice 
tested, respectively (Fig. 5.8). Peptide-specific proliferations to these two peptides were also 
A 
B 
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** 
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blocked by the addition in the culture of an anti-DR blocking antibody (L243) but not by the 
isotype control antibody, demonstrating the MHC class II restriction of the responses observed. 
Finally, peptide-specific IFNγ but not IL-5 production was observed for both peptides, 
suggesting a Th1-type response (Fig. 5.8E and 5.8F). Interestingly, after three rounds of DNA 
immunisation with the empty expression vector and in vitro re-stimulation of splenocytes from 
immunised animals with class II peptides, no proliferation was observed in both mice tested 
indicating that CD4+ T cell proliferations observed earlier are actually due to the DNA 
immunisation and not the in vitro re-stimulation (Data not shown). Moreover, similar results 
were obtained when C57BL/6-DR4 were immunised with one round of transfected syngeneic 
BM-DC. Indeed, peptide-specific and HLA-DR-dependent CD4+ T cell proliferations were 
achieved with identical percentages of mice responding to peptides HAGE 338 and HAGE 
506-II (Fig. 5.9). Altogether, these data demonstrate that both HAGE 338 and HAGE 506-II 
epitopes are naturally processed, presented by HLA-DR4 molecules and capable of eliciting 
peptide-specific CD4+ T cell proliferation and Th1/IFNγ secretion, at least in mice. 
 
 5.2.3 Investigation of the immunogenicity and the endogenous process of HAGE-derived 
peptides in HHDII/HLA-DR1 double transgenic mice 
In order to validate the natural processing and the immunogenicity of peptides HAGE 126, 
HAGE 338 and HAGE 506-II, peptide, DNA and transfected syngeneic BM-DC were injected 
to HHDII/DR1 double transgenic mice, which are also double knockout for murine MHC 
molecules. Peptide immunisation confirmed the capacity of HAGE 126, together with the 
helper HepB or HAGE 506-II peptides but not on its own, to trigger a peptide-specific 
cytotoxic response (Data not shown). Also, both peptides HAGE 338 and HAGE 506-II were 
shown capable of specifically priming CD4+ T cells to proliferate (Data not shown). 
Consequently, both DNA immunisation and syngeneic BM-DC injections were carried out in 
order to see if results obtained earlier in single transgenic mice were reproducible in double 
transgenic mice. 
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Figure 5.8: Proliferation assay and cytokine secretion using T cells generated from HLA-
DR4 transgenic mice immunised with HAGE DNA. Mice were immunised with gold-coated 
pcDNA3/HAGE plasmid. Proliferation assays were carried out after in vitro re-stimulation of 
immunised cells with HAGE 109 (A: ESLVKIFGSKAMQTK), HAGE 195 (B: 
KKNFYKESTATSAMS), HAGE 338 (C: KYSYKGLRSVCVYGG) and HAGE 506-II (D: 
DLILGNISVESLHGD) peptides. Cytokine analysis was carried out on supernatants harvested 
on day 3 of the in vitro re-stimulation with HAGE 338 (E) and HAGE 506-II (F). * p<0.05 
**p<0.01 are the statistical differences between HAGE-derived class II peptides and 
Irrelevant, or between L243 antibody and isotype control antibody determined by unpaired 
Student T test. n=a/b with “a” being the number of mice responding to the peptide 
immunisation and used to represent these graphs, and “b” being the total number of mice 
tested. 
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Figure 5.9: Proliferation assay using T cells generated from HLA-DR4 transgenic mice 
immunised with HAGE DNA. Mice were immunised with syngeneic BM-DC transiently 
transfected with pSHAME2a/HAGE. Proliferation assays were carried out after in vitro re-
stimulation of immunised cells with HAGE 338 (A: KYSYKGLRSVCVYGG) and HAGE 506-
II (B: DLILGNISVESLHGD) peptides. * p<0.05 **p<0.01 are the statistical differences 
between HAGE-derived class II peptides and Irrelevant, or between L243 antibody and isotype 
control antibody determined by unpaired Student T test. n=a/b with “a” being the number of 
mice responding to the peptide immunisation and used to represent these graphs, and “b” 
being the total number of mice immunised. 
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As seen in Fig. 5.10, DNA immunisation led to an unspecific response while syngeneic BM-
DC injection followed by in vitro re-stimulation allowed the generation of a significant and 
specific cytotoxic response towards target cells presenting class I peptide HAGE 126 (up to 
35% killing). Peptide HAGE 126 was therefore considered both naturally processed and 
immunogenic in double transgenic mice. Moreover, DNA immunisation also permitted the 
confirmation of the proteasomal processing of HAGE 338 and HAGE 506-II as both peptides 
were shown to induce peptide-specific and HLA-DR-dependent CD4+ T cell proliferations 
(Fig. 5.11). Results of the immunisation of HHDII, HLA-DR4 and HHDII/DR1 transgenic 
mice with DNA or syngeneic BM-DC were summarised in table 5.3 with highlighted in red, 
HAGE-derived peptides presenting natural processing and immunogenicity characteristics. 
 
Table 5.3: Endogenously processed and immunogenic HAGE-derived MHC class I and II 
peptides 
HLA haplotype Peptide Endogenously processed/immunogenic Mice 
HAGE 103 No/Yes 0/4 
HAGE 126 Yes/Yes 7/12 
HAGE 296 No/Yes 0/4 HLA-A2 
HAGE 506 No/Yes 0/4 
HAGE 109 No/Yes 0/8 
HAGE 195 No/Yes 0/8 
HAGE 338 Yes/Yes 5/10 HLA-DR1/-DR4 
HAGE 506-II Yes/Yes 10/10 
 
Altogether, these results proved the immunogenic potential of the cancer/testis antigen HAGE 
with the identification of one class I and two class II peptides that could be useful for 
vaccination strategies of A2, DR1/DR4 patients. However, further in vitro work with PBMC 
from healthy/cancer donors are needed to confirm the results obtained in mice. 
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Figure 5.10: Cytotoxicity assay using T cells generated from HHDII-DR1 double transgenic 
mice immunised with HAGE DNA. Mice were either immunised with gold coated 
pBudCE4.1/HAGE plasmid (A) or with syngeneic BM-DC transiently transfected with 
pBudCE4.1/HAGE (B). Cytotoxicity assay was carried out after in vitro re-stimulation of 
immunised cells with immunogenic HAGE 126 (AVIDNFVKKL) peptide. **p<0.01 are the 
statistical differences between HAGE-derived class I peptides and Irrelevant determined by 
unpaired Student T test. n=a/b with “a” being the number of mice responding to the peptide 
immunisation and used to represent these graphs, and “b” being the total number of mice 
immunised. 
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Figure 5.11: Proliferation assay using T cells generated from HHDII-DR1 double 
transgenic mice immunised with HAGE DNA. Mice were immunised with gold-coated 
pBudCE4.1/HAGE plasmid. Splenocytes were harvested a week later after last immunisation 
and re-stimulated in vitro with HAGE 338 (A: KYSYKGLRSVCVYGG) or HAGE 506-II (B: 
DLILGNISVESLHGD) peptides for 7 days and then tested for proliferation by incubating 
them with syngeneic BM-DC pulsed with peptide. *p<0.05 and **p<0.01 are the statistical 
differences between HAGE-derived class II peptides and Irrelevant, or between L243 antibody 
and isotype control antibody determined by unpaired Student T test. n=a/b with “a” being the 
number of mice responding to the peptide immunisation and used to represent these graphs, 
and “b” being the total number of mice immunised. 
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5.3 Discussion 
Synthetic peptide-based vaccines have been shown to produce peptide-specific CD8+ T cells 
with protective and therapeutic abilities against tumour cells in preclinical animal models. With 
the help of appropriate adjuvants, they represent convenient and safe modes of immunisation 
easily manufactured in large quantities. For example, vaccination with CTL epitopes derived 
from the HER2/neu antigen was demonstrated to be effective in protective and in therapeutic 
experiments in HER2/neu transgenic mice (Gritzapis et al., 2006), as well as being capable of 
activating both naive and memory CD4+ and CD8+ T cells when co-administered with GM-
CSF in breast cancer patients (Hueman et al., 2007). Unfortunately, the low number of peptide-
specific T cells generated following peptide vaccination in patients represents the major 
drawback of this method. However, positive clinical responses were observed when T cells 
were generated ex vivo from TIL in the presence of antigen-loaded DC or artificial APC and re-
injected back to the patients in adoptive T cell transfer strategies (Hueman et al., 2007). Again, 
it is generally believed that the number of T cells is too low in order to have a prolonged 
beneficial effect. Adoptive T cell therapy was recently further improved by genetically 
modifying non-reactive PBMC and TIL to express a specific TCR and up to two months later, 
at least 10% of peripheral circulating lymphocytes were constituted of transferred T cells, often 
correlating with objective clinical regression in some patients (Morgan et al., 2003; Johnson et 
al., 2006; Morgan et al., 2006). Furthermore, peptides have been used in DC vaccination 
strategies with different degrees of success as peptide-specific CTL were generated in most 
clinical trials (Takahashi et al., 2003), but objective clinical responses in only a few (Wierecky 
et al., 2006). TCR cloning, peptide-pulsed DC vaccination and monitoring of peptide-specific 
T cells in patients are only possible if the sequence of the peptide targeted is known. Therefore, 
peptide identification from known tumour antigens provides the platform for successful 
immunotherapy against several cancers. 
So far, hopes that peptide vaccination could be used therapeutically have been largely 
undermined by results obtained in clinical trials as the numbers of antigens and MHC alleles 
targeted remain low. Consequently, by proposing multiple epitopes from several antigens 
presented by different MHC alleles to reduce risks of immune escape by antigen or MHC 
down-regulation, the chances of successful cancer immunotherapy would be much increased. 
Several studies have demonstrated the feasibility of cancer immunotherapy when objective 
cancer responses were obtained after immunising patients with tumour antigen-derived 
peptides specifically recognised by CD8+ T cells (Rosenberg et al, 1998)(Yee et al, 2000). 
However, the responses observed were often weak and transient (Lee et al., 1999; Chen et al., 
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2004). In pathogenic infections, bacteria, viruses or parasites provide strong signals 
automatically up-regulating CD40 expression on DC and thereby bypassing the need for CD4+ 
T cell help. Unfortunately, in the case of tumours, data about the involvement of CD4+ T cells 
are still contradictory. Nowadays, it is generally believed that CD4+ T cells have a pivotal role 
not only in the initiation and the maintenance of an anti-tumour response but also in the direct 
mediation of tumour regression via IFNγ-dependent mechanisms or apoptosis pathway 
engagement (Echchakir et al., 2000; Egilmez et al., 2002; Assudani et al., 2006). CTL 
generation seems to depend on three distinct mechanisms: the duration of MHC-restricted 
peptide presentation by the APC, the affinity of TCR-MHC binding and the presence or not of 
CD4+ T cell help. The latter is of critical importance as high affinity MHC class I peptides do 
not require CD4+ T cell help (Franco et al., 2000), but because low-to-moderate affinity MHC 
class I peptides are more likely to be efficient against tumours expressing up-regulated self-
antigens, CD4+ T cell role in the anti-tumour response can be emphasised. Finally, the origin 
of the T helper epitope is still not clearly defined but may also have an influence on the 
quality/quantity of CD8+ T cells. Indeed, some researcher argue the use of irrelevant peptides 
derived from infectious pathogenic agent such as tetanus toxoid or hepatitis B, whereas others 
have suggested the incorporation of a CD4+ T cell epitope from either the same antigen as 
CTL epitope or a SEREX-defined self antigen in a peptide vaccine (Nishikawa et al., 2001; 
Nishikawa et al., 2005). Therefore, optimal immunisation will require the recruitment of both 
CD4+ and CD8+ T cells, in order to generate a long-lasting anti-tumour immune response.  
High scoring peptides for HLA-A0201, HLA-DR0101 and HLA-DR0401 molecules were 
therefore selected and evaluated for their immunogenicity in HHDII, HLA-DR1 and HLA-DR4 
transgenic mice, respectively. Of the eight peptides selected for evaluation in HHDII mice, four 
were moderate-to-high affinity binders as proven by stabilisation assay (Data not shown) and 
immunogenic as demonstrated by the development of peptide-specific cytotoxic responses and 
IFNγ secretion following immunisation with peptides only or DC pulsed with peptides. Since 
these HHDII mice are also mouse class I knockout (Firat et al., 1999), class I peptides can only 
bind to HLA-A2 molecules and cytotoxic responses were concluded to be HLA-A2-dependent. 
In this study, six peptides derived from HAGE predicted to bind with high affinity to HLA-
DR1 and –DR4 molecules were evaluated and four of them were found to be immunogenic in 
HLA-DR1 and HLA-DR4 transgenic mice with a capacity to induce both peptide-specific 
CD4+ T cell proliferation and IFNγ secretion. Since proliferation assays were systematically 
conducted with CD8+-depleted splenocytes and anti-HLA-DR blocking antibody with its 
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relevant isotype control antibody, proliferative responses were demonstrated to be CD4-driven 
and HLA-DR-restricted. Finally, it should be noticed that the binding affinity for both class I 
and class II peptides determined in silico correlated strongly with the efficiency of the peptide 
in generating an immune response. 
Peptide immunisation of transgenic mice allowed the identification of immunogenic HLA-A2 
and HLA-DR1 or –DR4 peptides derived from HAGE. However, these peptides cannot be used 
in future vaccine formulation if APC or tumour cells do not present them naturally on their 
surface as these would not be recognised by both CD4+ and CD8+ T cells and be eliminated by 
them. The next critical step of this study was therefore to prove whether any of these peptides 
are actually naturally processed by APC and/or tumour cells, and that CD4+ T cell 
proliferation and CD8+ cytotoxic response can still be induced. A popular way to assess the 
processing of a given immunogenic peptide is to immunise mice with a plasmid encoding the 
gene of interest using gene gun technology (Tuting, 1999). The expression of HAGE at the 
mRNA and protein levels by the pSHAME2a/HAGE expression vector was ascertained and 
described in section 4.2.3. Gene gun technology was successfully used in our laboratory to 
prove the processing of class I p53-derived peptides and was used here as a positive control for 
the procedure. No cytotoxic responses could however be generated when mice were 
immunised with DNA encoding HAGE and when splenocytes were re-stimulated in vitro with 
LPS blasts pulsed with one of the immunogenic HLA-A2-restricted HAGE-derived peptides. 
Cytotoxic T lymphocytes generated from HHDII transgenic mice were previously shown 
capable of lysing human tumour cells in a MHC-restricted fashion (Gritzapis et al., 2006). 
However, CTL generated against these peptides were unable to kill previously described 
HAGE-positive human lymphoblastic K562-A2 cells (data not shown), although these results 
were later explained by very low levels of HAGE expression in these cells due to 
hypermethylation of the HAGE promoter and therefore low levels of HAGE-derived peptide 
presentation at the cell surface (Roman-Gomez et al., 2007). 
In order to confirm these results, cells from the bone marrow of a naive mouse were prepared 
ex vivo and transfected to express the HAGE protein. Cytotoxic responses and IFNγ production 
were only achieved when mice were immunised with these transfected cells and when 
splenocytes were re-stimulated in vitro with LPS blasts pulsed with the HLA-A2-restricted 
peptide HAGE 126. Moreover, mice immunised with DC transfected with the empty 
expression vector did not generate any cytotoxic response when splenocytes were re-stimulated 
with the same peptide indicating that the cytotoxic response was related to the immunisation 
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with the transfected DC and not the actual in vitro re-stimulation with the peptide. The same 
phenomenon was later confirmed when mice underwent immunisation with DC loaded with a 
HAGE-rich melanoma cell lysate (Data not shown). In both experiments, cytotoxic responses 
were peptide-specific when compared with an irrelevant peptide and suggested that HAGE 126 
might also be processed. It means that the HAGE protein is indeed degraded by the proteasome 
into peptide fragments. Antigenic peptides such as HAGE 126 bind to the groove of MHC 
class I molecules, in that case HLA-A2, to be then presented at the cell surface of either 
dendritic cells to prime CD8+ T cells, or tumour cells to be specifically recognised and killed 
by primed cytotoxic T lymphocytes (Van den Eynde and Morel, 2001; Kloetzel et al., 2004). 
Following immunisation with DNA encoding the HAGE protein in HLA-DR1 and –DR4 
transgenic mice, peptide-specific CD4+ T cell proliferations were observed with HAGE 338 
and HAGE 506-II peptides. The reaction was blocked when the anti-HLA-DR antibody was 
added. Moreover, mice immunised with the empty expression vector did not show any 
proliferative response when splenocytes were re-stimulated with the same peptides (Data not 
shown). Altogether, these data showed that the proliferations observed were peptide- and HLA-
DR-specific and consecutive to the immunisation with the expression vector encoding the 
HAGE protein. These experiments brought strong evidence that these two HLA-DR peptides 
are likely to be endogenously processed. In the same way, CD4+-enriched T cells were shown 
to specifically proliferate in response to mature BM-DC pulsed with peptides 338 and 506-II 
after immunisation with BM-DC transfected with HAGE-containing plasmid. The reaction was 
blocked when the anti-HLA-DR antibody was added and CD4+ T cells did not proliferate 
when mice had been immunised with the same BM-DC transfected with the empty plasmid. 
Moreover, for both types of immunisation, the same pattern of cytokines production was 
observed. Indeed, peptide-specific IFNγ release was observed against both HAGE 338 and 
HAGE 506-II. Levels of IL-5 remained low indicating that the CD4+ T cell proliferation for 
HAGE 338 and HAGE 506-II were mostly Th1-orientated. The processing of endogenous 
proteins and presentation of tumour-derived class II peptides is still not fully understood and 
may result from cross-presentation and/or endogenous process. Indeed, Dissanayake et al 
(2005) recently proved that processing of tumour-derived MHC class II restricted epitopes is 
independent of the proteasome and the TAP complex. They suggested that MHC class II-
restricted endogenously synthesised epitopes might overlap with the classical endosomal 
pathway for presentation of exogenously synthesised molecules giving an explanation on how 
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peptides derived from intra-cellular proteins such as HAGE can be presented by MHC class II 
molecules to CD4+ T cells.   
Furthermore, Dr. A. Knights (Tuebingen University, personal communication) proved that the 
in vitro generation of CD4+ T cell lines from human PBMC with HAGE 506-II showed 
specific HLA class II-restricted recognition of HLA-DR matched tumour cell lines, as well as 
DC pulsed with HAGE-positive cell lysates. These results are therefore in agreement with 
those obtained from DNA immunisation of HLA class II transgenic mice, suggesting that the 
HAGE protein is produced and cleaved to give rise to the HAGE 506-II in ways that are 
similar in HLA-DR4 transgenic mice and human derived DC (Mathieu et al., 2007). In the 
future, peptides HAGE 126 and HAGE 338 will also be investigated for their ability to 
generate respectively CTL and T helper cells capable of specifically responding to target cells 
expressing the appropriate HLA molecules as well as HAGE.  
In conclusion, reverse immunology combined with the use of mice transgenic for HLA 
molecules proved to be a successful technique in the identification of candidate peptide targets 
for tumour immunotherapy as one class I and two class II immunogenic and naturally 
processed peptides derived from the HAGE protein have been described, at least in single and 
double transgenic mice. However, further work is required to prove that HAGE 126 and HAGE 
338 are both immunogenic and naturally processed in humans. Also, techniques such as 
overlapping peptides might also be envisaged in order to identify low-to-moderate affinity 
HAGE-derived peptide targets with immunogenic properties that might have been overlooked 
in this study using reverse immunology. 
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Chapter 6: Evaluation of HAGE as an immunotherapeutic target in an in 
vivo model 
6.1 Introduction 
Despite the numerous advantages offered by peptide vaccination, central and peripheral 
tolerance mechanisms are likely to delete high avidity T cells as well as low-to-moderate 
avidity T cells against tumour-shared self antigens creating a major limitation in the prospect of 
treating cancer. Moreover, techniques of identification of T cell epitopes such as reverse 
immunology often overlook peptides with low-to-moderate binding affinity as hundreds of 
them are predicted for a given tumour antigen and can only be tested to a limited number of 
HLA alleles in a transgenic mouse model. That is why DNA-based vaccination proposes an 
interesting alternative for cancer immunotherapy as it bypasses the need for individual peptide 
identification but also elicites both humoral and cellular immune responses simultaneously, 
which are both most likely required in order to induce tumour protection and/or regression.  
Several groups have investigated the use of DNA-based vaccines to promote tumour rejection 
in animal models with promising results. Indeed, H-2b and HHDII mice appeared to be 
protected against a lethal challenge with HPV E6/E7-expressing tumours following gene gun 
immunisation with DNA encoding mutated version or immunodominant epitopes of E6/E7 
genes (Smahel et al., 2001; Eiben et al., 2002). However, these antigens are already strongly 
immunogenic because of their viral origin. Targeting a self antigen, such as p53, renders the 
task more difficult as tumour escape mechanisms such as increased mutation frequencies and 
MHC class I down-regulation can take place and make immunisation more detrimental than 
beneficial in some cases (Cicinnati et al., 2005). In another study describing the use of the 
murine self antigen tyrosinase-related protein-1 (mTrp-1) by intra-muscular injection, mice 
were protected against poorly immunogenic B16 melanoma cells (Bronte et al., 2000). In 
addition, the introduction of this gene into a vaccinia virus vector allowed the mediation of 
tumour regression in mice challenged with B16 cells and despite being a self antigen widely 
expressed in normal skin tissues, there were no signs of vitiligo, a common auto-immune 
reaction described in several previous studies targeting melanoma antigens. Numerous 
strategies have been designed to further improve DNA-based vaccines. Indeed, orientation of 
an antigen to a specific processing pathway, system of antigen delivery and augmentation of 
the immunogenicity of an antigen are all factors that should also be taken into account in the 
design of a DNA-based vaccine. For instance, DNA-encoded proteins can be linked to specific 
signal sequences such as ubiquitin and lysosome-associated membrane protein-1 (LAMP-1) for 
   173 
a more efficient processing and presentation of a given antigen to CD8+ and CD4+ T 
lymphocytes, respectively (Ji et al., 1999; Velders et al., 2001). New systems of delivery have 
also been developed with the possibility to encapsulate the DNA into liposomes or to 
electroporate the DNA directly in vivo in order to transfect APC with improved efficacy.  
Interestingly, two of the common criticised features of DNA-based vaccines are their lack of 
immunogenicity and their inability to break tolerance. Several strategies were developed to 
counteract these features. The incorporation of minigenes or linear polyepitopes encoding CTL 
epitopes in a vector system rather than full gene sequences was proven to be a very efficient 
way of eliciting CTL responses (Tine et al., 2005). The use of minigenes targeting the tumour 
antigen gp100 was demonstrated to be even more efficient than linear polyepitopes with or 
without spacers, although both of them appeared to be unreliable in eliciting a balanced CTL 
response against all gp100 epitopes, at least in HHDII mice. In the same study, they also 
showed that by enhancing the epitope to increase its affinity towards specific HLA molecules, 
the CTL response was more likely to be balanced suggesting that epitope enhancement should 
be systemically envisaged in the design of vaccines containing both cryptic and 
immunodominant epitopes (Tine et al., 2005). In spite of relying on the identification of T cell 
epitopes that would bypass tolerance mechanisms, leading to tumour protection and/or 
regression, this approach has been used for several tumour antigens such as Trp-1, Trp-2 and 
gp100 (Weber et al., 1998; Gregor et al., 2004). Another study described the existence of 
CD8+ and CD4+ T cell epitopes in a nested configuration in the Ras oncogene and the use of 
this specific sequence rather than the CTL epitope sequence in a minigene vector correlated 
with efficient in vivo processing of both epitopes and quantitative improvement of the CTL 
response (Lindinger et al., 2003). This investigation was just one example among many 
emphasising the requirement of CD4+ T cell help in an anti-tumour vaccine, be it tumour-
specific with CD4+ T cell epitopes derived from TAA such as Ras or foreign with CD4+ T cell 
epitopes derived from pathogenic agents such as tetanus toxoid (Buchan et al., 2005).    
Finally, the addition of cytokine or co-stimulatory molecule genes in a plasmid already 
encoding a tumour antigen was investigated for their capacity to enhance the potency and 
effectiveness of the vaccine but also to polarise the adaptive immune system towards a Th1 
and/or a Th2 response. Several cytokines have been tested such as IL-2, IL-4, IL-15 and TNFα 
but much emphasis has been put on GM-CSF. Primary data indicated that tumour cells 
transfected to express GM-CSF, notably in murine acute myeloid leukaemia (AML), were 
potent activators of the differentiation of CD34+ bone marrow precursors into functionally 
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mature DC and the generation of a stronger anti-tumour immunity (Dunussi-Joannopoulos et 
al., 1998). Because of its strong ability to attract DC, GM-CSF is now primarily used to target 
administered antigens to professional APC. For instance, it has been associated with the 
tumour antigen gp100 and demonstrated a potent ability to mediate tumour protection and 
regression even at very low levels of gp100 expression (Rakhmilevich et al., 2001).  
One way for tumour cells to escape the immune system is to anergise T cells by down-
regulating co-stimulatory molecule expression on their cell surface. That is why a considerable 
effort has focused on the design of DNA vaccines co-administered with co-stimulatory 
molecules in order to thwart escape mechanisms and generate CTL responses capable of 
mediating protection (Corr et al., 1997). Conditioning of DC following DNA injection occurs 
via MHC class II-restricted T cells in both CD40-dependent and –independent manners, which 
underlines the critical role of co-stimulatory molecules such as B7.1 in priming optimal CD8+ 
T cell activity (Chan et al., 2001). Also, the administration of soluble CD28, a ligand for B7.1, 
B7.2 and CTLA-4 molecules, to DC in vitro triggered secretion of IL-6 indicating that both 
B7.1 and B7.2 co-stimulatory molecules were required for the generation of 
immunostimulatory signals and the prevention of IFNγ-driven expression of 
immunosuppressive tryptophan catabolism. Moreover, enhanced T cell activity to tumours and 
protection against tumour challenge were observed following injection of soluble CD28 in vivo 
(Orabona et al., 2004). Depending on the co-stimulatory molecule picked for the stimulation of 
DC, polarisation of the immune response can then take place as described in a previous study 
showing that transduction of a viral-based vaccine allowing co-delivery of active membrane-
anchored B7.1 and secreted IL-2 in AML cells led to higher levels of Th1-type cytokines and 
specificity towards autologous AML cells (Chan et al., 2005). More recently, B7.1 and B7.2 
molecules were both described as potential marker for a better survival against some forms of 
cancers (Chang et al., 2007). A third co-stimulatory molecule from the tumour necrosis factor 
family, termed 4.1BBL, has brought considerable interests as it seems to overcome the need for 
CD4+ T cell help in the induction, amplification and persistence of cytotoxic T lymphocytes. 
Although 4.1BBL is as potent as B7 molecules to mediate IL-2 secretion by resting T cells 
(Saoulli et al., 1998), intact CD28-B7.1 and CD28-B7.2 co-stimulatory pathways are still a 
pre-requesite for 4.1BBL to reach its full potential demonstrating its anti-tumour efficacy 
(Guinn et al., 1999; Guinn et al., 2001; Diehl et al., 2002). Altogether, these data demonstrate 
the strong potential of co-stimulatory molecules and the advantages they can bring by 
combining them with tumour antigens in DNA-based vaccines. Although lack of objective 
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clinical response has also been the feature of DNA-based strategies, they provide an interesting 
and safe mode of immunotherapy still investigated in several human clinical trials. 
In this study, HAGE DNA vaccination by gene gun or intra-muscular injection of HHDII-DR1 
double transgenic mice was undertaken in prophylactic challenge experiments with a HAGE-
expressing murine lymphoma cell line in order to investigate the immunogenic and anti-tumour 
potential of the cancer/testis antigen HAGE as well as determine the best mode of 
administration of the DNA. Challenge experiments were then repeated in a therapeutic model 
whereby HAGE DNA was associated or not with a murine co-stimulatory molecule in order to 
potentiate the anti-tumour response, thereby allowing direct comparison between each DNA 
vaccine. Finally, the eventual implication in the anti-tumour response of naturally processed 
HAGE-derived peptides described in Chapter 5 was studied. 
 
6.2 Results 
 6.2.1 In vitro and in vivo HAGE expression in tumour cells 
Full length HAGE cDNA was cloned into the pBudCE4.1 mammalian expression vector (See 
Section 4.2.1). A HLA-A2-positive murine lymphoma cell line (ALC) was then grown in a 
multi-chamber slide and transfected with this plasmid using lipofectamine 2000 reagent 
following manufacturer’s instructions to confirm HAGE protein expression (See Section 
2.2.2.1). Two days after transfection, cells were fixed, permeabilised and stained for HAGE 
expression for confocal analysis. Secondary antibody tagged with fluorescein highlights the 
expression and localisation of HAGE within the cells. High levels of HAGE protein expression 
ubiquitously found inside the cells were achieved when ALC cells were transfected with 
pBudCE4.1/HAGE (Fig. 6.1C). On the other hand, cells incubated with FITC-conjugated 
antibody showed only background staining (Fig. 6.1A and B).  
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Figure 6.1: Immunofluorescence assay for HAGE protein expression analysis and 
localisation in ALC/HAGE cells. Immunofluorescence was observed under a confocal 
microscope in ALC cells stably transfected with HAGE cDNA (C). No non-specific staining 
was obtained when cells were incubated in the absence of antibody (A) or with secondary 
antibody only (B). HAGE protein expression is mainly localised in the cytoplasm. 
 
A C B 
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ALC cells were thereafter stably transfected with pBudCE4.1/HAGE using lipofectamine 2000 
as the transfection reagent and following multiple passages in a media containing the selective 
antibiotic zeocin, the resulting ALC/HAGE cells were used in tumour challenge experiments in 
HHDII-DR1 double transgenic mice. Firstly, the TD50 of these cells was determined by 
injecting subcutaneously different numbers of cells to the mice, varying from 2*104 to 2*105 
cells in 100µl of serum free media. 6*104 ALC/HAGE cells appeared to be the minimum 
number of cells allowing tumours to grow in at least 50% of the mice injected. Secondly, ten 
times the TD50 are commonly used in in vivo tumour models. Consequently, mice were 
injected with 6*105 ALC or ALC/HAGE cells, and mice terminated and tumours excised when 
sizes reached about 1cm2. Tumours were embedded in OBC media, fixed in a cold solution of 
isopentane and sectioned using a cryostat. The in vivo expression of HAGE was then 
confirmed by performing immunohistochemistry and Fig. 6.2 demonstrates that whilst no 
significant staining in ALC tumours was obtained (Fig. 6.2C), ALC/HAGE tumours showed 
positive staining with the HAGE antiserum in a vast majority of cells present on the tumour 
sections (Fig. 6.2D). Sections incubated with biotin-conjugated secondary antibody only did 
not demonstrate any staining above background for both ALC and ALC/HAGE tumours (Fig. 
6.2A and B). 
 
 6.2.2 Evaluation of DNA immunisation for HAGE 
Firstly, the TD50 of ALC/HAGE cells in HHDII-DR1 double transgenic mice was determined 
(See Section 6.2.1) and found to be 6*104. In agreement with other published work, it was 
therefore decided that 6*105 cells were to be used for any further studies requiring tumour 
implantation. It is possible, however, that the introduction of a foreign gene will render the 
cells more immunogenic, which was not possible to assess using a small number of mice. So in 
order to confirm and expand these experiments, it was then necessary to determine whether 
mice injected with 6*105 ALC/HAGE cells subcutaneously would truly generate tumours that 
continuously grow or regress at some point. Tumour growth and survival were monitored two 
to three times a week for at least 30 days. Results showed that 40% of injected mice survived 
the tumour implantation with tumours reaching an average size of 0.8cm2 in 15 days before 
completely regressing in approximately 32 days.  
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Figure 6.2: Immunohistochemistry staining for HAGE protein expression in vitro in ALC 
and ALC/HAGE tumours. The immunohistochemistry demonstrates the in vivo expression of 
HAGE at the protein level in ALC/HAGE tumours (D), but not in ALC tumours (C) excised 
from DR1/HHDII mice. No non-specific secondary staining was obtained in both ALC (A) and 
ALC/HAGE (B) tumours. HAGE expression was found in the cytoplasm and in the nuclear and 
appeared to be granular. Objective magnification: x20. 
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The rest of the mice injected with ALC/HAGE cells were euthanised according to the Home 
Office regulations as tumours attained the size limit of 1cm2 20 to 25 days post-challenge (Fig. 
6.3). 
Gene gun immunisation has been recently used with good efficiency in several murine tumour 
models. Hence, pBudCE4.1/HAGE DNA was coated with 1 micron gold particles. These 
DNA-gold bullets were then administered intradermally three times at seven-day intervals to 
the shaved abdomen of HHDII-DR1 double transgenic mice using a helium gene gun. Seven 
days after the last immunisation, mice were challenged with 6*105 ALC/HAGE cells 
subcutaneously and monitored as described above. A delayed growth and complete regression 
of ALC/HAGE tumours were observed in 95% of mice immunised with pBudCE4.1/HAGE 
approximately 28 days after tumour challenge, while only 50% of mice immunised with the 
empty pBudCE4.1 plasmid survived the challenge with ALC/HAGE cells. Also, tumour 
stabilisation or regression occurred much later in time in mice immunised with the control 
plasmid (Fig. 6.4). Several studies have also suggested that gene gun immunisation is more 
likely to polarise the immune response to Th2 type, a response not as efficacious as Th1 type to 
generate CTL. To exclude the possibility that gene gun immunisation does not provide the best 
mode of immunisation and protection against tumour challenge, HHDII-DR1 double transgenic 
mice were immunised intramuscularly twice at seven-day interval with 100µg of 
pBudCE4.1/HAGE or control pBudCE4.1/(-) before being challenged with 6*105 ALC/HAGE 
cells seven days after the last immunisation. Results obtained were similar to those obtained 
using gene gun vaccination, where a delayed growth and complete regression of ALC/HAGE 
tumours were achieved in 90% of mice immunised with pBudCE4.1/HAGE DNA 
approximately 28 days after tumour challenge. On the other hand, only 60% of mice 
immunised with the empty plasmid showed signs of tumour stabilisation or regression (Fig. 
6.5). 
Some of the mice, which have undergone successful tumour remission, were re-challenged a 
second time with 6*105 ALC/HAGE cells two months after total disappearance of the tumour 
bulks. Tumour growth and survival were recorded. Interestingly, there was no signs of tumour 
re-emergence over a period of 30 days in all the mice that have been re-challenged (Data not 
shown) eventually suggesting the existence of a memory response against HAGE and/or other 
tumour antigens. 
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Figure 6.3: Tumour implantation experiment with ALC/HAGE in DR1/HHDII mice. Five 
mice were injected with 6*105 ALC/HAGE cells/mouse. Tumour growth rate (A) and survival 
(B) were recorded. Results shown are representative of two independent experiments. ( ) 
indicates termination. It seems that ALC/HAGE cells are naturally immunogenic since 4 out of 
10 tumours regressed without the need for any immunotherapeutic interventions. 
A 
B 
n=6 
n=4 
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Figure 6.4: Tumour challenge experiment following gene gun immunisation in DR1/HHDII 
mice. Two groups of 10 mice were immunised 3 times with gold particles coated with either 
pBudCE4.1/(-) or pBudCE4.1/HAGE at 7-day intervals, followed by challenge with 
ALC/HAGE cells. Vaccinated mice showed a slowdown of the tumour growth rate (A) as well 
as a statistically significant improvement of the survival (B) compared to controls. Results 
shown are representative of two independent experiments. *p<0.05 are the statistical 
differences between HAGE DNA immunisation and control DNA immunisation determined by 
unpaired Student T test. ( ) indicates termination. 
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Figure 6.5: Tumour challenge experiment following intra-muscular immunisation with 
HAGE cDNA in DR1/HHDII mice. Two groups of 10 mice were immunised twice with 100µg 
of naked pBudCE4.1/(-) or pBudCE4.1/HAGE DNA at 7-day intervals, followed by challenge 
with ALC/HAGE cells. Vaccinated mice showed a slowdown of the tumour growth rate (A) as 
well as an improvement of the survival (B) compared to controls. Results shown are 
representative of two independent experiments. Statistical differences between HAGE DNA 
immunisation and control DNA immunisation were determined by unpaired Student T test. ( ) 
indicates termination. 
A 
B 
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n=18 
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Amounts of DNA used in the preparation of gold particles and the immunisation procedures 
with gene gun are considerably lower than in intramuscular injections with naked DNA, and 
having established that gene gun with pBudCE4.1/HAGE DNA led to a statistically significant 
improvement of the percent of survival, it was next decided to assess the efficiency of gene gun 
immunisation with gold-coated pBudCE4.1/HAGE DNA in a therapeutic model. 
HHDII-DR1 double transgenic mice were first injected subcutaneously 6*105 ALC/HAGE 
cells and then vaccinated intradermally three days later with three rounds of DNA-gold bullets 
administrated at seven-day intervals. Tumour growth and survival were monitored two to three 
times a week for at least 30 days until the tumour size reached 1cm2, when mice were 
terminated as per the Home Office regulations. Results showed a statistically significant 
delayed tumour growth on day 12 in mice immunised with HAGE DNA with tumours barely 
reaching an average size of 0.4cm2 after 12 days before completely regressing after 25 days in 
comparison with the control group of mice, which displayed tumours of approximately 0.7cm2 
after 12 days before completely regressing after 32 days (Fig. 6.6A). Also, only 40% of the 
mice survived with the latter treatment while 80% of the mice survived with multiple injections 
of HAGE DNA (Fig. 6.6B). It is noteworthy that immunisations were undertaken at the early 
stages of the tumour formation when tumour bulks were not noticeable yet.  
 
 6.2.3 Effects of co-stimulatory molecules on tumour development 
Following the positive results of DNA immunisation to target the tumour antigen HAGE in a 
therapeutic experiment, it was next decided to wait for the presence of a tumour mass of about 
0.3cm2 before performing the first immunisation and check whether the addition of a murine 
co-stimulatory molecule to the HAGE DNA vaccine improves significantly the beneficial 
effects already observed in the therapeutic experiment detailed above. Hence, murine B7.1, 
B7.2 or 4.1BBL cDNA were cloned into the only multiple cloning site available of the 
pBudCE4.1/HAGE mammalian vector as described previously (See Section 4.2.2).  
HHDII-DR1 double transgenic mice were first injected subcutaneously 6*105 ALC/HAGE 
cells. Tumours of the required size (0.3cm2) were globally obtained seven days post-injection 
and on that day, mice received intradermally the first of three rounds of gold-coated DNA 
particles.  
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Figure 6.6: Therapy studies using gene gun immunisation in DR1/HHDII mice. Three days 
after injecting 6*105 ALC/HAGE cells to two groups of 10 mice, mice were immunised three 
times with gold particles coated with either pBudCE4.1/(-) or pBudCE4.1/HAGE at 7-day 
intervals and monitored for tumour growth (A) and survival (B). Results shown are 
representative of two independent experiments. *p<0.05 are the statistical differences between 
HAGE DNA immunisation and control DNA immunisation determined by unpaired Student T 
test. () indicates timepoints of immunisation, ( ) indicates termination. 
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The results of the immunisation with pBudCE4.1/HAGE were compared with the results of the 
control group immunised with the empty plasmid as well as each of the group having been 
injected HAGE cDNA with a murine co-stimulatory molecule, be it B7.1, B7.2 or 4.1BBL. As 
seen in Fig. 6.7, a statistically significant delayed tumour growth and improved survival in 
mice immunised with HAGE DNA was achieved, confirming the results obtained earlier but 
this time, with a visible and larger tumour mass before the primary immunisation emphasising 
the strong potential of pBudCE4.1/HAGE DNA vaccine against HAGE-positive tumour cells. 
Interestingly, out of the three murine co-stimulatory molecules, only B7.2 provided a 
statistically significant improvement of the beneficial effects observed with HAGE DNA. 
Indeed, complete tumour regression was achieved 17 days post-challenge in mice receiving 
HAGE and B7.2, opposite to 25 days post-challenge in mice receiving HAGE only. Survival 
curves are, on the other hand, similar for all HAGE DNA-based vaccines with or without 
murine co-stimulatory molecule suggesting that survival expectancy should be the same 
whatever the presence or not of a co-stimulatory molecule (Fig. 6.7B). However, larger groups 
of mice should, in the future, be challenged and vaccinated in order to confirm these 
observations and draw a conclusion on the different murine co-stimulatory molecules and their 
effects on tumour progression. 
 
 6.2.4 Involvement of identified HAGE-derived peptides in the anti-tumour response 
In order to investigate whether identified HAGE-derived peptides are involved in the anti-
tumour response observed in prophylactic and therapeutic experiments and could be used in 
monitoring experiments, splenocytes from regressing mice were harvested and re-stimulated in 
vitro with either HAGE 126 peptide-pulsed LPS blasts, or with HAGE 338 or HAGE 506-II 
peptides only. A cytotoxicity assay using T2 cells pulsed with peptides and ALC/HAGE cells 
as targets (Fig. 6.8) and a tritiated thymidine incorporation assay using peptide-pulsed BM-DC 
(Fig. 6.9) were carried out to confirm CD8+-dependent cell lysis to peptide HAGE 126 and 
CD4+ T cell proliferations to peptides HAGE 338 and HAGE 506-II, respectively. 
Unfortunately, none of these assays led to a peptide-specific response suggesting that these 
peptides might not be involved in the anti-tumour response. 
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Figure 6.7: Therapy studies combining HAGE with a murine co-stimulatory molecule in 
DR1/HHDII mice. Seven days after injecting 6*105 ALC/HAGE cells to five groups of five 
mice, mice were immunised three times with gold particles coated with pBudCE4.1/HAGE (A1) 
associated or not with mB7.1 (A2), mB7.2 (A3) or m4.1BBL (A4) at 7-day intervals and 
monitored for tumour growth (A) and survival (B). Results shown are representative of one 
experiment. *p<0.05 are the statistical differences between HAGE DNA immunisation and 
control DNA immunisation determined by paired Student T test. () indicates timepoints of 
immunisation, ( ) indicates termination. 
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Figure 6.8: Cytotoxicity assay using T cells generated from HHDII-DR1 double transgenic 
mice immunised with HAGE DNA and challenged with ALC/HAGE cells. Mice were 
immunised with gold coated pBudCE4.1/HAGE plasmid and challenged with ALC/HAGE cells. 
Splenocytes from 2 regressor mice were harvested after complete tumour regression and re-
stimulated in vitro with LPS blasts pulsed with HAGE 126 peptide. Cytotoxicity assay was 
carried out using peptide-pulsed T2 cells or ALC/HAGE as target cells on splenocytes.  
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Figure 6.9: Proliferation assay using T cells generated from HHDII-DR1 double transgenic 
mice immunised with HAGE DNA and challenged with ALC/HAGE. Mice were immunised 
with gold-coated pBudCE4.1/HAGE plasmid and challenged with ALC/HAGE cells. 
Splenocytes from 2 regressor mice were harvested after complete tumour regression and re-
stimulated in vitro with HAGE 338 (A) or HAGE 506-II (B) for 7 days and then tested for 
proliferation by incubating them with syngeneic BM-DC pulsed with peptide. 
A B 
   188 
6.3 Discussion 
Previous attempts to identify naturally processed epitopes from HAGE antigen were successful 
and could be useful for monitoring an immune response to HAGE as well as the elaboration of 
peptide-based vaccines, at least in HLA-A2, -DR1 or –DR4 patients. However, immunisation 
of cancer patients with peptides demonstrated low levels of efficiency in humans and hence, 
therapies targeting the full length HAGE gene were undertaken in HHDII-DR1 double 
transgenic mice. 
In this study, HLA-A2-positive murine lymphoma ALC cells were chosen for the development 
of an in vivo tumour model in HHDII-DR1 mice. ALC cells were first transiently and then 
stably transfected with pBudCE4.1/HAGE to express the HAGE protein. The in vitro and in 
vivo expression of HAGE was confirmed by immunofluorescence of transiently transfected 
ALC cells and immunohistochemistry of ALC/HAGE xenografts grown in HHDII-DR1 mice 
to a size of 1cm2 before excision. Transfection of ALC cells led to a nuclear expression of 
HAGE in vitro and in vivo with a characteristic granular staining as shown by 
immunohistochemistry. Interestingly, both ALC and ALC/HAGE cells were injected for this 
experiment and the latter appeared to grow much faster to the required size than the former 
(Data not shown). Although this difference between HAGE-negative and –positive cells has 
been previously observed in vitro (See Section 3.2.3), further experiments are needed to 
confirm this trend and the eventual implication of the transfected gene in the proliferation rate 
in vivo. 
After determination of the TD50 of ALC/HAGE, ten times this number was injected to naive 
HHDII-DR1 mice which had not previously encountered the HAGE antigen in order to 
document tumour growth and survival expectancy. Interestingly, still a very large number of 
mice injected (40%) showed signs of tumour regression and total regression 30 days post-
challenge, suggesting that anti-tumour responses could be readily raised against ALC/HAGE 
cells in a proportion of mice due to epitope spreading as well as the presence of HAGE, a 
foreign antigen with no known murine counterpart. Despite having a strong immunogenic 
potential, ALC/HAGE cells allowed a margin large enough to improve the rates of tumour 
growth and the percent of survival. Also and contrary to other tumour cells tested in this 
project such as EL4/HHDII cells (Data not shown), ALC/HAGE cells allowed reproducible 
and constant subcutaneous tumour development.  
Consequently, HHDII-DR1 mice were immunised with either gold particles coated with 
pBudCE4.1/HAGE using a helium gene gun or naked DNA in serum free media injected intra-
muscularly. Immunisations were then followed by challenge with ALC/HAGE tumour cells 
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expressing HAGE at high levels. Initial experiments demonstrated a delay in tumour growth in 
mice vaccinated with pBudCE4.1/HAGE DNA as well as improved survival with up to 95% of 
the mice challenged showing signs of complete remission. This delay in tumour progression 
and improved survival in vaccinated animals was reproducible. However, only gene gun 
allowed a statistically significant improvement of the survival. The ability to protect mice and 
improved the slowdown of the tumour growth as well as the percent of survival was surprising, 
considering that several groups have doubted the limited ability of DNA vaccines, especially 
when using gene gun. However, as shown earlier with HER2/neu (Curcio et al., 2003), HAGE 
is a foreign antigen and hence, holds a high immunogenic potential.  
Having established the efficacy of DNA immunisation by gene gun in a prophylactic 
experiment, the ability of DNA-based vaccines to cure mice from tumour development in a 
therapeutic model was evaluated. Mice were first injected ALC/HAGE cells and then 
immunised with gold-coated pBudCE4.1/HAGE DNA three days later in order to demonstrate 
the beneficial effects of the DNA vaccination at early stages of the tumour development. 
Significant delay in tumour growth, shorter period of time to reach complete regression as well 
as significant improvement of the percent of survival from 40% to 80% in mice vaccinated 
with pBudCE4.1/HAGE DNA were the three main observations consecutive to this therapeutic 
experiment. However, because all therapeutic tumour models rely on the immunisation of 
animals once tumours of palpable size are obtained (0.2 to 0.3cm2), mice were then injected 
with tumour cells and immunised at a later stage of tumour development seven days after 
injecting ALC/HAGE cells. The changes made in the immunisation schedule did not affect or 
modify extensively the outcome, as similar results were obtained. In the same experiment, mice 
were also injected with tumour cells and immunised with pBudCE4.1/HAGE DNA containing 
or not a murine co-stimulatory molecule (i.e.: B7.1, B7.2 or 4.1BBL). Although there was no 
significant difference between HAGE on its own and HAGE with B7.1 or 4.1BBL, a small 
beneficial effect was observed with the addition of the co-stimulatory molecule B7.2 in terms 
of maximal tumour size reached and shorter period of time leading to total tumour regression.  
B7.1, B7.2 and 4.1BBL have all been described as equally efficient as each other to generate T 
cell proliferation and when expressed together, create a synergistic effect allowing potent co-
stimulation of the immune response (Habib-Agahi et al., 2007). However, contrary to its 
counterparts, the co-stimulatory molecule B7.2 often displays the capacity to induce higher 
levels of cytokine secretion such as IFNγ, GM-CSF, TNFα and IL-10 (Kronfeld et al., 2005) 
and to promote tumour regression in animal models when incorporated in a DNA vaccine 
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(Yang et al., 2007). Unfortunately, lack of mice did not permit this experiment to be performed 
on larger cohorts of animals, which would be required for the comparison between each co-
stimulatory molecule and a more thorough statistical analysis.  
It is worth noting that ALC cells on their own were previously described as poorly 
immunogenic (Gritzapis et al., 2006). Indeed, in this study, animals were challenged with a 
number of ALC cells as low as 2*104 in order to obtain palpable tumours 22-25 days after 
injection. Also, 100% of the mice challenged with ALC cells were sacrificed about 65 days 
after the start of the experiment. These results indicate that the number of cells used for 
challenging animals is certainly critical for the level of immunogenicity of the cells and the 
outcome of the study, and that smaller number of ALC/HAGE cells injected might be 
considered in the future in order to decrease this immunogenicity. Moreover, the 
immunogenicity of these cells were not affected by the transfection with a foreign antigen as 
similar tumour growth rate and survival expectancy were achieved following transfection of 
ALC cells with the human HER2/neu gene. In this project, HAGE has proved to be by nature 
crucial in the increase of the proliferation rate and its involvement in the process of 
tumorogenesis might jeopardise the immunogenicity of ALC cells even when very low number 
of cells are used to challenge the mice. Thus, further work is needed to develop and optimise 
an in vivo tumour model with ALC/HAGE cells or use a poorly immunogenic tumour model 
such as the B16 melanoma cell line (Bronte et al., 2000).  
It is not clear whether reduced tumour growth and improved survival is due to the development 
of a specific T cell response or rather a combination of innate and adaptive immune response. 
However, it is worth mentionning that lesions were observed on the surface of a majority of 
regressing tumours suggesting the presence of an inflammatory response. Histology would 
have been able to confirm this hypothesis. However, due to time constraints, these were not 
performed. Inflammation and its association with cancer evolution has been well-studied with 
the common understanding that inflammation and innate immune responses can exert pro-
tumorogenic effects while inflammation and adaptive immune responses are more likely to 
generate anti-tumorogenic effects (Karin and Greten, 2005); although some discrepancies have 
also been reported (de Visser et al., 2005). However, evidence accumulated in this study 
suggests the promotion of an adaptive immune response against ALC/HAGE cells, but it 
remains to be established whether the anti-tumour response is HAGE-specific. 
As demonstrated in Chapter 5, reverse immunology and transgenic mice allowed the 
identification of one class I (HAGE 126) and two class II peptides (HAGE 338 and HAGE 
506-II) derived from the HAGE protein. In order to confirm the hypothesis of a HAGE-specific 
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T cell response towards ALC/HAGE tumours in HHDII-DR1 mice, spleens of mice with 
regressing tumours were harvested and tested in vitro in cytotoxicity and proliferation assays 
following in vitro re-stimulation with the identified naturally processed and immunogenic 
HAGE-derived peptides. Unfortunately, non-specific responses were obtained for both class I 
and class II peptides. This result was expected for peptide HAGE 126 as its endogenous 
processing has only been shown following DC immunisation and not gene gun. However, 
some of the T cells from regressor mice were expected to be HAGE 338 or HAGE 506-II 
specific even following gene gun immunisation suggesting that other HAGE-derived epitopes 
could be involved in the anti-tumour responses observed. Therefore, it remains difficult to 
confirm at this stage whether the tumour protection observed in these experiments were 
HAGE-related with immune responses specifically targeting the antigen or due to epitope 
spreading. Challenging the mice with ALC and ALC/HAGE cells three weeks after the last 
immunisation instead of seven days is something to be considered in the future in order to 
answer that question. Also, tumour growth in immunised animals should be compared with 
tumour growth in non-immunised animals in order to rule non-specific effects and confirm that 
immunisation with the empty vector did not naturally increase in a positive way tumour growth. 
Unfortunately, lack of time did not permit these experiments to be conducted, which would be 
necessary to conclusively prove the presence of a HAGE-specific immune response towards 
ALC/HAGE tumour cells, at least in a prophylactic setting. Further experiments are therefore 
required to allow us to conclude that these three HAGE-derived peptides are not involved in 
the anti-tumour process and that the eventual T cell response is HAGE-specific and not due to 
epitope spreading.    
Collectively, these data showed that gene gun gave better results than intra-muscular 
immunisation in this in vivo HAGE-positive tumour model and that the pBudCE4.1/HAGE 
vector seems to offer better protection to tumour challenge and better overall survival of 
HHDII-DR1 double transgenic mice than the empty vector in both prophylactic and therapeutic 
experiments. Finally, immunogenic and naturally processed HAGE-derived peptides may or 
may not be involved in the anti-tumour response and further work is needed to prove that these 
peptides are indeed responsible for the beneficial effects of the DNA vaccine on the tumour 
development by trying other modes of immunisation such as DC- or SFV-based vaccines.  
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Chapter 7: Discussion 
The scope of this project was to identify potential candidate T cell epitopes derived from a 
novel cancer/testis antigen with immunogenic potential for cancer immmunotherapy by 
directly combining reverse immunology with transgenic mouse models. Furthermore, the 
second part of the project aimed to design DNA-based vaccine strategies and assess them in an 
in vivo tumour model in order to assess the immunotherapeutic abilities of this new antigen. 
But before undertaking series of experiments involving the use of several animals, the primary 
objective of this project was to ensure that this antigen was a valid target for cancer 
immunotherapy and an essential gene for cancer in order to avoid the immunoediting 
phenomenon and hence, tumour escape to take place.  
 
7.1 HAGE as a potential candidate for cancer, expression and validation 
Since the cloning of MAGE-1, the first gene reported to encode a tumour antigen recognised 
by T cells, molecular identification and characterisation of novel tumour antigens has rapidly 
progressed with the hidden promise of being useful in selectively targeting cancer cells 
expressing these antigens by immunotherapy. Using the immune response to eliminate cancer 
cells is a seducing idea as harmful and severe side effects can be avoided unlike chemotherapy 
and radiotherapy. Although successful results were achieved in animal models, very little 
clinical benefits were observed in humans, slowly breaking the hopes emitted in cancer 
immunotherapy. It is now generally admitted that immunotherapy should indeed be utilised 
against metastases in combination with more conventional cancer therapies such as surgery to 
remove the original tumour mass. Association of both modalities will allow the immune 
system to deal with fewer malignant cells as well as the reduction of immunosuppressive 
factors released by cancer cells. 
The good completion of this project relied on the gathering of two determinative conditions: 
the validity of the tumour antigen for use in immunotherapy and the relevant animal model 
used to investigate it. In order to ensure the former, an ideal tumour antigen that could be 
useful for immunotherapy has to combine four main characteristics before pursuing with 
animal and human studies. The possibility of designing personalised vaccines against 
individual antigens has been defended by several researchers. However, this strategy appears to 
be time-consuming, expensive and most of all impractical, especially in developing countries. 
Thus, antigens with the characteristics of being totally absent from normal tissues and 
expressed with high frequencies in tumours represent the most interesting targets. Two of the 
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best and most studied tumour antigens are the tumour-specific protein Bcr/Abl expressed in 
CML patients and the viral antigen E7 expressed in cervical cancers, and are subject of several 
clinical trials (Pinilla-Ibarz et al., 2005; Lin et al., 2007). Tumour-specific proteins and viral 
antigens are very specific for certain tumours but unfortunately not all cancers have been so far 
characterised by such antigens. Also, cancers can over-express essential genes involved in cell 
growth and proliferation, and these genes, shared between different types of tumours, could 
represent valid targets if the risks of generating auto-immune responses were not often greater 
than the eventual beneficial anti-tumour effects. The last characteristic for an antigen to be an 
ideal target for immunotherapy is its involvement in tumorogenesis. Indeed, the down-
regulation of the antigen is likely to be triggered if the latter is non-essential to the tumour 
transformation, leaving less immunogenic and escape variants from tumours to multiply 
according to the immunoediting theory (Dunn et al., 2004). However, several non-essential 
antigens could be targeted simultaneously to avoid the generation of escape variants but ideally, 
targeting essential antigens with oncogenic properties would prevent the tumour cells to escape 
and make it a very promising immunotherapeutic modality.  
Initially identified in a human sarcoma by Martelange et al. (2000) using representational 
difference analysis, several studies have reported the over-expression of the cancer/testis 
antigen HAGE in more than 50% of myelogenous leukaemia (Adams et al., 2002), and in some 
cases of benign and malignant neoplasms of the salivary glands (Nagel et al., 2003). HAGE 
was also demonstrated to be frequently expressed in about 30% of brain, colon and lung 
cancers among others (Scanlan et al., 2004). Moreover, very little is known about HAGE but 
its belonging to the DEAD-box family of ATP-dependent RNA helicase and evidences of the 
involvement of other members of this family in tumour cell proliferation (Eberle et al., 2002; 
Yang et al., 2005) suggest a crucial role in the RNA metabolism of tumour cells. For these 
reasons, HAGE seems to be a good target for immunotherapy as it would be applicable for the 
majority of the population. 
To verify HAGE expression at the mRNA and protein levels in normal tissues and cancer cells, 
quantitative real time PCR, immunohistochemistry and immunofluorescence were used. As 
expected, HAGE expression was at very low levels in normal tissues and then found to be 
negative using RT-Q-PCR with the exception of testis. Expression of HAGE was confirmed in 
several tumours of different histological origin such as blood, breast, colon, gastric, head & 
neck and skin malignancy. Despite the number of samples for some forms of cancer being very 
small and quantities of mRNA available very low, levels of HAGE expression in CML, colon 
carcinoma and melanoma samples were in line with those previously published. Furthermore, 
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neither gastric nor head & neck carcinoma have already been described in the literature. 
Respectively, approximately 22% and 40% of the cancer samples tested were shown to be 
over-expressing HAGE and the rise was at least two folds. Also, they are discrepancies 
between cancer cells from patients and cancer cell lines prepared in vitro and although, they 
often behave quite similarly when both types of cells are from the same cancer, they display 
quite a different phenotype. Indeed, in this study, we have confirmed the over-expression of 
HAGE in about 60% of CML samples. However, none of the CML cell lines tested expressed 
HAGE at any kind of detectable levels by real time PCR. This result was later explained by a 
study by Roman-Gomez et al., (2007) describing a very high hypermethylation status of the 
HAGE promoter in CML cell lines and hence, preventing transcription of the HAGE gene. 
Low levels of HAGE expression were shown to be easily reversed in CML cell lines with the 
addition of a demethylating agent and synergistically enhanced with the extra addition of a 
deacetylase inhibitor confirming that the methylation status of the HAGE promoter was critical 
to the HAGE gene transcription. On the other hand, HAGE promoter in HAGE-positive 
melanoma cell lines might be naturally hypomethylated which would translate into high levels 
of HAGE expression in these cells.  
Over the course of this project, relative expressions of genes of interest were normalised to two 
different housekeeping genes (GAPDH and rRNA), but due to very high level of expression of 
18S RNA, GAPDH levels were taken into account for normalisation. However, it has been 
reported that GAPDH can be an unreliable housekeeping gene for normalisation in RT-PCR 
due to its wide variability in response to different factors (Bustin., 2002). With hindsight, other 
housekeeping genes such as β-glucuronidase, protein kinase cGMP-dependent type 1 or 
TATA-box binding protein, described as more reliable should have been utilised in this project 
(Lossos et al., 2003).  
Results obtained at the mRNA level were further confirmed at the protein level for HAGE as 
mRNA and protein do not necessarily always correlate. In this study, immunohistochemistry 
and immunofluorescence validated the results of real time PCR proving and changing the 
status of putative protein of the cancer/testis antigen HAGE into an actual product of 
translation mechanisms. Expression of HAGE at the protein level was not detected in any 
normal tissues, except testis and expression at the mRNA level correlated with expression at 
the protein level in head & neck carcinoma and melanoma samples, as well as melanoma cell 
lines. A previous study has demonstrated that a differentiation antigen termed metastasis-
associated antigen-1 (MTA1) was not detected by immunohistochemistry because of its low 
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levels of sensitivity and that by concentrating the samples and performing western-blotting, 
this given protein could be highlighted (D. Assudani, personal communication). Here, HAGE 
staining appears quite intensively on normal testis sections and several other sections from 
different cancers suggesting high quantities of HAGE protein in these tissues. Furthermore, the 
use of multiple cancer tissue microarrays allowed showing up HAGE expression in cancer 
tissues which are very difficult to get access to such as bladder and liver carcinoma. 
Unfortunately, unpurified polyclonal antisera were used to highlight the expression of HAGE 
at the protein level hindering the quality of the staining with some residual background, even 
after adsorption of the antisera with rabbit liver powder. In the future, a purified monoclonal 
antibody customised to target a specific amino acid sequence from the HAGE protein should 
replace the polyclonal antisera for the staining of HAGE by immunohistochemistry and 
immunofluorescence.  
These last two techniques also brought important additional information. Indeed, it allowed the 
determination of the localisation of HAGE inside the cells and interestingly enough, it seems to 
be expressed in different compartments of the cells depending on the culture conditions and on 
the cell type, be it cell lines, transfected cells or tissues. Indeed, HAGE appears to be 
cytoplasmic in cell lines as shown in the melanoma cell line ESTDAB-27, whilst being mainly 
nuclear in transfected cells and tissue sections as demonstrated in transfected murine ALC cells, 
BM-DC and human testis. Therefore, like other RNA helicases, HAGE could be involved in 
different processes of RNA metabolism depending on the cell requirements in vitro and in vivo 
(Charroux et al., 1999; Charroux et al., 2000). It remains difficult to determine at this stage 
what these processes and the links with the cancer phenotype are. However, it is possible to 
bring a few clues on what the consequences of the expression of HAGE are. Like other DEAD-
box RNA helicases such as DDX1, DDX2 and DDX5, HAGE seems to be critical to the 
proliferation of tumour cells as shown by siRNA and cDNA transfection experiments, as well 
as in vivo in challenge experiments although this last observation will have to be repeated in 
the future. Moreover, cell cycle as well as cell morphology did not display any signs of being 
altered by the silencing of HAGE gene suggesting that HAGE is not crucial for the cells to 
survive but only to proliferate. Finally, the expression analysis carried out by real time PCR 
with CML patient cDNA showed a correlation between the expressions of Bcr/Abl and HAGE 
which is in line with a study published by Roman-Gomez et al. (2007) describing a link 
between high levels of HAGE expression and poor clinical outcome. Several proteins including 
oncogenes such as Pim1 and Jun are up-regulated following expression of the Bcr/Abl protein 
(Hakansson et al., 2004) but the link between the latter and HAGE has been not proven yet. 
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Also, it is very unlikely that HAGE is produced because of the Philadelphia chromosome as it 
is found in other forms of cancer such as melanoma where the chromosome translocation is not 
found. However, it can be hypothesised that downstream of the Bcr/Abl chain of events, some 
mechanisms shared by a variety of cancers such as the increased expression of proto-
oncogenes, growth factors, factors related to tyrosine kinase activity or factors related directly 
to the cell proliferation cycle (Ohba et al., 2004), and production of reactive oxygen species 
(Kim et al., 2005) could participate to the sudden transcription of numerous genes with 
oncogenic properties responsible for the severity of cancer and associated with poor prognosis, 
including HAGE.  
Finally, not all tumour antigens are capable of eliciting specific immune responses and 
immunogenicity of an antigen would be the deciding factor in validating it as a potential 
immunotherapeutic target. Combined together, these data strongly suggested that should 
HAGE be immunogenic, it would represent the ideal immunotherapeutic target against several 
cancers. Although no previous evidences have been reported describing the generation of a B 
cell and/or T cell specific immune response towards it, HAGE immunogenicity was 
investigated in transgenic mouse models. 
 
7.2 Identification of novel T-cell epitopes derived from HAGE 
The modeling of human diseases such as cancer goes through the utilisation of animal models 
although promising results obtained with the latter rarely translate into significant clinical 
benefits in patients. Nonetheless, animal models remain a reliable and convenient source of 
great discoveries such as revolutionary drugs and other medical interventions to treat diseases 
in humans. The main argument against animal models is that their physiological system can 
differ from humans. However, failure of clinical trials in humans can often rather be explained 
by the choice of poor animal models in numerous studies. For instance, the use of mice in 
immunotherapeutic models of cancer can be explained by several reasons, among which the 
quick provision of answers, low costs, the facility to handle and to genetically transform, and 
the similarity of their physiological system with humans. But the transplantation of tumours 
does not represent an ideal model as tumour cells are injected at a site different from their usual 
anatomical location and often express foreign and highly immunogenic antigens, whereas 
tumours are more likely to be self in origin and less immunogenic (Dullaers et al., 2006). 
Hence, selection of an animal model to investigate a novel therapeutic antigen or any other 
intervention can be most critical in attaining results which can be translated into humans. Over 
the last thirty years, the field of transgenic mouse models has revolutionised the research 
   197 
against cancer by providing a wealth of new knowledge about mechanisms of tumorogenesis 
and anti-tumour immune responses. With the likes of oncomice in which tumours arise 
spontaneously, transgenic mice with epitope-specific human TCR or HLA transgenic mice, it is 
now possible to answer several questions about the roles of an antigen in tumour development, 
the kinetics of an antigen-specific T cell response and its regulatory mechanisms, or the 
immunogenicity of a given tumour antigen (Ostrand-Rosenberg., 2004). In this project, the use 
of mice transgenic for HLA molecules were first used to investigate the immunogenicity and 
the natural processing of HAGE-derived peptides selected by reverse immunology and 
secondly to evaluate a model of transplantable tumours over-expressing the HAGE gene in 
order to study different DNA-based vaccine strategies. 
There are a number of different approaches that can be applied to identify new candidate class 
I/II-restricted target antigens for immunotherapy. In this report, the application of the reverse 
immunology approach to identify potential T cell epitopes from the product of the cancer/testis 
antigen HAGE in transgenic mice expressing human HLA molecules is described. Peptides are 
convenient, easy to synthesise for clinical use, easy to modify and to administer to patients. 
Disis et al. (1996) described that the administration of peptides derived from a self tumour 
protein rather than the whole protein was able to induce antibody production and T cell 
activation. Moreover, peptides can be easily administrated together with adjuvants, cytokines 
or dendritic cells using wild-type sequences or sequences optimised to increase their binding 
affinity to MHC molecules. Also, using, ex vivo monitoring based on tetramer technology, it 
was shown that T cell responses to peptide vaccines can be followed. One of the major 
advantages of identifying immunogenic tumour-associated peptides is the subsequent 
identification of T cell receptors specific for these peptides. Once identified, vectors encoding 
these TCR can be engineered and used to transfect lymphocytes from peripheral blood for 
transfer to patients (Morgan et al., 2003). A recent study conducted by Morgan et al. (2006) 
indicated the presence of circulating transduced lymphocytes one year post-transfusion and 
metastatic regression in two of 17 treated patients. Numerous studies have demonstrated the 
feasibility of cancer immunotherapy using tumour antigens recognised by CD8+ T cells 
(Rosenberg et al., 1998; Yee et al., 2000). However, the responses observed were 
unfortunately weak and transient. CD4+ T cells play a central role in initiating and maintaining 
anti-tumour therapy. Thus, optimal immunisation will require the recruitment of both CD4+ 
and CD8+ T cells, in order to generate a long-lasting anti-tumour immune response (Assudani 
et al., 2007).  
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To this end, eight HAGE-derived peptides predicted to bind strongly to HLA-A0201 were 
selected using the evidence-based computer algorithm SYFPEITHI. Four out of eight peptides 
evaluated in HHDII mice were found to be immunogenic. However, CTL generated by gene 
gun immunisation with HAGE cDNA and in vitro peptide re-stimulation were unable to kill 
tumour cells expressing HAGE or loaded with peptides suggesting that these peptides were not 
naturally processed and presented by antigen-presenting cells and tumour cells. Lack of lysis of 
targets could have been due to low expression of HAGE in these tumour cells, lack of 
expression of these specific peptides at the cell surface or low avidity of generated T cells for 
these peptides. However, following immunisation with DC transfected to express HAGE or 
loaded with HAGE-rich melanoma cell lysate, peptide HAGE 126 was proven to be naturally 
processed. It is difficult at this stage to explain the natural processing of peptide HAGE 126 
following transfected DC immunisation but not by gene gun. The main difference between this 
two means of vaccination being the population of APC targeted (i.e.: BM-DC and Langerhans 
cells by DC and gene gun immunisation, respectively), it can be hypothesised that processing 
of HAGE by the immunoproteasome in BM-DC, but not by the proteasome in Langerhans cells, 
leads to the generation of peptide HAGE 126. Indeed, the proteolytic activity of these two 
degradation machineries differs leading to the production of two distinct panels of peptides 
(Kloetzel et al., 2004). The exclusive processing of peptide HAGE 126 by the 
immunoproteasome suggest that tumour cells, which only express the proteasome, would not 
be presenting this peptide emphasising the importance of an adapted mode of immunisation for 
accurate identification of peptides naturally processed by tumour cells.  
Since HAGE is an endogenous antigen, it is likely to be processed by MHC class I processing 
pathway. However, some of these intracellular antigens might also be presented in MHC class 
II-restricted context as previously described (Dissanayake et al., 2005). Considering this, six 
HAGE-derived peptides predicted by SYFPEITHI to bind strongly to HLA-DR0101 and HLA-
DR0401 molecules were synthesised. Four of them were immunogenic in both HLA-DR1 and 
HLA-DR4 transgenic mice. Furthermore, two of them (HAGE 338 and HAGE 506-II) were 
naturally processed as tested using two different methods (gene gun and transfected DC 
immunisation, See Chapter 5) suggesting that contrary to class I peptides, both types of APC 
targeted by these two means of vaccination produce both HAGE-derived class II peptides 
identically. With the MHC class II processing pathway being supposedly identical in both 
populations of APC targeted, similar results between gene and DC immunisation were 
therefore expected. In agreement with the results obtained following immunisation with HAGE 
cDNA of transgenic mice, specific HLA class II-restricted recognition of HLA-DR-matched 
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tumour cell lines as well as DC pulsed with HAGE-positive cell lysates were also achieved 
following the in vitro generation of CD4+ T cell lines from human PBMC with peptide HAGE 
506-II indicating that this peptide was processed identically in both species (Mathieu et al., 
2007). Thereafter, both class I peptide HAGE 126 and class II peptide HAGE 338 will now 
need to be investigated for their ability to respectively generate in vitro CTL and T helper cells 
capable of specifically responding to target cells expressing the appropriate HLA molecules as 
well as HAGE. Also, natural processing of peptide HAGE 126 by the immunoproteasome and 
not the proteasome will need to be confirmed. Finally, only high binding affinity peptides were 
evaluated among which, three of them could be useful for the vaccination of A2, DR1 or DR4 
patients but more low-to-moderate binding affinity peptides could still be valid candidate T cell 
epitopes and will need to be investigated. 
 
7.3 Vaccines strategies and HAGE 
The need to identify specific epitopes from antigens can be circumvented by the use of DNA-
based vaccine strategies targeting whole antigens, which allow the generation of an immune 
response against multiple epitopes regardless of HLA haplotypes. To test this, HAGE cDNA 
sequence was cloned into a mammalian expression vector, which was then used to immunise 
HHDII-DR1 double transgenic mice using either gene gun or intra-muscular method in 
prophylactic and therapeutic experiments. Immunisation with HAGE by gene gun or intra-
muscular injection was able to provide protection from ALC/HAGE tumour challenge. 
Moreover, only gene gun immunisation led to a statistically significant improvement of the 
percent of survival. This is in correlation with several studies defending gene gun as a method 
of choice to generate an anti-tumour response (Bowne et al., 1999; Gold et al., 2003). Also, 
significant delayed tumour growth and improved overall survival were achieved when mice 
were injected ALC/HAGE tumour cells first and then immunised three days later by gene gun 
in a therapeutic setup. The latter was then repeated but this time, immunisation took place 
when tumours were palpable. Similar delayed tumour growth and improved survival were 
recorded.  
In spite of a number of advantages of DNA vaccines, lack of potency is often blamed as the 
causative factor for failure of DNA vaccines in humans and the presence in the plasmid DNA 
of unmethylated CpG islands, which can act as good adjuvants, is not sufficient to overcome 
this situation. To make up for this, attaching signalling molecules to direct antigens towards 
MHC class I or class II processing pathway, or co-administrating the targeted antigen with 
cytokine genes or co-stimulatory molecules to potentiate the immune response have all been 
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evaluated with different degrees of success. In order to address this issue, murine B7.1, B7.2 or 
4.1BBL cDNA sequences were each cloned into a mammalian expression vector containing 
already HAGE cDNA. Comparisons were then made and although experiments were carried 
out in small groups of mice and are not statistically significant, the addition of the murine co-
stimulatory molecule B7.2 to HAGE in a single mammalian expression vector seems to 
convincingly slow down tumour growth but unfortunately, no further improvement of the 
percent survival. Further experiments are required with larger cohorts to draw definitive 
conclusions on the beneficial effects of co-stimulatory molecules to a HAGE DNA vaccine. 
The ability of HAGE DNA vaccine to generate immune response was not surprising as several 
studies targeting cancer/testis antigens using plasmid vaccines in mice have demonstrated 
similar promising results (Park et al., 1999; Ma et al., 2005). However, it remains difficult to 
determine if the response observed was HAGE-specific and not due to epitope spreading 
despite differences between immunisation with empty plasmid and HAGE plasmid being 
significant in both protection and therapeutic experiments. More work is then needed to prove 
the specificity of the anti-tumour response by refining protection experiments and prolonging 
the duration between DNA vaccination and challenge with HAGE-expressing tumour cells.   
With hindsight, other modalities of vaccination should have also been attempted such as 
HAGE-transfected DC. Indeed, the identification of the naturally processed and immunogenic 
class I peptide HAGE 126 relied strictly on the immunisation of transgenic mice with 
syngeneic DC transfected to express the HAGE protein suggesting that BM-DC provide a 
different panel of antigenic peptides from Langerhans cells to T lymphocytes. Having 
identified this peptide, it would have allowed monitoring of the immune response as well as 
undertaking peptide-based vaccination in HHDII-DR1 double transgenic mice injected with 
ALC/HAGE tumour cells. Unfortunately, neither gene gun nor intra-muscular injection 
allowed confirming whether any of the naturally processed and immunogenic peptides HAGE 
126, HAGE 338 and HAGE 506-II were responsible for the tumour eradications achieved.  
Finally, the presence of regressor mice in the non-immunised group indicates that ALC/HAGE 
tumour cells are immunogenic on their own and that number and type of cells injected to the 
mice might be critical to the elaboration of a fatal tumour challenge. It also means that in the 
future, immunogenicity rather than aggressiveness should be privileged in the elaboration of an 
in vivo tumour model. This immunogenic potential of ALC/HAGE tumour cells was later 
confirmed when mice were challenged a second time two months after the primary challenge 
and showed no signs of tumour growth suggesting the existence of a strong memory response. 
However, it cannot be certified that by lowering the number of cells or replacing the cells with 
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a proven poorly immunogenic cell line such as B16, the immunogenicity of the cells will also 
be lowered with HAGE being a foreign antigen and therefore strongly immunogenic. This is a 
crucial point as it reappraises the use of transplantable tumours in tumour immunology 
research and emphasises the need for the creation of closer to reality in vivo tumour models. 
That is why mimicking the reality by optimising this in vivo model with HAGE-expressing 
tumour cells will turn out to be critical for the development of proper vaccine strategies in 
order to avoid the failure of DNA-based vaccines in future human clinical trials. 
 
7.4 Conclusions and future work 
Cancer/testis antigens represent one of the most promising groups of tumour-associated 
antigens identified till date because of their almost unique and specific expression in tumours, 
and are rightly being investigated for the development of novel immunotherapeutic strategies. 
However, caution had to be taken to validate HAGE, a member of this family, as target for 
immunotherapy in order to avoid the appearance of unwanted side-effects such as auto-
immunity. Based on the results presented here and should it be immunogenic, the cancer/testis 
antigen HAGE represents an ideal target for immunotherapy against several cancers. It is 
strongly expressed at the mRNA and protein levels in a variety of cancers, totally absent from 
normal tissues except testis and seems to have critical oncogenic properties as cell proliferation 
correlates with HAGE expression.  
With the clinical outcome of cancer patients often correlating with the existence of an 
immunological response (Mine et al., 2004), the importance of CD8+ and CD4+ T cells has 
become apparent, which leads to the requirement for protocols to rapidly identify MHC class I 
and class II epitopes that could be used in the clinic. The use of HLA transgenic mice 
immunised with predicted peptides has provided a mean to rapidly identify these epitopes 
bypassing the need for time-consuming in vitro re-stimulation of human PBMC. A large panel 
of peptides can consequently be pre-screened in transgenic mice before finally assessing a 
reduced number of them in human T cell cultures. Put together, peptide, DNA and DC 
immunisations allowed the identification of several immunogenic HAGE-derived HLA-A2 and 
HLA-DR1/-DR4 peptides among which one class I (HAGE 126) and two class II (HAGE 338 
and HAGE 506-II) peptides were also found to be naturally processed. Several studies have 
demonstrated that CD4+ T cells were essential for the promotion of an effector and memory 
CTL response (Gao et al., 2002; Shedlock et al., 2003) and that the administration of a 
heterogeneous T cell population is more efficient than transfer of CD8+ T lymphocytes alone  
(Dudley et al., 2002; Rosenberg et al., 2004). Having identified HAGE-derived class I and 
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class II epitopes, it remains to establish if the administration of class I and class II peptides 
derived from the same protein will result in increased CTL activity, long-lasting immunity and 
whether tumour protection and/or clearance can be achieved with these helped CTL responses, 
at least in mice. Also, identification of these epitopes could also be useful for the vaccination of 
HLA-A2, -DR1 and -DR4-positive patients and/or the monitoring of the immune response 
directed against HAGE in these patients.  
The use of pre-clinical models allows valuable information to be obtained regarding the 
optimal conditions required for tumour clearance and follow-up such as mode of vaccination, 
use of adjuvants, system of delivery, administration schedule and immune response monitoring. 
Moreover, it is critical to design novel vaccine strategies that will also be suitable for clinical 
use. Therefore, the ideal vaccine should combine the following characteristics in order to 
overcome immunological barriers: low toxicity such as DNA-based vaccine, ability to 
stimulate all the anti-tumorogenic arms of the immune response, immunomodulatory signals 
such as cytokines or co-stimulatory molecules for DC and T cell stimulation and eventually, a 
strategy to deplete immunosuppressive cells such as Tregs and NKT cells. As part of this 
project, a tumour model was developed in HHDII-DR1 double transgenic mice. This tumour 
model relied on the creation of stable transfectants expressing HAGE, the transplantation of 
these genetically-modified tumour cells in mice and the assessment of several DNA-based 
vaccine strategies. Using a standard analysis of tumour regressions, tumour protection and/or 
clearance were achieved in a majority of mice immunised with HAGE DNA vaccine 
administrated intra-dermally by gene gun or intra-muscularly by injection indicating that 
HAGE as a whole antigen is strongly immunogenic, at least in mice. Moreover, tumour 
clearance was further improved by the addition of the murine co-stimulatory molecule B7.2 to 
the HAGE DNA vaccine but not B7.1 or 4.1BBL, although this result will have to be 
reproduced in the future to confirm the boosting of the anti-tumour response by B7.2. 
Transgenics have been previously used successfully in our laboratory and in others 
(Touloukian et al., 2000; Rojas et al., 2004) and are central to this study hopefully providing 
important information for the formulation of future cancer vaccines and an accurate insight of 
the immune response taking places in humans. 
Future studies should aim to clarify certain aspects of this study and/or to build on some of 
these findings. Repeat experiments testing HAGE expression on tumour sections must be 
carried out with customised and purified anti-HAGE antibody to confirm previous results, to 
assess whether HAGE can be found at the protein level in CML PBMC, and to link expression 
of this antigen with tumour stage or clinical outcome in several types of cancers. Also, 
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experiments about the role of HAGE in tumour cells should be expanded to clarify its link with 
cell proliferation both upstream and downstream of its potential pathway by performing gene 
microarray analysis in melanoma cell lines, CML cell lines as well as in a histiocytic 
lymphoma cell line (U937) where the Bcr/Abl translocation characteristic of the CML 
phenotype can be induced. Studying the phosphorylation status of HAGE would also bring 
further clues on a potential correlation between HAGE and Bcr/Abl expressions. 
In order to further optimise the tumour model used in this project, immunogenicity of the 
transplantable tumour cells has to decrease and vaccine strategies will have to be refined in 
order to ensure the specificity of the immune response elicited against HAGE-expressing 
tumours. Challenge and therapy experiments could then be setup with different modes of 
vaccinations such as mature DC transfected to process and present HAGE-derived peptides or 
the SFV/HAGE viruses generated over the course of this project. More detailed investigation 
of the effects of co-stimulatory molecules is also a pre-requisite in order to conclude on their 
ability to boost the immune response achieved against the cancer/testis antigen HAGE. Finally 
and before making the final link with the clinic and undertaking different  immunotherapeutic 
approaches to target HAGE-expressing tumours in clinical trials, identified peptides will have 
to be tested in vitro in order to see their ability to generate peptide-specific CTL and T helpers 
using PBMC from healthy donors and patients that are A-0201-, DR-0101- and DR-0401-
positive. 
By completing the information gathered on HAGE and improving the transgenic tumour model, 
it may be then possible to develop a more efficient mode of cancer vaccination that could 
translate into the clinic with a more successful prognostic. 
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Figure A1: Expression of HAGE in AML and CML samples by RT-PCR. This figure 
represents the semi-quantitative analysis of expression of HAGE in AML and CML samples, 
using water as a negative control. PCR products for 18S ribosome and HAGE should be of 110 
and 432bp, respectively. 
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Appendix 2 
Table A1: Breast carcinoma information and their relative HAGE expression 
Sample code TNM stage Differentiation Histology Relative HAGE 
expression 
Br1T 
Br1N 
Br2T 
Br2N 
Br6T 
Br6N 
Br7T 
Br7N 
Br8T 
Br8N 
Br9T 
Br9N 
Br10T 
Br10N 
Br11T 
Br11N 
Br12T 
Br12N 
Br13T 
Br13N 
1.0.0 
 
3.1.0 
 
2.1.0 
 
2.1.0 
 
3.1.0 
 
- 
 
1.0.0 
 
2.3.0 
 
4.-.- 
 
1.0.0 
 
Moderate 
 
Low 
 
Moderate 
 
Moderate 
 
Moderate 
 
Fibroma 
 
Moderate 
 
Moderate 
 
N/A 
 
Moderate 
 
Infiltrative 
 
Infiltrative 
 
Infiltrative 
 
Infiltrative 
 
Infiltrative 
 
N/A 
 
Infiltrative 
 
Infiltrative 
 
Infiltrative 
 
Infiltrative 
 
- 
- 
- 
- 
32.6 
0.14 
0.00 
- 
0.06 
- 
60.1 
0.02 
0.02 
- 
0.41 
41.0 
0.06 
83.1 
- 
65.6 
 
-: low amount or poor quality of RNA. 
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Table A2: Colon carcinoma information and their relative HAGE expression 
Sample code TNM stage Differentiation Localisation Relative HAGE 
expression 
Co21T 
Co21N 
Co22T 
Co22N 
Co27T 
Co27N 
Co30T 
Co30N 
Co33T 
Co33N  
Co100T 
Co100N 
Co102T 
Co102N 
Co103T 
Co103N 
Co425T 
Co425N 
Co437T 
Co437N 
3.1.0 
 
3.0.0 
 
4.0.0 
 
3.1.0 
 
3.0.0 
 
3.1.0 
 
3.0.0 
 
3.0.0 
 
1.0.0 
 
3.1.0 
 
Moderate 
 
Low 
 
Moderate 
 
Moderate 
 
Well 
 
Moderate 
 
Moderate 
 
Moderate 
 
Moderate 
 
Low 
 
Ascendens 
 
Rectum 
 
Sigmoid 
 
Caecum 
 
Sigmoid 
 
Rectum/Sigmoid 
 
Rectum 
 
Rectum/Sigmoid 
 
Rectum/Sigmoid 
 
Sigmoid 
 
0.00 
0.03 
0.00 
0.16 
0.000 
0.002 
- 
- 
0.00 
0.01 
0.004 
0.002 
0.000 
0.002 
0.10 
0.00 
- 
- 
- 
- 
 
-: low amount or poor quality of RNA. 
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Table A3: Gastric carcinoma information and their relative HAGE expression  
Sample code TNM stage Differentiation Lauren’s 
classification 
Relative HAGE 
expression 
Ga47T 
Ga47N 
Ga55T 
Ga55N 
Ga201T 
Ga201N 
Ga411T 
Ga411N 
Ga418T 
Ga418N 
Ga421T 
Ga421N 
Ga434T 
Ga434N 
Ga436T 
Ga436N 
Ga438T 
Ga438N 
Ga440T 
Ga440N 
N/A 
 
4.1.0 
 
N/A 
 
3.0.0 
 
3.0.0 
 
3.0.0 
 
2.0.0 
 
2.0.0 
 
2.0.0 
 
3.1.0 
 
GIII 
 
GIV 
 
Low 
 
GIV 
 
GIII 
 
GIII 
 
GII 
 
GI 
 
GII 
 
GIII 
 
Intestinal 
 
Diffuse 
 
N/A 
 
Intestinal 
 
Diffuse 
 
Diffuse 
 
Intestinal 
 
Intestinal 
 
Intestinal 
 
Diffuse 
 
0.00 
0.04 
- 
0.002 
0.000 
0.003 
0.000 
0.003 
0.009 
0.004 
0.004 
0.005 
- 
- 
0.00 
0.05 
0.01 
0.02 
0.006 
0.002 
 
-: low amount or poor quality of RNA. 
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Table A4: Head & neck carcinoma information and their relative HAGE expression 
Sample code 
Relative 
HAGE 
expression 
HN28T 
HN28N 
HN35T 
HN35N 
HN36T 
HN36N 
HN38T 
HN38N 
0.025 
0.005 
0.001 
0.004 
0.02 
0.01 
0.002 
0.001 
 
  
   209 
References 
Aarts, W. M., J. Schlom, et al. (2002). "Vector-based vaccine/cytokine combination therapy to 
enhance induction of immune responses to a self-antigen and antitumor activity." Cancer Res 
62(20): 5770-7. 
 
Adam, J. K., B. Odhav, et al. (2003). "Immune responses in cancer." Pharmacol Ther 99(1): 
113-32. 
 
Adams, S. P., S. S. Sahota, et al. (2002). "Frequent expression of HAGE in presentation 
chronic myeloid leukaemias." Leukemia 16(11): 2238-42. 
 
Ahmad, M., R. C. Rees, et al. (2004). "Escape from immunotherapy: possible mechanisms that 
influence tumor regression/progression." Cancer Immunol Immunother 53(10): 844-54. 
 
Ahmad, M., R. C. Rees, et al. (2005). "Regulation of CTL responses to MHC-restricted class I 
peptide of the gp70 tumour antigen by splenic parenchymal CD4+ T cells in mice failing 
immunotherapy with DISC-mGM-CSF." Int J Cancer 115(6): 951-9. 
 
Akagi, T. (2004). "Oncogenic transformation of human cells: shortcomings of rodent model 
systems." Trends Mol Med 10(11): 542-8. 
 
Akao, Y., O. Marukawa, et al. (1995). "The rck/p54 candidate proto-oncogene product is a 54-
kilodalton D-E-A-D box protein differentially expressed in human and mouse tissues." Cancer 
Res 55(15): 3444-9. 
 
Ali, S. A., M. Ahmad, et al. (2004). "Anti-tumour therapeutic efficacy of OX40L in murine 
tumour model." Vaccine 22(27-28): 3585-94. 
 
Ali, S. A., J. Lynam, et al. (2002). "Tumor regression induced by intratumor therapy with a 
disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine 
granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive 
immunity." J Immunol 168(7): 3512-9. 
 
Ali, S. A., C. S. McLean, et al. (2000). "Preclinical evaluation of "whole" cell vaccines for 
prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to 
transduce cytokine genes." Cancer Res 60(6): 1663-70. 
 
Amler, L.C., J. Schurmann, et al. (1996). "The DDX1 gene maps within 400 kbp 5' to MYCN 
and is frequently coamplified in human neuroblastoma." Genes Chromosomes Cancer 15(2): 
134-7 
 
Andersen, M. H., D. Schrama, et al. (2006). "Cytotoxic T cells." J Invest Dermatol 126(1): 32-
41. 
 
Anderton, S. M., N. J. Viner, et al. (2002). "Influence of a dominant cryptic epitope on 
autoimmune T cell tolerance." Nat Immunol 3(2): 175-81. 
 
Antony, P. A., C. M. Paulos, et al. (2006). "Interleukin-2-dependent mechanisms of tolerance 
and immunity in vivo." J Immunol 176(9): 5255-66. 
   210 
Antony, P. A., C. A. Piccirillo, et al. (2005). "CD8+ T cell immunity against a tumor/self-
antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory 
cells." J Immunol 174(5): 2591-601. 
 
Arai, H., D. Gordon, et al. (1997). "Gene transfer of Fas ligand induces tumor regression in 
vivo." Proc Natl Acad Sci U S A 94(25): 13862-7. 
 
Arnold-Schild, D., C. Kleist, et al. (2000). "One-step single-chain Fv recombinant antibody-
based purification of gp96 for vaccine development." Cancer Res 60(15): 4175-8. 
 
Ashkenazi, A., R. C. Pai, et al. (1999). "Safety and antitumor activity of recombinant soluble 
Apo2 ligand." J Clin Invest 104(2): 155-62. 
 
Asselin-Paturel, C., H. Echchakir, et al. (1998). "Quantitative analysis of Th1, Th2 and TGF-
beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients." Int J 
Cancer 77(1): 7-12. 
 
Assudani, D. P., R. B. Horton, et al. (2007). "The role of CD4+ T cell help in cancer immunity 
and the formulation of novel cancer vaccines." Cancer Immunol Immunother 56(1): 70-80. 
 
Atkins, G. J., B. J. Sheahan, et al. (1999). "The molecular pathogenesis of Semliki Forest virus: 
a model virus made useful?" J Gen Virol 80 ( Pt 9): 2287-97. 
 
Baak, J. P., F. R. Path, et al. (2003). "Genomics and proteomics in cancer." Eur J Cancer 39(9): 
1199-215. 
 
Bagot, M., H. Echchakir, et al. (1998). "Isolation of tumor-specific cytotoxic CD4+ and 
CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma." Blood 91(11): 4331-
41. 
 
Baldwin, A. S. (2001). "Control of oncogenesis and cancer therapy resistance by the 
transcription factor NF-kappaB." J Clin Invest 107(3): 241-246. 
 
Bamne, M. N., P. N. Ghule, et al. (2005). "Constitutional and somatic RB1 mutation spectrum 
in nonfamilial unilateral and bilateral retinoblastoma in India." Genet Test 9(3): 200-11. 
 
Bar-Haim, E., A. Paz, et al. (2004). "MAGE-A8 overexpression in transitional cell carcinoma 
of the bladder: identification of two tumour-associated antigen peptides." Br J Cancer 91(2): 
398-407. 
 
Barnea, E., I. Beer, et al. (2002). "Analysis of endogenous peptides bound by soluble MHC 
class I molecules: a novel approach for identifying tumor-specific antigens." Eur J Immunol 
32(1): 213-22. 
 
Bauer, S., V. Groh, et al. (1999). "Activation of NK cells and T cells by NKG2D, a receptor 
for stress-inducible MICA." Science 285(5428): 727-9. 
 
Benitez, R., D. Godelaine, et al. (1998). "Mutations of the beta2-microglobulin gene result in a 
lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE 
peptides." Tissue Antigens 52(6): 520-9. 
   211 
Bennett, K., T. Levine, et al. (1992). "Antigen processing for presentation by class II major 
histocompatibility complex requires cleavage by cathepsin E." Eur J Immunol 22(6): 1519-24. 
 
Berd, D. (2001). "Autologous, hapten-modified vaccine as a treatment for human cancers." 
Vaccine 19(17-19): 2565-70. 
 
Bertram, J. S. (2000). "The molecular biology of cancer." Mol Aspects Med 21(6): 167-223. 
 
Beutler, B., K. Hoebe, et al. (2003). "How we detect microbes and respond to them: the Toll-
like receptors and their transducers." J Leukoc Biol 74(4): 479-85. 
 
Bikoff, E. K., L. Y. Huang, et al. (1993). "Defective major histocompatibility complex class II 
assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant 
chain expression." J Exp Med 177(6): 1699-712. 
 
Binder, R. J., R. Vatner, et al. (2004). "The heat-shock protein receptors: some answers and 
more questions." Tissue Antigens 64(4): 442-51. 
 
Bjerkvig, R., B. B. Tysnes, et al. (2005). "Opinion: the origin of the cancer stem cell: current 
controversies and new insights." Nat Rev Cancer 5(11): 899-904. 
 
Bjorkman, P. J., M. A. Saper, et al. (1987). "The foreign antigen binding site and T cell 
recognition regions of class I histocompatibility antigens." Nature 329(6139): 512-8. 
 
Blattman, J. N., J. M. Grayson, et al. (2003). "Therapeutic use of IL-2 to enhance antiviral T-
cell responses in vivo." Nat Med 9(5): 540-7. 
 
Boeckmann, B., A. Bairoch, et al. (2003). "The SWISS-PROT protein knowledgebase and its 
supplement TrEMBL in 2003." Nucleic Acids Res 31(1): 365-70. 
 
Bogdan, C., M. Rollinghoff, et al. (2000). "Reactive oxygen and reactive nitrogen 
intermediates in innate and specific immunity." Curr Opin Immunol 12(1): 64-76. 
 
Bonner, P. L., J. R. Lill, et al. (2002). "Electrospray mass spectrometry for the identification of 
MHC class I-associated peptides expressed on cancer cells." J Immunol Methods 262(1-2): 5-
19. 
 
Bonnet, M. C., J. Tartaglia, et al. (2000). "Recombinant viruses as a tool for therapeutic 
vaccination against human cancers." Immunol Lett 74(1): 11-25. 
 
Boursnell, M. E., C. Entwisle, et al. (1997). "A genetically inactivated herpes simplex virus 
type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 
disease." J Infect Dis 175(1): 16-25. 
 
Bowne, W. B., R. Srinivasan, et al. (1999). "Coupling and uncoupling of tumor immunity and 
autoimmunity." J Exp Med 190(11): 1717-22. 
 
Brabletz, T., A. Jung, et al. (2005). "Opinion: migrating cancer stem cells - an integrated 
concept of malignant tumour progression." Nat Rev Cancer 5(9): 744-9. 
 
   212 
Bredenbeck, A., F. O. Losch, et al. (2005). "Identification of noncanonical melanoma-
associated T cell epitopes for cancer immunotherapy." J Immunol 174(11): 6716-24. 
 
Bronte, V., E. Apolloni, et al. (2000). "Genetic vaccination with "self" tyrosinase-related 
protein 2 causes melanoma eradication but not vitiligo." Cancer Res 60(2): 253-8. 
 
Buchan, S., E. Gronevik, et al. (2005). "Electroporation as a "prime/boost" strategy for naked 
DNA vaccination against a tumor antigen." J Immunol 174(10): 6292-8. 
 
Bueler, H. and R. C. Mulligan (1996). "Induction of antigen-specific tumor immunity by 
genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of 
granulocyte-macrophage colony-stimulating factor and B7-1." Mol Med 2(5): 545-55. 
 
Burnet, F. M. (1970). "The concept of immunological surveillance." Prog Exp Tumor Res 13: 
1-27. 
 
Bustin, S. A. (2002). "Quantification of mRNA using real-time reverse transcription PCR (RT-
PCR): trends and problems." J Mol Endocrinol 29(1): 23-39. 
 
Calle, E. E. and M. J. Thun (2004). "Obesity and cancer." Oncogene 23(38): 6365-78. 
 
Campbell, R. D. and J. Trowsdale (1993). "Map of the human MHC." Immunol Today 14(7): 
349-52. 
 
Cao, D. Y., J. Y. Yang, et al. (2007). "alpha-fetoprotein and interleukin-18 gene-modified 
dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response 
from hepatocellular carcinoma patients in Vitro." Hum Immunol 68(5): 334-41. 
 
Carreno, B. M., F. Bennett, et al. (2000). "CTLA-4 (CD152) can inhibit T cell activation by 
two different mechanisms depending on its level of cell surface expression." J Immunol 165(3): 
1352-6. 
 
Caruthers, J.M., D.B. McKay (2002). "Helicase structure and mechanism." Curr Opin Struct 
Biol 12(1): 123-33. 
 
Caux, C., C. Dezutter-Dambuyant, et al. (1992). "GM-CSF and TNF-alpha cooperate in the 
generation of dendritic Langerhans cells." Nature 360(6401): 258-61. 
 
Chakraborty, M., J. Schlom, et al. (2007). "The combined activation of positive costimulatory 
signals with modulation of a negative costimulatory signal for the enhancement of vaccine-
mediated T-cell responses." Cancer Immunol Immunother 56(9): 1471-84. 
 
Chakraborty, N. G., S. Chattopadhyay, et al. (2004). "Regulatory T-cell response and tumor 
vaccine-induced cytotoxic T lymphocytes in human melanoma." Hum Immunol 65(8): 794-802. 
 
Chambers, C. A. and J. P. Allison (1997). "Co-stimulation in T cell responses." Curr Opin 
Immunol 9(3): 396-404. 
 
Chan, C. W., E. Crafton, et al. (2006). "Interferon-producing killer dendritic cells provide a 
link between innate and adaptive immunity." Nat Med 12(2): 207-13. 
   213 
 
Chan, K., D. J. Lee, et al. (2001). "The roles of MHC class II, CD40, and B7 costimulation in 
CTL induction by plasmid DNA." J Immunol 166(5): 3061-6. 
 
Chan, L., N. Hardwick, et al. (2005). "IL-2/B7.1 (CD80) fusagene transduction of AML blasts 
by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate 
whole cell vaccines for AML." Mol Ther 11(1): 120-31. 
 
Chang, C. S., J. H. Chang, et al. (2007). "Expression of CD80 and CD86 costimulatory 
molecules are potential markers for better survival in nasopharyngeal carcinoma." BMC 
Cancer 7: 88. 
 
Chen, G., G.J. Tharib, et al. (2002). "Discordant protein and mRNA expression in lung 
adenocarcinomas." Mol Cell Proteomics 1(4): 304-13. 
 
Chen, Y. F., C. W. Lin, et al. (2004). "Cytotoxic-T-lymphocyte human papillomavirus type 16 
E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice." J 
Virol 78(3): 1333-43. 
 
Chikamatsu, K., K. Nakano, et al. (1999). "Generation of anti-p53 cytotoxic T lymphocytes 
from human peripheral blood using autologous dendritic cells." Clin Cancer Res 5(6): 1281-8. 
 
Cho, Y., S. Gorina, et al. (1994). "Crystal structure of a p53 tumor suppressor-DNA complex: 
understanding tumorigenic mutations." Science 265(5170): 346-55. 
 
Cicinnati, V. R., G. Dworacki, et al. (2005). "Impact of p53-based immunization on primary 
chemically-induced tumors." Int J Cancer 113(6): 961-70. 
 
Clark, R. E., I. A. Dodi, et al. (2001). "Direct evidence that leukemic cells present HLA-
associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein." Blood 
98(10): 2887-93. 
 
Condomines, M., D. Hose, et al. (2007). "Cancer/testis genes in multiple myeloma: expression 
patterns and prognosis value determined by microarray analysis." J Immunol 178(5): 3307-15. 
 
Cordin, O., J. Banroques, et al. (2006). "The DEAD-box protein family of RNA helicases." 
Gene 367: 17-37. 
 
Cormier, J. N., M. L. Salgaller, et al. (1997). "Enhancement of cellular immunity in melanoma 
patients immunized with a peptide from MART-1/Melan A." Cancer J Sci Am 3(1): 37-44. 
 
Corr, M., H. Tighe, et al. (1997). "Costimulation provided by DNA immunization enhances 
antitumor immunity." J Immunol 159(10): 4999-5004. 
 
Costa, F. F., K. Le Blanc, et al. (2007). "Concise review: cancer/testis antigens, stem cells, and 
cancer." Stem Cells 25(3): 707-11. 
 
Coussens, L. M. and Z. Werb (1996). "Matrix metalloproteinases and the development of 
cancer." Chem Biol 3(11): 895-904. 
 
   214 
Cronwright, G., K. Le Blanc, et al. (2005). "Cancer/testis antigen expression in human 
mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix 
metalloproteinase 2 expression." Cancer Res 65(6): 2207-15. 
 
Cross, M. and T. M. Dexter (1991). "Growth factors in development, transformation, and 
tumorigenesis." Cell 64(2): 271-80. 
 
Curcio, C., E. Di Carlo, et al. (2003). "Nonredundant roles of antibody, cytokines, and perforin 
in the eradication of established Her-2/neu carcinomas." J Clin Invest 111(8): 1161-70. 
 
Curiel, T. J., G. Coukos, et al. (2004). "Specific recruitment of regulatory T cells in ovarian 
carcinoma fosters immune privilege and predicts reduced survival." Nat Med 10(9): 942-9. 
 
Daemen, T., F. Pries, et al. (2000). "Genetic immunization against cervical carcinoma: 
induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing 
human papillomavirus type 16 E6 and E7." Gene Ther 7(21): 1859-66. 
 
Daemen, T., A. Riezebos-Brilman, et al. (2003). "Eradication of established HPV16-
transformed tumours after immunisation with recombinant Semliki Forest virus expressing a 
fusion protein of E6 and E7." Vaccine 21(11-12): 1082-8. 
 
Daniel, D., C. Chiu, et al. (2005). "CD4+ T cell-mediated antigen-specific immunotherapy in a 
mouse model of cervical cancer." Cancer Res 65(5): 2018-25. 
 
Davila, E., R. Kennedy, et al. (2003). "Generation of antitumor immunity by cytotoxic T 
lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 
blockade." Cancer Res 63(12): 3281-8. 
 
de Haan, A., I. van der Gun, et al. (2000). "Activation of alloreactive T cells by allogeneic 
nonprofessional antigen-presenting cells and interleukin-12 from bystander autologous 
professional antigen-presenting cells." Transplantation 69(8): 1637-44. 
 
De Lange, T. (2005). "Telomere-related genome instability in cancer." Cold Spring Harb Symp 
Quant Biol 70: 197-204. 
 
De Plaen, E., C. Lurquin, et al. (1988). "Immunogenic (tum-) variants of mouse tumor P815: 
cloning of the gene of tum- antigen P91A and identification of the tum- mutation." Proc Natl 
Acad Sci U S A 85(7): 2274-8. 
 
de Visser, K. E., L. V. Korets, et al. (2005). "De novo carcinogenesis promoted by chronic 
inflammation is B lymphocyte dependent." Cancer Cell 7(5): 411-23. 
 
Degli-Esposti, M. A. and M. J. Smyth (2005). "Close encounters of different kinds: dendritic 
cells and NK cells take centre stage." Nat Rev Immunol 5(2): 112-24. 
 
Deininger, M. W., S. Vieira, et al. (2000). "BCR-ABL tyrosine kinase activity regulates the 
expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia." 
Cancer Res 60(7): 2049-55. 
 
   215 
DiCiommo, D. P. and R. Bremner (1998). "Rapid, high level protein production using DNA-
based Semliki Forest virus vectors." J Biol Chem 273(29): 18060-6. 
 
DiCiommo, D. P., A. Duckett, et al. (2004). "Retinoblastoma protein purification and 
transduction of retina and retinoblastoma cells using improved alphavirus vectors." Invest 
Ophthalmol Vis Sci 45(9): 3320-9. 
 
Dicker, F., A. P. Kater, et al. (2005). "Fas-ligand (CD178) and TRAIL synergistically induce 
apoptosis of CD40-activated chronic lymphocytic leukemia B cells." Blood 105(8): 3193-8. 
 
Dieckmann, D., C. H. Bruett, et al. (2002). "Human CD4(+)CD25(+) regulatory, contact-
dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory 
T cells [corrected]." J Exp Med 196(2): 247-53. 
 
Diehl, L., G. J. van Mierlo, et al. (2002). "In vivo triggering through 4-1BB enables Th-
independent priming of CTL in the presence of an intact CD28 costimulatory pathway." J 
Immunol 168(8): 3755-62. 
 
Disis, M. L., J. R. Gralow, et al. (1996). "Peptide-based, but not whole protein, vaccines elicit 
immunity to HER-2/neu, oncogenic self-protein." J Immunol 156(9): 3151-8. 
 
Dissanayake, S. K., N. Tuera, et al. (2005). "Presentation of endogenously synthesized MHC 
class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter 
associated with Ag processing and the proteasome." J Immunol 174(4): 1811-9. 
 
Dorothee, G., I. Vergnon, et al. (2002). "Tumor-infiltrating CD4+ T lymphocytes express 
APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: 
role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity." J Immunol 
169(2): 809-17. 
 
Dranoff, G., E. Jaffee, et al. (1993). "Vaccination with irradiated tumor cells engineered to 
secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, 
and long-lasting anti-tumor immunity." Proc Natl Acad Sci U S A 90(8): 3539-43. 
 
Dredge, K., J. B. Marriott, et al. (2002). "Adjuvants and the promotion of Th1-type cytokines 
in tumour immunotherapy." Cancer Immunol Immunother 51(10): 521-31. 
 
Dudley, M. E., J. Wunderlich, et al. (2001). "Adoptive transfer of cloned melanoma-reactive T 
lymphocytes for the treatment of patients with metastatic melanoma." J Immunother (1997) 
24(4): 363-73. 
 
Dudley, M. E., J. R. Wunderlich, et al. (2002). "A phase I study of nonmyeloablative 
chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in 
patients with metastatic melanoma." J Immunother (1997) 25(3): 243-51. 
 
Dudley, M. E., J. R. Wunderlich, et al. (2005). "Adoptive cell transfer therapy following non-
myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory 
metastatic melanoma." J Clin Oncol 23(10): 2346-57. 
 
   216 
Dullaers, M., S. Van Meirvenne, et al. (2006). "Induction of effective therapeutic antitumor 
immunity by direct in vivo administration of lentiviral vectors." Gene Ther 13(7): 630-40. 
 
Dunn, G. P., L. J. Old, et al. (2004). "The immunobiology of cancer immunosurveillance and 
immunoediting." Immunity 21(2): 137-48. 
 
Dunn, G. P., L. J. Old, et al. (2004). "The three Es of cancer immunoediting." Annu Rev 
Immunol 22: 329-60. 
 
Dunussi-Joannopoulos, K., G. Dranoff, et al. (1998). "Gene immunotherapy in murine acute 
myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines 
elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines." 
Blood 91(1): 222-30. 
 
Eberle, J., L.F. Fecker, et al. (2002). "Decreased proliferation of human melanoma cell lines 
caused by antisense RNA against translation factor eIF-4A1." Br J Cancer 86(12): 1957-62.  
 
Echchakir, H., M. Bagot, et al. (2000). "Cutaneous T cell lymphoma reactive CD4+ cytotoxic 
T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for 
specific tumor cell lysis." J Invest Dermatol 115(1): 74-80. 
 
Egilmez, N. K., S. D. Hess, et al. (2002). "Human CD4+ effector T cells mediate indirect 
interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative 
lung tumor xenografts in severe combined immunodeficient mice." Cancer Res 62(9): 2611-7. 
 
Eiben, G. L., M. P. Velders, et al. (2002). "Establishment of an HLA-A*0201 human 
papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in 
HLA-A*0201 transgenic mice." Cancer Res 62(20): 5792-9. 
 
el-Deiry, W. S., T. Tokino, et al. (1993). "WAF1, a potential mediator of p53 tumor 
suppression." Cell 75(4): 817-25. 
 
Ellyard, J. I., L. Simson, et al. (2007). "Th2-mediated anti-tumour immunity: friend or foe?" 
Tissue Antigens 70(1): 1-11. 
 
Engelhard, V. H., T. N. Bullock, et al. (2002). "Antigens derived from melanocyte 
differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy." 
Immunol Rev 188: 136-46. 
 
Falk, K., O. Rotzschke, et al. (1990). "Cellular peptide composition governed by major 
histocompatibility complex class I molecules." Nature 348(6298): 248-51. 
 
Falkenburg, J.H.F., L. van de Corput, et al. (2003). "Minor histocompatibility antigens in 
human stem cell transplantation." Exp Hematology 31: 743-751.  
 
Fearnhead, N. S., J. L. Wilding, et al. (2004). "Multiple rare variants in different genes account 
for multifactorial inherited susceptibility to colorectal adenomas." Proc Natl Acad Sci U S A 
101(45): 15992-7. 
 
   217 
Fearon, E. R. and B. Vogelstein (1990). "A genetic model for colorectal tumorigenesis." Cell 
61(5): 759-67. 
 
Feili-Hariri, M., D. H. Falkner, et al. (2005). "Polarization of naive T cells into Th1 or Th2 by 
distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy." J 
Leukoc Biol 78(3): 656-64. 
 
Feltkamp, M. C., H. L. Smits, et al. (1993). "Vaccination with cytotoxic T lymphocyte epitope-
containing peptide protects against a tumor induced by human papillomavirus type 16-
transformed cells." Eur J Immunol 23(9): 2242-9. 
 
Feltquate, D. M., S. Heaney, et al. (1997). "Different T helper cell types and antibody isotypes 
generated by saline and gene gun DNA immunization." J Immunol 158(5): 2278-84. 
 
Ferrone, S. and F. M. Marincola (1995). "Loss of HLA class I antigens by melanoma cells: 
molecular mechanisms, functional significance and clinical relevance." Immunol Today 16(10): 
487-94. 
 
Fifis, T., P. Mottram, et al. (2004). "Short peptide sequences containing MHC class I and/or 
class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of 
antigen-specific tumour challenge in mice." Vaccine 23(2): 258-66. 
 
Firat, H., F. Garcia-Pons, et al. (1999). "H-2 class I knockout, HLA-A2.1-transgenic mice: a 
versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies." 
Eur J Immunol 29(10): 3112-21. 
 
Flad, T., B. Spengler, et al. (1998). "Direct identification of major histocompatibility complex 
class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass 
spectrometric method." Cancer Res 58(24): 5803-11. 
 
Fong, L. and E. J. Small (2007). "Immunotherapy for prostate cancer." Curr Oncol Rep 9(3): 
226-33. 
 
Forastiere, A., W. Koch, et al. (2001). "Head and neck cancer." N Engl J Med 345(26): 1890-
900. 
 
Franco, A., D. A. Tilly, et al. (2000). "Epitope affinity for MHC class I determines helper 
requirement for CTL priming." Nat Immunol 1(2): 145-50. 
 
Fynan, E. F., R. G. Webster, et al. (1993). "DNA vaccines: protective immunizations by 
parenteral, mucosal, and gene-gun inoculations." Proc Natl Acad Sci U S A 90(24): 11478-82. 
 
Gallucci, S., M. Lolkema, et al. (1999). "Natural adjuvants: endogenous activators of dendritic 
cells." Nat Med 5(11): 1249-55. 
 
Gao, F. G., V. Khammanivong, et al. (2002). "Antigen-specific CD4+ T-cell help is required to 
activate a memory CD8+ T cell to a fully functional tumor killer cell." Cancer Res 62(22): 
6438-41. 
 
   218 
Garcia-Lora, A., I. Algarra, et al. (2003). "MHC class I antigens, immune surveillance, and 
tumor immune escape." J Cell Physiol 195(3): 346-55. 
 
Garrido, F., F. Ruiz-Cabello, et al. (1997). "Implications for immunosurveillance of altered 
HLA class I phenotypes in human tumours." Immunol Today 18(2): 89-95. 
 
Gilkeson, G. S., P. Ruiz, et al. (1996). "Modulation of renal disease in autoimmune NZB/NZW 
mice by immunization with bacterial DNA." J Exp Med 183(4): 1389-97. 
 
Girolomoni, G. and P. Ricciardi-Castagnoli (1997). "Dendritic cells hold promise for 
immunotherapy." Immunol Today 18(3): 102-4. 
 
Gjertsen, M. K., T. Buanes, et al. (2001). "Intradermal ras peptide vaccination with 
granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological 
responses in patients with pancreatic adenocarcinoma." Int J Cancer 92(3): 441-50. 
 
Godbout, R., M. Packer, et al. (1998). "Overexpression of a DEAD box protein (DDX1) in 
neuroblastoma and retinoblastoma cell lines." J Biol Chem 273(33): 21161-8. 
 
Godfrey, D. I., K. J. Hammond, et al. (2000). "NKT cells: facts, functions and fallacies." 
Immunol Today 21(11): 573-83. 
 
Goepel, J. R., R. C. Rees, et al. (1991). "Loss of monomorphic and polymorphic HLA antigens 
in metastatic breast and colon carcinoma." Br J Cancer 64(5): 880-3. 
 
Gold, J. S., C. R. Ferrone, et al. (2003). "A single heteroclitic epitope determines cancer 
immunity after xenogeneic DNA immunization against a tumor differentiation antigen." J 
Immunol 170(10): 5188-94. 
 
Goulmy, E. (1996). "Human minor histocompatibility antigens." Curr Opi Immunol 8: 75-81. 
 
Graeber, T. G., C. Osmanian, et al. (1996). "Hypoxia-mediated selection of cells with 
diminished apoptotic potential in solid tumours." Nature 379(6560): 88-91. 
 
Greenberg, M. E., R. Brackenbury, et al. (1984). "Changes in the distribution of the 34-kdalton 
tyrosine kinase substrate during differentiation and maturation of chicken tissues." J Cell Biol 
98(2): 473-86. 
 
Gregor, P. D., J. D. Wolchok, et al. (2004). "CTLA-4 blockade in combination with 
xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to 
self antigens in animal and cellular model systems." Vaccine 22(13-14): 1700-8. 
 
Gritzapis, A. D., L. G. Mahaira, et al. (2006). "Vaccination with human HER-2/neu (435-443) 
CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells 
in vivo." Cancer Res 66(10): 5452-60. 
 
Gudmundsdottir, I., J. Gunnlaugur Jonasson, et al. (2000). "Altered expression of HLA class I 
antigens in breast cancer: association with prognosis." Int J Cancer 89(6): 500-5. 
 
   219 
Guinn, B. A., E. M. Bertram, et al. (2001). "4-1BBL enhances anti-tumor responses in the 
presence or absence of CD28 but CD28 is required for protective immunity against parental 
tumors." Cell Immunol 210(1): 56-65. 
 
Guinn, B. A., M. A. DeBenedette, et al. (1999). "4-1BBL cooperates with B7-1 and B7-2 in 
converting a B cell lymphoma cell line into a long-lasting antitumor vaccine." J Immunol 
162(8): 5003-10. 
 
Guse, K., T. Ranki, et al. (2007). "Treatment of metastatic renal cancer with capsid-modified 
oncolytic adenoviruses." Mol Cancer Ther 6(10): 2728-36. 
 
Habib-Agahi, M., T. T. Phan, et al. (2007). "Co-stimulation with 4-1BB ligand allows 
extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells." 
Int Immunol. 
 
Hahne, M., D. Rimoldi, et al. (1996). "Melanoma cell expression of Fas(Apo-1/CD95) ligand: 
implications for tumor immune escape." Science 274(5291): 1363-6. 
 
Hakansson, P., D. Segal, et al. (2004). "Identification of genes differentially regulated by the 
P210 BCR/ABL1 fusion oncogene using cDNA microarrays." Exp Hematol 32(5): 476-82. 
 
Halder, T., G. Pawelec, et al. (1997). "Isolation of novel HLA-DR restricted potential tumor-
associated antigens from the melanoma cell line FM3." Cancer Res 57(15): 3238-44. 
 
Hambach, L. and E. Goulmy (2005). "Immunotherapy of cancer through targeting of minor 
histocompatibility antigens." Curr Opi Immunol 17: 202-210. 
 
Hanahan, D. and J. Folkman (1996). "Patterns and emerging mechanisms of the angiogenic 
switch during tumorigenesis." Cell 86(3): 353-64. 
 
Hanks, B. A., J. Jiang, et al. (2005). "Re-engineered CD40 receptor enables potent 
pharmacological activation of dendritic-cell cancer vaccines in vivo." Nat Med 11(2): 130-7. 
 
Harris, S. L. and A. J. Levine (2005). "The p53 pathway: positive and negative feedback 
loops." Oncogene 24(17): 2899-908. 
 
Haurum, J. S., I. B. Hoier, et al. (1999). "Presentation of cytosolic glycosylated peptides by 
human class I major histocompatibility complex molecules in vivo." J Exp Med 190(1): 145-50. 
 
Heiser, A., P. Dahm, et al. (2000). "Human dendritic cells transfected with RNA encoding 
prostate-specific antigen stimulate prostate-specific CTL responses in vitro." J Immunol 
164(10): 5508-14. 
 
Heuer, J. G., C. Tucker-McClung, et al. (1996). "Retrovirus-mediated gene transfer of B7-1 
and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic 
one." Hum Gene Ther 7(17): 2059-68. 
Huang, E. H., D. G. Heidt, et al. (2007). "Cancer stem cells: a new paradigm for understanding 
tumor progression and therapeutic resistance." Surgery 141(4): 415-9. 
 
   220 
Huckriede, A., L. Bungener, et al. (2004). "Induction of cytotoxic T lymphocyte activity by 
immunization with recombinant Semliki Forest virus: indications for cross-priming." Vaccine 
22(9-10): 1104-13. 
 
Hueman, M. T., A. Stojadinovic, et al. (2007). "Analysis of naive and memory CD4 and CD8 
T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF 
vaccine." Cancer Immunol Immunother 56(2): 135-46. 
 
Hurtado, J. C., S. H. Kim, et al. (1995). "Potential role of 4-1BB in T cell activation. 
Comparison with the costimulatory molecule CD28." J Immunol 155(7): 3360-7. 
 
Huttner, K. G., S. K. Breuer, et al. (2005). "Generation of potent anti-tumor immunity in mice 
by interleukin-12-secreting dendritic cells." Cancer Immunol Immunother 54(1): 67-77. 
 
Ichihara, F., K. Kono, et al. (2003). "Increased populations of regulatory T cells in peripheral 
blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers." Clin 
Cancer Res 9(12): 4404-8. 
 
Ikeda, H., L. J. Old, et al. (2002). "The roles of IFN gamma in protection against tumor 
development and cancer immunoediting." Cytokine Growth Factor Rev 13(2): 95-109. 
 
Inaba, K., M. Inaba, et al. (1992). "Generation of large numbers of dendritic cells from mouse 
bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor." 
J Exp Med 176(6): 1693-702. 
 
Ivry, G. B., C. A. Ogle, et al. (2006). "Role of sun exposure in melanoma." Dermatol Surg 
32(4): 481-92. 
 
Iwasaki, A., B. J. Stiernholm, et al. (1997). "Enhanced CTL responses mediated by plasmid 
DNA immunogens encoding costimulatory molecules and cytokines." J Immunol 158(10): 
4591-601. 
 
Jager, E., S. Gnjatic, et al. (2000). "Induction of primary NY-ESO-1 immunity: CD8+ T 
lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers." 
Proc Natl Acad Sci U S A 97(22): 12198-203. 
 
Jager, E., Y. Nagata, et al. (2000). "Monitoring CD8 T cell responses to NY-ESO-1: 
correlation of humoral and cellular immune responses." Proc Natl Acad Sci U S A 97(9): 4760-
5. 
 
Jager, E., M. Ringhoffer, et al. (1996). "Granulocyte-macrophage-colony-stimulating factor 
enhances immune responses to melanoma-associated peptides in vivo." Int J Cancer 67(1): 54-
62. 
 
Janetzki, S., D. Palla, et al. (2000). "Immunization of cancer patients with autologous cancer-
derived heat shock protein gp96 preparations: a pilot study." Int J Cancer 88(2): 232-8. 
 
Janeway, C. (1991). "Immune recognition. Mls: makes a little sense." Nature 349(6309): 459-
61. 
 
   221 
Jariel-Encontre, I., M. Pariat, et al. (1995). "Ubiquitinylation is not an absolute requirement for 
degradation of c-Jun protein by the 26 S proteasome." J Biol Chem 270(19): 11623-7. 
 
Ji, H., T. L. Wang, et al. (1999). "Targeting human papillomavirus type 16 E7 to the 
endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against 
murine human papillomavirus type 16 E7-expressing tumors." Hum Gene Ther 10(17): 2727-
40. 
 
Johnson, L. A., B. Heemskerk, et al. (2006). "Gene transfer of tumor-reactive TCR confers 
both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and 
tumor-infiltrating lymphocytes." J Immunol 177(9): 6548-59. 
 
June, C. H. (2007). "Adoptive T cell therapy for cancer in the clinic." J Clin Invest 117(6): 
1466-76. 
 
Kalkanidis, M., G. A. Pietersz, et al. (2006). "Methods for nano-particle based vaccine 
formulation and evaluation of their immunogenicity." Methods 40(1): 20-9. 
 
Kao, J. Y., M. Zhang, et al. (2006). "Aberrant T helper cell response in tumor-bearing mice 
limits the efficacy of dendritic cell vaccine." Immunol Lett 105(1): 16-25. 
 
Karin, M. and F. R. Greten (2005). "NF-kappaB: linking inflammation and immunity to cancer 
development and progression." Nat Rev Immunol 5(10): 749-59. 
 
Karpinets, T. V. and B. D. Foy (2005). "Tumorigenesis: the adaptation of mammalian cells to 
sustained stress environment by epigenetic alterations and succeeding matched mutations." 
Carcinogenesis 26(8): 1323-34. 
 
Kawaida, H., K. Kono, et al. (2005). "Distribution of CD4+CD25high regulatory T-cells in 
tumor-draining lymph nodes in patients with gastric cancer." J Surg Res 124(1): 151-7. 
 
Kawakami, Y., S. Eliyahu, et al. (1994). "Cloning of the gene coding for a shared human 
melanoma antigen recognized by autologous T cells infiltrating into tumor." Proc Natl Acad 
Sci U S A 91(9): 3515-9. 
 
Kay, M. A., J. C. Glorioso, et al. (2001). "Viral vectors for gene therapy: the art of turning 
infectious agents into vehicles of therapeutics." Nat Med 7(1): 33-40. 
 
Khong, H. T. and N. P. Restifo (2002). "Natural selection of tumor variants in the generation of 
"tumor escape" phenotypes." Nat Immunol 3(11): 999-1005. 
 
Kim, J. H., S. C. Chu, et al. (2005). "Activation of the PI3K/mTOR pathway by BCR-ABL 
contributes to increased production of reactive oxygen species." Blood 105(4): 1717-23. 
 
Kim, J. J. and I. F. Tannock (2005). "Repopulation of cancer cells during therapy: an important 
cause of treatment failure." Nat Rev Cancer 5(7): 516-25. 
 
Kloetzel, P. M. and F. Ossendorp (2004). "Proteasome and peptidase function in MHC-class-I-
mediated antigen presentation." Curr Opin Immunol 16(1): 76-81. 
 
   222 
Knudson, A. G. (2001). "Two genetic hits (more or less) to cancer." Nat Rev Cancer 1(2): 157-
62. 
 
Knutson, K. L., K. Schiffman, et al. (2001). "Immunization with a HER-2/neu helper peptide 
vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients." J Clin Invest 107(4): 
477-84. 
 
Koenig, S., R. M. Woods, et al. (1993). "Characterization of MHC class I restricted cytotoxic T 
cell responses to tax in HTLV-1 infected patients with neurologic disease." J Immunol 151(7): 
3874-83. 
 
Koziel, M. J., D. Dudley, et al. (1995). "HLA class I-restricted cytotoxic T lymphocytes 
specific for hepatitis C virus. Identification of multiple epitopes and characterization of 
patterns of cytokine release." J Clin Invest 96(5): 2311-21. 
 
Krammer, P. H. (2000). "CD95's deadly mission in the immune system." Nature 407(6805): 
789-95. 
 
Kronfeld, K., H. Abken, et al. (2005). "B7-1 and B7-2 act differentially in the induction of a T 
cell response: their impact for a HLA-matched and HLA-mismatched anti-tumor 
immunotherapy." Int J Cancer 117(5): 794-9. 
 
Kugler, A., G. Stuhler, et al. (2000). "Regression of human metastatic renal cell carcinoma 
after vaccination with tumor cell-dendritic cell hybrids." Nat Med 6(3): 332-6. 
 
Kwissa, M., K. von Kampen, et al. (2000). "Efficient vaccination by intradermal or 
intramuscular inoculation of plasmid DNA expressing hepatitis B surface antigen under desmin 
promoter/enhancer control." Vaccine 18(22): 2337-44. 
 
Lai, P., H. Rabinowich, et al. (1996). "Alterations in expression and function of signal-
transducing proteins in tumor-associated T and natural killer cells in patients with ovarian 
carcinoma." Clin Cancer Res 2(1): 161-73. 
 
Lee, K. H., E. Wang, et al. (1999). "Increased vaccine-specific T cell frequency after peptide-
based vaccination correlates with increased susceptibility to in vitro stimulation but does not 
lead to tumor regression." J Immunol 163(11): 6292-300. 
 
Lehmann, C., M. Zeis, et al. (2000). "Impaired binding of perforin on the surface of tumor cells 
is a cause of target cell resistance against cytotoxic effector cells." Blood 96(2): 594-600. 
 
Lejeune, F. J., C. Ruegg, et al. (1998). "Clinical applications of TNF-alpha in cancer." Curr 
Opin Immunol 10(5): 573-80. 
 
Levine, A. J. (1997). "p53, the cellular gatekeeper for growth and division." Cell 88(3): 323-31. 
 
Levy, F., L. Burri, et al. (2002). "The final N-terminal trimming of a subaminoterminal 
proline-containing HLA class I-restricted antigenic peptide in the cytosol is mediated by two 
peptidases." J Immunol 169(8): 4161-71. 
 
   223 
Li, Z., J. Dai, et al. (2002). "An integrated view of the roles and mechanisms of heat shock 
protein gp96-peptide complex in eliciting immune response." Front Biosci 7: d731-51. 
 
Liljestrom, P. and H. Garoff (1991). "A new generation of animal cell expression vectors based 
on the Semliki Forest virus replicon." Biotechnology (N Y) 9(12): 1356-61. 
 
Lin, C. T., Y. C. Tsai, et al. (2007). "DNA vaccines encoding IL-2 linked to HPV-16 E7 
antigen generate enhanced E7-specific CTL responses and antitumor activity." Immunol Lett. 
 
Lindinger, P., S. Mostbock, et al. (2003). "Induction of murine ras oncogene peptide-specific T 
cell responses by immunization with plasmid DNA-based minigene vectors." Vaccine 21(27-
30): 4285-96. 
 
Linke, S. P., K. C. Clarkin, et al. (1996). "A reversible, p53-dependent G0/G1 cell cycle arrest 
induced by ribonucleotide depletion in the absence of detectable DNA damage." Genes Dev 
10(8): 934-47. 
 
Lipsitch, M., C. T. Bergstrom, et al. (2003). "Effect of human leukocyte antigen heterozygosity 
on infectious disease outcome: the need for allele-specific measures." BMC Med Genet 4: 2. 
 
Liu, M., B. Acres, et al. (2004). "Gene-based vaccines and immunotherapeutics." Proc Natl 
Acad Sci U S A 101 Suppl 2: 14567-71. 
 
Lodge, P. A., L. A. Jones, et al. (2000). "Dendritic cell-based immunotherapy of prostate 
cancer: immune monitoring of a phase II clinical trial." Cancer Res 60(4): 829-33. 
 
Lossos, I. S., D. K. Czerwinski, et al. (2003). "Optimization of quantitative real-time RT-PCR 
parameters for the study of lymphoid malignancies." Leukemia 17(4): 789-95. 
 
Lucas, L., V. Penalva, et al. (2002). "Modulation of phospholipase D by Ras proteins mediated 
by its effectors Ral-GDS, PI3K and Raf-1." Int J Oncol 21(3): 477-85. 
 
Ludewig, B., K. McCoy, et al. (2001). "Rapid peptide turnover and inefficient presentation of 
exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells." J 
Immunol 166(6): 3678-87. 
 
Lundstrom, K. (2003). "Semliki Forest virus vectors for gene therapy." Expert Opin Biol Ther 
3(5): 771-7. 
 
Lundstrom, K. and T. Boulikas (2003). "Viral and non-viral vectors in gene therapy: 
technology development and clinical trials." Technol Cancer Res Treat 2(5): 471-86. 
 
Ma, J. H., Y. F. Sui, et al. (2005). "Heat shock protein 70/MAGE-3 fusion protein vaccine can 
enhance cellular and humoral immune responses to MAGE-3 in vivo." Cancer Immunol 
Immunother 54(9): 907-14. 
 
Maccalli, C., P. Pisarra, et al. (1999). "Differential loss of T cell signaling molecules in 
metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions." 
J Immunol 163(12): 6912-23. 
 
   224 
Mackay, J. and L. Williams (2003). "American Association for Cancer Research--94th Annual 
Meeting. New compounds. 11-14 July 2003, Washington, DC, USA." IDrugs 6(8): 733-5. 
 
Mahdavi, A. and B. J. Monk (2005). "Vaccines against human papillomavirus and cervical 
cancer: promises and challenges." Oncologist 10(7): 528-38. 
 
Malik, D. K., S. Baboota, et al. (2007). "Recent advances in protein and peptide drug delivery 
systems." Curr Drug Deliv 4(2): 141-51. 
 
Malmberg, K.J., R. Lenkei, et al. (2002). A short-term dietary supplementation of high doses 
of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal 
cancer. Clin Cancer Res, 8, 1772-8. 
 
Marchand, M., N. van Baren, et al. (1999). "Tumor regressions observed in patients with 
metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and 
presented by HLA-A1." Int J Cancer 80(2): 219-30. 
 
Marincola, F. M., E. M. Jaffee, et al. (2000). "Escape of human solid tumors from T-cell 
recognition: molecular mechanisms and functional significance." Adv Immunol 74: 181-273. 
 
Martelange, V., C. De Smet, et al. (2000). "Identification on a human sarcoma of two new 
genes with tumor-specific expression." Cancer Res 60(14): 3848-55. 
 
Martin, G. S. (1970). "Rous sarcoma virus: a function required for the maintenance of the 
transformed state." Nature 227(5262): 1021-3. 
 
Martin, G. S. (2004). "The road to Src." Oncogene 23(48): 7910-7. 
 
Mathieu, M. G., A. J. Knights, et al. (2007). "HAGE, a cancer/testis antigen with potential for 
melanoma immunotherapy: identification of several MHC class I/II HAGE-derived 
immunogenic peptides." Cancer Immunol Immunother 56(12): 1885-95. 
 
McDevitt, H. O. (2000). "Discovering the role of the major histocompatibility complex in the 
immune response." Annu Rev Immunol 18: 1-17. 
 
McKallip, R., R. Li, et al. (1999). "Tumor gangliosides inhibit the tumor-specific immune 
response." J Immunol 163(7): 3718-26. 
 
Medema, J. P., J. de Jong, et al. (2001). "Blockade of the granzyme B/perforin pathway 
through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for 
immune escape by tumors." Proc Natl Acad Sci U S A 98(20): 11515-20. 
 
Milde-Langosch, K., A. M. Bamberger, et al. (2005). "Expression and prognostic relevance of 
activated extracellular-regulated kinases (ERK1/2) in breast cancer." Br J Cancer 92(12): 2206-
15. 
 
Miles, A. K., A. Rogers, et al. (2007). "Identification of a novel prostate cancer-associated 
tumor antigen." Prostate 67(3): 274-87. 
 
   225 
Mine, T., Y. Sato, et al. (2004). "Humoral responses to peptides correlate with overall survival 
in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific 
cellular responses." Clin Cancer Res 10(3): 929-37. 
 
Mohamadzadeh, M., F. Berard, et al. (2001). "Interleukin 15 skews monocyte differentiation 
into dendritic cells with features of Langerhans cells." J Exp Med 194(7): 1013-20. 
 
Mohanty, K., A. Saha, et al. (2007). "Anti-tumor immunity induced by an anti-idiotype 
antibody mimicking human Her-2/neu." Breast Cancer Res Treat 104(1): 1-11. 
 
Moretta, L., M. C. Mingari, et al. (1996). "The molecular basis of natural killer (NK) cell 
recognition and function." J Clin Immunol 16(5): 243-53. 
 
Morgan, R. A., M. E. Dudley, et al. (2006). "Cancer regression in patients after transfer of 
genetically engineered lymphocytes." Science 314(5796): 126-9. 
 
Morgan, R. A., M. E. Dudley, et al. (2003). "High efficiency TCR gene transfer into primary 
human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and 
does not alter the recognition of autologous melanoma antigens." J Immunol 171(6): 3287-95. 
 
Moyer, J. S., G. Maine, et al. (2006). "Early vaccination with tumor-lysate-pulsed dendritic 
cells after allogeneic bone marrow transplantation has antitumor effects." Biol Blood Marrow 
Transplant 12(10): 1010-9. 
 
Muller, L., R. Kiessling, et al. (2002). "Escape mechanisms in tumor immunity: an update." J 
Environ Pathol Toxicol Oncol 21(4): 277-330. 
 
Munn, D. H. and A. L. Mellor (2007). "Indoleamine 2,3-dioxygenase and tumor-induced 
tolerance." J Clin Invest 117(5): 1147-54. 
Murnane, J. P. (2006). "Telomeres and chromosome instability." DNA Repair (Amst) 5(9-10): 
1082-92. 
 
Murphy, G., B. Tjoa, et al. (1996). "Phase I clinical trial: T-cell therapy for prostate cancer 
using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-
specific membrane antigen." Prostate 29(6): 371-80. 
 
Murray, R. J., M. G. Kurilla, et al. (1992). "Identification of target antigens for the human 
cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of 
EBV-positive malignancies." J Exp Med 176(1): 157-68. 
 
Murugaiyan, G., S. Martin, et al. (2007). "Levels of CD40 expression on dendritic cells dictate 
tumour growth or regression." Clin Exp Immunol 149(1): 194-202. 
 
Nagel, H., R. Laskawi, et al. (2003). "Analysis of the tumour suppressor genes, FHIT and WT-
1, and the tumour rejection genes, BAGE, GAGE-1/2, HAGE, MAGE-1, and MAGE-3, in 
benign and malignant neoplasms of the salivary glands." Mol Pathol 56(4): 226-31. 
 
Napolitani, G., A. Rinaldi, et al. (2005). "Selected Toll-like receptor agonist combinations 
synergistically trigger a T helper type 1-polarizing program in dendritic cells." Nat Immunol 
6(8): 769-76. 
   226 
 
Neefjes, J. J. and F. Momburg (1993). "Cell biology of antigen presentation." Curr Opin 
Immunol 5(1): 27-34. 
 
Ni, B., Z. Lin, et al. (2004). "Induction of P815 tumor immunity by DNA-based recombinant 
Semliki Forest virus or replicon DNA expressing the P1A gene." Cancer Detect Prev 28(6): 
418-25. 
 
Nichols, W. W., B. J. Ledwith, et al. (1995). "Potential DNA vaccine integration into host cell 
genome." Ann N Y Acad Sci 772: 30-9. 
 
Nieda, M., A. Nicol, et al. (1998). "Dendritic cells stimulate the expansion of bcr-abl specific 
CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid 
leukemia." Blood 91(3): 977-83. 
 
Nikolic-Zugic, J. and F. R. Carbone (1991). "Peptide presentation by class-I major 
histocompatibility complex molecules." Immunol Res 10(1): 54-65. 
 
Nishikawa, H., T. Kato, et al. (2005). "IFN-gamma controls the generation/activation of CD4+ 
CD25+ regulatory T cells in antitumor immune response." J Immunol 175(7): 4433-40. 
 
Nishikawa, H., K. Tanida, et al. (2001). "Role of SEREX-defined immunogenic wild-type 
cellular molecules in the development of tumor-specific immunity." Proc Natl Acad Sci U S A 
98(25): 14571-6. 
 
O'Connell, J., M. W. Bennett, et al. (1999). "Expression of Fas (CD95/APO-1) ligand by 
human breast cancers: significance for tumor immune privilege." Clin Diagn Lab Immunol 
6(4): 457-63. 
 
Ohba, H., Z. Zhelev, et al. (2004). "Inhibition of bcr-abl and/or c-abl gene expression by small 
interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other 
oncogenes." Cancer 101(6): 1390-403. 
 
Orabona, C., U. Grohmann, et al. (2004). "CD28 induces immunostimulatory signals in 
dendritic cells via CD80 and CD86." Nat Immunol 5(11): 1134-42. 
Ortmann, B., J. Copeman, et al. (1997). "A critical role for tapasin in the assembly and 
function of multimeric MHC class I-TAP complexes." Science 277(5330): 1306-9. 
 
Ostrand-Rosenberg, S. (2004). "Animal models of tumor immunity, immunotherapy and 
cancer vaccines." Curr Opin Immunol 16(2): 143-50. 
 
O'Sullivan, B. and R. Thomas (2003). "Recent advances on the role of CD40 and dendritic 
cells in immunity and tolerance." Curr Opin Hematol 10(4): 272-8. 
 
Palmowski, M. J., E. M. Choi, et al. (2002). "Competition between CTL narrows the immune 
response induced by prime-boost vaccination protocols." J Immunol 168(9): 4391-8. 
 
Papamichail, M., S. A. Perez, et al. (2004). "Natural killer lymphocytes: biology, development, 
and function." Cancer Immunol Immunother 53(3): 176-86. 
 
   227 
Parada, L. F., C. J. Tabin, et al. (1982). "Human EJ bladder carcinoma oncogene is homologue 
of Harvey sarcoma virus ras gene." Nature 297(5866): 474-8. 
 
Pardoll, D. M. (1998). "Cancer vaccines." Nat Med 4(5 Suppl): 525-31. 
 
Park, J. H., C. J. Kim, et al. (1999). "Effective immunotherapy of cancer by DNA vaccination." 
Mol Cells 9(4): 384-91. 
 
Parmiani, G., M. Rodolfo, et al. (2000). "Immunological gene therapy with ex vivo gene-
modified tumor cells: a critique and a reappraisal." Hum Gene Ther 11(9): 1269-75. 
 
Paschen, A., R. M. Mendez, et al. (2003). "Complete loss of HLA class I antigen expression on 
melanoma cells: a result of successive mutational events." Int J Cancer 103(6): 759-67. 
 
Pavlenko, M., A. K. Roos, et al. (2004). "A phase I trial of DNA vaccination with a plasmid 
expressing prostate-specific antigen in patients with hormone-refractory prostate cancer." Br J 
Cancer 91(4): 688-94. 
 
Pegram, M. D., A. Lipton, et al. (1998). "Phase II study of receptor-enhanced chemosensitivity 
using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in 
patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy 
treatment." J Clin Oncol 16(8): 2659-71. 
 
Peng, B. G., Q. He, et al. (2006). "Induction of cytotoxic T-lymphocyte responses using 
dendritic cells transfected with hepatocellular carcinoma mRNA." Br J Biomed Sci 63(3): 123-
8. 
 
Peng, G., Z. Guo, et al. (2005). "Toll-like receptor 8-mediated reversal of CD4+ regulatory T 
cell function." Science 309(5739): 1380-4. 
 
Peters, J.A. (1997). "Applications of genetic technologies to cancer screening, prevention, 
diagnosis, prognosis, and treatment." Semin Oncol Nurs 13(2): 74-81.  
 
Phan, G. Q., J. C. Yang, et al. (2003). "Cancer regression and autoimmunity induced by 
cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma." 
Proc Natl Acad Sci U S A 100(14): 8372-7. 
 
Pignatari G. C., D. Takeshita, et al. (2007). "Carcinoembryonic antigen (CEA) mimicry by an 
anti-idiotypic scFv isolated from anti-Id 6.C4 hybridoma." J Biotechnol 127(4): 615-625. 
 
Pinilla-Ibarz, J., K. Cathcart, et al. (2000). "CML vaccines as a paradigm of the specific 
immunotherapy of cancer." Blood Rev 14(2): 111-20. 
 
Pinilla-Ibarz, J., T. Korontsvit, et al. (2005). "Synthetic peptide analogs derived from bcr/abl 
fusion proteins and the induction of heteroclitic human T-cell responses." Haematologica 
90(10): 1324-32. 
 
Pisetsky, D. S. (1996). "The immunologic properties of DNA." J Immunol 156(2): 421-3. 
 
   228 
Plunkett, T. A. and D. W. Miles (2002). "13. New biological therapies for breast cancer." Int J 
Clin Pract 56(4): 261-6. 
 
Ponzielli, R., S. Katz, et al. (2005). "Cancer therapeutics: targeting the dark side of Myc." Eur J 
Cancer 41(16): 2485-501. 
 
Rafiq, K., A. Bergtold, et al. (2002). "Immune complex-mediated antigen presentation induces 
tumor immunity." J Clin Invest 110(1): 71-9. 
 
Rakhmilevich, A. L., M. Imboden, et al. (2001). "Effective particle-mediated vaccination 
against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and 
granulocyte-macrophage colony-stimulating factor." Clin Cancer Res 7(4): 952-61. 
 
Ramakrishna, V., M. M. Ross, et al. (2003). "Naturally occurring peptides associated with 
HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-
restricted cytotoxic T cells." Int Immunol 15(6): 751-63. 
 
Reche, P. A. and E. L. Reinherz (2003). "Sequence variability analysis of human class I and 
class II MHC molecules: functional and structural correlates of amino acid polymorphisms." J 
Mol Biol 331(3): 623-41. 
 
Reits, E. A., J. C. Vos, et al. (2000). "The major substrates for TAP in vivo are derived from 
newly synthesized proteins." Nature 404(6779): 774-8. 
 
Restifo, N. P., Y. Kawakami, et al. (1993). "Molecular mechanisms used by tumors to escape 
immune recognition: immunogenetherapy and the cell biology of major histocompatibility 
complex class I." J Immunother Emphasis Tumor Immunol 14(3): 182-90. 
 
Reya, T., S. J. Morrison, et al. (2001). "Stem cells, cancer, and cancer stem cells." Nature 
414(6859): 105-11. 
 
Ridge, J. P., F. Di Rosa, et al. (1998). "A conditioned dendritic cell can be a temporal bridge 
between a CD4+ T-helper and a T-killer cell." Nature 393(6684): 474-8. 
 
Riezebos-Brilman, A., J. Regts, et al. (2005). "Induction of human papilloma virus E6/E7-
specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice." Gene 
Ther 12(18): 1410-4. 
 
Rizzuto, G., M. Cappelletti, et al. (1999). "Efficient and regulated erythropoietin production by 
naked DNA injection and muscle electroporation." Proc Natl Acad Sci U S A 96(11): 6417-22. 
 
Robertson, N.J., J. Chai, et al. (2007). "Natural regulation of immunity to minor 
histocompatibility antigens." J Immunol 178: 3558-65. 
 
Rocak, S. and P. Linder (2004). "DEAD-box proteins: the driving forces behind RNA 
metabolism." Nat Rev Mol Cell Biol 5(3): 232-41. 
 
Rogel, A., M. Popliker, et al. (1985). "p53 cellular tumor antigen: analysis of mRNA levels in 
normal adult tissues, embryos, and tumors." Mol Cell Biol 5(10): 2851-5. 
 
   229 
Rojas, J. M., S. E. McArdle, et al. (2005). "Peptide immunisation of HLA-DR-transgenic mice 
permits the identification of a novel HLA-DRbeta1*0101- and HLA-DRbeta1*0401-restricted 
epitope from p53." Cancer Immunol Immunother 54(3): 243-53. 
 
Roman-Gomez, J., A. Jimenez-Velasco, et al. (2007). "Epigenetic regulation of human 
cancer/testis antigen gene, HAGE, in chronic myeloid leukemia." Haematologica 92(2): 153-62. 
 
Romanov, S. R., B. K. Kozakiewicz, et al. (2001). "Normal human mammary epithelial cells 
spontaneously escape senescence and acquire genomic changes." Nature 409(6820): 633-7. 
 
Romero, P., J. C. Cerottini, et al. (2004). "Monitoring tumor antigen specific T-cell responses 
in cancer patients and phase I clinical trials of peptide-based vaccination." Cancer Immunol 
Immunother 53(3): 249-55. 
 
Roper, R. L. and R. P. Phipps (1994). "Prostaglandin E2 regulation of the immune response." 
Adv Prostaglandin Thromboxane Leukot Res 22: 101-11. 
 
Rosenberg, S. A. and M. E. Dudley (2004). "Cancer regression in patients with metastatic 
melanoma after the transfer of autologous antitumor lymphocytes." Proc Natl Acad Sci U S A 
101 Suppl 2: 14639-45. 
 
Rosenberg, S. A., J. C. Yang, et al. (2004). "Cancer immunotherapy: moving beyond current 
vaccines." Nat Med 10(9): 909-15. 
 
Rosenberg, S. A., J. C. Yang, et al. (1998). "Immunologic and therapeutic evaluation of a 
synthetic peptide vaccine for the treatment of patients with metastatic melanoma." Nat Med 
4(3): 321-7. 
 
Rosenberg, S. A., J. R. Yannelli, et al. (1994). "Treatment of patients with metastatic 
melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2." J Natl Cancer 
Inst 86(15): 1159-66. 
 
Rosenblatt, J., D. Kufe, et al. (2005). "Dendritic cell fusion vaccines for cancer 
immunotherapy." Expert Opin Biol Ther 5(5): 703-15. 
 
Rudensky, A., P. Preston-Hurlburt, et al. (1991). "Sequence analysis of peptides bound to 
MHC class II molecules." Nature 353(6345): 622-7. 
 
Ruffini, P. A., S. S. Neelapu, et al. (2002). "Idiotypic vaccination for B-cell malignancies as a 
model for therapeutic cancer vaccines: from prototype protein to second generation vaccines." 
Haematologica 87(9): 989-1001. 
 
Ruiz-Godoy, L., L. Suarez, et al. (2007). "Polymorphous low-grade adenocarcinoma of the 
parotid gland. Case report and review of the literature." Med Oral Patol Oral Cir Bucal 12(1): 
E30-3. 
 
Ryan, M. H., J. A. Bristol, et al. (2001). "Regression of extensive pulmonary metastases in 
mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells 
expressing a naturally occurring rejection epitope." J Immunol 167(8): 4286-92. 
 
   230 
Saito, T. and S. Yamasaki (2003). "Negative feedback of T cell activation through inhibitory 
adapters and costimulatory receptors." Immunol Rev 192: 143-60. 
 
Saoulli, K., S. Y. Lee, et al. (1998). "CD28-independent, TRAF2-dependent costimulation of 
resting T cells by 4-1BB ligand." J Exp Med 187(11): 1849-62. 
 
Sasaki, H., S. Moriyama, et al. (2003). "SAGE mRNA expression in advanced-stage lung 
cancers." Eur J Surg Oncol 29(10): 900-3. 
 
Scanlan, M. J., A. J. Simpson, et al. (2004). "The cancer/testis genes: review, standardization, 
and commentary." Cancer Immun 4: 1. 
 
Schadendorf, D., F. Belardelli, et al. (2000). "Conference on cancer vaccines." Cancer 
Immunol Immunother 49(4-5): 281-4. 
 
Schartner, J. M., A. R. Hagar, et al. (2005). "Impaired capacity for upregulation of MHC class 
II in tumor-associated microglia." Glia 51(4): 279-85. 
 
Schattner, E. J., J. Mascarenhas, et al. (1996). "CD4+ T-cell induction of Fas-mediated 
apoptosis in Burkitt's lymphoma B cells." Blood 88(4): 1375-82. 
 
Schirle, M., W. Keilholz, et al. (2000). "Identification of tumor-associated MHC class I ligands 
by a novel T cell-independent approach." Eur J Immunol 30(8): 2216-25. 
 
Schoenberger, S. P., L. E. Jonges, et al. (1998). "Efficient direct priming of tumor-specific 
cytotoxic T lymphocyte in vivo by an engineered APC." Cancer Res 58(14): 3094-100. 
 
Scholl, F. A., P. A. Dumesic, et al. (2005). "Effects of active MEK1 expression in vivo." 
Cancer Lett 230(1): 1-5. 
 
Schreiber, S., E. Kampgen, et al. (1999). "Immunotherapy of metastatic malignant melanoma 
by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a 
phase I study." Hum Gene Ther 10(6): 983-93. 
 
Seong, S. Y. and P. Matzinger (2004). "Hydrophobicity: an ancient damage-associated 
molecular pattern that initiates innate immune responses." Nat Rev Immunol 4(6): 469-78. 
 
Shedlock, D. J. and H. Shen (2003). "Requirement for CD4 T cell help in generating functional 
CD8 T cell memory." Science 300(5617): 337-9. 
 
Shi, Y., J. E. Evans, et al. (2003). "Molecular identification of a danger signal that alerts the 
immune system to dying cells." Nature 425(6957): 516-21. 
 
Shiina, T., H. Inoko, et al. (2004). "An update of the HLA genomic region, locus information 
and disease associations: 2004." Tissue Antigens 64(6): 631-49. 
 
Siena, S., M. Di Nicola, et al. (1995). "Massive ex vivo generation of functional dendritic cells 
from mobilized CD34+ blood progenitors for anticancer therapy." Exp Hematol 23(14): 1463-
71. 
 
   231 
Silverman E., G. Edwalds-Gilbert, et al. (2003). "DExD/H-box proteins and their partners: 
helping RNA helicases unwind." Gene 312: 1-16. 
 
Skipper, J. C., R. C. Hendrickson, et al. (1996). "An HLA-A2-restricted tyrosinase antigen on 
melanoma cells results from posttranslational modification and suggests a novel pathway for 
processing of membrane proteins." J Exp Med 183(2): 527-34. 
 
Smahel, M., P. Sima, et al. (2001). "Modified HPV16 E7 Genes as DNA Vaccine against E7-
Containing Oncogenic Cells." Virology 281(2): 231-8. 
 
Smith, C. M., N. S. Wilson, et al. (2004). "Cognate CD4(+) T cell licensing of dendritic cells 
in CD8(+) T cell immunity." Nat Immunol 5(11): 1143-8. 
 
Smith, E. S., A. Mandokhot, et al. (2001). "Lethality-based selection of recombinant genes in 
mammalian cells: application to identifying tumor antigens." Nat Med 7(8): 967-72. 
 
Smyth, M. J., M. E. Wallace, et al. (2005). "Sequential activation of NKT cells and NK cells 
provides effective innate immunotherapy of cancer." J Exp Med 201(12): 1973-85. 
 
Srivastava, P. K., A. Menoret, et al. (1998). "Heat shock proteins come of age: primitive 
functions acquire new roles in an adaptive world." Immunity 8(6): 657-65. 
 
Stevenson, F. K., C. H. Ottensmeier, et al. (2004). "DNA vaccines to attack cancer." Proc Natl 
Acad Sci U S A 101 Suppl 2: 14646-52. 
 
Storkus, W. J., H. J. Zeh, 3rd, et al. (1993). "Identification of T-cell epitopes: rapid isolation of 
class I-presented peptides from viable cells by mild acid elution." J Immunother Emphasis 
Tumor Immunol 14(2): 94-103. 
 
Street, M. D., T. Doan, et al. (2002). "Limitations of HLA-transgenic mice in presentation of 
HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus 
type 16 E7 protein." Immunology 106(4): 526-36. 
 
Stripecke, R., R. C. Koya, et al. (2003). "The use of lentiviral vectors in gene therapy of 
leukemia: combinatorial gene delivery of immunomodulators into leukemia cells by state-of-
the-art vectors." Blood Cells Mol Dis 31(1): 28-37. 
 
Sun, Y., K. Jurgovsky, et al. (1998). "Vaccination with IL-12 gene-modified autologous 
melanoma cells: preclinical results and a first clinical phase I study." Gene Ther 5(4): 481-90. 
 
Tanaka, K., K. J. Isselbacher, et al. (1985). "Reversal of oncogenesis by the expression of a 
major histocompatibility complex class I gene." Science 228(4695): 26-30. 
 
Tanaka, M., Y. Kaneda, et al. (2002). "Induction of a systemic immune response by a 
polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of 
malignant melanoma." Mol Ther 5(3): 291-9. 
Tanaka, M., T. Suda, et al. (1996). "Fas ligand in human serum." Nat Med 2(3): 317-22. 
Terabe, M., S. Matsui, et al. (2000). "NKT cell-mediated repression of tumor 
immunosurveillance by IL-13 and the IL-4R-STAT6 pathway." Nat Immunol 1(6): 515-20. 
 
   232 
Theobald, M., J. Biggs, et al. (1995). "Targeting p53 as a general tumor antigen." Proc Natl 
Acad Sci U S A 92(26): 11993-7. 
 
Theobald, M., J. Biggs, et al. (1997). "Tolerance to p53 by A2.1-restricted cytotoxic T 
lymphocytes." J Exp Med 185(5): 833-41. 
 
Thomas, W. D. and P. Hersey (1998). "TNF-related apoptosis-inducing ligand (TRAIL) 
induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of 
target cells." J Immunol 161(5): 2195-200. 
 
Thornton, A. M. and E. M. Shevach (1998). "CD4+CD25+ immunoregulatory T cells suppress 
polyclonal T cell activation in vitro by inhibiting interleukin 2 production." J Exp Med 188(2): 
287-96. 
 
Thurner, B., I. Haendle, et al. (1999). "Vaccination with mage-3A1 peptide-pulsed mature, 
monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of 
some metastases in advanced stage IV melanoma." J Exp Med 190(11): 1669-78. 
 
Tine, J. A., H. Firat, et al. (2005). "Enhanced multiepitope-based vaccines elicit CD8+ 
cytotoxic T cells against both immunodominant and cryptic epitopes." Vaccine 23(8): 1085-91. 
 
Tite, J. P. (1990). "Evidence of a role for TNF-alpha in cytolysis by CD4+, class II MHC-
restricted cytotoxic T cells." Immunology 71(2): 208-12. 
 
Torres, C. A., A. Iwasaki, et al. (1997). "Differential dependence on target site tissue for gene 
gun and intramuscular DNA immunizations." J Immunol 158(10): 4529-32. 
 
Touloukian, C. E., W. W. Leitner, et al. (2000). "Identification of a MHC class II-restricted 
human gp100 epitope using DR4-IE transgenic mice." J Immunol 164(7): 3535-42. 
 
Traversari, C., P. van der Bruggen, et al. (1992). "A nonapeptide encoded by human gene 
MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen 
MZ2-E." J Exp Med 176(5): 1453-7. 
 
Tsang, K. Y., S. Zaremba, et al. (1995). "Generation of human cytotoxic T cells specific for 
human carcinoembryonic antigen epitopes from patients immunized with recombinant 
vaccinia-CEA vaccine." J Natl Cancer Inst 87(13): 982-90. 
 
Tsiambas, E., A. Karameris, et al. (2006). "HER2/neu expression and gene alterations in 
pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in 
situ hybridization study based on tissue microarrays and computerized image analysis." Jop 
7(3): 283-94. 
 
Tsung, K., J. P. Dolan, et al. (2002). "Macrophages as effector cells in interleukin 12-induced 
T cell-dependent tumor rejection." Cancer Res 62(17): 5069-75. 
 
Tsung, K., J. B. Meko, et al. (1997). "IL-12 induces T helper 1-directed antitumor response." J 
Immunol 158(7): 3359-65. 
 
   233 
Tuting, T. (1999). "The immunology of cutaneous DNA immunization." Curr Opin Mol Ther 
1(2): 216-25. 
 
Ulmer, J. B., J. J. Donnelly, et al. (1993). "Heterologous protection against influenza by 
injection of DNA encoding a viral protein." Science 259(5102): 1745-9. 
 
Uyttenhove, C., L. Pilotte, et al. (2003). "Evidence for a tumoral immune resistance 
mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase." Nat Med 9(10): 
1269-74. 
 
Valmori, D., N. E. Souleimanian, et al. (2005). "Identification of B cell epitopes recognized by 
antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous 
immune responses." Clin Immunol 117(1): 24-30. 
 
Van den Eynde, B. J. and S. Morel (2001). "Differential processing of class-I-restricted 
epitopes by the standard proteasome and the immunoproteasome." Curr Opin Immunol 13(2): 
147-53. 
 
van der Bruggen, P., C. Traversari, et al. (1991). "A gene encoding an antigen recognized by 
cytolytic T lymphocytes on a human melanoma." Science 254(5038): 1643-7. 
 
van Mierlo, G. J., Z. F. Boonman, et al. (2004). "Activation of dendritic cells that cross-present 
tumor-derived antigen licenses CD8+ CTL to cause tumor eradication." J Immunol 173(11): 
6753-9. 
 
Velasquez, J. L. and S. M. Lipkin (2007). "Genetic testing to identify high-risk populations for 
chemoprevention studies." Cancer Biomark 3(3): 163-8. 
 
Velders, M. P., S. Weijzen, et al. (2001). "Defined flanking spacers and enhanced proteolysis 
is essential for eradication of established tumors by an epitope string DNA vaccine." J 
Immunol 166(9): 5366-73. 
 
Viani, G. A., S. L. Afonso, et al. (2007). "Adjuvant trastuzumab in the treatment of her-2-
positive early breast cancer: a meta-analysis of published randomized trials." BMC Cancer 7: 
153. 
 
Vinay, D. S. and B. S. Kwon (1998). "Role of 4-1BB in immune responses." Semin Immunol 
10(6): 481-9. 
 
von Boehmer, H. (2005). "Mechanisms of suppression by suppressor T cells." Nat Immunol 
6(4): 338-44. 
 
Wang, B., C. C. Norbury, et al. (2001). "Multiple paths for activation of naive CD8+ T cells: 
CD4-independent help." J Immunol 167(3): 1283-9. 
 
Wang, C., H. M. Al-Omar, et al. (1999). "Clonal heterogeneity of dendritic cells derived from 
patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity 
by IFN-alpha." Exp Hematol 27(7): 1176-84. 
 
   234 
Wang, H. Y., D. A. Lee, et al. (2004). "Tumor-specific human CD4+ regulatory T cells and 
their ligands: implications for immunotherapy." Immunity 20(1): 107-18. 
 
Wang, H. Y., G. Peng, et al. (2005). "Recognition of a new ARTC1 peptide ligand uniquely 
expressed in tumor cells by antigen-specific CD4+ regulatory T cells." J Immunol 174(5): 
2661-70. 
 
Weaver, C. T. and E. R. Unanue (1990). "The costimulatory function of antigen-presenting 
cells." Immunol Today 11(2): 49-55. 
 
Weber, J. (2000). "Melanoma peptide vaccines: from preclinical background to clinical trials." 
Curr Oncol Rep 2(1): 38-47. 
 
Weber, L. W., W. B. Bowne, et al. (1998). "Tumor immunity and autoimmunity induced by 
immunization with homologous DNA." J Clin Invest 102(6): 1258-64. 
 
Weigel, B. J., A. Panoskaltsis-Mortari, et al. (2006). "Dendritic cells pulsed or fused with 
AML cellular antigen provide comparable in vivo antitumor protective responses." Exp 
Hematol 34(10): 1403-12. 
 
Weiss, R., S. Scheiblhofer, et al. (2002). "Gene gun bombardment with gold particles displays 
a particular Th2-promoting signal that over-rules the Th1-inducing effect of 
immunostimulatory CpG motifs in DNA vaccines." Vaccine 20(25-26): 3148-54. 
 
Wierecky, J., M. Mueller, et al. (2006). "Dendritic cell-based cancer immunotherapy targeting 
MUC-1." Cancer Immunol Immunother 55(1): 63-7. 
 
Williams, D. B. and T. H. Watts (1995). "Molecular chaperones in antigen presentation." Curr 
Opin Immunol 7(1): 77-84. 
 
Wilson, B.J., G.J. Bates, et al. (2004). "The p68 and p72 DEAD box RNA helicases interact 
with HDAC1 and repress transcription in a promoter-specific manner." BMC Mol Biol  5:11. 
 
Winegar, R. A., J. A. Monforte, et al. (1996). "Determination of tissue distribution of an 
intramuscular plasmid vaccine using PCR and in situ DNA hybridization." Hum Gene Ther 
7(17): 2185-94. 
 
Witzig, T. E., A. Molina, et al. (2007). "Long-term responses in patients with recurring or 
refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan." 
Cancer 109(9): 1804-10. 
 
Wolff, J. A., R. W. Malone, et al. (1990). "Direct gene transfer into mouse muscle in vivo." 
Science 247(4949 Pt 1): 1465-8. 
 
Woodland, D. L. (2004). "Jump-starting the immune system: prime-boosting comes of age." 
Trends Immunol 25(2): 98-104. 
 
Xiang, J., H. Huang, et al. (2005). "A new dynamic model of CD8+ T effector cell responses 
via CD4+ T helper-antigen-presenting cells." J Immunol 174(12): 7497-505. 
 
   235 
Yang, J., G. Jin, et al. (2007). "Therapeutic effect of pEgr-IL18-B7.2 gene radiotherapy in B16 
melanoma-bearing mice." Hum Gene Ther 18(4): 323-32. 
 
Yang, N. S., J. Burkholder, et al. (1990). "In vivo and in vitro gene transfer to mammalian 
somatic cells by particle bombardment." Proc Natl Acad Sci U S A 87(24): 9568-72. 
 
Yang, S., D. Kittlesen, et al. (2000). "Dendritic cells infected with a vaccinia vector carrying 
the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T 
cells reactive to multiple epitopes and restricted by HLA-A2 and -A3." J Immunol 164(8): 
4204-11. 
 
Yang, X. J., J. Liu, et al. (2006). "HCV NS2 protein inhibits cell proliferation and induces cell 
cycle arrest in the S-phase in mammalian cells through down-regulation of cyclin A 
expression." Virus Res 121(2): 134-43. 
 
Yee, C., J. A. Thompson, et al. (2000). "Melanocyte destruction after antigen-specific 
immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo." J Exp Med 192(11): 
1637-44. 
 
Zarling, A. L., S. B. Ficarro, et al. (2000). "Phosphorylated peptides are naturally processed 
and presented by major histocompatibility complex class I molecules in vivo." J Exp Med 
192(12): 1755-62. 
 
Zarour, H. M., J. M. Kirkwood, et al. (2000). "Melan-A/MART-1(51-73) represents an 
immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells." 
Proc Natl Acad Sci U S A 97(1): 400-5. 
 
Zeng, G. (2001). "MHC Class II-Restricted Tumor Antigens Recognized by CD4+ T Cells: 
New Strategies for Cancer Vaccine Design." J Immunother 24(3): 195-204. 
 
Zeng, G., Y. Li, et al. (2002). "Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a 
single peptide with dual MHC class I and class II specificities: a new strategy for vaccine 
design." Cancer Res 62(13): 3630-5. 
 
Zhang, L. and P. A. Insel (2004). "The pro-apoptotic protein Bim is a convergence point for 
cAMP/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells." J Biol 
Chem 279(20): 20858-65. 
 
Zhang, W. G., S. H. Liu, et al. (2005). "A phase-I clinical trial of active immunotherapy for 
acute leukemia using inactivated autologous leukemia cells mixed with IL-2, GM-CSF, and IL-
6." Leuk Res 29(1): 3-9. 
 
Zhao, Y., Z. Zheng, et al. (2006). "Transduction of an HLA-DP4-restricted NY-ESO-1-specific 
TCR into primary human CD4+ lymphocytes." J Immunother (1997) 29(4): 398-406. 
 
Zhao, Y., Z. Zheng, et al. (2005). "Primary human lymphocytes transduced with NY-ESO-1 
antigen-specific TCR genes recognize and kill diverse human tumor cell lines." J Immunol 
174(7): 4415-23. 
 
   236 
Communications resulting from the study 
 
Research article: 
M.G. Mathieu, A.J. Knights, G. Pawelec, C.L. Riley, D. Wernet, F.A. Lemonnier, P.T. Straten, 
L. Mueller, R.C. Rees, S.E.B. McArdle (2007). HAGE, a cancer/testis antigen with potential 
for melanoma immunotherapy: Identification of several MHC class-I/-II HAGE derived 
immunogenic peptides. Cancer Immunology Immunotherapy, 56, 1885-1895. 
 
Review: 
D.P. Assudani, R.B.V. Horton, M.G. Mathieu, S.E.B. McArdle, R.C. Rees (2006). The role of 
CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. Cancer 
Immunology Immunotherapy, 56, 70-80. 
 
Abstracts: 
M.G. Mathieu, P.L.R. Bonner, R.C. Rees, S.E.B. McArdle (2006). Identification of candidate 
tumour antigen peptides derived from the tumour antigen HAGE for potential use in cancer 
immunotherapy. Poster presentation at the AACR symposium, Tumour immunology: an 
integrated perspective, Miami. 
 
M.G. Mathieu, P.L.R. Bonner, R.C. Rees, S.E.B. McArdle (2006). Identification of candidate 
tumour antigen peptides derived from the tumour antigen HAGE for potential use in cancer 
immunotherapy. Poster and oral presentations at the Nottingham Trent University, BNS 
research conference, Nottingham. 
 
 
 
 
 
 
 
 
 
 
